{"docstore/data": {"2f3848ba-87c2-4cf3-bec3-a58ce48756f5": {"__data__": {"id_": "2f3848ba-87c2-4cf3-bec3-a58ce48756f5", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded. ", "original_text": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f1611e9-b0b7-497d-8587-38b687e4c16f", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations. ", "original_text": "Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n"}, "hash": "62e970438f73bd15a54a5f4732d90a97bd7847ab053204a18c0dee117c1b33c8", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f1611e9-b0b7-497d-8587-38b687e4c16f": {"__data__": {"id_": "5f1611e9-b0b7-497d-8587-38b687e4c16f", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations. ", "original_text": "Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f3848ba-87c2-4cf3-bec3-a58ce48756f5", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded. ", "original_text": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4630dd88447c295317fa30a062a00f33b0e62c599b6b8db5bbdda5406a3c4628", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcffea4e-3a3b-4f13-bb07-fea3d5fa5cca", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n", "original_text": "Earnings Conference Call. "}, "hash": "39c0a01069e8b7be8746a2b9a317595102ee115bb17d088efcf2d69c878957a2", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n", "start_char_idx": 48, "end_char_idx": 220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcffea4e-3a3b-4f13-bb07-fea3d5fa5cca": {"__data__": {"id_": "dcffea4e-3a3b-4f13-bb07-fea3d5fa5cca", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n", "original_text": "Earnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f1611e9-b0b7-497d-8587-38b687e4c16f", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations. ", "original_text": "Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ddce99cb6e84941c5a8680018f2f0958945b1f21cc360d5836bbdf1e9d3e91f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bcd385bf-05b9-4530-97b3-d4e9653e412a", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call. ", "original_text": "This meeting is being recorded. "}, "hash": "9e5de6cc21bf5e9969f7c428bab8bed701b8e59b74bfdb690bf4d4697297d25b", "class_name": "RelatedNodeInfo"}}, "text": "Earnings Conference Call. ", "start_char_idx": 220, "end_char_idx": 246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bcd385bf-05b9-4530-97b3-d4e9653e412a": {"__data__": {"id_": "bcd385bf-05b9-4530-97b3-d4e9653e412a", "embedding": null, "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call. ", "original_text": "This meeting is being recorded. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcffea4e-3a3b-4f13-bb07-fea3d5fa5cca", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n", "original_text": "Earnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39120f9355f9ce77a74d56af0b55e9622560ff45ff801ab7fbd4a4e947040e51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "707073c4-694c-4cc2-8c16-e702670bd52d", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n", "original_text": "At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations. "}, "hash": "117db31b9b1b26a24f59cdc2bec8da7781b8d3d6a66338dd51f02cd1f166a63e", "class_name": "RelatedNodeInfo"}}, "text": "This meeting is being recorded. ", "start_char_idx": 246, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "707073c4-694c-4cc2-8c16-e702670bd52d": {"__data__": {"id_": "707073c4-694c-4cc2-8c16-e702670bd52d", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n", "original_text": "At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bcd385bf-05b9-4530-97b3-d4e9653e412a", "node_type": "1", "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call. ", "original_text": "This meeting is being recorded. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4f614ce7f1c50fae351da097ebec814fd820002bcbda2f4aeb35f43436b50bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2cab5b5-45c2-4a2a-80bb-8b66827cf027", "node_type": "1", "metadata": {"window": "Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com . ", "original_text": "Please, go ahead  sir. \n \n"}, "hash": "3aa9fe8d9b0e069d9bcd23a83c72a1fc9b49b88b0c990966090845864c6af7a0", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations. ", "start_char_idx": 278, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2cab5b5-45c2-4a2a-80bb-8b66827cf027": {"__data__": {"id_": "b2cab5b5-45c2-4a2a-80bb-8b66827cf027", "embedding": null, "metadata": {"window": "Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com . ", "original_text": "Please, go ahead  sir. \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "707073c4-694c-4cc2-8c16-e702670bd52d", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n", "original_text": "At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e875536974ce980340f52fe5a071b64c70821289a6e851e1321a883024d60eee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64b09bd3-f490-4575-b265-80123928d632", "node_type": "1", "metadata": {"window": "This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n", "original_text": "Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call. "}, "hash": "40ab97cb517815cc3db9b4f92e17e71e1f1ade7bfd53f2adb6967a0202da93d2", "class_name": "RelatedNodeInfo"}}, "text": "Please, go ahead  sir. \n \n", "start_char_idx": 381, "end_char_idx": 407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64b09bd3-f490-4575-b265-80123928d632": {"__data__": {"id_": "64b09bd3-f490-4575-b265-80123928d632", "embedding": null, "metadata": {"window": "This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n", "original_text": "Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2cab5b5-45c2-4a2a-80bb-8b66827cf027", "node_type": "1", "metadata": {"window": "Earnings Conference Call.  This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com . ", "original_text": "Please, go ahead  sir. \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6219e4c27c806ea20bacc5ede148fc9d7979b70090e825ddddef8a994d04c070", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d10be3c-6c31-4230-a2fe-ab5abee3e967", "node_type": "1", "metadata": {"window": "At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.  ", "original_text": "On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n"}, "hash": "016538ccc44c5cc5880391dfa5817c824c2b8381494bd5ab71fe5252742a08e3", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call. ", "start_char_idx": 407, "end_char_idx": 541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d10be3c-6c31-4230-a2fe-ab5abee3e967": {"__data__": {"id_": "0d10be3c-6c31-4230-a2fe-ab5abee3e967", "embedding": null, "metadata": {"window": "At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.  ", "original_text": "On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64b09bd3-f490-4575-b265-80123928d632", "node_type": "1", "metadata": {"window": "This meeting is being recorded.  At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n", "original_text": "Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66a27f8d4b0368c5928db3485b02151c31412df4d722a3a79b5cff2c5f236590", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8e176be-be9e-4371-8ac4-98e42bb5c85b", "node_type": "1", "metadata": {"window": "Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n", "original_text": "You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com . "}, "hash": "377a68d06d6818011285a20796aa5c0cf8e1ea64095dd3fef34b116bfc4b184f", "class_name": "RelatedNodeInfo"}}, "text": "On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n", "start_char_idx": 541, "end_char_idx": 656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8e176be-be9e-4371-8ac4-98e42bb5c85b": {"__data__": {"id_": "d8e176be-be9e-4371-8ac4-98e42bb5c85b", "embedding": null, "metadata": {"window": "Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n", "original_text": "You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com . ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d10be3c-6c31-4230-a2fe-ab5abee3e967", "node_type": "1", "metadata": {"window": "At this time, I would like to hand the call \nover to Matt Sims , Vice President of Investor Relations.  Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.  ", "original_text": "On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08b9eef2d9f7fc5616591b1ed9a12d413e8b8360b111bd385d11de6e09ec4092", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4eb8b3f-c0b9-4e3d-92f7-d6b455e163ed", "node_type": "1", "metadata": {"window": "Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  ", "original_text": "As a reminder, during the call we will be making forward -looking statements .  \n"}, "hash": "ff54fbbea31d6e881db76e3033e30254f76e8bbedaa9df5f8cb7ccbe0cff1e4d", "class_name": "RelatedNodeInfo"}}, "text": "You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com . ", "start_char_idx": 656, "end_char_idx": 778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4eb8b3f-c0b9-4e3d-92f7-d6b455e163ed": {"__data__": {"id_": "e4eb8b3f-c0b9-4e3d-92f7-d6b455e163ed", "embedding": null, "metadata": {"window": "Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  ", "original_text": "As a reminder, during the call we will be making forward -looking statements .  \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8e176be-be9e-4371-8ac4-98e42bb5c85b", "node_type": "1", "metadata": {"window": "Please, go ahead  sir. \n \n Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n", "original_text": "You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com . ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e60314fcbf8cc87b78fda506c3565958425971b6d1f716cc6b24579ca1cdc358", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a66c1c2b-18c7-4204-a865-9f801a233763", "node_type": "1", "metadata": {"window": "On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.  "}, "hash": "e22e163b1c56a3fd1bee03ff9fed87c57a9cd15475b6008dcaaaf2cba6e3e9ac", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, during the call we will be making forward -looking statements .  \n", "start_char_idx": 778, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a66c1c2b-18c7-4204-a865-9f801a233763": {"__data__": {"id_": "a66c1c2b-18c7-4204-a865-9f801a233763", "embedding": null, "metadata": {"window": "On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.  ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4eb8b3f-c0b9-4e3d-92f7-d6b455e163ed", "node_type": "1", "metadata": {"window": "Matt Sims :  Good morning , and  thank you for joining us for Cardinal Health\u2019s First-Quarter Fiscal \n2024 E arnings conference call.  On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  ", "original_text": "As a reminder, during the call we will be making forward -looking statements .  \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9977dfd7d8dfb184af388e84bc91ecbb62cd6516e38fbd7b1052f6a3a027a37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d325935-288b-447a-a567-ceee3243fc3f", "node_type": "1", "metadata": {"window": "You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n"}, "hash": "1f6e05b1cbb95d843f53d2e9f82f00c40d8b3be40a9d7ebcb1c50b0ebfeaa3f5", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.  ", "start_char_idx": 859, "end_char_idx": 1026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d325935-288b-447a-a567-ceee3243fc3f": {"__data__": {"id_": "4d325935-288b-447a-a567-ceee3243fc3f", "embedding": null, "metadata": {"window": "You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a66c1c2b-18c7-4204-a865-9f801a233763", "node_type": "1", "metadata": {"window": "On the call with me today are Jason Hollar, Chief Executive Officer, \nand Aaron Alt, Chief Financial Officer .  \n \n You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.  ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d699919832b6c6b11a9273a5fda3687859f97ca06371fa1bd4f4d571c8f17fd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "430136dc-7592-45d5-a5f1-81a32baacf4d", "node_type": "1", "metadata": {"window": "As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n", "original_text": "Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  "}, "hash": "d980a6815ccae8d5c90530f9694c7e1586baef428a552003e9b88142f130b8e9", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n", "start_char_idx": 1026, "end_char_idx": 1194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "430136dc-7592-45d5-a5f1-81a32baacf4d": {"__data__": {"id_": "430136dc-7592-45d5-a5f1-81a32baacf4d", "embedding": null, "metadata": {"window": "As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n", "original_text": "Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d325935-288b-447a-a567-ceee3243fc3f", "node_type": "1", "metadata": {"window": "You can find today\u2019s press release and earnings presentation on the IR section of our website at \nir.cardinalhealth.com .  As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  ", "original_text": "Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55f18f830571aaac35ceaae29b7f0fe3197194ae0baa6ffb0121f9208dbe72be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c49c955a-a7b2-4393-bc2d-f40dbc9d1ae3", "node_type": "1", "metadata": {"window": "The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n"}, "hash": "03e8eeffbf4e9a4fd7fdc68e7c82dc7ff1332ae431106687bef2e7a941348419", "class_name": "RelatedNodeInfo"}}, "text": "Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  ", "start_char_idx": 1194, "end_char_idx": 1334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c49c955a-a7b2-4393-bc2d-f40dbc9d1ae3": {"__data__": {"id_": "c49c955a-a7b2-4393-bc2d-f40dbc9d1ae3", "embedding": null, "metadata": {"window": "The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "430136dc-7592-45d5-a5f1-81a32baacf4d", "node_type": "1", "metadata": {"window": "As a reminder, during the call we will be making forward -looking statements .  \n The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n", "original_text": "Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6ce05e43de3c830c59d86808751cf0a72d0e2bb90f393e2e078e5f534abc016", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da683bb3-78ba-47b5-8b40-1544be9a80ce", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year. ", "original_text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  "}, "hash": "815a8e9e166a04189ba82ac4bd0dbfd19e0857a8952d26c06d99f0feba37c5b6", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n", "start_char_idx": 1334, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da683bb3-78ba-47b5-8b40-1544be9a80ce": {"__data__": {"id_": "da683bb3-78ba-47b5-8b40-1544be9a80ce", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year. ", "original_text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c49c955a-a7b2-4393-bc2d-f40dbc9d1ae3", "node_type": "1", "metadata": {"window": "The matters addressed in the statements are subject to risks and uncertainties that could cause \nactual results to differ materially from those projected or implied.   Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00d7ee267f96ca3682a09187c750e563240a549fc21d89fc568ac855bc26ac71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a784b4ff-917a-4ae3-8082-99a3a57f2796", "node_type": "1", "metadata": {"window": "Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n", "original_text": "With that, I will now turn the call over to Jason.  \n \n"}, "hash": "03c9ae5bd18eaed308b241d579551d9daf34f6c59001831fa2c35ac7e02030b2", "class_name": "RelatedNodeInfo"}}, "text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  ", "start_char_idx": 1459, "end_char_idx": 1614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a784b4ff-917a-4ae3-8082-99a3a57f2796": {"__data__": {"id_": "a784b4ff-917a-4ae3-8082-99a3a57f2796", "embedding": null, "metadata": {"window": "Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n", "original_text": "With that, I will now turn the call over to Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da683bb3-78ba-47b5-8b40-1544be9a80ce", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and \nthe forward -looking statement slide at the beginning of our presentation for a description of these \nrisks and uncertainties.  \n \n Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year. ", "original_text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "061d4cea6c6fda33e2fa9e8b5cd8866a9b99f26a53767a16e7640b8cbdee9e46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a5ef303-ead0-43cf-aa73-ff98de7b4037", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n", "original_text": "Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n"}, "hash": "6ec3bce6ddb08d37fd48be3efe707c937075e3910f11aa16dadf9a74de321029", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will now turn the call over to Jason.  \n \n", "start_char_idx": 1614, "end_char_idx": 1669, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a5ef303-ead0-43cf-aa73-ff98de7b4037": {"__data__": {"id_": "2a5ef303-ead0-43cf-aa73-ff98de7b4037", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n", "original_text": "Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a784b4ff-917a-4ae3-8082-99a3a57f2796", "node_type": "1", "metadata": {"window": "Please note, that during the discussion today, our comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.   GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n", "original_text": "With that, I will now turn the call over to Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80de391e48e7038783da1785d22a622a65db9640058771f5bf0b0e066ea4b445", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22e5a2e8-7bf2-4d8b-b533-c775a503f4d4", "node_type": "1", "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program. ", "original_text": "Overall, it was a great start to our fiscal year. "}, "hash": "db0f656b9c498d8d8da5d5f92f939e1b8cd4a77211c352e0eec3cf156552c592", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n", "start_char_idx": 1669, "end_char_idx": 1730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22e5a2e8-7bf2-4d8b-b533-c775a503f4d4": {"__data__": {"id_": "22e5a2e8-7bf2-4d8b-b533-c775a503f4d4", "embedding": null, "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program. ", "original_text": "Overall, it was a great start to our fiscal year. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a5ef303-ead0-43cf-aa73-ff98de7b4037", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n", "original_text": "Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a4cf2f145234e8501ed13f36cfbbd93fb3ccdd5832d86b5de4f69d2a4dc9a4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "559c2658-489e-4c95-afe6-3916de83fd21", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n", "original_text": "With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n"}, "hash": "af0eb918bf79f662a71568ce65c7baa73e38e83996140113b40642405a8b1e6e", "class_name": "RelatedNodeInfo"}}, "text": "Overall, it was a great start to our fiscal year. ", "start_char_idx": 1730, "end_char_idx": 1780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "559c2658-489e-4c95-afe6-3916de83fd21": {"__data__": {"id_": "559c2658-489e-4c95-afe6-3916de83fd21", "embedding": null, "metadata": {"window": "With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n", "original_text": "With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22e5a2e8-7bf2-4d8b-b533-c775a503f4d4", "node_type": "1", "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.   With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program. ", "original_text": "Overall, it was a great start to our fiscal year. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "275011c519c03c42242972afaad3dab00447b83028fecb9f467bcf0070ca88cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "104b78be-f357-4138-be65-cb60299cfe2f", "node_type": "1", "metadata": {"window": "Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications. ", "original_text": "In the first quarter , we delivered significant profit growth in both segments.  \n \n"}, "hash": "a5f748f0bb439a8a4ba6bac3e070fa04a319efc6074b86710b155bca3013cdb1", "class_name": "RelatedNodeInfo"}}, "text": "With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n", "start_char_idx": 1780, "end_char_idx": 1915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "104b78be-f357-4138-be65-cb60299cfe2f": {"__data__": {"id_": "104b78be-f357-4138-be65-cb60299cfe2f", "embedding": null, "metadata": {"window": "Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications. ", "original_text": "In the first quarter , we delivered significant profit growth in both segments.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "559c2658-489e-4c95-afe6-3916de83fd21", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n", "original_text": "With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "510faa5fab0ba39077671574a9fcedc01e118357ccba8123c7e429b15d6d064c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11bbd84b-e055-4fe8-84c3-bfc3cbd74662", "node_type": "1", "metadata": {"window": "Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n", "original_text": "In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program. "}, "hash": "8eed10f6dbe58d4c35047ecec90ff80b5dfad00b53d048c949eb119c3dbf7ccc", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter , we delivered significant profit growth in both segments.  \n \n", "start_char_idx": 1915, "end_char_idx": 1999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11bbd84b-e055-4fe8-84c3-bfc3cbd74662": {"__data__": {"id_": "11bbd84b-e055-4fe8-84c3-bfc3cbd74662", "embedding": null, "metadata": {"window": "Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n", "original_text": "In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "104b78be-f357-4138-be65-cb60299cfe2f", "node_type": "1", "metadata": {"window": "Jason Hollar :  Thanks Matt, and good morning, everyone.  \n \n Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications. ", "original_text": "In the first quarter , we delivered significant profit growth in both segments.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "552efa1fdb6680758ae101c51380ec688fda4bee8989194db5ef50cc04630d5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c06ed333-1d18-4899-99a6-66d71c16abba", "node_type": "1", "metadata": {"window": "With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness. ", "original_text": "We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n"}, "hash": "b0f1f012e3565255fea4137a2ef8a9f40e124f988875c3ba0b6eb20871bed2b3", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program. ", "start_char_idx": 1999, "end_char_idx": 2140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c06ed333-1d18-4899-99a6-66d71c16abba": {"__data__": {"id_": "c06ed333-1d18-4899-99a6-66d71c16abba", "embedding": null, "metadata": {"window": "With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness. ", "original_text": "We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11bbd84b-e055-4fe8-84c3-bfc3cbd74662", "node_type": "1", "metadata": {"window": "Overall, it was a great start to our fiscal year.  With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n", "original_text": "In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b020da6e589b55447a4ef8e615807bc707580166ca165781847c020d7149f22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd899c7d-260c-4210-a106-ff77e937ebd9", "node_type": "1", "metadata": {"window": "In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago. ", "original_text": "Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications. "}, "hash": "da2e22546cad02e20cfa680d5673dd43b4b81ab70658d2ca86035d8b7eb0e89a", "class_name": "RelatedNodeInfo"}}, "text": "We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n", "start_char_idx": 2140, "end_char_idx": 2285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd899c7d-260c-4210-a106-ff77e937ebd9": {"__data__": {"id_": "cd899c7d-260c-4210-a106-ff77e937ebd9", "embedding": null, "metadata": {"window": "In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago. ", "original_text": "Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c06ed333-1d18-4899-99a6-66d71c16abba", "node_type": "1", "metadata": {"window": "With strong first -quarter results and an improved outlook \nfor the year, we are continuing our operating momentum into fiscal \u201824. \n \n In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness. ", "original_text": "We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b2c73294ebd3b241a3adaa5e211e1c1e2206ebffdb9f302175d18ce9bf0bcdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b65047a4-bc49-43e7-9795-cc23108d2a41", "node_type": "1", "metadata": {"window": "In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n"}, "hash": "ba56737546e12c26031a7c4988a5f4dcf2ca6a9c9b46be792ef4398fce8b95eb", "class_name": "RelatedNodeInfo"}}, "text": "Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications. ", "start_char_idx": 2285, "end_char_idx": 2436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b65047a4-bc49-43e7-9795-cc23108d2a41": {"__data__": {"id_": "b65047a4-bc49-43e7-9795-cc23108d2a41", "embedding": null, "metadata": {"window": "In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd899c7d-260c-4210-a106-ff77e937ebd9", "node_type": "1", "metadata": {"window": "In the first quarter , we delivered significant profit growth in both segments.  \n \n In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago. ", "original_text": "Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d25ee6f5487eb06c82c7ed6dd0ef4c6e5e6ea1da49503393c6e496859a6f241c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f272b30-e7ce-4a88-ba29-c0136d061553", "node_type": "1", "metadata": {"window": "We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness. "}, "hash": "1749e7143910ccb741534c998de36ae58e248e1247708e0be527116b50476bd0", "class_name": "RelatedNodeInfo"}}, "text": "And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n", "start_char_idx": 2436, "end_char_idx": 2540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f272b30-e7ce-4a88-ba29-c0136d061553": {"__data__": {"id_": "3f272b30-e7ce-4a88-ba29-c0136d061553", "embedding": null, "metadata": {"window": "We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b65047a4-bc49-43e7-9795-cc23108d2a41", "node_type": "1", "metadata": {"window": "In Pharma, the results were driven by the strength across our business, including continued positive \nperformance from our generics program.  We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f025746029f795ede475fc1599e6940fca4d5c0538da5f49349161bf0455948f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfe36bbf-fdcb-4553-83d9-89ce516ca686", "node_type": "1", "metadata": {"window": "Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "Recall the segment was unprofitable only a year ago. "}, "hash": "f2279fd363a14e45d73abd01cdd8565eef13a22634e9114ef03f19235074615f", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness. ", "start_char_idx": 2540, "end_char_idx": 2655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfe36bbf-fdcb-4553-83d9-89ce516ca686": {"__data__": {"id_": "dfe36bbf-fdcb-4553-83d9-89ce516ca686", "embedding": null, "metadata": {"window": "Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "Recall the segment was unprofitable only a year ago. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f272b30-e7ce-4a88-ba29-c0136d061553", "node_type": "1", "metadata": {"window": "We also benefitted from our role distributing the recently \ncommercialized COVID -19 vaccines, which I\u2019ll elaborate on  later in my remarks.  \n \n Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98e3041dd24b5043c2b5d607b188e99c6958a07e8a348b121e3a24c9a21fd193", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0241e82-2271-462e-a7c9-01a7fb1f0c19", "node_type": "1", "metadata": {"window": "And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to "}, "hash": "114bca804dc8beb291656a0a96907fe0456d75d0f569f69cd3df217e7a7f0fbb", "class_name": "RelatedNodeInfo"}}, "text": "Recall the segment was unprofitable only a year ago. ", "start_char_idx": 2655, "end_char_idx": 2708, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0241e82-2271-462e-a7c9-01a7fb1f0c19": {"__data__": {"id_": "d0241e82-2271-462e-a7c9-01a7fb1f0c19", "embedding": null, "metadata": {"window": "And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "babee6b7-56fc-4416-b788-8fe24ee564b8", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "13cb36371812b76454b764ec264abe29cb40766876410addf433eef7fb0ce774", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfe36bbf-fdcb-4553-83d9-89ce516ca686", "node_type": "1", "metadata": {"window": "Macro trends in the core distribution business remain stable, and we continue to see strong \npharmaceutical demand, including with GLP -1 medications.  And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "Recall the segment was unprofitable only a year ago. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10545cb0e513bf4dd39e2bed7bae87988073a6a73a045b756c6c0991ed925652", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2eff0640-d37d-49b7-a034-eeb3d178da57", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n", "original_text": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance . "}, "hash": "256be68c3e93cae02bb9c84a82436dbcc425ac15d21b79be8e9f99fe27cea2d5", "class_name": "RelatedNodeInfo"}}, "text": "Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "start_char_idx": 2708, "end_char_idx": 2846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2eff0640-d37d-49b7-a034-eeb3d178da57": {"__data__": {"id_": "2eff0640-d37d-49b7-a034-eeb3d178da57", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n", "original_text": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance . ", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0241e82-2271-462e-a7c9-01a7fb1f0c19", "node_type": "1", "metadata": {"window": "And both our higher -growth Specialty and \nNuclear businesses tracked ahead of plan in the quarter.  \n \n In Medical, the first quarter was another proof point of the inflection we began to see last Q2 in this \nbusiness.  Recall the segment was unprofitable only a year ago.  Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "original_text": "Overall, the results tracked slightly \nahead of our expectations, and we continue to execu te our Medical Improvement Plan initiatives to ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c086f01d04f6ee9fd5b3646f3b84e0125eda7e4df6dce2654f10416f07c80385", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91ac8485-2a92-49bf-8598-d42ae10ec432", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n", "original_text": "In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n"}, "hash": "087d7ffb8debdbc40a82a677ab37b0d69899b71c3fa766db5f4ac0e7526593c4", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance . ", "start_char_idx": 0, "end_char_idx": 76, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91ac8485-2a92-49bf-8598-d42ae10ec432": {"__data__": {"id_": "91ac8485-2a92-49bf-8598-d42ae10ec432", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n", "original_text": "In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2eff0640-d37d-49b7-a034-eeb3d178da57", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n", "original_text": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance . ", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1583086b02890933d19f53a5f9cfbb42c4768668c1b4085e914f737ba5fabf18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c024bbe4-4675-4a63-98e3-669c3dc47be2", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n", "original_text": "At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n"}, "hash": "a0b9ef8aaa42a1bce977dd389d4fcb03d87b11cf2ac682c8e5850c8b29fd483b", "class_name": "RelatedNodeInfo"}}, "text": "In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n", "start_char_idx": 76, "end_char_idx": 161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c024bbe4-4675-4a63-98e3-669c3dc47be2": {"__data__": {"id_": "c024bbe4-4675-4a63-98e3-669c3dc47be2", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n", "original_text": "At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91ac8485-2a92-49bf-8598-d42ae10ec432", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n", "original_text": "In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e764024645ea85d4d5f604a8d8286d51b2fe0177405caadcdb5e1b623b911d08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cea8529f-202c-46f8-bdb0-e672303070c2", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "original_text": "And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n"}, "hash": "40dbf07ea7b2ef333182a56fdb18be68db81c45e9c1c672e2c2ebead49adc166", "class_name": "RelatedNodeInfo"}}, "text": "At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n", "start_char_idx": 161, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cea8529f-202c-46f8-bdb0-e672303070c2": {"__data__": {"id_": "cea8529f-202c-46f8-bdb0-e672303070c2", "embedding": null, "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "original_text": "And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c024bbe4-4675-4a63-98e3-669c3dc47be2", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n", "original_text": "At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0de6a1e9a9432d5e9bd14d2f2527acc0927eddff7851ed7a3dde532f1814930f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e7ba431-2d7d-4216-986f-d31e30346df6", "node_type": "1", "metadata": {"window": "In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n", "original_text": "In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n"}, "hash": "7dd1a19d4ef66d7d976b1d2770e873fd3d2b9b3482c8ab2ae0df5eead7847f3f", "class_name": "RelatedNodeInfo"}}, "text": "And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n", "start_char_idx": 283, "end_char_idx": 449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e7ba431-2d7d-4216-986f-d31e30346df6": {"__data__": {"id_": "6e7ba431-2d7d-4216-986f-d31e30346df6", "embedding": null, "metadata": {"window": "In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n", "original_text": "In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cea8529f-202c-46f8-bdb0-e672303070c2", "node_type": "1", "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "original_text": "And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "febfbf79fcb28c8177230111dce747cf5aa2925ade86a27d01cce6c6d5558337", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7491cae-aa47-4636-991a-33b51848fabf", "node_type": "1", "metadata": {"window": "At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.  ", "original_text": "Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n"}, "hash": "6e927e80b5da7ec6124531602857c0cdd51544a3f24ce604582fecbc27d170a0", "class_name": "RelatedNodeInfo"}}, "text": "In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n", "start_char_idx": 449, "end_char_idx": 586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7491cae-aa47-4636-991a-33b51848fabf": {"__data__": {"id_": "b7491cae-aa47-4636-991a-33b51848fabf", "embedding": null, "metadata": {"window": "At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.  ", "original_text": "Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e7ba431-2d7d-4216-986f-d31e30346df6", "node_type": "1", "metadata": {"window": "In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n", "original_text": "In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b744d1f9d4c0d599c97402f6454b25da1368574d25e342531480e7cad1ca4944", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd42a543-3b7a-4f29-bf14-4650a67d49c4", "node_type": "1", "metadata": {"window": "And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n", "original_text": "I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n"}, "hash": "2436bd344745b29f82cb409f71a3409e813e23e5b13007463d830edbb9ae4bcb", "class_name": "RelatedNodeInfo"}}, "text": "Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n", "start_char_idx": 586, "end_char_idx": 705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd42a543-3b7a-4f29-bf14-4650a67d49c4": {"__data__": {"id_": "bd42a543-3b7a-4f29-bf14-4650a67d49c4", "embedding": null, "metadata": {"window": "And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n", "original_text": "I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7491cae-aa47-4636-991a-33b51848fabf", "node_type": "1", "metadata": {"window": "At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.  ", "original_text": "Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba917821df9fd1d6032c4eb5b59c2d9f72a8ed03f14f321ff5e0b21db624227e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fe2dba7-3027-4559-a434-dff0bcd53a7f", "node_type": "1", "metadata": {"window": "In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n", "original_text": "Aaron Alt :  Thanks Jason, and good morning.  \n \n"}, "hash": "c774fb0f2480eb023e17acce8ae7ee85a91575a7cb813cc58a5ad9967393d0f9", "class_name": "RelatedNodeInfo"}}, "text": "I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "start_char_idx": 705, "end_char_idx": 896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fe2dba7-3027-4559-a434-dff0bcd53a7f": {"__data__": {"id_": "6fe2dba7-3027-4559-a434-dff0bcd53a7f", "embedding": null, "metadata": {"window": "In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n", "original_text": "Aaron Alt :  Thanks Jason, and good morning.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd42a543-3b7a-4f29-bf14-4650a67d49c4", "node_type": "1", "metadata": {"window": "And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n", "original_text": "I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28d1fb35d17140b21adada2fd0eedd4372110d93d9c917afdb23a568a3d5f000", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "802c7326-d786-4cc8-9a29-cf8f7bb19911", "node_type": "1", "metadata": {"window": "Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n", "original_text": "Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.  "}, "hash": "d3f25698c1a74c5911a5bfc5014c4757c0b28edf1675062a9095d571c0e77d7d", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt :  Thanks Jason, and good morning.  \n \n", "start_char_idx": 896, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "802c7326-d786-4cc8-9a29-cf8f7bb19911": {"__data__": {"id_": "802c7326-d786-4cc8-9a29-cf8f7bb19911", "embedding": null, "metadata": {"window": "Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n", "original_text": "Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.  ", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fe2dba7-3027-4559-a434-dff0bcd53a7f", "node_type": "1", "metadata": {"window": "In short, the broad -based performance to -date gives us confidence to raise fiscal \u201824 EPS guidance, \nonly a quarter into the year.  \n \n Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n", "original_text": "Aaron Alt :  Thanks Jason, and good morning.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db0c75e1b9bf85919314855e6c36ff38dd24695c2d0a53dc2bad6b0f3650325c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b39de5ee-4909-4fce-aa50-04b3a9c26994", "node_type": "1", "metadata": {"window": "I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n", "original_text": "The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n"}, "hash": "a7ccf9132c66f64c6089301293ba996f7e54ce1ed3ce929b242cd9959306770c", "class_name": "RelatedNodeInfo"}}, "text": "Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.  ", "start_char_idx": 945, "end_char_idx": 1067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b39de5ee-4909-4fce-aa50-04b3a9c26994": {"__data__": {"id_": "b39de5ee-4909-4fce-aa50-04b3a9c26994", "embedding": null, "metadata": {"window": "I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n", "original_text": "The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "802c7326-d786-4cc8-9a29-cf8f7bb19911", "node_type": "1", "metadata": {"window": "Our team continues to prioritize focused execution to best serve our customers and create value for \nshareholders.  \n \n I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n", "original_text": "Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.  ", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f3d4424dcdd379d3eda21dab6a73f221cc578bd2067949ca0688bec3a413ab4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5abd2e9b-ee5f-410c-b843-dd2b0a894008", "node_type": "1", "metadata": {"window": "Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n", "original_text": "We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n"}, "hash": "90d31107447474f387af4bcc4f0520cd94851426de138c63c1cde068215f580b", "class_name": "RelatedNodeInfo"}}, "text": "The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n", "start_char_idx": 1067, "end_char_idx": 1291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5abd2e9b-ee5f-410c-b843-dd2b0a894008": {"__data__": {"id_": "5abd2e9b-ee5f-410c-b843-dd2b0a894008", "embedding": null, "metadata": {"window": "Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n", "original_text": "We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b39de5ee-4909-4fce-aa50-04b3a9c26994", "node_type": "1", "metadata": {"window": "I will update you on our progress in advancing our 3 key strategic imperatives shortly, but first let me \nturn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n", "original_text": "The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f062d2461635c8f8fba737b4a6d24d75cba9d685033fa7f54ce2d2acf61ac42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc7085a0-9f01-4206-9d9e-14c64c058b41", "node_type": "1", "metadata": {"window": "Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n", "original_text": "Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n"}, "hash": "8f32a695df53f927a8355d54bac9ee8bc04f777f6c14ad45a314edf2c1aa8fca", "class_name": "RelatedNodeInfo"}}, "text": "We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n", "start_char_idx": 1291, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc7085a0-9f01-4206-9d9e-14c64c058b41": {"__data__": {"id_": "fc7085a0-9f01-4206-9d9e-14c64c058b41", "embedding": null, "metadata": {"window": "Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n", "original_text": "Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5abd2e9b-ee5f-410c-b843-dd2b0a894008", "node_type": "1", "metadata": {"window": "Aaron Alt :  Thanks Jason, and good morning.  \n \n Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n", "original_text": "We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8222c1e71778d5fad069987f25016787c2e1d7a037188321c71410ba759775ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5462e242-7fcb-4df3-8309-918001d368c2", "node_type": "1", "metadata": {"window": "The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n", "original_text": "Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n"}, "hash": "0fed196f7a449198590f1974719706dde9b08be818490d7b1da3de10e717bd7d", "class_name": "RelatedNodeInfo"}}, "text": "Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n", "start_char_idx": 1381, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5462e242-7fcb-4df3-8309-918001d368c2": {"__data__": {"id_": "5462e242-7fcb-4df3-8309-918001d368c2", "embedding": null, "metadata": {"window": "The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n", "original_text": "Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc7085a0-9f01-4206-9d9e-14c64c058b41", "node_type": "1", "metadata": {"window": "Q1 delivered a strong financial start to the year with EPS of $1.73, surpassing our expectations in \nPharma and Medical.   The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n", "original_text": "Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f3dde836b20cfd7e52fe78ea4bc9dd7e5cde215c448c43bfb859781ce94a794", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6753711-5613-41de-9cea-4cfe8bf5967d", "node_type": "1", "metadata": {"window": "We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents . ", "original_text": "Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n"}, "hash": "06c42b6010da6e6c373f4bfa7e9a4713bb468035389c63f3304442109dfb78ba", "class_name": "RelatedNodeInfo"}}, "text": "Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n", "start_char_idx": 1460, "end_char_idx": 1540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6753711-5613-41de-9cea-4cfe8bf5967d": {"__data__": {"id_": "f6753711-5613-41de-9cea-4cfe8bf5967d", "embedding": null, "metadata": {"window": "We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents . ", "original_text": "Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5462e242-7fcb-4df3-8309-918001d368c2", "node_type": "1", "metadata": {"window": "The strength of our Pharma business, the progress on our Medical turnaround \nefforts and our disciplined approach to capital allocation contributed to new first quarter highs for the \nEnterprise on both revenue and EPS.  \n \n We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n", "original_text": "Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "681fc5e018b4b996759a725ef4a24e2676501f53aec8447ca022c0c9a27ac2d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17d8a14c-0d72-4db4-b987-3b8132ffa3bd", "node_type": "1", "metadata": {"window": "Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n"}, "hash": "804cfcb247ff11f62c175db7c0f9493d4eb5271269363619019500524869056e", "class_name": "RelatedNodeInfo"}}, "text": "Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n", "start_char_idx": 1540, "end_char_idx": 1641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17d8a14c-0d72-4db4-b987-3b8132ffa3bd": {"__data__": {"id_": "17d8a14c-0d72-4db4-b987-3b8132ffa3bd", "embedding": null, "metadata": {"window": "Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6753711-5613-41de-9cea-4cfe8bf5967d", "node_type": "1", "metadata": {"window": "We also delivered strong cash flow and ended the quarter with $3.9  billion  of cash.  \n \n Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents . ", "original_text": "Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "661ef59811cb300e08f9336b9e6d7b9f3486180975150c229762670d6980f40c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f56653e-2858-4236-82ec-2e19c33f073e", "node_type": "1", "metadata": {"window": "Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n"}, "hash": "0bac03ac4f5e470a0f8a325214b39d8d91e2747c45a81b19a0398d4bd2416343", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n", "start_char_idx": 1641, "end_char_idx": 1790, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f56653e-2858-4236-82ec-2e19c33f073e": {"__data__": {"id_": "3f56653e-2858-4236-82ec-2e19c33f073e", "embedding": null, "metadata": {"window": "Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17d8a14c-0d72-4db4-b987-3b8132ffa3bd", "node_type": "1", "metadata": {"window": "Let\u2019s start with the consolidated enterprise results  as seen  on slide 4 . \n \n Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd7f073f812b878893477eef2c883ef88529700053dd46d69c8b38bb421e9b04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a110531d-5719-4ae5-b2f7-eb21980eb3d0", "node_type": "1", "metadata": {"window": "Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents . "}, "hash": "fa862c0d06d130a5ecf7f1610324d683b854ec1d7f227e948af67b842caf2ac8", "class_name": "RelatedNodeInfo"}}, "text": "With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n", "start_char_idx": 1790, "end_char_idx": 1918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a110531d-5719-4ae5-b2f7-eb21980eb3d0": {"__data__": {"id_": "a110531d-5719-4ae5-b2f7-eb21980eb3d0", "embedding": null, "metadata": {"window": "Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents . ", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f56653e-2858-4236-82ec-2e19c33f073e", "node_type": "1", "metadata": {"window": "Total revenue increased 10% to $54.8 billion, driven by the Pharma segment.  \n \n Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11994d335fe03e6e3b7eaaa51ed35198134025d0072a854b7a797ed75990f545", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97a72503-efee-4ce0-8428-ac7b3b90aedb", "node_type": "1", "metadata": {"window": "Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n "}, "hash": "6cae032573422acaf2c4fbeafe9969d55d067612a9fcb8425234251469f90d50", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents . ", "start_char_idx": 1918, "end_char_idx": 2063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97a72503-efee-4ce0-8428-ac7b3b90aedb": {"__data__": {"id_": "97a72503-efee-4ce0-8428-ac7b3b90aedb", "embedding": null, "metadata": {"window": "Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d256ca5816477c53128f6e36627964fd6da68a726c64ecd07c44327dd57bfd77", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a110531d-5719-4ae5-b2f7-eb21980eb3d0", "node_type": "1", "metadata": {"window": "Gross margin also increased 10% to $1.8 billion, driven by both the Medical and Pharma segments.  \n \n Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents . ", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e4f74dd67f35c98c1652389afe0e3386c7b6d138c1a26e5eae45b695b373e09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e501a3dc-97b6-4017-84bb-0a1fabf685a0", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n", "original_text": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints. "}, "hash": "c55136e5650655e6bbbc59f8957df7ace7728ac212f1f40ea7929f02eb4dcee0", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "start_char_idx": 2063, "end_char_idx": 2186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e501a3dc-97b6-4017-84bb-0a1fabf685a0": {"__data__": {"id_": "e501a3dc-97b6-4017-84bb-0a1fabf685a0", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n", "original_text": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints. ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97a72503-efee-4ce0-8428-ac7b3b90aedb", "node_type": "1", "metadata": {"window": "Consolidated SG&A was generally in -line with the prior year at $1.2 billion, reflecting our disciplined \ncost management across the enterprise.  \n \n With the significant profit growth in both segments, we delivered total operating earnings of $571 \nmillion, growth of 35%.  \n \n Moving below the line, interest and other decreased by $15 million to $12 million, due to increased \ninterest income from cash and equivalents .  As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "original_text": "As a reminder, our debt is largely fixed rate, resulting in a \nnet benefit from rising interest rates in the near term.  \n ", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1baad2d5682ea37e39a5bebdd83298e02bd2f6ca871f126c327aa64b81d057b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcb059ba-3d8f-4b8b-b810-2f205f0e5f28", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "original_text": "We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n"}, "hash": "cd2200ad8bd0f9f32acb60b3c00c76edb2b9b725c975f2238ae78418e138eb41", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints. ", "start_char_idx": 0, "end_char_idx": 128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcb059ba-3d8f-4b8b-b810-2f205f0e5f28": {"__data__": {"id_": "fcb059ba-3d8f-4b8b-b810-2f205f0e5f28", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "original_text": "We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e501a3dc-97b6-4017-84bb-0a1fabf685a0", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n", "original_text": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints. ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21046bee6d55ac73db79b1dea53ff2385888a3707e5985d8c16bbb6b809fff7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cc45b94-9872-4294-9364-ade1929264d7", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "original_text": "First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n"}, "hash": "6e3b16d6b6e20c2c2a484e32011f4733284adcb4e4580dd2481c3fa1d9d9c641", "class_name": "RelatedNodeInfo"}}, "text": "We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n", "start_char_idx": 128, "end_char_idx": 247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cc45b94-9872-4294-9364-ade1929264d7": {"__data__": {"id_": "0cc45b94-9872-4294-9364-ade1929264d7", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "original_text": "First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcb059ba-3d8f-4b8b-b810-2f205f0e5f28", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "original_text": "We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e449d8eec4aab059066acc47d058a6203d690e7e668bbe7395be1382ca71b4eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "057eea99-543a-457a-8d89-d2ba1288d020", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers. ", "original_text": "And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n"}, "hash": "2916d5936cbdce9ecbaa2760a46da01148227b8c16c458a806dfcf45c006abd0", "class_name": "RelatedNodeInfo"}}, "text": "First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n", "start_char_idx": 247, "end_char_idx": 370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "057eea99-543a-457a-8d89-d2ba1288d020": {"__data__": {"id_": "057eea99-543a-457a-8d89-d2ba1288d020", "embedding": null, "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers. ", "original_text": "And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cc45b94-9872-4294-9364-ade1929264d7", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "original_text": "First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78bbecf491c4706f502c07ee5aee7facd32841cd49a4a35dfa835fbd1b781d1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b94e48c-0e4a-43d7-b695-9b2430f064c4", "node_type": "1", "metadata": {"window": "We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n", "original_text": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n"}, "hash": "fd0eac5aca63470645eda0c379ea82f003de26a4427e123eeb7ca26c48a378a3", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n", "start_char_idx": 370, "end_char_idx": 515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b94e48c-0e4a-43d7-b695-9b2430f064c4": {"__data__": {"id_": "6b94e48c-0e4a-43d7-b695-9b2430f064c4", "embedding": null, "metadata": {"window": "We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n", "original_text": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "057eea99-543a-457a-8d89-d2ba1288d020", "node_type": "1", "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers. ", "original_text": "And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fb6b562326e6ecf26a1d2bf8a51e922ec345b5ce5abb9cc686ecf47f42b1275", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2188e672-3a2e-4767-b0a0-d2c46018894d", "node_type": "1", "metadata": {"window": "First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n", "original_text": "First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. "}, "hash": "77f8179fb041459e4e5a0870b7f820b4dab41619f2754e586a260d17ed5d8cca", "class_name": "RelatedNodeInfo"}}, "text": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "start_char_idx": 515, "end_char_idx": 564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2188e672-3a2e-4767-b0a0-d2c46018894d": {"__data__": {"id_": "2188e672-3a2e-4767-b0a0-d2c46018894d", "embedding": null, "metadata": {"window": "First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n", "original_text": "First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b94e48c-0e4a-43d7-b695-9b2430f064c4", "node_type": "1", "metadata": {"window": "We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n", "original_text": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc0104155218a27f55ba0167df554a41095c7ec2edc72cc9e669388934270fce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "829b4a27-8e83-45dc-bcda-92995da0b123", "node_type": "1", "metadata": {"window": "And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n", "original_text": "We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers. "}, "hash": "3372bf8763f4b91b5aa266b5690ba1cadb931d0b67ab39915ea5de83c1f6b57d", "class_name": "RelatedNodeInfo"}}, "text": "First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "start_char_idx": 564, "end_char_idx": 700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "829b4a27-8e83-45dc-bcda-92995da0b123": {"__data__": {"id_": "829b4a27-8e83-45dc-bcda-92995da0b123", "embedding": null, "metadata": {"window": "And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n", "original_text": "We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers. ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2188e672-3a2e-4767-b0a0-d2c46018894d", "node_type": "1", "metadata": {"window": "First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n", "original_text": "First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "666c3aaecd1ba9a9e3f4d4dbb15406b9692401c81af0177eae590a756acaef99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9921e69-0254-49d4-80f0-2779626411de", "node_type": "1", "metadata": {"window": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n", "original_text": "Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n"}, "hash": "76bf103bb112fe87539b33d7e6b2eda324ab3e009eaf798aadda407ab2ae18d7", "class_name": "RelatedNodeInfo"}}, "text": "We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers. ", "start_char_idx": 700, "end_char_idx": 887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9921e69-0254-49d4-80f0-2779626411de": {"__data__": {"id_": "b9921e69-0254-49d4-80f0-2779626411de", "embedding": null, "metadata": {"window": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n", "original_text": "Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "829b4a27-8e83-45dc-bcda-92995da0b123", "node_type": "1", "metadata": {"window": "And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n", "original_text": "We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers. ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6171e2a4c1a96d6539cb817c109e2d0c6e18b577e25d90b456c249795c249955", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "928b4b7e-8e46-4f00-b80f-0560ed8d6117", "node_type": "1", "metadata": {"window": "First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n", "original_text": "Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n"}, "hash": "a7cfe1e35406b7098ee5139fcd7d0ee002e982e8e0360a1f849f7ec38224145a", "class_name": "RelatedNodeInfo"}}, "text": "Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n", "start_char_idx": 887, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "928b4b7e-8e46-4f00-b80f-0560ed8d6117": {"__data__": {"id_": "928b4b7e-8e46-4f00-b80f-0560ed8d6117", "embedding": null, "metadata": {"window": "First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n", "original_text": "Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9921e69-0254-49d4-80f0-2779626411de", "node_type": "1", "metadata": {"window": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n", "original_text": "Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90e504b5365f3b90b3e85d139104b6988e94ec5cb8c214fd7f05f46d5cd3a52d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5687b4e6-690b-476f-b452-b69f91744a49", "node_type": "1", "metadata": {"window": "We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n", "original_text": "We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n"}, "hash": "c89945ba54409de2bb83de0464b618576fcfbb500934831b48f56cb69acad4c8", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n", "start_char_idx": 984, "end_char_idx": 1280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5687b4e6-690b-476f-b452-b69f91744a49": {"__data__": {"id_": "5687b4e6-690b-476f-b452-b69f91744a49", "embedding": null, "metadata": {"window": "We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n", "original_text": "We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "928b4b7e-8e46-4f00-b80f-0560ed8d6117", "node_type": "1", "metadata": {"window": "First-quarter revenue increased 11% to $51 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n", "original_text": "Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "702a3a77d320b85439448b478f6023507dbb29626a37ce380b26e87afcb1d11b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c0c84f3-fc7a-4e05-b0e2-5717e9136abc", "node_type": "1", "metadata": {"window": "Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n", "original_text": "Turning to Medical on slide 6 . \n \n"}, "hash": "9f34a1499e1b3873f18a5e1db27454e383ef18482bee5aaac9b7340df0bfec51", "class_name": "RelatedNodeInfo"}}, "text": "We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n", "start_char_idx": 1280, "end_char_idx": 1397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c0c84f3-fc7a-4e05-b0e2-5717e9136abc": {"__data__": {"id_": "4c0c84f3-fc7a-4e05-b0e2-5717e9136abc", "embedding": null, "metadata": {"window": "Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n", "original_text": "Turning to Medical on slide 6 . \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5687b4e6-690b-476f-b452-b69f91744a49", "node_type": "1", "metadata": {"window": "We continued to see broad -based strength in pharmaceutical \ndemand spanning across product categories: brand, specialty, c onsumer health, and generics, and \nfrom our largest customers.  Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n", "original_text": "We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3576fbde6a67a64104acdb94d6485f800f94ad0362f9adfa92cd9733bb481cd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db9d432f-eedd-4f9b-87cd-9dd4f2c74b32", "node_type": "1", "metadata": {"window": "Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales. ", "original_text": "First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n"}, "hash": "42a11184fc744566a2dc49fbe6ab968f733d1d6966ca1678b06f523b5a175154", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical on slide 6 . \n \n", "start_char_idx": 1397, "end_char_idx": 1432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db9d432f-eedd-4f9b-87cd-9dd4f2c74b32": {"__data__": {"id_": "db9d432f-eedd-4f9b-87cd-9dd4f2c74b32", "embedding": null, "metadata": {"window": "Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales. ", "original_text": "First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c0c84f3-fc7a-4e05-b0e2-5717e9136abc", "node_type": "1", "metadata": {"window": "Similar to trends last year, GLP -1 medications provided a revenue \ntailwind in the quarter.  \n \n Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n", "original_text": "Turning to Medical on slide 6 . \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "342eccada66bb2da6716c1b7e4052ed5856400e4f9a95bf63e5a4b6a07f16d96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dcb295d-29cb-4592-8eba-455f2466d333", "node_type": "1", "metadata": {"window": "We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n", "original_text": "In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n"}, "hash": "6920c1982c6d94b014270960a598dda82179c44e028f421726ce0c2962dd38a2", "class_name": "RelatedNodeInfo"}}, "text": "First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n", "start_char_idx": 1432, "end_char_idx": 1526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dcb295d-29cb-4592-8eba-455f2466d333": {"__data__": {"id_": "4dcb295d-29cb-4592-8eba-455f2466d333", "embedding": null, "metadata": {"window": "We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n", "original_text": "In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db9d432f-eedd-4f9b-87cd-9dd4f2c74b32", "node_type": "1", "metadata": {"window": "Segment profit increased 18% to $507 million in the first quarter, driven by a higher contribution from \nbrand and specialty products, including distribution of COVID -19 vaccines, which provided a modest \ncontribution as customers stocked up in preparation f or the fall vaccination season.  \n \n We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales. ", "original_text": "First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e33e667c47541bbf5aed64a7c7b72ad42ece28765969b9cee45f8eae11c75864", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "205c1063-0549-4925-bd35-77f196dfb391", "node_type": "1", "metadata": {"window": "Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n", "original_text": "Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n"}, "hash": "84e043eb1de6bd5ba56ec846cae9987cd84cea430f95a9c475986cc9e05e33e6", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n", "start_char_idx": 1526, "end_char_idx": 1780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "205c1063-0549-4925-bd35-77f196dfb391": {"__data__": {"id_": "205c1063-0549-4925-bd35-77f196dfb391", "embedding": null, "metadata": {"window": "Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n", "original_text": "Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dcb295d-29cb-4592-8eba-455f2466d333", "node_type": "1", "metadata": {"window": "We also saw positive generics program performance, with continued volume growth and consistent \nmarket dynamics.  \n \n Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n", "original_text": "In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4324f3641cc68a9d2af15bb81e195febcbe31a049be14a4110aada9aa05b8ff1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32a7a169-1e47-4874-89a1-96bbecfd49ef", "node_type": "1", "metadata": {"window": "First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales. "}, "hash": "2ebefbc3f4d12c34ecdec2574c620e5d0967c989c2626804ced67c9870a18608", "class_name": "RelatedNodeInfo"}}, "text": "Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n", "start_char_idx": 1780, "end_char_idx": 1974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32a7a169-1e47-4874-89a1-96bbecfd49ef": {"__data__": {"id_": "32a7a169-1e47-4874-89a1-96bbecfd49ef", "embedding": null, "metadata": {"window": "First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales. ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "205c1063-0549-4925-bd35-77f196dfb391", "node_type": "1", "metadata": {"window": "Turning to Medical on slide 6 . \n \n First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n", "original_text": "Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d68d5ae048e9b12fbdc44b8a207b3e8e3a92dc0b570a5773c95b3d2dcaf7e24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5987a61-8d3d-4af7-87d3-5c573e3a85de", "node_type": "1", "metadata": {"window": "In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "In Q1, we saw slight year -over-year volume growth.  \n \n"}, "hash": "f560f25d733bcf09008348faff5fede07ed8628750c9dd52ee91d7060df56f1e", "class_name": "RelatedNodeInfo"}}, "text": "Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales. ", "start_char_idx": 1974, "end_char_idx": 2181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5987a61-8d3d-4af7-87d3-5c573e3a85de": {"__data__": {"id_": "c5987a61-8d3d-4af7-87d3-5c573e3a85de", "embedding": null, "metadata": {"window": "In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "In Q1, we saw slight year -over-year volume growth.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32a7a169-1e47-4874-89a1-96bbecfd49ef", "node_type": "1", "metadata": {"window": "First-quarter revenue, at $3.8 billion, was largely flat to prior year and prior quarter.  \n \n In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales. ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2a53b46d4a4393529901cc3577fe3e723f4aac97b110833079a3cbbf6429201", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "919ecf47-b3f3-4017-b13c-1243f4b7e148", "node_type": "1", "metadata": {"window": "Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n"}, "hash": "366c8e824722ffc19b1a5e6559eb493c12d154c5691c4687605063c0b70e5075", "class_name": "RelatedNodeInfo"}}, "text": "In Q1, we saw slight year -over-year volume growth.  \n \n", "start_char_idx": 2181, "end_char_idx": 2237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "919ecf47-b3f3-4017-b13c-1243f4b7e148": {"__data__": {"id_": "919ecf47-b3f3-4017-b13c-1243f4b7e148", "embedding": null, "metadata": {"window": "Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5987a61-8d3d-4af7-87d3-5c573e3a85de", "node_type": "1", "metadata": {"window": "In the first quarter, we saw lower PP &E volumes and pricing, including the impact from the prior year \nexit of our non -healthcare gloves portfolio, offset by growth in at -Home Solutions and inflationary \nimpacts, including mitigation initiatives.  \n \n Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "In Q1, we saw slight year -over-year volume growth.  \n \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0522b86e25454b0697c930263e0f5b22c1f05383e4b321b9d708c5589d13f42b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a872749-9e06-46ee-bbb5-701df2fceab0", "node_type": "1", "metadata": {"window": "Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n "}, "hash": "376324e3f9cfa540f5f7904e49d45270bbdcb23d77b69570a4eb769a05ab7105", "class_name": "RelatedNodeInfo"}}, "text": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n", "start_char_idx": 2237, "end_char_idx": 2340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a872749-9e06-46ee-bbb5-701df2fceab0": {"__data__": {"id_": "4a872749-9e06-46ee-bbb5-701df2fceab0", "embedding": null, "metadata": {"window": "Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02191f68ffda266e2d91ccca9a3d2a9037983c4c9dcd505f86e013c8592215c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "919ecf47-b3f3-4017-b13c-1243f4b7e148", "node_type": "1", "metadata": {"window": "Medical slightly exceeded our expectations in Q1 and delivered segment profit of $71 million, which \nrepresents an approximate $80 million increase from the prior year\u2019s first quarter loss.  \n \n Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d566c5e2fd3bdee5df2324822feacd31ef872a5fc2fe835e41ff5cf2409d9ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55f51ea6-54d3-4d49-9a53-d678083ddec5", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n", "original_text": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results. "}, "hash": "94ef15faa7bc734195acf9ccf1e71423ceccdf585a7c07ce42d426fe3b88d8b5", "class_name": "RelatedNodeInfo"}}, "text": "We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "start_char_idx": 2340, "end_char_idx": 2469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55f51ea6-54d3-4d49-9a53-d678083ddec5": {"__data__": {"id_": "55f51ea6-54d3-4d49-9a53-d678083ddec5", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n", "original_text": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a872749-9e06-46ee-bbb5-701df2fceab0", "node_type": "1", "metadata": {"window": "Consistent with the expectations communicated at Investor Day and last quarter, we continue to be \nencouraged by indicators of improvement in trends with respect to our Cardinal Health Brand product \nsales.  In Q1, we saw slight year -over-year volume growth.  \n \n As expected, we saw an improvement in net inflationary impacts, including our mitigation initiatives. \n We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "original_text": "We also continued to see normalized PP &E margins \u2013 which were impacted by unfavorable price -\ncost timing in the prior year.  \n ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21f66bb218afefc2262c248280649e1931326bd7b5ab4593fa8f541f571bec2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77fbd534-60f5-45d2-ac10-cda069dc5c64", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n", "original_text": "This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n"}, "hash": "485cbd2c8fd9cc243df78dc12cb94c579d6942c257b0949571d1211c91bc7728", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results. ", "start_char_idx": 0, "end_char_idx": 192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77fbd534-60f5-45d2-ac10-cda069dc5c64": {"__data__": {"id_": "77fbd534-60f5-45d2-ac10-cda069dc5c64", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n", "original_text": "This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55f51ea6-54d3-4d49-9a53-d678083ddec5", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n", "original_text": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c91b4315bf7d60e83d0d5726f723be6a745f4cb20f8a9c4b3141316cd0c4bcc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a4ac9a1-683a-4339-882c-e44e8185e831", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.  ", "original_text": "Now, turning to the balance sheet . \n \n"}, "hash": "a8bb9f29f580d1a9babddb030ad6ccb3fca8e96bcb2f68b8951e7d5c08cdbed0", "class_name": "RelatedNodeInfo"}}, "text": "This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n", "start_char_idx": 192, "end_char_idx": 309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a4ac9a1-683a-4339-882c-e44e8185e831": {"__data__": {"id_": "5a4ac9a1-683a-4339-882c-e44e8185e831", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.  ", "original_text": "Now, turning to the balance sheet . \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77fbd534-60f5-45d2-ac10-cda069dc5c64", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n", "original_text": "This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6bc68f2ef86b564db761819d1bbac289e1050e56d36140c1ca138b390835163f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "874cac7f-2c4b-41c2-bef6-18eb519119d8", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.  ", "original_text": "As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n"}, "hash": "edef26b5bcd82ad14fda5e765109e50948eb5bee81011ee9997779b606ba7604", "class_name": "RelatedNodeInfo"}}, "text": "Now, turning to the balance sheet . \n \n", "start_char_idx": 309, "end_char_idx": 348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "874cac7f-2c4b-41c2-bef6-18eb519119d8": {"__data__": {"id_": "874cac7f-2c4b-41c2-bef6-18eb519119d8", "embedding": null, "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.  ", "original_text": "As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a4ac9a1-683a-4339-882c-e44e8185e831", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.  ", "original_text": "Now, turning to the balance sheet . \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a926846f1d5da950230b04996ae77e4923991b4764dcedea9465c8a732c9efd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ae05320-5489-4436-b35e-e8bff9486dd5", "node_type": "1", "metadata": {"window": "This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2. ", "original_text": "We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n"}, "hash": "ee57b40890656c74ab5fba42ff8416144528abef808458017c66474a6f4c101c", "class_name": "RelatedNodeInfo"}}, "text": "As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n", "start_char_idx": 348, "end_char_idx": 518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ae05320-5489-4436-b35e-e8bff9486dd5": {"__data__": {"id_": "5ae05320-5489-4436-b35e-e8bff9486dd5", "embedding": null, "metadata": {"window": "This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2. ", "original_text": "We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "874cac7f-2c4b-41c2-bef6-18eb519119d8", "node_type": "1", "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.  ", "original_text": "As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50ace052b03ccd7eed1239943c245d2af664e267f7a200d8207d63a8e2923319", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e07d468c-235b-4496-9170-fa9665351dd5", "node_type": "1", "metadata": {"window": "Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n", "original_text": "In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.  "}, "hash": "107aafe6d5c108874519a35c17ec233665b2836739392defb2f5019f059254da", "class_name": "RelatedNodeInfo"}}, "text": "We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n", "start_char_idx": 518, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e07d468c-235b-4496-9170-fa9665351dd5": {"__data__": {"id_": "e07d468c-235b-4496-9170-fa9665351dd5", "embedding": null, "metadata": {"window": "Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n", "original_text": "In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.  ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ae05320-5489-4436-b35e-e8bff9486dd5", "node_type": "1", "metadata": {"window": "This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2. ", "original_text": "We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7adca0d1e4c4c7e4492235ecc04297e1702f49be9c403d09b50d131e3027cf38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17c8732f-eb80-4700-98db-df9248430876", "node_type": "1", "metadata": {"window": "As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n", "original_text": "We m ade our \nthird annual payment on our national opioid settlement obligation.  "}, "hash": "7826b4a5231fd1de4d63565841186d15682907c45e4df21c4cd8a413c8f0fa3c", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.  ", "start_char_idx": 657, "end_char_idx": 842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17c8732f-eb80-4700-98db-df9248430876": {"__data__": {"id_": "17c8732f-eb80-4700-98db-df9248430876", "embedding": null, "metadata": {"window": "As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n", "original_text": "We m ade our \nthird annual payment on our national opioid settlement obligation.  ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e07d468c-235b-4496-9170-fa9665351dd5", "node_type": "1", "metadata": {"window": "Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n", "original_text": "In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.  ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6926731fa73e35eb95bab81b6e9a12d9116a9100d127d0c790ea331fd3f4b33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bf0fae0-0b22-4291-854e-a94a8da484b3", "node_type": "1", "metadata": {"window": "We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results. ", "original_text": "We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2. "}, "hash": "282ea4ff453e8c46b9bb2cc0e790bb37029663fb6b15ed38aae85d7950f9c1dc", "class_name": "RelatedNodeInfo"}}, "text": "We m ade our \nthird annual payment on our national opioid settlement obligation.  ", "start_char_idx": 842, "end_char_idx": 924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bf0fae0-0b22-4291-854e-a94a8da484b3": {"__data__": {"id_": "1bf0fae0-0b22-4291-854e-a94a8da484b3", "embedding": null, "metadata": {"window": "We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results. ", "original_text": "We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17c8732f-eb80-4700-98db-df9248430876", "node_type": "1", "metadata": {"window": "As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n", "original_text": "We m ade our \nthird annual payment on our national opioid settlement obligation.  ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d3743a5da5c492de7605de02855da9b5bd8fb4e9f4b4f9a9aa0b8ddd075047c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f88f2da-8b9b-42d0-bdd6-c417b303449b", "node_type": "1", "metadata": {"window": "In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n", "original_text": "We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n"}, "hash": "c67c212cc6b59fa12581c39103ecc05abc612875c93e24eafe90b8a0645da6a7", "class_name": "RelatedNodeInfo"}}, "text": "We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2. ", "start_char_idx": 924, "end_char_idx": 1086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f88f2da-8b9b-42d0-bdd6-c417b303449b": {"__data__": {"id_": "5f88f2da-8b9b-42d0-bdd6-c417b303449b", "embedding": null, "metadata": {"window": "In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n", "original_text": "We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bf0fae0-0b22-4291-854e-a94a8da484b3", "node_type": "1", "metadata": {"window": "We remain focused on doing what we said we would, and deploying capital in a balanced, disciplined, \nand shareholder -friendly manner.  \n \n In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results. ", "original_text": "We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1163f4703eb26c21d37e49dc921e58597fc1477b0a5f19b0649af83230ef4d9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f27c981-74b0-42a6-a24c-65957aa1ab22", "node_type": "1", "metadata": {"window": "We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business. ", "original_text": "Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n"}, "hash": "e30b04571c6f4cbf4693dfee83cd4f1b159ab4419635c0e0169567aea72359b0", "class_name": "RelatedNodeInfo"}}, "text": "We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n", "start_char_idx": 1086, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f27c981-74b0-42a6-a24c-65957aa1ab22": {"__data__": {"id_": "6f27c981-74b0-42a6-a24c-65957aa1ab22", "embedding": null, "metadata": {"window": "We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business. ", "original_text": "Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f88f2da-8b9b-42d0-bdd6-c417b303449b", "node_type": "1", "metadata": {"window": "In the first quarter, we  continued to invest against our highest priorities, including investing \napproximately $92 million of capex back into the businesses to drive organic growth.   We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n", "original_text": "We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fae16f8f616e7249ac456681f883dc5b680665b33f01703712497ba3911e47c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc4febb9-7397-42ef-bd13-d9d3e6d80442", "node_type": "1", "metadata": {"window": "We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n", "original_text": "Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results. "}, "hash": "3a880e8d48178e9cf8fc7dc034f97e537c370b27f22c5b006be0c3e2d427a45f", "class_name": "RelatedNodeInfo"}}, "text": "Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n", "start_char_idx": 1278, "end_char_idx": 1335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc4febb9-7397-42ef-bd13-d9d3e6d80442": {"__data__": {"id_": "fc4febb9-7397-42ef-bd13-d9d3e6d80442", "embedding": null, "metadata": {"window": "We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n", "original_text": "Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f27c981-74b0-42a6-a24c-65957aa1ab22", "node_type": "1", "metadata": {"window": "We m ade our \nthird annual payment on our national opioid settlement obligation.   We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business. ", "original_text": "Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d409429fecf7ae65ac20e936f8a286c04ac7f8bcea591d80c2d1d500e3330fb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "703cc76a-f348-4b59-acac-befb17fa8751", "node_type": "1", "metadata": {"window": "We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n", "original_text": "This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n"}, "hash": "a66799ccfb6e3c7305546bfeb2d22c46500985e161b32e25cb0af3405140e69d", "class_name": "RelatedNodeInfo"}}, "text": "Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results. ", "start_char_idx": 1335, "end_char_idx": 1482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "703cc76a-f348-4b59-acac-befb17fa8751": {"__data__": {"id_": "703cc76a-f348-4b59-acac-befb17fa8751", "embedding": null, "metadata": {"window": "We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n", "original_text": "This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc4febb9-7397-42ef-bd13-d9d3e6d80442", "node_type": "1", "metadata": {"window": "We d id not draw on our credit \nfacilities and  received a positive change to the outlook  on our investment grade rating from Fitch, as \nwell as from S&P in Q2.  We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n", "original_text": "Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1d55eaf17c2e695a817a80497c7e4234f1b9fadecc4f1a1d65dc8d71e81b2ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07a05c2b-abc2-4435-b3fb-fd7edc4f4388", "node_type": "1", "metadata": {"window": "Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year. ", "original_text": "We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business. "}, "hash": "701b7fa12a978f685b4f9860cd22b6c322389768178c36257f33ab62bbce021e", "class_name": "RelatedNodeInfo"}}, "text": "This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n", "start_char_idx": 1482, "end_char_idx": 1626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07a05c2b-abc2-4435-b3fb-fd7edc4f4388": {"__data__": {"id_": "07a05c2b-abc2-4435-b3fb-fd7edc4f4388", "embedding": null, "metadata": {"window": "Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year. ", "original_text": "We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "703cc76a-f348-4b59-acac-befb17fa8751", "node_type": "1", "metadata": {"window": "We r eturned over $630 million to shareholders, through payment of our \nquarterly dividend and t he launch of a new $500M Accelerated Share Repurchase Program which \ncompleted in October.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n", "original_text": "This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68134093d897fa80439d7253cb7ef7e61c73d9c1da57d2ff8c04166c359debe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af05461d-b1c8-411b-bd76-a49c360dbdbc", "node_type": "1", "metadata": {"window": "Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted. ", "original_text": "Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n"}, "hash": "dad6746c6d218a8c442fe5297f1190f405eeb4a33d86791414e8b0c85d215e5e", "class_name": "RelatedNodeInfo"}}, "text": "We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business. ", "start_char_idx": 1626, "end_char_idx": 1758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af05461d-b1c8-411b-bd76-a49c360dbdbc": {"__data__": {"id_": "af05461d-b1c8-411b-bd76-a49c360dbdbc", "embedding": null, "metadata": {"window": "Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted. ", "original_text": "Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07a05c2b-abc2-4435-b3fb-fd7edc4f4388", "node_type": "1", "metadata": {"window": "Now, for our updated fiscal \u201824 guidance on slide 8.  \n \n Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year. ", "original_text": "We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d1381c034bdc49de968168244ac2c5d4d689146f852d8f871b2a10394a94087", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4b893b8-b5aa-4c30-aebe-9bc005703481", "node_type": "1", "metadata": {"window": "This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged. ", "original_text": "Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n"}, "hash": "519fbfb52ded06ab15b6875cd93fc29bbe6936a6145cc00afaf929cbc7048600", "class_name": "RelatedNodeInfo"}}, "text": "Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n", "start_char_idx": 1758, "end_char_idx": 2071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4b893b8-b5aa-4c30-aebe-9bc005703481": {"__data__": {"id_": "f4b893b8-b5aa-4c30-aebe-9bc005703481", "embedding": null, "metadata": {"window": "This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged. ", "original_text": "Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af05461d-b1c8-411b-bd76-a49c360dbdbc", "node_type": "1", "metadata": {"window": "Today, we are raising our fiscal \u2018 24 EPS guidance to a range of $6.75 to $7.00, the mid -point of which \nis 19% above our fiscal \u201823 EPS results.  This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted. ", "original_text": "Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d98f49d6d4152d2ce8e74afa4ff66c24f32f8ea2fe159f6910983d36518db991", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3dec6d5-e9ee-4dfc-8557-2dca7ec3ad19", "node_type": "1", "metadata": {"window": "We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n", "original_text": "In Medical, we are reiterating our outlook of $400  million  of segment profit for the year. "}, "hash": "dffea646c24d2b09f320586b344757619ba37915b40020fc6b81e78bde060867", "class_name": "RelatedNodeInfo"}}, "text": "Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n", "start_char_idx": 2071, "end_char_idx": 2213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3dec6d5-e9ee-4dfc-8557-2dca7ec3ad19": {"__data__": {"id_": "e3dec6d5-e9ee-4dfc-8557-2dca7ec3ad19", "embedding": null, "metadata": {"window": "We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n", "original_text": "In Medical, we are reiterating our outlook of $400  million  of segment profit for the year. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4b893b8-b5aa-4c30-aebe-9bc005703481", "node_type": "1", "metadata": {"window": "This $0.25 increase to our EPS range primarily reflects an \nimprovement to our Pharma outlook, as well as some improvements below the line.  \n \n We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged. ", "original_text": "Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d778bfee3c1704f85c046de8ce467526d61b8bd343850b5b1ecd3684b1570a3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb82fb8f-1ec7-45c7-9570-ae0bc7968cad", "node_type": "1", "metadata": {"window": "Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness. ", "original_text": "Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted. "}, "hash": "646c42b17c2ba9829e478c1bb89283338d0e6c68c7bd93fa77f6e0308e01e724", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, we are reiterating our outlook of $400  million  of segment profit for the year. ", "start_char_idx": 2213, "end_char_idx": 2306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb82fb8f-1ec7-45c7-9570-ae0bc7968cad": {"__data__": {"id_": "fb82fb8f-1ec7-45c7-9570-ae0bc7968cad", "embedding": null, "metadata": {"window": "Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness. ", "original_text": "Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3dec6d5-e9ee-4dfc-8557-2dca7ec3ad19", "node_type": "1", "metadata": {"window": "We are raising our Pharma segment profit guide to 7% to 9% growth for the year and  are pleased \nwith the momentum in the business.  Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n", "original_text": "In Medical, we are reiterating our outlook of $400  million  of segment profit for the year. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "594a354ddf5776f806cac0c8c34eb09104de037171cda96f6c7648514bea9db9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bb13edc-7714-466d-b454-3988e2f8e6c7", "node_type": "1", "metadata": {"window": "Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "That \nassumption remains unchanged. "}, "hash": "443b24ee3ff908882ea698f86acb67d2f110eaba40eded04e147d9e53e6b8935", "class_name": "RelatedNodeInfo"}}, "text": "Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted. ", "start_char_idx": 2306, "end_char_idx": 2412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bb13edc-7714-466d-b454-3988e2f8e6c7": {"__data__": {"id_": "6bb13edc-7714-466d-b454-3988e2f8e6c7", "embedding": null, "metadata": {"window": "Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "That \nassumption remains unchanged. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb82fb8f-1ec7-45c7-9570-ae0bc7968cad", "node_type": "1", "metadata": {"window": "Our updated guidance reflects : the strong first quarter \nperformance , higher than originally assumed contributions from COVID -19 vaccine distribution, which \ncontinued into Octobe r, the ongoing strength of our business  consistent with a 4% to 6% growth \ntrajectory for the segment on a normalized basis.  \n \n Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness. ", "original_text": "Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6f4faf085ff83dc4700b7820d9823deee1e57e290a7fa5f662d74ebb91ec3ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "229c7720-91f7-4d1b-a030-c5fdc6865767", "node_type": "1", "metadata": {"window": "In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n"}, "hash": "948193225e9ea760225d50d3202c6aa4f3b124868fa3279f2d6f1ee06c8b1b50", "class_name": "RelatedNodeInfo"}}, "text": "That \nassumption remains unchanged. ", "start_char_idx": 2412, "end_char_idx": 2448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "229c7720-91f7-4d1b-a030-c5fdc6865767": {"__data__": {"id_": "229c7720-91f7-4d1b-a030-c5fdc6865767", "embedding": null, "metadata": {"window": "In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bb13edc-7714-466d-b454-3988e2f8e6c7", "node_type": "1", "metadata": {"window": "Finally, as a reminder on the Pharma quarterly cadence, we continue to assume Q3 branded inflation \nwill not repeat at fiscal \u201823 levels.  \n \n In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "That \nassumption remains unchanged. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad4ef9b5ae6de37362e71c409b5eec5eb13602d5716a39ad27d816d6e3795176", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28c868cf-96b6-44a7-a548-ea2ee14f7b93", "node_type": "1", "metadata": {"window": "Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness. "}, "hash": "1bd16dd7e9ac8c8ac5be44164c9c3bbfd8ca5529a942d61e5a93fe8dbd2246be", "class_name": "RelatedNodeInfo"}}, "text": "The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n", "start_char_idx": 2448, "end_char_idx": 2654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28c868cf-96b6-44a7-a548-ea2ee14f7b93": {"__data__": {"id_": "28c868cf-96b6-44a7-a548-ea2ee14f7b93", "embedding": null, "metadata": {"window": "Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "229c7720-91f7-4d1b-a030-c5fdc6865767", "node_type": "1", "metadata": {"window": "In Medical, we are reiterating our outlook of $400  million  of segment profit for the year.  Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a25cb15abbfdfbf9bad1b86a68d3b658a06d350d3eeb71c9bc04282ff210939", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f15a560-06f7-440d-9af5-4879293c57ec", "node_type": "1", "metadata": {"window": "That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "Altogether , Q2 segment profit should be slightly higher than Q1, "}, "hash": "b6a1c84d2f66101b310f29e21194d4a1ed075b1fd444a25fd6b51b2e2d1ae0e4", "class_name": "RelatedNodeInfo"}}, "text": "While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness. ", "start_char_idx": 2654, "end_char_idx": 2987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f15a560-06f7-440d-9af5-4879293c57ec": {"__data__": {"id_": "7f15a560-06f7-440d-9af5-4879293c57ec", "embedding": null, "metadata": {"window": "That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "Altogether , Q2 segment profit should be slightly higher than Q1, ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b12326deb6c3d9bfbb409496b0818acf9e18929d4c4d88f73a70893a887e1468", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28c868cf-96b6-44a7-a548-ea2ee14f7b93", "node_type": "1", "metadata": {"window": "Recall that we \npreviously guided that Medical segment profit would be significantly back -half weighted.  That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8070e4c6f13a7b5cfb96e4cdeeebc0cbe26ea2e73ccbd678fc14c279a5978c54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63de44cc-ebb5-4ed3-99f8-4f73cee2f0ee", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n", "original_text": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery. "}, "hash": "f8239d170e668bcb6152787c65aa3638d9d98589a67a7f877b8a1e498f805a51", "class_name": "RelatedNodeInfo"}}, "text": "Altogether , Q2 segment profit should be slightly higher than Q1, ", "start_char_idx": 2987, "end_char_idx": 3053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63de44cc-ebb5-4ed3-99f8-4f73cee2f0ee": {"__data__": {"id_": "63de44cc-ebb5-4ed3-99f8-4f73cee2f0ee", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n", "original_text": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f15a560-06f7-440d-9af5-4879293c57ec", "node_type": "1", "metadata": {"window": "That \nassumption remains unchanged.  The first half -second half cadence continues to be driven by \nprogress on Cardinal He alth Brand volume growth, the cumulative impact of inflation mitigation, and \nsome business -specific seasonality.  \n \n While we are encouraged that the business slightly over -performed relative to our expectation in Q1, \ndue to execution against our plans and our cost management efforts, our expectation for Q2 segment \nprofit is unchanged from our original guidance which ref lected some seasonality in Q2 specific \nexpenses like Health & Wellness.  Altogether , Q2 segment profit should be slightly higher than Q1, ", "original_text": "Altogether , Q2 segment profit should be slightly higher than Q1, ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41352204fb52e6651ea43e6f663f2de8c2a155bdc419aa7d7643ad392f142298", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37971da2-8838-4c6e-9742-40d468b42c34", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n", "original_text": "We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n"}, "hash": "b649dbada65763a467fd972f789f0f621be510a3bba0fbd7af9c06606a0d75a9", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery. ", "start_char_idx": 0, "end_char_idx": 56, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37971da2-8838-4c6e-9742-40d468b42c34": {"__data__": {"id_": "37971da2-8838-4c6e-9742-40d468b42c34", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n", "original_text": "We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63de44cc-ebb5-4ed3-99f8-4f73cee2f0ee", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n", "original_text": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93ec584aee6faafd51de815459a0f90b25c60faa44459198cd218886ee204aa2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ac4250a-30e8-4e90-94ef-2e7e86cfc5f7", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase . ", "original_text": "Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%. "}, "hash": "a477b23b7e67672a8fe376bbb4ad35261feb3f6100832f47cba80d6a1708a469", "class_name": "RelatedNodeInfo"}}, "text": "We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n", "start_char_idx": 56, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ac4250a-30e8-4e90-94ef-2e7e86cfc5f7": {"__data__": {"id_": "6ac4250a-30e8-4e90-94ef-2e7e86cfc5f7", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase . ", "original_text": "Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37971da2-8838-4c6e-9742-40d468b42c34", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n", "original_text": "We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99e1d4b01200e5bcc0ce35cbe47292f8128bb98655cc4aefbd9b0dd1fd6294d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4ecdd8e-b7d5-4032-b8eb-71eb91c60c82", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n", "original_text": "We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n"}, "hash": "6e444c94051d9c249ee84b5eabe1c547608142dc17d9f8fe71c5062a78ab80c7", "class_name": "RelatedNodeInfo"}}, "text": "Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%. ", "start_char_idx": 165, "end_char_idx": 333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4ecdd8e-b7d5-4032-b8eb-71eb91c60c82": {"__data__": {"id_": "b4ecdd8e-b7d5-4032-b8eb-71eb91c60c82", "embedding": null, "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n", "original_text": "We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ac4250a-30e8-4e90-94ef-2e7e86cfc5f7", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase . ", "original_text": "Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12dbdda09948bfb3dc1abc201b9323332f7afc3ff71fde2ee92f4778a8479e17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dead4661-a24d-4345-9a77-1ffcde33f512", "node_type": "1", "metadata": {"window": "We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter. ", "original_text": "We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n"}, "hash": "9298e61975b176eb7dec7c4436eab4d044ecd32c88c668b820b822a62b80f7a8", "class_name": "RelatedNodeInfo"}}, "text": "We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n", "start_char_idx": 333, "end_char_idx": 420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dead4661-a24d-4345-9a77-1ffcde33f512": {"__data__": {"id_": "dead4661-a24d-4345-9a77-1ffcde33f512", "embedding": null, "metadata": {"window": "We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter. ", "original_text": "We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4ecdd8e-b7d5-4032-b8eb-71eb91c60c82", "node_type": "1", "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n", "original_text": "We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28e7b2a40853db4ca4c8a1c6db7bffb43309c712a8149f8e32f4b7d250b1b0bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35f6a5ff-398a-49c9-8535-6083d62d66e5", "node_type": "1", "metadata": {"window": "Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments . ", "original_text": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase . "}, "hash": "0ce9f7af7d4f6d45841641da5c20769cadaf4b339100a7e00b363a3e1ee73509", "class_name": "RelatedNodeInfo"}}, "text": "We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n", "start_char_idx": 420, "end_char_idx": 575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35f6a5ff-398a-49c9-8535-6083d62d66e5": {"__data__": {"id_": "35f6a5ff-398a-49c9-8535-6083d62d66e5", "embedding": null, "metadata": {"window": "Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments . ", "original_text": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase . ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dead4661-a24d-4345-9a77-1ffcde33f512", "node_type": "1", "metadata": {"window": "We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter. ", "original_text": "We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "beb7775ec50d3cfdebf334a1f5000b27b06bf80a759631085a2c6c4e7b36441c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "670c18d8-1d5c-4140-8369-3753da40c908", "node_type": "1", "metadata": {"window": "We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us. ", "original_text": "We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n"}, "hash": "78556f4530702809cf25a07ee39b28abb46a56bb7496ec2452e90e19dac9e964", "class_name": "RelatedNodeInfo"}}, "text": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase . ", "start_char_idx": 575, "end_char_idx": 862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "670c18d8-1d5c-4140-8369-3753da40c908": {"__data__": {"id_": "670c18d8-1d5c-4140-8369-3753da40c908", "embedding": null, "metadata": {"window": "We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us. ", "original_text": "We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35f6a5ff-398a-49c9-8535-6083d62d66e5", "node_type": "1", "metadata": {"window": "Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments . ", "original_text": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase . ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d19862b9500e690c4f64e8c56f55d51139b636a12c0d40763da687d210c353df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "403d8ee1-980b-4732-b14e-18ccb77c7dec", "node_type": "1", "metadata": {"window": "We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n", "original_text": "So, an overall successful first quarter. "}, "hash": "60b3031b59b6be59059b5bec0179556a7b60d9da5dbbcafa2f52e0ea73dc4990", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n", "start_char_idx": 862, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "403d8ee1-980b-4732-b14e-18ccb77c7dec": {"__data__": {"id_": "403d8ee1-980b-4732-b14e-18ccb77c7dec", "embedding": null, "metadata": {"window": "We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n", "original_text": "So, an overall successful first quarter. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "670c18d8-1d5c-4140-8369-3753da40c908", "node_type": "1", "metadata": {"window": "We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us. ", "original_text": "We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2ed25301a0db1ae152fd3c5c552fde75a952ae0b6a52536af34f5ac3b8e8c3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb89fbe7-4b93-483f-9b36-1f1bf358a509", "node_type": "1", "metadata": {"window": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron . ", "original_text": "The Cardinal Team has a lot of be proud of with respect to our \naccomplishments . "}, "hash": "c836abd0a5c60e51c9a5bd817ac7851129f9b31a0b92063a832a2ad0c04813a5", "class_name": "RelatedNodeInfo"}}, "text": "So, an overall successful first quarter. ", "start_char_idx": 946, "end_char_idx": 987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb89fbe7-4b93-483f-9b36-1f1bf358a509": {"__data__": {"id_": "eb89fbe7-4b93-483f-9b36-1f1bf358a509", "embedding": null, "metadata": {"window": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron . ", "original_text": "The Cardinal Team has a lot of be proud of with respect to our \naccomplishments . ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "403d8ee1-980b-4732-b14e-18ccb77c7dec", "node_type": "1", "metadata": {"window": "We also are lowering our shares outlook to approximately 249 million, which reflects the already -\ncompleted $500M of our baseline share repurchase .   \n \n I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n", "original_text": "So, an overall successful first quarter. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a13fe78f046362665824f75acc4af67165e69088a387ccee0d6ad15c3918275c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "506f6454-72e4-45c3-8e81-59009d0ae286", "node_type": "1", "metadata": {"window": "We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n", "original_text": "We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us. "}, "hash": "0e66fd00b23f422021018ab92c0a7b2847b310fcca690360f79b0b683c6de8ab", "class_name": "RelatedNodeInfo"}}, "text": "The Cardinal Team has a lot of be proud of with respect to our \naccomplishments . ", "start_char_idx": 987, "end_char_idx": 1069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "506f6454-72e4-45c3-8e81-59009d0ae286": {"__data__": {"id_": "506f6454-72e4-45c3-8e81-59009d0ae286", "embedding": null, "metadata": {"window": "We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n", "original_text": "We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb89fbe7-4b93-483f-9b36-1f1bf358a509", "node_type": "1", "metadata": {"window": "I want to reiterate that as we shared at Investor Day, neither our fiscal \u201824 guidance nor our long -term \ntargets reflect M&A, which is difficult to predict in timing or magnitude, or additional opportunistic \ndeployment of capital to share repurchases beyond our baseline repurchase .  We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron . ", "original_text": "The Cardinal Team has a lot of be proud of with respect to our \naccomplishments . ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "340970a69d95b4485bd1f3fb731ef9112f517f5cd653dea9faa1c491cf81d9be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b07b5ae-c82e-4091-914a-cd3171b6636c", "node_type": "1", "metadata": {"window": "So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n", "original_text": "With that, I will turn it back over to \nJason.  \n \n"}, "hash": "c6d4e2323073ad847b6cec4fb4976dd7a81e930af91b884041452b754b7931ce", "class_name": "RelatedNodeInfo"}}, "text": "We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us. ", "start_char_idx": 1069, "end_char_idx": 1229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b07b5ae-c82e-4091-914a-cd3171b6636c": {"__data__": {"id_": "4b07b5ae-c82e-4091-914a-cd3171b6636c", "embedding": null, "metadata": {"window": "So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n", "original_text": "With that, I will turn it back over to \nJason.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "506f6454-72e4-45c3-8e81-59009d0ae286", "node_type": "1", "metadata": {"window": "We will continue to \nevaluate both opportunistically to drive long -term value.  \n \n So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n", "original_text": "We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2dff489dd15d731bba76b7c256eb400d1913b67dc746c6a8b89da185655649b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f490209-183e-4ae4-80d0-c57ef81aa8d0", "node_type": "1", "metadata": {"window": "The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n", "original_text": "Jason Hollar:  Thanks  Aaron . "}, "hash": "2d8605fbb269d4c234632a7c4055745963271eac22bd89f9536107f305cadead", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will turn it back over to \nJason.  \n \n", "start_char_idx": 1229, "end_char_idx": 1280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f490209-183e-4ae4-80d0-c57ef81aa8d0": {"__data__": {"id_": "0f490209-183e-4ae4-80d0-c57ef81aa8d0", "embedding": null, "metadata": {"window": "The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n", "original_text": "Jason Hollar:  Thanks  Aaron . ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b07b5ae-c82e-4091-914a-cd3171b6636c", "node_type": "1", "metadata": {"window": "So, an overall successful first quarter.  The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n", "original_text": "With that, I will turn it back over to \nJason.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8f5ecd02be91ac671647378046e950cd1fbc3cdbd589e7a79e602c993ab6c25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14c74394-8e52-411c-8d4e-2e6bbdf48f63", "node_type": "1", "metadata": {"window": "We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component. ", "original_text": "Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n"}, "hash": "fd47683a964bddb2570773100bd0f9e3c3703c3257aa586fa31337388428b275", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks  Aaron . ", "start_char_idx": 1280, "end_char_idx": 1311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14c74394-8e52-411c-8d4e-2e6bbdf48f63": {"__data__": {"id_": "14c74394-8e52-411c-8d4e-2e6bbdf48f63", "embedding": null, "metadata": {"window": "We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component. ", "original_text": "Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f490209-183e-4ae4-80d0-c57ef81aa8d0", "node_type": "1", "metadata": {"window": "The Cardinal Team has a lot of be proud of with respect to our \naccomplishments .  We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n", "original_text": "Jason Hollar:  Thanks  Aaron . ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea0c46b58969e678afa52b6ecab2aaf3c14f9a2a526d8173adeacaadd0c75f0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54cd75b9-632e-4184-9c8a-cb08dad080c2", "node_type": "1", "metadata": {"window": "With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n", "original_text": "The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n"}, "hash": "b17cd5c7266758ba1d488bad74acc109f2dae9cd0e9cb212b40c469354426fc4", "class_name": "RelatedNodeInfo"}}, "text": "Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n", "start_char_idx": 1311, "end_char_idx": 1502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54cd75b9-632e-4184-9c8a-cb08dad080c2": {"__data__": {"id_": "54cd75b9-632e-4184-9c8a-cb08dad080c2", "embedding": null, "metadata": {"window": "With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n", "original_text": "The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14c74394-8e52-411c-8d4e-2e6bbdf48f63", "node_type": "1", "metadata": {"window": "We are confident in the plans we have in place,  and we are excited for our team to \nrealize the significant value creation opportunities still in front of us.  With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component. ", "original_text": "Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4f03a1ebb282ef957a47f12a77b3f0dd4fa9e521a5c7e3d6ed1d741b76406d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0613dd19-cf56-4ce4-a613-6f664e7ca53e", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products. ", "original_text": "We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n"}, "hash": "e7237cbaa50aa186d43e48e179f9a1617c1b389868dcec81ec36d55ec582d11c", "class_name": "RelatedNodeInfo"}}, "text": "The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n", "start_char_idx": 1502, "end_char_idx": 1703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0613dd19-cf56-4ce4-a613-6f664e7ca53e": {"__data__": {"id_": "0613dd19-cf56-4ce4-a613-6f664e7ca53e", "embedding": null, "metadata": {"window": "Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products. ", "original_text": "We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54cd75b9-632e-4184-9c8a-cb08dad080c2", "node_type": "1", "metadata": {"window": "With that, I will turn it back over to \nJason.  \n \n Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n", "original_text": "The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcef4e3a74daab3090c7b71e72615ba86539f2e008cf8eda67bfbd962469e9d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66ddbf86-6c11-4e14-8313-db4f02bb67c2", "node_type": "1", "metadata": {"window": "Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season. ", "original_text": "Within the core, our generics program remains a critical component. "}, "hash": "2d56099e313c46f9be9b53733f9b2d2a7a4e8e375c0d20cbd757152c7e8d91e1", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n", "start_char_idx": 1703, "end_char_idx": 1855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66ddbf86-6c11-4e14-8313-db4f02bb67c2": {"__data__": {"id_": "66ddbf86-6c11-4e14-8313-db4f02bb67c2", "embedding": null, "metadata": {"window": "Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season. ", "original_text": "Within the core, our generics program remains a critical component. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0613dd19-cf56-4ce4-a613-6f664e7ca53e", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks  Aaron .  Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products. ", "original_text": "We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "309e7d31bada4dc8773ad4704957e60f8e3c5319ddc580865a346fcd4f392df5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ee855b9-d5a9-45ba-a037-cdf945452157", "node_type": "1", "metadata": {"window": "The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n", "original_text": "Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n"}, "hash": "0bd5bf2d21be6301f4b24c281f59aaf682bb27b18837eb16c5c59c224dd0d9d9", "class_name": "RelatedNodeInfo"}}, "text": "Within the core, our generics program remains a critical component. ", "start_char_idx": 1855, "end_char_idx": 1923, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ee855b9-d5a9-45ba-a037-cdf945452157": {"__data__": {"id_": "7ee855b9-d5a9-45ba-a037-cdf945452157", "embedding": null, "metadata": {"window": "The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n", "original_text": "Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66ddbf86-6c11-4e14-8313-db4f02bb67c2", "node_type": "1", "metadata": {"window": "Now, for a few updates regarding our recent progress on our three key  \nstrategic priorities, beginning with priority number one  and building upon the resiliency of the Pharma \nsegment . \n \n The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season. ", "original_text": "Within the core, our generics program remains a critical component. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "566c1922719a6f360413bb25faa6e709d8279174c2496ec2a7dd380952300300", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a3afda5-e6c8-4011-b7d6-45bd9080c33f", "node_type": "1", "metadata": {"window": "We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference. ", "original_text": "I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products. "}, "hash": "a232a26cd627de58788bee91aebf69f22c42bfec886a0c81eb478c6c8017c78c", "class_name": "RelatedNodeInfo"}}, "text": "Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n", "start_char_idx": 1923, "end_char_idx": 2126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a3afda5-e6c8-4011-b7d6-45bd9080c33f": {"__data__": {"id_": "3a3afda5-e6c8-4011-b7d6-45bd9080c33f", "embedding": null, "metadata": {"window": "We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference. ", "original_text": "I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ee855b9-d5a9-45ba-a037-cdf945452157", "node_type": "1", "metadata": {"window": "The key enabler to the Pharma business\u2019s outstanding performance over a number of quarters now \nhas been the team\u2019s consistent prioritization of what matters most , operational execution in the core. \n We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n", "original_text": "Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e28046c8f818befc1a37481db68eb175f7efd6cf7e4b432dee5935ad854f2809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91100f83-3111-42b8-a325-bc9f0377c6db", "node_type": "1", "metadata": {"window": "Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene. ", "original_text": "Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season. "}, "hash": "939d7d0e2319a88cb743bbe132315407ef7637c65c66db74373b6cc148a3d80f", "class_name": "RelatedNodeInfo"}}, "text": "I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products. ", "start_char_idx": 2126, "end_char_idx": 2447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91100f83-3111-42b8-a325-bc9f0377c6db": {"__data__": {"id_": "91100f83-3111-42b8-a325-bc9f0377c6db", "embedding": null, "metadata": {"window": "Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene. ", "original_text": "Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a3afda5-e6c8-4011-b7d6-45bd9080c33f", "node_type": "1", "metadata": {"window": "We\u2019re leveraging our scale, efficiency and breadth of essential products and service capabilities to \ndeliver for our customers and their patients.  \n \n Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference. ", "original_text": "I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5dd7ffca5482debff1c077035e0160afed12d4bb544a4a05c4c8f1fc8d017f16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0957c6d3-3aad-4e92-8add-e82e704aeb45", "node_type": "1", "metadata": {"window": "Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n"}, "hash": "0dbd4bcb2ec837aa7a8eb9220d3a4a1038c8760ddea15baf6bbbf060adb1ae11", "class_name": "RelatedNodeInfo"}}, "text": "Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season. ", "start_char_idx": 2447, "end_char_idx": 2672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0957c6d3-3aad-4e92-8add-e82e704aeb45": {"__data__": {"id_": "0957c6d3-3aad-4e92-8add-e82e704aeb45", "embedding": null, "metadata": {"window": "Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91100f83-3111-42b8-a325-bc9f0377c6db", "node_type": "1", "metadata": {"window": "Within the core, our generics program remains a critical component.  Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene. ", "original_text": "Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58a96f06250cc809faee9ac7b5332561050ccfe1f7af394c80c80e7ef674dc04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f0719b0-e391-46bb-b1ea-49c324d4bc6c", "node_type": "1", "metadata": {"window": "I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference. "}, "hash": "b0abc3cd32529296783d1bf2e5856f6c62516ad77944dd5d6a674ed38545a86d", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n", "start_char_idx": 2672, "end_char_idx": 2800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f0719b0-e391-46bb-b1ea-49c324d4bc6c": {"__data__": {"id_": "3f0719b0-e391-46bb-b1ea-49c324d4bc6c", "embedding": null, "metadata": {"window": "I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0957c6d3-3aad-4e92-8add-e82e704aeb45", "node_type": "1", "metadata": {"window": "Our performance is anchored by \nRed Oak Sourcing, which continues to do a fantastic job fulfilling its dual mandate  managing both \ncost and supply , to help maximize service delivery for customers.  \n \n I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab04b75e4feacd5f476d14f863070006b0a55946a55cdb263df05a932a75b64c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6a09db3-8c70-4526-82b4-9e7ca3ac7b87", "node_type": "1", "metadata": {"window": "Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene. "}, "hash": "e4188a6e215f3f16f8863ee2a4442e5c715f56efeb1c1f219ad11efc93622b3b", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference. ", "start_char_idx": 2800, "end_char_idx": 3014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6a09db3-8c70-4526-82b4-9e7ca3ac7b87": {"__data__": {"id_": "c6a09db3-8c70-4526-82b4-9e7ca3ac7b87", "embedding": null, "metadata": {"window": "Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f0719b0-e391-46bb-b1ea-49c324d4bc6c", "node_type": "1", "metadata": {"window": "I recently saw our customer -focused mindset on display when I visited our Specialty Pharmaceutical \nDistribution facility in LaVergne, Tennessee, where our team worked extensively to prepare for \ncommercial distribution of COVID -19 vaccines, while maintainin g their terrific service for our other \nSpecialty products.  Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb0ba6ca69dfcf6be7a2618da29b1b72c8ac0283d847641ebbd9fa20add880b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03768f15-3584-4a27-8683-30ffc33e7f1c", "node_type": "1", "metadata": {"window": "We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "We are confident about our "}, "hash": "27f41a62ddf34ee2e59a2d6d56cfeb8eae437674d2860df9556dd021955a2e4a", "class_name": "RelatedNodeInfo"}}, "text": "It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene. ", "start_char_idx": 3014, "end_char_idx": 3155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03768f15-3584-4a27-8683-30ffc33e7f1c": {"__data__": {"id_": "03768f15-3584-4a27-8683-30ffc33e7f1c", "embedding": null, "metadata": {"window": "We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "We are confident about our ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe574081274b04543cd5017cfcf55b64bc2bdbb85d2bbfae57d19f6cd55bdb02", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6a09db3-8c70-4526-82b4-9e7ca3ac7b87", "node_type": "1", "metadata": {"window": "Our team successfully navigated complex cold chain requirements for the \nvaccines, enabling us to quickly meet demand and begin making shipments immediately following \nFDA approval, in time for the f all immunization season.  We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "060bc1fa4f15f7dda23eb730540680d210c33140a4e93df7fa883289cb105ccf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "433df34d-f9a1-41bd-80df-fb076c7f5aa2", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time. ", "original_text": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n"}, "hash": "78f6e39a8b7d0ed43d4129118b0d7a99dfd575d09477bcb51a5f821ca77f3135", "class_name": "RelatedNodeInfo"}}, "text": "We are confident about our ", "start_char_idx": 3155, "end_char_idx": 3182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "433df34d-f9a1-41bd-80df-fb076c7f5aa2": {"__data__": {"id_": "433df34d-f9a1-41bd-80df-fb076c7f5aa2", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time. ", "original_text": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03768f15-3584-4a27-8683-30ffc33e7f1c", "node_type": "1", "metadata": {"window": "We\u2019re pleased to support our customers in \nthis manner, which patients rely upon for care, convenience,  and accessibility.  \n \n We\u2019re committed to supporting customers and manufacturers, and our Strategic Sourcing and \nManufacturer Services team recently hosted hundreds of our supplier partners for our annual \nBusiness Partners Conference.  It was energizing to hear the excitement aro und various industry \nopportunities, such as biosimilars and emerging areas like cell and gene.  We are confident about our ", "original_text": "We are confident about our ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5af47dbc4fbd90010f134edbcf313797e67f54eb88498d78701a8d6a63e63ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "259a6bec-f3aa-46cd-aa86-da932892be4a", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence. ", "original_text": "We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space. "}, "hash": "d913cc28e7ee48710e92d938de4bc371abbd93669fcd0158ed058ee386636738", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n", "start_char_idx": 0, "end_char_idx": 170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "259a6bec-f3aa-46cd-aa86-da932892be4a": {"__data__": {"id_": "259a6bec-f3aa-46cd-aa86-da932892be4a", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence. ", "original_text": "We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "433df34d-f9a1-41bd-80df-fb076c7f5aa2", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time. ", "original_text": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "964e1deac5912f6507d6506012a4d23b83d8e8be37dfbe36b336b3669508e328", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba57c2e0-2acb-48fe-97dd-fe5cc7744d4c", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board. ", "original_text": "We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n"}, "hash": "320759ffc2b4991a22c6432534a6fe776e473ac3135956d0fb4cd8b1263ec49f", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space. ", "start_char_idx": 170, "end_char_idx": 316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba57c2e0-2acb-48fe-97dd-fe5cc7744d4c": {"__data__": {"id_": "ba57c2e0-2acb-48fe-97dd-fe5cc7744d4c", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board. ", "original_text": "We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "259a6bec-f3aa-46cd-aa86-da932892be4a", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence. ", "original_text": "We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7931e10b763314efd6fe3943ce03f9856e49744594594afb42b5d2a7620f1bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5855f92-07e3-4e75-810a-ef3eb95d66b8", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n", "original_text": "We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time. "}, "hash": "580d26469bf712a59cb712b4323f02c086bcc866cbf9dd6679cea9c169b6c293", "class_name": "RelatedNodeInfo"}}, "text": "We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n", "start_char_idx": 316, "end_char_idx": 484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5855f92-07e3-4e75-810a-ef3eb95d66b8": {"__data__": {"id_": "b5855f92-07e3-4e75-810a-ef3eb95d66b8", "embedding": null, "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n", "original_text": "We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba57c2e0-2acb-48fe-97dd-fe5cc7744d4c", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board. ", "original_text": "We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08621c53a87607462fb7f5e4ce43d148ab5e68079140b405284cc6e9a623e4f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82c0ffa5-c95d-414b-9121-eba592c313e1", "node_type": "1", "metadata": {"window": "We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics . ", "original_text": "Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence. "}, "hash": "cd88e97c1e86a5f3f6c4c9e11d319203bf50a017746b270f0cdf56a7c6cf495d", "class_name": "RelatedNodeInfo"}}, "text": "We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time. ", "start_char_idx": 484, "end_char_idx": 615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82c0ffa5-c95d-414b-9121-eba592c313e1": {"__data__": {"id_": "82c0ffa5-c95d-414b-9121-eba592c313e1", "embedding": null, "metadata": {"window": "We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics . ", "original_text": "Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5855f92-07e3-4e75-810a-ef3eb95d66b8", "node_type": "1", "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n", "original_text": "We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38bab65c2780a22c0a43e3429f696310a83c4f542da1a808b797924b78620933", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d3b84d2-e476-49ac-a95d-5717572cc4c6", "node_type": "1", "metadata": {"window": "We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners. ", "original_text": "Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board. "}, "hash": "b38f985fd7c2431def755f3852807ed9cb9beb2e5a29e3f45e8739b3048814b8", "class_name": "RelatedNodeInfo"}}, "text": "Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence. ", "start_char_idx": 615, "end_char_idx": 761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d3b84d2-e476-49ac-a95d-5717572cc4c6": {"__data__": {"id_": "3d3b84d2-e476-49ac-a95d-5717572cc4c6", "embedding": null, "metadata": {"window": "We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners. ", "original_text": "Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82c0ffa5-c95d-414b-9121-eba592c313e1", "node_type": "1", "metadata": {"window": "We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics . ", "original_text": "Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49fde1c0ea83aad0c230549cdf72ffcb58f1f299e80b7025fbe65b2339d8420e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "987d0f58-6d97-46c6-959d-25cee92604f9", "node_type": "1", "metadata": {"window": "We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day. ", "original_text": "Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n"}, "hash": "95f6388b3ce833d66097ccc2d66c66c914698c2e19e2e2120bd14b19a2f00122", "class_name": "RelatedNodeInfo"}}, "text": "Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board. ", "start_char_idx": 761, "end_char_idx": 861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "987d0f58-6d97-46c6-959d-25cee92604f9": {"__data__": {"id_": "987d0f58-6d97-46c6-959d-25cee92604f9", "embedding": null, "metadata": {"window": "We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day. ", "original_text": "Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d3b84d2-e476-49ac-a95d-5717572cc4c6", "node_type": "1", "metadata": {"window": "We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners. ", "original_text": "Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d515757d6c470ce81013cbeb38a0252debf33270228761f709cd6acc5a1d7bc0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d41e161d-399e-4626-9bee-9ea52c48c27f", "node_type": "1", "metadata": {"window": "Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed. ", "original_text": "In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics . "}, "hash": "31336ecd5d8b8cba477ed68c02e9253ca67be52ca559e97e1f1606d66be86ca9", "class_name": "RelatedNodeInfo"}}, "text": "Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n", "start_char_idx": 861, "end_char_idx": 1093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d41e161d-399e-4626-9bee-9ea52c48c27f": {"__data__": {"id_": "d41e161d-399e-4626-9bee-9ea52c48c27f", "embedding": null, "metadata": {"window": "Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed. ", "original_text": "In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics . ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "987d0f58-6d97-46c6-959d-25cee92604f9", "node_type": "1", "metadata": {"window": "We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time.  Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day. ", "original_text": "Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e88cb38ec5a700572364f9ebce3163fcebbd77105b99664161c162a0af04cb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e80597aa-9e1c-42b9-b5b6-27b3cf8bf1b3", "node_type": "1", "metadata": {"window": "Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center. ", "original_text": "We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners. "}, "hash": "e6dc5e120526585fb9f27210737dcf9f4448f73249347a43ea0e273da93366dd", "class_name": "RelatedNodeInfo"}}, "text": "In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics . ", "start_char_idx": 1093, "end_char_idx": 1236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e80597aa-9e1c-42b9-b5b6-27b3cf8bf1b3": {"__data__": {"id_": "e80597aa-9e1c-42b9-b5b6-27b3cf8bf1b3", "embedding": null, "metadata": {"window": "Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center. ", "original_text": "We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d41e161d-399e-4626-9bee-9ea52c48c27f", "node_type": "1", "metadata": {"window": "Our differentiated model in community oncology is focused on \ndriving practice growth and sharing value, while maintaining practice independence.  Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed. ", "original_text": "In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics . ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bcdc4a5c0ed2b4bbe1abfe4b086e3c9e3a252ac25dbe9e20db2439e8dd41d715", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbaed71a-c55a-4db4-9c02-07f888c0b672", "node_type": "1", "metadata": {"window": "Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n", "original_text": "We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day. "}, "hash": "c8844ca1048a1965e5c52052ed1a487711fa5c64a31920bf3abd3cd9538fc62e", "class_name": "RelatedNodeInfo"}}, "text": "We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners. ", "start_char_idx": 1236, "end_char_idx": 1438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbaed71a-c55a-4db4-9c02-07f888c0b672": {"__data__": {"id_": "cbaed71a-c55a-4db4-9c02-07f888c0b672", "embedding": null, "metadata": {"window": "Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n", "original_text": "We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e80597aa-9e1c-42b9-b5b6-27b3cf8bf1b3", "node_type": "1", "metadata": {"window": "Our approach is \nbeing refined through en gagement with clinicians and our customer advisory board.  Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center. ", "original_text": "We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0475392bcf9672267078342ab31c217eafe738843014b912df969fa84eecba49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7620a6b0-a7d7-43ca-b49f-15efcc5090c4", "node_type": "1", "metadata": {"window": "In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n", "original_text": "Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed. "}, "hash": "32da0f3e4f379cbe14128295fcd8935921c0668b7f70131bfd0e1e2ef8feb69b", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day. ", "start_char_idx": 1438, "end_char_idx": 1518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7620a6b0-a7d7-43ca-b49f-15efcc5090c4": {"__data__": {"id_": "7620a6b0-a7d7-43ca-b49f-15efcc5090c4", "embedding": null, "metadata": {"window": "In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n", "original_text": "Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbaed71a-c55a-4db4-9c02-07f888c0b672", "node_type": "1", "metadata": {"window": "Overall, we are \ndeveloping solutions strategically aligned to supporting the clinical and operational needs of \ncommunity oncologists that dri ve long -term practice independence and allow physicians to focus on \npatient care.  \n \n In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n", "original_text": "We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d0d658ae7ac55a4381e23e16d56b654006ef0547123875ca86c512ae9f5116f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "674a1216-def1-40e3-9178-ddded5dd495f", "node_type": "1", "metadata": {"window": "We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n", "original_text": "We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center. "}, "hash": "785d7373b352c3aa94a0836a6ee3b705fc511b5bc5af6722e42cadd14eb17812", "class_name": "RelatedNodeInfo"}}, "text": "Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed. ", "start_char_idx": 1518, "end_char_idx": 1612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "674a1216-def1-40e3-9178-ddded5dd495f": {"__data__": {"id_": "674a1216-def1-40e3-9178-ddded5dd495f", "embedding": null, "metadata": {"window": "We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n", "original_text": "We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7620a6b0-a7d7-43ca-b49f-15efcc5090c4", "node_type": "1", "metadata": {"window": "In Nuclear, the business continues its double -digit growth trajectory, with strong performance across \nour core categories and Theranostics .  We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n", "original_text": "Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b30a34581bf8561777e0fb9039771eb3f7a8e0ff352dd2d59e2bed8c4818f53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aed07d5-6f44-44e7-8690-776eca66cf7d", "node_type": "1", "metadata": {"window": "We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n", "original_text": "With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n"}, "hash": "011e5f68bd491f1d9fcf5bcbaaaf381044d03925a400ce73fa51439d0c3e1ea1", "class_name": "RelatedNodeInfo"}}, "text": "We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center. ", "start_char_idx": 1612, "end_char_idx": 1759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aed07d5-6f44-44e7-8690-776eca66cf7d": {"__data__": {"id_": "8aed07d5-6f44-44e7-8690-776eca66cf7d", "embedding": null, "metadata": {"window": "We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n", "original_text": "With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "674a1216-def1-40e3-9178-ddded5dd495f", "node_type": "1", "metadata": {"window": "We continue to experience increasing demand for our Center \nfor Theranostics Advancement, with more than sixty projects at various stages in our pipeline with our \npharmaceutical manufacturer partners.  We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n", "original_text": "We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center. ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2eef94c3af0f448310b672aeda3d00670576a8ad836fdd3f8eced724c8ab4157", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64151535-cae5-4520-9c42-e79335b03085", "node_type": "1", "metadata": {"window": "Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n", "original_text": "Now turning to Medical and priority number two.  \n \n"}, "hash": "2548106e9041934d5b8da85f10287f88515eb6957918e9bdf3c8825e40efdf00", "class_name": "RelatedNodeInfo"}}, "text": "With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n", "start_char_idx": 1759, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64151535-cae5-4520-9c42-e79335b03085": {"__data__": {"id_": "64151535-cae5-4520-9c42-e79335b03085", "embedding": null, "metadata": {"window": "Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n", "original_text": "Now turning to Medical and priority number two.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aed07d5-6f44-44e7-8690-776eca66cf7d", "node_type": "1", "metadata": {"window": "We\u2019re progressing on our Phase 2 investment that we \nannounced at Investor Day.  Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n", "original_text": "With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed4a53d269fb38f91a84b7718a4b80c598aafbfd91c4048c542b7949807d4c17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c50ca827-ec1a-4ab0-b260-b409a95d07e2", "node_type": "1", "metadata": {"window": "We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n", "original_text": "The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n"}, "hash": "6df783a6aac885a3ef2dfb90f545e5ff6c49127eb377e3fed261f92c5f93798c", "class_name": "RelatedNodeInfo"}}, "text": "Now turning to Medical and priority number two.  \n \n", "start_char_idx": 1961, "end_char_idx": 2013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c50ca827-ec1a-4ab0-b260-b409a95d07e2": {"__data__": {"id_": "c50ca827-ec1a-4ab0-b260-b409a95d07e2", "embedding": null, "metadata": {"window": "We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n", "original_text": "The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64151535-cae5-4520-9c42-e79335b03085", "node_type": "1", "metadata": {"window": "Our Innovation Center and Pre -Commercial Manufacturing Center are \nalready highly utili zed.  We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n", "original_text": "Now turning to Medical and priority number two.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12a34c5d43c08c8dbe9cb9d8f888ba926739284cfbbedf91b1073be8acb3c349", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9f34189-4675-4830-a241-6ff1997997b5", "node_type": "1", "metadata": {"window": "With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n"}, "hash": "56d93b87580e703c72f3b2fd6457c77747d0fedcf11406c87c8094fd40959b53", "class_name": "RelatedNodeInfo"}}, "text": "The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n", "start_char_idx": 2013, "end_char_idx": 2148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9f34189-4675-4830-a241-6ff1997997b5": {"__data__": {"id_": "c9f34189-4675-4830-a241-6ff1997997b5", "embedding": null, "metadata": {"window": "With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c50ca827-ec1a-4ab0-b260-b409a95d07e2", "node_type": "1", "metadata": {"window": "We \u2019re underway and progressing according to plan with the expansions of our \nCentral Pharmacy capability and our Commercial Manufacturing Center.  With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n", "original_text": "The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01c886147f0eb9cd734ac9411874f34d5170f7cf3638533c69cec5aaf987e75e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12eaa204-30d1-4e69-9809-be8bc8370287", "node_type": "1", "metadata": {"window": "Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n"}, "hash": "9bb68dbcec26d7bb134b19c7f4e745c57ef015fc7ea0a4dd60d27c6522cf817d", "class_name": "RelatedNodeInfo"}}, "text": "As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n", "start_char_idx": 2148, "end_char_idx": 2355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12eaa204-30d1-4e69-9809-be8bc8370287": {"__data__": {"id_": "12eaa204-30d1-4e69-9809-be8bc8370287", "embedding": null, "metadata": {"window": "Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9f34189-4675-4830-a241-6ff1997997b5", "node_type": "1", "metadata": {"window": "With our strong foundation \nand continued investment, the Nuclear business is well on track to deliver its long -term target of \ndoubling profits by fiscal \u201826, relative to our fiscal \u201821 baseline.  \n \n Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4db918aa4d421ee37a80901b0e98d6d198ebf5e2604433e85ea0799db8355f21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29e9e2bb-296c-401b-b6c5-78eb0cf545dc", "node_type": "1", "metadata": {"window": "The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n"}, "hash": "683809f3d15647898b1bbbf8647320530d9faf71c028b6d16ca795e74d0bc3cb", "class_name": "RelatedNodeInfo"}}, "text": "We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n", "start_char_idx": 2355, "end_char_idx": 2540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29e9e2bb-296c-401b-b6c5-78eb0cf545dc": {"__data__": {"id_": "29e9e2bb-296c-401b-b6c5-78eb0cf545dc", "embedding": null, "metadata": {"window": "The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12eaa204-30d1-4e69-9809-be8bc8370287", "node_type": "1", "metadata": {"window": "Now turning to Medical and priority number two.  \n \n The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3504cbf2025b9f9f1bcd14fad42768a7439c28af536a5b46fb9a2ba2508ec96c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16a532d1-2ae6-4a8f-b415-495d6499eeb4", "node_type": "1", "metadata": {"window": "As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n "}, "hash": "c66253fe74c822f38a0ed447339b13991499c44d7b92bdaa0f60e2d1da6c1c3a", "class_name": "RelatedNodeInfo"}}, "text": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n", "start_char_idx": 2540, "end_char_idx": 2680, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16a532d1-2ae6-4a8f-b415-495d6499eeb4": {"__data__": {"id_": "16a532d1-2ae6-4a8f-b415-495d6499eeb4", "embedding": null, "metadata": {"window": "As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "526a0570b16f70b6b2a6433fce6f471afe98c36ab232894d0671366e448d2c38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29e9e2bb-296c-401b-b6c5-78eb0cf545dc", "node_type": "1", "metadata": {"window": "The Medical business has now delivered back -to-back quarters of meaningfully improved profitability, \nand we expect more to come.  \n \n As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d36ef18e78553a9929dbc2bbe1453b6653afebe55c655c1ea0e3ba904ab11195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f47c276b-7ed4-4c03-afbd-c44d6f3b3e0f", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n", "original_text": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n"}, "hash": "43814c9ea061fed851fb016034a44a1c3b0bc4ea3c6abb53d473c11f3d8d02f4", "class_name": "RelatedNodeInfo"}}, "text": "We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "start_char_idx": 2680, "end_char_idx": 2913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f47c276b-7ed4-4c03-afbd-c44d6f3b3e0f": {"__data__": {"id_": "f47c276b-7ed4-4c03-afbd-c44d6f3b3e0f", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n", "original_text": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16a532d1-2ae6-4a8f-b415-495d6499eeb4", "node_type": "1", "metadata": {"window": "As part of our Medical Improvement Plan, we\u2019ve been taking action to address the challenges in the \ncore Products and Distribution business, with the #1 priority being mitigating supply chain inflation.  \n \n We remain on track to address the impact of inflation and global supply chain constraints by the time \nwe exit fiscal \u201824, and we\u2019re pleased to note we are now over 70 % to target.  \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated.  \n \n We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "original_text": "We continue to execute our mitigation initiatives to offset elevated inflation, are making progress with \nour commercial contracting efforts, and are seeing benefits from our additional actions, such as our \nsourcing initiatives.  \n ", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0d389e597c1fa0c489d07c6321bbb81fa9ba43ac8191208a06edd6286c20600", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4ccdd39-b07e-47b5-9222-24b76e75193c", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n", "original_text": "We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n"}, "hash": "88182e24059997d23f258af1fe61215a2d60e2ac331d9db1d75906f49fc066ab", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n", "start_char_idx": 0, "end_char_idx": 160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4ccdd39-b07e-47b5-9222-24b76e75193c": {"__data__": {"id_": "c4ccdd39-b07e-47b5-9222-24b76e75193c", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n", "original_text": "We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f47c276b-7ed4-4c03-afbd-c44d6f3b3e0f", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n", "original_text": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4cbfc9736cd05608b6506f7a00498b8568d29628cc5c9b9443c33ef474bbd59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9c26e02-7e37-4a15-879e-df74f7f16213", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n", "original_text": "We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n"}, "hash": "4773043862172159d5a25af3f57f9ec5947f866fc97903b53d4eb9ac7bf59fb1", "class_name": "RelatedNodeInfo"}}, "text": "We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n", "start_char_idx": 160, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9c26e02-7e37-4a15-879e-df74f7f16213": {"__data__": {"id_": "b9c26e02-7e37-4a15-879e-df74f7f16213", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n", "original_text": "We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4ccdd39-b07e-47b5-9222-24b76e75193c", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n", "original_text": "We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22aa9e8879ea3fbdde01180a671ff1aafc30a4ab935d481877ddc1cc97ee5b97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61a74da0-10d0-4a63-936d-a7080e4253fa", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward . ", "original_text": "We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n"}, "hash": "33b852a1e755aa79e096e39af09f2ff43ca8ff17b51ade246dcd23838004748e", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n", "start_char_idx": 339, "end_char_idx": 574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61a74da0-10d0-4a63-936d-a7080e4253fa": {"__data__": {"id_": "61a74da0-10d0-4a63-936d-a7080e4253fa", "embedding": null, "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward . ", "original_text": "We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9c26e02-7e37-4a15-879e-df74f7f16213", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n", "original_text": "We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e91592ea05e9bf99df55c68b24aacb5daa543b6bac9ae77a4cd3c487f78320c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97272ba8-52d1-4a30-bc77-68a21cb752fa", "node_type": "1", "metadata": {"window": "We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S. ", "original_text": "We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n"}, "hash": "ee10e752942b14a86eea4093889baa6da1545c9e9ad3a8c2e676819faec5b1db", "class_name": "RelatedNodeInfo"}}, "text": "We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n", "start_char_idx": 574, "end_char_idx": 824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97272ba8-52d1-4a30-bc77-68a21cb752fa": {"__data__": {"id_": "97272ba8-52d1-4a30-bc77-68a21cb752fa", "embedding": null, "metadata": {"window": "We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S. ", "original_text": "We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61a74da0-10d0-4a63-936d-a7080e4253fa", "node_type": "1", "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward . ", "original_text": "We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fd409b2b6a763f5ce73dcd8aafbedb9b9e828d28046586272982c9d3236464d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fca99689-82b0-408d-ae4d-92b11cbe1c2d", "node_type": "1", "metadata": {"window": "We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day. ", "original_text": "I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n"}, "hash": "d1620f5d6da3d6afd37d603b985e3daa6799999f3572c85e141e328f4f56c2bc", "class_name": "RelatedNodeInfo"}}, "text": "We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n", "start_char_idx": 824, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fca99689-82b0-408d-ae4d-92b11cbe1c2d": {"__data__": {"id_": "fca99689-82b0-408d-ae4d-92b11cbe1c2d", "embedding": null, "metadata": {"window": "We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day. ", "original_text": "I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97272ba8-52d1-4a30-bc77-68a21cb752fa", "node_type": "1", "metadata": {"window": "We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S. ", "original_text": "We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa95ca057619783421b39daab46b69dfc22ed7740a2870f511bbc35263624ecb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d67b270a-86d5-4dfc-82de-1bdad334b5b9", "node_type": "1", "metadata": {"window": "We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n", "original_text": "We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward . "}, "hash": "7626dd5da04cd9af05704819dafd26a7f7c54a3b490ad92e396063a8a7083f26", "class_name": "RelatedNodeInfo"}}, "text": "I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n", "start_char_idx": 1103, "end_char_idx": 1279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d67b270a-86d5-4dfc-82de-1bdad334b5b9": {"__data__": {"id_": "d67b270a-86d5-4dfc-82de-1bdad334b5b9", "embedding": null, "metadata": {"window": "We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n", "original_text": "We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward . ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fca99689-82b0-408d-ae4d-92b11cbe1c2d", "node_type": "1", "metadata": {"window": "We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day. ", "original_text": "I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ef3c74d68675283e59e8ed00d4033c8237a17843d3edbf03f12c2273b466236", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b04a9e00-da7a-495a-92dd-9dc1bf5eed75", "node_type": "1", "metadata": {"window": "We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses. ", "original_text": "For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S. "}, "hash": "184afe9b2900152d6368dec10d8e0fff543f26d913cebb4bbcf10d71ffd3ffe6", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward . ", "start_char_idx": 1279, "end_char_idx": 1606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b04a9e00-da7a-495a-92dd-9dc1bf5eed75": {"__data__": {"id_": "b04a9e00-da7a-495a-92dd-9dc1bf5eed75", "embedding": null, "metadata": {"window": "We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses. ", "original_text": "For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S. ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d67b270a-86d5-4dfc-82de-1bdad334b5b9", "node_type": "1", "metadata": {"window": "We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n", "original_text": "We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward . ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2f0e52f0d3190a344c27aa8f68ce8cb756de8c32aecec0408469e3b45a1e1f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6baff83-eeff-481c-a0b0-95941e3762e0", "node_type": "1", "metadata": {"window": "I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home. ", "original_text": "distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day. "}, "hash": "c1447ec72d877ad1b4a42fd788df8dac7c7bb5a2bc370e9844a8461a576b4dbe", "class_name": "RelatedNodeInfo"}}, "text": "For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S. ", "start_char_idx": 1606, "end_char_idx": 1696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6baff83-eeff-481c-a0b0-95941e3762e0": {"__data__": {"id_": "f6baff83-eeff-481c-a0b0-95941e3762e0", "embedding": null, "metadata": {"window": "I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home. ", "original_text": "distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day. ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b04a9e00-da7a-495a-92dd-9dc1bf5eed75", "node_type": "1", "metadata": {"window": "We also announced the launch of our next generation NTrainer \u2122 System 2.0, a medical device \ndesigned to help premature and newborn infants develop the oral coordination skills to make the \ntransition to independent feeding faster and  help reduce their NICU length of stay.  \n \n I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses. ", "original_text": "For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S. ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31390752f39466d40d9faeca4392cb938ccb62d8a03b90e86bcc75be791128a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2585e936-646f-4524-a65d-42f3fb6a5360", "node_type": "1", "metadata": {"window": "We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n", "original_text": "And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n"}, "hash": "a5dea770ed62db6b237401468cb701401a770b88fc2c38bef787568a59a1732f", "class_name": "RelatedNodeInfo"}}, "text": "distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day. ", "start_char_idx": 1696, "end_char_idx": 1793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2585e936-646f-4524-a65d-42f3fb6a5360": {"__data__": {"id_": "2585e936-646f-4524-a65d-42f3fb6a5360", "embedding": null, "metadata": {"window": "We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n", "original_text": "And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6baff83-eeff-481c-a0b0-95941e3762e0", "node_type": "1", "metadata": {"window": "I\u2019m excited about what our products can do for patients and the progress we are making as we now \nturn to playing more offense to grow our Cardinal Health Brand portfolio.  \n \n We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home. ", "original_text": "distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day. ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "922fdc1e27cba78a689d48d864aefec498478ee2b241032fc94a9791958b3332", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f812cd30-4871-4c56-8fae-d92a39890bd8", "node_type": "1", "metadata": {"window": "For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n", "original_text": "Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses. "}, "hash": "1ae7e457426997759455f7af56ea74006a81b3a79e1846d26093ebbdb51290a3", "class_name": "RelatedNodeInfo"}}, "text": "And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n", "start_char_idx": 1793, "end_char_idx": 1941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f812cd30-4871-4c56-8fae-d92a39890bd8": {"__data__": {"id_": "f812cd30-4871-4c56-8fae-d92a39890bd8", "embedding": null, "metadata": {"window": "For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n", "original_text": "Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses. ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2585e936-646f-4524-a65d-42f3fb6a5360", "node_type": "1", "metadata": {"window": "We\u2019re continuing to see the results of our actions benefitting our leading indicators, such as our \ncustomer experience metrics and portfolio health for key categories, which gives us confidence that \nwe\u2019ll be able to better participate in the growth from an overall improving Medical utilization \nenvironment moving forward .  For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n", "original_text": "And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cdae54f35e68dbe8298f34464e803660260cfdae209c073185b4f4d6bd520b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6546a90b-4ac0-4de0-9591-147e3a7ed7dc", "node_type": "1", "metadata": {"window": "distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n", "original_text": "In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home. "}, "hash": "772cca045fc111932b877b91f8b83d8faa596b7d1acbb42f831d856df34a0c3d", "class_name": "RelatedNodeInfo"}}, "text": "Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses. ", "start_char_idx": 1941, "end_char_idx": 2033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6546a90b-4ac0-4de0-9591-147e3a7ed7dc": {"__data__": {"id_": "6546a90b-4ac0-4de0-9591-147e3a7ed7dc", "embedding": null, "metadata": {"window": "distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n", "original_text": "In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home. ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f812cd30-4871-4c56-8fae-d92a39890bd8", "node_type": "1", "metadata": {"window": "For example, we\u2019ve seen further improvement in our Customer Loyalty \nIndex score for U.S.  distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n", "original_text": "Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses. ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f49542b170a12fc768a39975e41a6e282e768aa04701a5157c1f305fb312302b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1ff3de7-a095-40b9-9ab3-8f77734e026e", "node_type": "1", "metadata": {"window": "And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n", "original_text": "Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n"}, "hash": "eef96dbee239c3700e8fdf19e9f2db6dbc0cab52fa9934a66fc41d906dc09515", "class_name": "RelatedNodeInfo"}}, "text": "In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home. ", "start_char_idx": 2033, "end_char_idx": 2131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1ff3de7-a095-40b9-9ab3-8f77734e026e": {"__data__": {"id_": "c1ff3de7-a095-40b9-9ab3-8f77734e026e", "embedding": null, "metadata": {"window": "And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n", "original_text": "Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6546a90b-4ac0-4de0-9591-147e3a7ed7dc", "node_type": "1", "metadata": {"window": "distribution beyond the 13 -point increase in the last two years that we noted at \nInvestor Day.  And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n", "original_text": "In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home. ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2223ba9bf3d47715b3f4f07296bd5cdc00801a44c800e2174077007e806014f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10fc315d-854d-44bb-884a-ec26c8945056", "node_type": "1", "metadata": {"window": "Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment. ", "original_text": "To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n"}, "hash": "3ef29976a1a979f677e4d4693852cc83a53aae6e9eaa0ba10d20e90ee7481b71", "class_name": "RelatedNodeInfo"}}, "text": "Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n", "start_char_idx": 2131, "end_char_idx": 2296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10fc315d-854d-44bb-884a-ec26c8945056": {"__data__": {"id_": "10fc315d-854d-44bb-884a-ec26c8945056", "embedding": null, "metadata": {"window": "Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment. ", "original_text": "To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1ff3de7-a095-40b9-9ab3-8f77734e026e", "node_type": "1", "metadata": {"window": "And we\u2019ve seen a continued reduction in our product back -orders, which are now at a \nmulti -year low and consistent with pre -pandemic levels.  \n \n Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n", "original_text": "Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1df1d1c908d875b6bd0fcfa4ab31922d57c202d8092100065b748a02890d0445", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0261c168-aac4-4881-a5d3-bbd6b030ed3f", "node_type": "1", "metadata": {"window": "In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "Finally, priority number three , maximizing shareholder value creation . \n \n"}, "hash": "120336b2696d44998baf1715a40a4dd3a410436edfb9523e95e26a3e7c0eb6ee", "class_name": "RelatedNodeInfo"}}, "text": "To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n", "start_char_idx": 2296, "end_char_idx": 2484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0261c168-aac4-4881-a5d3-bbd6b030ed3f": {"__data__": {"id_": "0261c168-aac4-4881-a5d3-bbd6b030ed3f", "embedding": null, "metadata": {"window": "In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "Finally, priority number three , maximizing shareholder value creation . \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10fc315d-854d-44bb-884a-ec26c8945056", "node_type": "1", "metadata": {"window": "Outside of Products and Distribution, we\u2019re continuing to accelerate our growth businesses.  In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment. ", "original_text": "To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ac733ac77030285fafbc485cf8169c9caf21913ddddd18885efd602ba9a1b9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "921d67b3-8555-427e-8532-87c00ccd3139", "node_type": "1", "metadata": {"window": "Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n"}, "hash": "725013d1ba52329ae706bd0a5986a07f350935a5d8d48ae43421ebb4080dd5ad", "class_name": "RelatedNodeInfo"}}, "text": "Finally, priority number three , maximizing shareholder value creation . \n \n", "start_char_idx": 2484, "end_char_idx": 2560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "921d67b3-8555-427e-8532-87c00ccd3139": {"__data__": {"id_": "921d67b3-8555-427e-8532-87c00ccd3139", "embedding": null, "metadata": {"window": "Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0261c168-aac4-4881-a5d3-bbd6b030ed3f", "node_type": "1", "metadata": {"window": "In at -\nHome Solutions, we continue to see strong demand as care increasingly shifts to the home.  Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "Finally, priority number three , maximizing shareholder value creation . \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14706a2beffe89a06e3634fe73b12cbbb10061c47c43ae4aa94ba3f128532247", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0837afd4-266a-46e2-b41b-d2a0a8956c68", "node_type": "1", "metadata": {"window": "To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment. "}, "hash": "845e8ee6c75ce421728983e4670dc0368828ec52b15c983557d5056d09aada5a", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n", "start_char_idx": 2560, "end_char_idx": 2712, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0837afd4-266a-46e2-b41b-d2a0a8956c68": {"__data__": {"id_": "0837afd4-266a-46e2-b41b-d2a0a8956c68", "embedding": null, "metadata": {"window": "To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment. ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "921d67b3-8555-427e-8532-87c00ccd3139", "node_type": "1", "metadata": {"window": "Our \nteam\u2019s focus on operational efficiency is producing better opera ting leverage in this business, \nresulting in increased contributions to the bottom -line.  \n \n To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c248143ad1792631875303708af9adb9bd794a784dca3ec5425ba57f5889f5da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2116156e-bcb2-4af8-935f-ae697c652cf6", "node_type": "1", "metadata": {"window": "Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "With our financial flexibility, we\u2019ll "}, "hash": "6686dbdb6fd1b5da700f783a80e971c3379ae8fb45bfb7275fe1e65f684b2a55", "class_name": "RelatedNodeInfo"}}, "text": "As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment. ", "start_char_idx": 2712, "end_char_idx": 2971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2116156e-bcb2-4af8-935f-ae697c652cf6": {"__data__": {"id_": "2116156e-bcb2-4af8-935f-ae697c652cf6", "embedding": null, "metadata": {"window": "Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "With our financial flexibility, we\u2019ll ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "33477d9f-24c3-496c-9932-7d3b3369370d", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d12000f3694c8fa9b01f2d12e7eb6630caa13d421ae0a16b47f367c8a748d638", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0837afd4-266a-46e2-b41b-d2a0a8956c68", "node_type": "1", "metadata": {"window": "To wrap up in Medical, we\u2019re continuing to execute our simplification and cost savings initiatives \nacross the segment, which contributed to the strong SG&A management in the quarter.  \n \n Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment. ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b703aec9dcf6cf73c0b13ddc81f3b963b34995e8e3d0190bb769bb19935fec6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2820eaec-c762-4334-9280-0d5891773c28", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us. ", "original_text": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases. "}, "hash": "e072e836dba672440e77eda40901394a86044d44620a4286e7fa483b3e725a0c", "class_name": "RelatedNodeInfo"}}, "text": "With our financial flexibility, we\u2019ll ", "start_char_idx": 2971, "end_char_idx": 3009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2820eaec-c762-4334-9280-0d5891773c28": {"__data__": {"id_": "2820eaec-c762-4334-9280-0d5891773c28", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us. ", "original_text": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2116156e-bcb2-4af8-935f-ae697c652cf6", "node_type": "1", "metadata": {"window": "Finally, priority number three , maximizing shareholder value creation . \n \n We\u2019re maximizing shareholder value creation through our improved operational performance, robust \ncash flow and responsible allocation of capital .  \n \n As Aaron detailed, our confidence in our cash flow generation enabled execution of our fiscal \u201824 \nbaseline share repurchases , continued evidence of our willingness to return excess capital to \nshareholders and our value creation through capital deployment.  With our financial flexibility, we\u2019ll ", "original_text": "With our financial flexibility, we\u2019ll ", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8dbc2970b73b0202abf3f8400754add62c6b34a5689e6f32562cdf9b5da2c6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95df35be-101b-420b-8b33-c231008cd303", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n", "original_text": "We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n"}, "hash": "c3c2ecd7c8332760d2bbb42243db81a8f7a12f1498a29eebc0131dbbc37a8c40", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases. ", "start_char_idx": 0, "end_char_idx": 131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95df35be-101b-420b-8b33-c231008cd303": {"__data__": {"id_": "95df35be-101b-420b-8b33-c231008cd303", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n", "original_text": "We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2820eaec-c762-4334-9280-0d5891773c28", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us. ", "original_text": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3de4de63dabe3b152db21016b474100127a6943b94eb4a3aef2199cf842d0762", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66c20b87-fe56-4041-9aef-458a80089c56", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum. ", "original_text": "We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment. "}, "hash": "9d9279c44663495faafb133ae5a05f7e5a57e0d24b7168aa601bc00776a84e16", "class_name": "RelatedNodeInfo"}}, "text": "We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n", "start_char_idx": 131, "end_char_idx": 399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66c20b87-fe56-4041-9aef-458a80089c56": {"__data__": {"id_": "66c20b87-fe56-4041-9aef-458a80089c56", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum. ", "original_text": "We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95df35be-101b-420b-8b33-c231008cd303", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n", "original_text": "We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a44b8538e8cf01b107cf23d7ae85920e9619381af5a700797176fa54407f8b40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7265d2f4-2732-424b-84ab-186996e39401", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n", "original_text": "While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us. "}, "hash": "65e58488f96e90537c1c8e612714128b8988099facc00a4501bd235172b887bb", "class_name": "RelatedNodeInfo"}}, "text": "We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment. ", "start_char_idx": 399, "end_char_idx": 503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7265d2f4-2732-424b-84ab-186996e39401": {"__data__": {"id_": "7265d2f4-2732-424b-84ab-186996e39401", "embedding": null, "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n", "original_text": "While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66c20b87-fe56-4041-9aef-458a80089c56", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum. ", "original_text": "We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5cfcc6d2a035262f8357f13c79715ae8a8145627f0c7712693254a7da22500e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e704df97-bc24-457a-9fa9-de3a1074cbb6", "node_type": "1", "metadata": {"window": "We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n", "original_text": "We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n"}, "hash": "8c6b4c5206c229d1e523e52ea077e20a41bd690fea16cb8c6903f0e6d110e82f", "class_name": "RelatedNodeInfo"}}, "text": "While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us. ", "start_char_idx": 503, "end_char_idx": 693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e704df97-bc24-457a-9fa9-de3a1074cbb6": {"__data__": {"id_": "e704df97-bc24-457a-9fa9-de3a1074cbb6", "embedding": null, "metadata": {"window": "We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n", "original_text": "We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7265d2f4-2732-424b-84ab-186996e39401", "node_type": "1", "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n", "original_text": "While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0dff0eca7f5ab1dbfb2b41481f22c14e1e8cec774b2c2c08c30d08835bd92cdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03e01d84-f932-412d-bfbb-85d5a33cf84c", "node_type": "1", "metadata": {"window": "We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you. ", "original_text": "To close, we had a great first quarter and are excited to build upon last year\u2019s momentum. "}, "hash": "0e8f97fbc52971ffd1bb8a1cd7d1cc8b555b0589bc354faea34fe4b939451c75", "class_name": "RelatedNodeInfo"}}, "text": "We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n", "start_char_idx": 693, "end_char_idx": 883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03e01d84-f932-412d-bfbb-85d5a33cf84c": {"__data__": {"id_": "03e01d84-f932-412d-bfbb-85d5a33cf84c", "embedding": null, "metadata": {"window": "We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you. ", "original_text": "To close, we had a great first quarter and are excited to build upon last year\u2019s momentum. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e704df97-bc24-457a-9fa9-de3a1074cbb6", "node_type": "1", "metadata": {"window": "We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n", "original_text": "We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9d0eb2ced92f19e58911e665ca1132dfdfc344a86315cc1abad8bb86dc73b70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ede66f6-f888-475b-a0ef-d82c7cf557f9", "node_type": "1", "metadata": {"window": "While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one. ", "original_text": "This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n"}, "hash": "e620873b7ae2108c5d74d5a3645a6ed273744fae534faad6f077f8c8fa8f2a2a", "class_name": "RelatedNodeInfo"}}, "text": "To close, we had a great first quarter and are excited to build upon last year\u2019s momentum. ", "start_char_idx": 883, "end_char_idx": 974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ede66f6-f888-475b-a0ef-d82c7cf557f9": {"__data__": {"id_": "9ede66f6-f888-475b-a0ef-d82c7cf557f9", "embedding": null, "metadata": {"window": "While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one. ", "original_text": "This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03e01d84-f932-412d-bfbb-85d5a33cf84c", "node_type": "1", "metadata": {"window": "We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you. ", "original_text": "To close, we had a great first quarter and are excited to build upon last year\u2019s momentum. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf75c07582af4a5847e89e1268cd748fb1069056af42c77682164d8416cb21ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcae312b-b09e-487b-b9d0-c8235d8f648a", "node_type": "1", "metadata": {"window": "We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan. ", "original_text": "With that, we will take your questions.  \n \n"}, "hash": "7a1ae10d4d9b676e20655b4f1bba6908f7c8429f3a929cf012ec771f6dc6139b", "class_name": "RelatedNodeInfo"}}, "text": "This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n", "start_char_idx": 974, "end_char_idx": 1158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcae312b-b09e-487b-b9d0-c8235d8f648a": {"__data__": {"id_": "fcae312b-b09e-487b-b9d0-c8235d8f648a", "embedding": null, "metadata": {"window": "We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan. ", "original_text": "With that, we will take your questions.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ede66f6-f888-475b-a0ef-d82c7cf557f9", "node_type": "1", "metadata": {"window": "While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us.  We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one. ", "original_text": "This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed9013f628b7732a0da73a9145fa3e154bcff066e5bc1e183099f95a7d685cdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3587cc60-d459-4628-ad59-47f8bf955558", "node_type": "1", "metadata": {"window": "To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n", "original_text": "Operator :  Thank you. "}, "hash": "c8a8943d5942e27148d71e44e57e44a43ac1792f18b5df05cd6a0eff351ba5fd", "class_name": "RelatedNodeInfo"}}, "text": "With that, we will take your questions.  \n \n", "start_char_idx": 1158, "end_char_idx": 1202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3587cc60-d459-4628-ad59-47f8bf955558": {"__data__": {"id_": "3587cc60-d459-4628-ad59-47f8bf955558", "embedding": null, "metadata": {"window": "To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n", "original_text": "Operator :  Thank you. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcae312b-b09e-487b-b9d0-c8235d8f648a", "node_type": "1", "metadata": {"window": "We \ncontinue to work collaboratively with our Business Review Committee to evaluate additional value \ncreation initiatives and  expect to provide further updates in the coming quarters.  \n \n To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan. ", "original_text": "With that, we will take your questions.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8c8c0de4b3028c6fc43b2601b43a4b2e3390a610552f33754cf97c3ec103f87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5eefcf5-c930-44cf-8295-c12e221adf7b", "node_type": "1", "metadata": {"window": "This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter. ", "original_text": "As a reminder to ask a question, please signal by pressing star one. "}, "hash": "80cba37887401a72a722cfceb011cad0702393924abfd90d37f9d63301b1a2df", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you. ", "start_char_idx": 1202, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5eefcf5-c930-44cf-8295-c12e221adf7b": {"__data__": {"id_": "d5eefcf5-c930-44cf-8295-c12e221adf7b", "embedding": null, "metadata": {"window": "This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter. ", "original_text": "As a reminder to ask a question, please signal by pressing star one. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3587cc60-d459-4628-ad59-47f8bf955558", "node_type": "1", "metadata": {"window": "To close, we had a great first quarter and are excited to build upon last year\u2019s momentum.  This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n", "original_text": "Operator :  Thank you. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21f57dfb98ba287e5e7ef2c45a35b465eea9e1bee7b2c4455c880d1a93635982", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cddde3a-cbe1-47a4-b606-831a3df043ed", "node_type": "1", "metadata": {"window": "With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines. ", "original_text": "And our \nnext question comes from Lisa Gill from JP Morgan. "}, "hash": "57d253ca4bf6f190f9ceab9f17c2ec8aa6e77214cea834a3a4f60e26bb59ae68", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder to ask a question, please signal by pressing star one. ", "start_char_idx": 1225, "end_char_idx": 1294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cddde3a-cbe1-47a4-b606-831a3df043ed": {"__data__": {"id_": "4cddde3a-cbe1-47a4-b606-831a3df043ed", "embedding": null, "metadata": {"window": "With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines. ", "original_text": "And our \nnext question comes from Lisa Gill from JP Morgan. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5eefcf5-c930-44cf-8295-c12e221adf7b", "node_type": "1", "metadata": {"window": "This was \ndriven by our highly engaged  and talented team, and I would like to thank them for all their efforts \nfulfilling our critical role as healthcare\u2019s most trusted partner.  \n \n With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter. ", "original_text": "As a reminder to ask a question, please signal by pressing star one. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0e676720245a04d828c363da4686de28c8996dc385c499eb3f22d3b974d43db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50e8ad10-e52b-4093-a275-a3f6e4ff7445", "node_type": "1", "metadata": {"window": "Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that? ", "original_text": "Please go ahead.  \n \n"}, "hash": "442f039ecc54a5853f67f0c75c7e88268b41aa3c426b2ee3cb5157f86fd895e2", "class_name": "RelatedNodeInfo"}}, "text": "And our \nnext question comes from Lisa Gill from JP Morgan. ", "start_char_idx": 1294, "end_char_idx": 1354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50e8ad10-e52b-4093-a275-a3f6e4ff7445": {"__data__": {"id_": "50e8ad10-e52b-4093-a275-a3f6e4ff7445", "embedding": null, "metadata": {"window": "Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that? ", "original_text": "Please go ahead.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cddde3a-cbe1-47a4-b606-831a3df043ed", "node_type": "1", "metadata": {"window": "With that, we will take your questions.  \n \n Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines. ", "original_text": "And our \nnext question comes from Lisa Gill from JP Morgan. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1da3fbc574247d7c5c4ad57c8ed1b4c39e134280b8f585f54144370e0ce928cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbd82db0-e328-4aba-b8cb-b7247b7e4c39", "node_type": "1", "metadata": {"window": "As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution? ", "original_text": "Lisa Gill:   Thanks very much , and congratulations on the quarter. "}, "hash": "b603027939cc04cbad4849a93ef8483275e906069f3b7b1d07bbc9600dfd02a6", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1354, "end_char_idx": 1375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbd82db0-e328-4aba-b8cb-b7247b7e4c39": {"__data__": {"id_": "cbd82db0-e328-4aba-b8cb-b7247b7e4c39", "embedding": null, "metadata": {"window": "As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution? ", "original_text": "Lisa Gill:   Thanks very much , and congratulations on the quarter. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50e8ad10-e52b-4093-a275-a3f6e4ff7445", "node_type": "1", "metadata": {"window": "Operator :  Thank you.  As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that? ", "original_text": "Please go ahead.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40dc8a560403b0be1e0cf6d22c694c39949e833fc7aec220845a296b2a36322d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ecae08a-396c-4732-be4b-f54f58d778ab", "node_type": "1", "metadata": {"window": "And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n", "original_text": "Jason, I just want to understand the \nCOVID -19 vaccines. "}, "hash": "8f021ac66d02c59baea7b85d76d9a397a0d5443650685e73dcb552b0df4fcfee", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:   Thanks very much , and congratulations on the quarter. ", "start_char_idx": 1375, "end_char_idx": 1443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ecae08a-396c-4732-be4b-f54f58d778ab": {"__data__": {"id_": "5ecae08a-396c-4732-be4b-f54f58d778ab", "embedding": null, "metadata": {"window": "And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n", "original_text": "Jason, I just want to understand the \nCOVID -19 vaccines. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbd82db0-e328-4aba-b8cb-b7247b7e4c39", "node_type": "1", "metadata": {"window": "As a reminder to ask a question, please signal by pressing star one.  And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution? ", "original_text": "Lisa Gill:   Thanks very much , and congratulations on the quarter. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15a7d79778da150e8993328a1a3a08ba49cddcaf0bc7a24322641df8f83adfbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91b3091e-8172-48d2-9d44-e6a2c01c7cf6", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa. ", "original_text": "Can you maybe just talk about the economics of that? "}, "hash": "734eab7cb9fd24bff445112a4420afd037ce3233626a636edf5eee9da1a72bc9", "class_name": "RelatedNodeInfo"}}, "text": "Jason, I just want to understand the \nCOVID -19 vaccines. ", "start_char_idx": 1443, "end_char_idx": 1501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91b3091e-8172-48d2-9d44-e6a2c01c7cf6": {"__data__": {"id_": "91b3091e-8172-48d2-9d44-e6a2c01c7cf6", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa. ", "original_text": "Can you maybe just talk about the economics of that? ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ecae08a-396c-4732-be4b-f54f58d778ab", "node_type": "1", "metadata": {"window": "And our \nnext question comes from Lisa Gill from JP Morgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n", "original_text": "Jason, I just want to understand the \nCOVID -19 vaccines. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7dd69b6052d285a2c5ff1b995665907083de3f6c7f2840391ec10015e390a4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb35b404-79ca-4b6d-b3ed-59efb0d36840", "node_type": "1", "metadata": {"window": "Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide. ", "original_text": "Is that substantially better \nthan kind of traditional drug distribution? "}, "hash": "9e07d984f821250ada5a1f6e622a5e55affc7102fca4b30bab9530209c8c036c", "class_name": "RelatedNodeInfo"}}, "text": "Can you maybe just talk about the economics of that? ", "start_char_idx": 1501, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb35b404-79ca-4b6d-b3ed-59efb0d36840": {"__data__": {"id_": "eb35b404-79ca-4b6d-b3ed-59efb0d36840", "embedding": null, "metadata": {"window": "Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide. ", "original_text": "Is that substantially better \nthan kind of traditional drug distribution? ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91b3091e-8172-48d2-9d44-e6a2c01c7cf6", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa. ", "original_text": "Can you maybe just talk about the economics of that? ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e30d4d2a10bedaac5c707ad152b934ba9c0502e381b92cfc6daa7b30bf83a2c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66a9d1f8-8b33-4ffa-ae8e-d32312e8a0f6", "node_type": "1", "metadata": {"window": "Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements. ", "original_text": "And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n"}, "hash": "b9fa0e3aad98ec778ad2faead73cd28062f56d1441a92443afb0fd3103bf7552", "class_name": "RelatedNodeInfo"}}, "text": "Is that substantially better \nthan kind of traditional drug distribution? ", "start_char_idx": 1554, "end_char_idx": 1628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66a9d1f8-8b33-4ffa-ae8e-d32312e8a0f6": {"__data__": {"id_": "66a9d1f8-8b33-4ffa-ae8e-d32312e8a0f6", "embedding": null, "metadata": {"window": "Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements. ", "original_text": "And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb35b404-79ca-4b6d-b3ed-59efb0d36840", "node_type": "1", "metadata": {"window": "Lisa Gill:   Thanks very much , and congratulations on the quarter.  Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide. ", "original_text": "Is that substantially better \nthan kind of traditional drug distribution? ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f54d55e7e06839e79c1c3587023d34d43a8d6076d96fc3df484867bb8644eb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fcb0ee8-5445-4dbf-931e-76873dbfc399", "node_type": "1", "metadata": {"window": "Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities. ", "original_text": "Jason Hollar:   Yeah , thanks  Lisa. "}, "hash": "f7d5424434f6a1ef118b5000b48fcb28a997ea8e57eb11c9e6c22b7bd3643e4d", "class_name": "RelatedNodeInfo"}}, "text": "And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n", "start_char_idx": 1628, "end_char_idx": 1798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fcb0ee8-5445-4dbf-931e-76873dbfc399": {"__data__": {"id_": "2fcb0ee8-5445-4dbf-931e-76873dbfc399", "embedding": null, "metadata": {"window": "Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities. ", "original_text": "Jason Hollar:   Yeah , thanks  Lisa. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66a9d1f8-8b33-4ffa-ae8e-d32312e8a0f6", "node_type": "1", "metadata": {"window": "Jason, I just want to understand the \nCOVID -19 vaccines.  Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements. ", "original_text": "And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3da3a9b86d2abba8a7c7e750af1eab2763e52ac8617780a331bea55aa469877", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e6521b2-2e3e-414d-bd9f-fe4fece21eab", "node_type": "1", "metadata": {"window": "Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time. ", "original_text": "How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide. "}, "hash": "7a88da5658e82933717eb8d1d8846026ee19fe41d25ea2f12a702900a67f42ca", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:   Yeah , thanks  Lisa. ", "start_char_idx": 1798, "end_char_idx": 1835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e6521b2-2e3e-414d-bd9f-fe4fece21eab": {"__data__": {"id_": "3e6521b2-2e3e-414d-bd9f-fe4fece21eab", "embedding": null, "metadata": {"window": "Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time. ", "original_text": "How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fcb0ee8-5445-4dbf-931e-76873dbfc399", "node_type": "1", "metadata": {"window": "Can you maybe just talk about the economics of that?  Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities. ", "original_text": "Jason Hollar:   Yeah , thanks  Lisa. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdf6b85074456f5c22fa18be27a2985db914ac127e7672572a899ad09b68fd75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e95b822-6e7e-434b-b60b-1f03a5a3f4a0", "node_type": "1", "metadata": {"window": "And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question. ", "original_text": "And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements. "}, "hash": "9f721cf9d4ae99e3680129f844e9069be04961a6a8219a4aa4037e43e84ca5ed", "class_name": "RelatedNodeInfo"}}, "text": "How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide. ", "start_char_idx": 1835, "end_char_idx": 2021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e95b822-6e7e-434b-b60b-1f03a5a3f4a0": {"__data__": {"id_": "3e95b822-6e7e-434b-b60b-1f03a5a3f4a0", "embedding": null, "metadata": {"window": "And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question. ", "original_text": "And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e6521b2-2e3e-414d-bd9f-fe4fece21eab", "node_type": "1", "metadata": {"window": "Is that substantially better \nthan kind of traditional drug distribution?  And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time. ", "original_text": "How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2bc83297fcd0d302133e2b730ffd6b9d22b448a00d855007d13ee88373971f2c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff993a18-95aa-45f9-8bc2-cf4e2b14373c", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n", "original_text": "And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities. "}, "hash": "0a351e7710cf3dc9d5160394a1766badf3e27a162e0d8ee7901e89e26eadcb11", "class_name": "RelatedNodeInfo"}}, "text": "And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements. ", "start_char_idx": 2021, "end_char_idx": 2150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff993a18-95aa-45f9-8bc2-cf4e2b14373c": {"__data__": {"id_": "ff993a18-95aa-45f9-8bc2-cf4e2b14373c", "embedding": null, "metadata": {"window": "Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n", "original_text": "And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e95b822-6e7e-434b-b60b-1f03a5a3f4a0", "node_type": "1", "metadata": {"window": "And I know you said it only goes thro ugh October, but are \nthere other vaccine opportunities that that would be similar and incremental opportunities for \nCardinal?  \n \n Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question. ", "original_text": "And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cf45d8c7c20406f6d71791f2019701f2f96e66e520e1abf5bb6217fa13a6a92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6e0e0d4-337d-41f4-bafa-679b3c5e2847", "node_type": "1", "metadata": {"window": "How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines. ", "original_text": "And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time. "}, "hash": "ef97c1afe42e7c4d381c7da45b4a89910646d8d9405db18a1ba8b0087b104204", "class_name": "RelatedNodeInfo"}}, "text": "And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities. ", "start_char_idx": 2150, "end_char_idx": 2271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6e0e0d4-337d-41f4-bafa-679b3c5e2847": {"__data__": {"id_": "b6e0e0d4-337d-41f4-bafa-679b3c5e2847", "embedding": null, "metadata": {"window": "How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines. ", "original_text": "And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff993a18-95aa-45f9-8bc2-cf4e2b14373c", "node_type": "1", "metadata": {"window": "Jason Hollar:   Yeah , thanks  Lisa.  How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n", "original_text": "And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70d85f8b625f5ebb36b1885d5cb139a13a537be14a9231124196b3c95ac3915d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbfdb949-d191-4ea3-9948-d17856b3cc9b", "node_type": "1", "metadata": {"window": "And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business. ", "original_text": "So, there's not a one size fits all answer to your question. "}, "hash": "be85e3803f316b803e68a762670475d7921a4790a45a1230deee331484061c74", "class_name": "RelatedNodeInfo"}}, "text": "And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time. ", "start_char_idx": 2271, "end_char_idx": 2453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbfdb949-d191-4ea3-9948-d17856b3cc9b": {"__data__": {"id_": "fbfdb949-d191-4ea3-9948-d17856b3cc9b", "embedding": null, "metadata": {"window": "And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business. ", "original_text": "So, there's not a one size fits all answer to your question. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6e0e0d4-337d-41f4-bafa-679b3c5e2847", "node_type": "1", "metadata": {"window": "How I think about the vaccines is,  again we're not going to get into \nobviously product and customer level type of detail, but overall, it all comes down to the value that we \nprovide.  And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines. ", "original_text": "And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c6885338e0d6bd4ec50bd0dc4ef0d8a6c81db0cd68c637457bf9b20f03337d59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "845f05b8-5180-4277-b73a-1390fed5ec55", "node_type": "1", "metadata": {"window": "And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter. ", "original_text": "And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n"}, "hash": "6e8ebadbf7a83f3495c428b843e7dff87633adb78f07ead2dff1d57bbedf3120", "class_name": "RelatedNodeInfo"}}, "text": "So, there's not a one size fits all answer to your question. ", "start_char_idx": 2453, "end_char_idx": 2514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "845f05b8-5180-4277-b73a-1390fed5ec55": {"__data__": {"id_": "845f05b8-5180-4277-b73a-1390fed5ec55", "embedding": null, "metadata": {"window": "And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter. ", "original_text": "And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbfdb949-d191-4ea3-9948-d17856b3cc9b", "node_type": "1", "metadata": {"window": "And so, when you think about COVID -19 vaccines and vaccines in general, you really have \nto understand what's the requirements.  And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business. ", "original_text": "So, there's not a one size fits all answer to your question. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c66eba775c8b7ba8f232c5bc7cf7ad3c9569d891db71f49888e672d890cf4fe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66f41d19-0e04-47c4-8bdb-bb68e581bb7f", "node_type": "1", "metadata": {"window": "And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.  ", "original_text": "And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines. "}, "hash": "981557efabe0c763e6fc7918f0fa0e60ac8dbdc06c6e2e746c5987cb34bca2ec", "class_name": "RelatedNodeInfo"}}, "text": "And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n", "start_char_idx": 2514, "end_char_idx": 2661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66f41d19-0e04-47c4-8bdb-bb68e581bb7f": {"__data__": {"id_": "66f41d19-0e04-47c4-8bdb-bb68e581bb7f", "embedding": null, "metadata": {"window": "And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.  ", "original_text": "And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "845f05b8-5180-4277-b73a-1390fed5ec55", "node_type": "1", "metadata": {"window": "And so, with COVID and with some vaccines, it requires more \ncomplex distribution, cold chain capacity and capabilities.  And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter. ", "original_text": "And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96f3a9db8c40ef0807528f13336621909025f2635580da6a3fd77a4629fe0cd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23cbf49e-cc9f-4978-9e3e-dfd30cea3bc2", "node_type": "1", "metadata": {"window": "So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1. ", "original_text": "So, it was a component of it, but certainly not the majority of the \ndriver of the business. "}, "hash": "2cab6cb588db30591193a324111803375c4648def8f7ace8df9a7da64b67eeb0", "class_name": "RelatedNodeInfo"}}, "text": "And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines. ", "start_char_idx": 2661, "end_char_idx": 2804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23cbf49e-cc9f-4978-9e3e-dfd30cea3bc2": {"__data__": {"id_": "23cbf49e-cc9f-4978-9e3e-dfd30cea3bc2", "embedding": null, "metadata": {"window": "So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1. ", "original_text": "So, it was a component of it, but certainly not the majority of the \ndriver of the business. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66f41d19-0e04-47c4-8bdb-bb68e581bb7f", "node_type": "1", "metadata": {"window": "And of course,  there's also  the unique thing \nabout vaccines is that you scale up and down quickly, and so you're spreading a lot of that cost over \na pretty short period of time.  So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.  ", "original_text": "And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61478b12f106ae48116947eb59d0871b4e24288e29cae5d2623f1e2d98a35043", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88aba52c-0ce1-4d38-8699-d75daf831d5f", "node_type": "1", "metadata": {"window": "And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution. ", "original_text": "The core part of the business remained very strong within the segment for the \nquarter. "}, "hash": "2d50445aa3308f4bb7dc32e7008ce737aec193dd377c9ba9965cd797b70df12d", "class_name": "RelatedNodeInfo"}}, "text": "So, it was a component of it, but certainly not the majority of the \ndriver of the business. ", "start_char_idx": 2804, "end_char_idx": 2897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88aba52c-0ce1-4d38-8699-d75daf831d5f": {"__data__": {"id_": "88aba52c-0ce1-4d38-8699-d75daf831d5f", "embedding": null, "metadata": {"window": "And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution. ", "original_text": "The core part of the business remained very strong within the segment for the \nquarter. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23cbf49e-cc9f-4978-9e3e-dfd30cea3bc2", "node_type": "1", "metadata": {"window": "So, there's not a one size fits all answer to your question.  And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1. ", "original_text": "So, it was a component of it, but certainly not the majority of the \ndriver of the business. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4559b2ed47c5a127f812223492a1534bd8e92553cdc62560e04444e77cf5a8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeaab8b4-c04c-4ae4-8ca9-4909fdd5ab86", "node_type": "1", "metadata": {"window": "And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline . ", "original_text": "And our guidance that quarter to continue to be strong.  "}, "hash": "44806dedc21f7e7b9daad5b3ac8174f68f07733207343bb018db64b7de1bd7d1", "class_name": "RelatedNodeInfo"}}, "text": "The core part of the business remained very strong within the segment for the \nquarter. ", "start_char_idx": 2897, "end_char_idx": 2985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aeaab8b4-c04c-4ae4-8ca9-4909fdd5ab86": {"__data__": {"id_": "aeaab8b4-c04c-4ae4-8ca9-4909fdd5ab86", "embedding": null, "metadata": {"window": "And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline . ", "original_text": "And our guidance that quarter to continue to be strong.  ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88aba52c-0ce1-4d38-8699-d75daf831d5f", "node_type": "1", "metadata": {"window": "And we \nprovided a little bit of color  for you in Aaron's comments there, so you can get a general \nunderstanding of the benefit that we had.  \n \n And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution. ", "original_text": "The core part of the business remained very strong within the segment for the \nquarter. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b72b90e1ba40961bacd8d211c47b2af791c5e70cb04ac416cc00fd4b55a209f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "733f079b-d6ae-49e8-bae0-e2870b3c7624", "node_type": "1", "metadata": {"window": "So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October. ", "original_text": "We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1. "}, "hash": "1f3bc290066d330267fbfdddd56e6e34b5a6de39b4fc392b9e378eddee7d6166", "class_name": "RelatedNodeInfo"}}, "text": "And our guidance that quarter to continue to be strong.  ", "start_char_idx": 2985, "end_char_idx": 3042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "733f079b-d6ae-49e8-bae0-e2870b3c7624": {"__data__": {"id_": "733f079b-d6ae-49e8-bae0-e2870b3c7624", "embedding": null, "metadata": {"window": "So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October. ", "original_text": "We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aeaab8b4-c04c-4ae4-8ca9-4909fdd5ab86", "node_type": "1", "metadata": {"window": "And to go a little bit further, I can say that about one third of the growth for the Pharma segment this \nquarter was related to the vaccines.  So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline . ", "original_text": "And our guidance that quarter to continue to be strong.  ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c685c4aa56d80be3ecfaa64407a6276ac6a36bae6e4adf7cbebd5445140ccff3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2852579-9f63-4a47-abb0-64b0bffba9a4", "node_type": "1", "metadata": {"window": "The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution. "}, "hash": "4e534b29686420b6731f652a2b31f809fcbb10d67fdeb290b0aac56b93d8334a", "class_name": "RelatedNodeInfo"}}, "text": "We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1. ", "start_char_idx": 3042, "end_char_idx": 3175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2852579-9f63-4a47-abb0-64b0bffba9a4": {"__data__": {"id_": "c2852579-9f63-4a47-abb0-64b0bffba9a4", "embedding": null, "metadata": {"window": "The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "733f079b-d6ae-49e8-bae0-e2870b3c7624", "node_type": "1", "metadata": {"window": "So, it was a component of it, but certainly not the majority of the \ndriver of the business.  The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October. ", "original_text": "We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68159282904605ccb27394152db3df34b52d9dbd6f548df5b9634351c9ca084f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b444d533-9a36-41f7-902e-354afc854ee9", "node_type": "1", "metadata": {"window": "And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "And then we'd expect that to ramp down as we get the pipeline . "}, "hash": "5151610fed6d39a16ba64daebb4c1c32299c18c8188059fcec9442c041426f7b", "class_name": "RelatedNodeInfo"}}, "text": "Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution. ", "start_char_idx": 3175, "end_char_idx": 3303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b444d533-9a36-41f7-902e-354afc854ee9": {"__data__": {"id_": "b444d533-9a36-41f7-902e-354afc854ee9", "embedding": null, "metadata": {"window": "And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "And then we'd expect that to ramp down as we get the pipeline . ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2852579-9f63-4a47-abb0-64b0bffba9a4", "node_type": "1", "metadata": {"window": "The core part of the business remained very strong within the segment for the \nquarter.  And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f44cfb362bdd3c848754e87791660e54381361364bd86358e5c794de550e2dce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1169e367-416d-4bcb-9a0e-ef7392ac2b8d", "node_type": "1", "metadata": {"window": "We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "We've got the \npipeline pretty full here as we exited October. "}, "hash": "2d6ac76b251a8bd37a91ef71369d7a881df797427d0376a2c545fcf5822b4494", "class_name": "RelatedNodeInfo"}}, "text": "And then we'd expect that to ramp down as we get the pipeline . ", "start_char_idx": 3303, "end_char_idx": 3367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1169e367-416d-4bcb-9a0e-ef7392ac2b8d": {"__data__": {"id_": "1169e367-416d-4bcb-9a0e-ef7392ac2b8d", "embedding": null, "metadata": {"window": "We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "We've got the \npipeline pretty full here as we exited October. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b444d533-9a36-41f7-902e-354afc854ee9", "node_type": "1", "metadata": {"window": "And our guidance that quarter to continue to be strong.   We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "And then we'd expect that to ramp down as we get the pipeline . ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df32eda07509e0970fcec7f3473f419e554431cf75f35e1cb8200f31c53d5f33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e54aa47-997d-4b6b-9ea6-67fc06413c95", "node_type": "1", "metadata": {"window": "Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . "}, "hash": "49ccd45689e936f692269e9025e3485aab5b0fb0301541192abe3fd56de2080c", "class_name": "RelatedNodeInfo"}}, "text": "We've got the \npipeline pretty full here as we exited October. ", "start_char_idx": 3367, "end_char_idx": 3430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e54aa47-997d-4b6b-9ea6-67fc06413c95": {"__data__": {"id_": "7e54aa47-997d-4b6b-9ea6-67fc06413c95", "embedding": null, "metadata": {"window": "Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a67c6fde-3741-4839-b762-38a12ca39ac5", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575e5c8f0704912f5d5d2a72f919860631d10edafbcbfea555bdd3f601735d9e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1169e367-416d-4bcb-9a0e-ef7392ac2b8d", "node_type": "1", "metadata": {"window": "We do expect the vaccine benefit to \nbe a bit greater in the second quarter, because of course there's more volume in Q2 than in Q1.  Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "We've got the \npipeline pretty full here as we exited October. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0a8da46a02b6cbc5994abf17b4e40dcff94b2d30f43fb84595e94c557cd0071", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82962c72-87c5-487b-956b-c956734d978c", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you. ", "original_text": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n"}, "hash": "52762aa023a139a29b261a5d74690c5383ffc2c785404b122bbb92c749cc2ea8", "class_name": "RelatedNodeInfo"}}, "text": "And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "start_char_idx": 3430, "end_char_idx": 3580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82962c72-87c5-487b-956b-c956734d978c": {"__data__": {"id_": "82962c72-87c5-487b-956b-c956734d978c", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you. ", "original_text": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e54aa47-997d-4b6b-9ea6-67fc06413c95", "node_type": "1", "metadata": {"window": "Jus t \ngiven the nature of the October most likely being the peak volume that we would expect to see for \nvaccine distribution.  And then we'd expect that to ramp down as we get the pipeline .  We've got the \npipeline pretty full here as we exited October.  And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "original_text": "And now the future volumes will be much more \npredicated on what the actual demand is, which of course, at this point in time is hard to anticipate . ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75ff9943bf955707bffc75beb213906ce869ef021afd3a27e1d288d0b4a0d806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34d28b23-6e5a-4aac-aaed-660f644d746d", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations . ", "original_text": "Operator:   We'll now move to our next question from Eric Percher from Nephron Research. "}, "hash": "5b97f544ce6e03752615260ff4f437617cb2e807ffb57e4c82061a21770411c0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n", "start_char_idx": 0, "end_char_idx": 58, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34d28b23-6e5a-4aac-aaed-660f644d746d": {"__data__": {"id_": "34d28b23-6e5a-4aac-aaed-660f644d746d", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations . ", "original_text": "Operator:   We'll now move to our next question from Eric Percher from Nephron Research. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82962c72-87c5-487b-956b-c956734d978c", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you. ", "original_text": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "171f9b27bf86eccd4e8c2ed67dda05e4496f26c6bc3006305585b8301f890432", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7eb52375-febd-4b5e-8c88-c8015f94b926", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts? ", "original_text": "Please go \nahead.  \n \n"}, "hash": "eb8763c7e9b0031ac4f1cb11cc70798d6d4f2b37ec8e1cde1c9ae6205b0d6a5d", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   We'll now move to our next question from Eric Percher from Nephron Research. ", "start_char_idx": 58, "end_char_idx": 147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7eb52375-febd-4b5e-8c88-c8015f94b926": {"__data__": {"id_": "7eb52375-febd-4b5e-8c88-c8015f94b926", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts? ", "original_text": "Please go \nahead.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34d28b23-6e5a-4aac-aaed-660f644d746d", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations . ", "original_text": "Operator:   We'll now move to our next question from Eric Percher from Nephron Research. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65d78ac96026be33672a8d869dddf9440c90d9e3b95ecfc9660ccd2935e1d48c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d8c2712-6ea4-432e-9e02-b4ec24de6648", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not? ", "original_text": "Eric Percher:   Thank you. "}, "hash": "0a8d2c732f2a6bc31dd676190eb085b150ca0e65e321e1a4dc156a46f2b189f9", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 147, "end_char_idx": 169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d8c2712-6ea4-432e-9e02-b4ec24de6648": {"__data__": {"id_": "9d8c2712-6ea4-432e-9e02-b4ec24de6648", "embedding": null, "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not? ", "original_text": "Eric Percher:   Thank you. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7eb52375-febd-4b5e-8c88-c8015f94b926", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts? ", "original_text": "Please go \nahead.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3b4395568cdc86992b70c39e84844e3fba1ac62c97f16ee9b42c5d244489759", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "338f6738-7751-48fa-acea-fade553f5375", "node_type": "1", "metadata": {"window": "Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on? ", "original_text": "A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations . "}, "hash": "34d1ec0d46d3eb203772cf65944ad53320d6c5f8d678a0a3a5b7c371e0823525", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:   Thank you. ", "start_char_idx": 169, "end_char_idx": 196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "338f6738-7751-48fa-acea-fade553f5375": {"__data__": {"id_": "338f6738-7751-48fa-acea-fade553f5375", "embedding": null, "metadata": {"window": "Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on? ", "original_text": "A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations . ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d8c2712-6ea4-432e-9e02-b4ec24de6648", "node_type": "1", "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not? ", "original_text": "Eric Percher:   Thank you. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "128c3153b83d98286663d09751e8670515ee8e598f363061f742084bbb16545b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ea1318-93fc-4ed3-b306-1eee90bfa3d3", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n", "original_text": "How much of that is core Medical and mitigation efforts? "}, "hash": "7d2ee4a3838895e4bbada3eae70ac6e52a42df0180c347ebc8b6021103866766", "class_name": "RelatedNodeInfo"}}, "text": "A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations . ", "start_char_idx": 196, "end_char_idx": 314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ea1318-93fc-4ed3-b306-1eee90bfa3d3": {"__data__": {"id_": "34ea1318-93fc-4ed3-b306-1eee90bfa3d3", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n", "original_text": "How much of that is core Medical and mitigation efforts? ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "338f6738-7751-48fa-acea-fade553f5375", "node_type": "1", "metadata": {"window": "Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on? ", "original_text": "A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations . ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32ed14e5a09b5d52e7835b1d53371c071775f64ee1a6e1285dc912b63569bf17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6831192f-ed4e-4331-b978-884ab35ac9e6", "node_type": "1", "metadata": {"window": "Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron. ", "original_text": "What \nwill carry through to the future versus not? "}, "hash": "ba2f51cefb10b35785c6712f76b150a5cb208f031630df5ef68c4aa077fa258c", "class_name": "RelatedNodeInfo"}}, "text": "How much of that is core Medical and mitigation efforts? ", "start_char_idx": 314, "end_char_idx": 371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6831192f-ed4e-4331-b978-884ab35ac9e6": {"__data__": {"id_": "6831192f-ed4e-4331-b978-884ab35ac9e6", "embedding": null, "metadata": {"window": "Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron. ", "original_text": "What \nwill carry through to the future versus not? ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ea1318-93fc-4ed3-b306-1eee90bfa3d3", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n", "original_text": "How much of that is core Medical and mitigation efforts? ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "641c8f58ea15ea350ec0696318e4b54fbd5fcf27a1dd0999d654110fda201eca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7bcf9f7-f3f4-4018-b4dd-d84a015d719f", "node_type": "1", "metadata": {"window": "A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations. ", "original_text": "And then were there any one -time items in Q1 we should \nkeep an eye on? "}, "hash": "cf1ea04fedc14115163eda8f8372207427b79275618be88fc4a8c3dc0f3c6442", "class_name": "RelatedNodeInfo"}}, "text": "What \nwill carry through to the future versus not? ", "start_char_idx": 371, "end_char_idx": 422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7bcf9f7-f3f4-4018-b4dd-d84a015d719f": {"__data__": {"id_": "e7bcf9f7-f3f4-4018-b4dd-d84a015d719f", "embedding": null, "metadata": {"window": "A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations. ", "original_text": "And then were there any one -time items in Q1 we should \nkeep an eye on? ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6831192f-ed4e-4331-b978-884ab35ac9e6", "node_type": "1", "metadata": {"window": "Eric Percher:   Thank you.  A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron. ", "original_text": "What \nwill carry through to the future versus not? ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33f34396223573595e2d98bc9ad93aa8f53d40e4d63b7b267a5861cd4761f964", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f067dcaa-d79f-4e00-9236-c9d76f7cc4cb", "node_type": "1", "metadata": {"window": "How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio. ", "original_text": "Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n"}, "hash": "d995676e2293cd7c6f3b09229d8bbd37844892cb14ab522cf0cc1e3388010685", "class_name": "RelatedNodeInfo"}}, "text": "And then were there any one -time items in Q1 we should \nkeep an eye on? ", "start_char_idx": 422, "end_char_idx": 495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f067dcaa-d79f-4e00-9236-c9d76f7cc4cb": {"__data__": {"id_": "f067dcaa-d79f-4e00-9236-c9d76f7cc4cb", "embedding": null, "metadata": {"window": "How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio. ", "original_text": "Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7bcf9f7-f3f4-4018-b4dd-d84a015d719f", "node_type": "1", "metadata": {"window": "A question on Medical , specifically the over -delivery this quarter or upside \nthat you showed versus expectations .  How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations. ", "original_text": "And then were there any one -time items in Q1 we should \nkeep an eye on? ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9466165ac87205831e90fff9801fbd17a8dd310b26cb078bdccc37179ad50dfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54769bbb-c65a-4360-9d0a-55b803a567a5", "node_type": "1", "metadata": {"window": "What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan. ", "original_text": "Aaron Alt:   Good morning, Eric , it\u2019s Aaron. "}, "hash": "b566124a4027f7582a944ba413f4f22297404e80339ea019254887857e670097", "class_name": "RelatedNodeInfo"}}, "text": "Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n", "start_char_idx": 495, "end_char_idx": 624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54769bbb-c65a-4360-9d0a-55b803a567a5": {"__data__": {"id_": "54769bbb-c65a-4360-9d0a-55b803a567a5", "embedding": null, "metadata": {"window": "What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan. ", "original_text": "Aaron Alt:   Good morning, Eric , it\u2019s Aaron. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f067dcaa-d79f-4e00-9236-c9d76f7cc4cb", "node_type": "1", "metadata": {"window": "How much of that is core Medical and mitigation efforts?  What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio. ", "original_text": "Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74807729c39c13921da80e42c088f72a1d2497b298e15a1cf656102dc0a52f41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d094a9b2-7d3c-433f-89ac-188a39fd4a01", "node_type": "1", "metadata": {"window": "And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults. ", "original_text": "Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations. "}, "hash": "c56a93969e941e27fb91fe8c0c1f6ad78061cfb0c774f0a3bebc9089ed4d6a52", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:   Good morning, Eric , it\u2019s Aaron. ", "start_char_idx": 624, "end_char_idx": 670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d094a9b2-7d3c-433f-89ac-188a39fd4a01": {"__data__": {"id_": "d094a9b2-7d3c-433f-89ac-188a39fd4a01", "embedding": null, "metadata": {"window": "And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults. ", "original_text": "Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54769bbb-c65a-4360-9d0a-55b803a567a5", "node_type": "1", "metadata": {"window": "What \nwill carry through to the future versus not?  And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan. ", "original_text": "Aaron Alt:   Good morning, Eric , it\u2019s Aaron. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fca7bbb5d8971f6ab12fcb2defe63036bcb8a4825366beba080f37f2480195", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cf4d05f-5110-4f2f-bf38-346bda62acf1", "node_type": "1", "metadata": {"window": "Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n", "original_text": "The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio. "}, "hash": "f4a6813e53dc22b072d13a76cacc5ccaade655f8a7071c2db08927f6c035bc2c", "class_name": "RelatedNodeInfo"}}, "text": "Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations. ", "start_char_idx": 670, "end_char_idx": 784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cf4d05f-5110-4f2f-bf38-346bda62acf1": {"__data__": {"id_": "2cf4d05f-5110-4f2f-bf38-346bda62acf1", "embedding": null, "metadata": {"window": "Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n", "original_text": "The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d094a9b2-7d3c-433f-89ac-188a39fd4a01", "node_type": "1", "metadata": {"window": "And then were there any one -time items in Q1 we should \nkeep an eye on?  Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults. ", "original_text": "Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b79646671640c82cba2bf373f006dbaa24eb7c44d7bb97e81010a9e074259f08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ff30789-82c1-4dc7-97d6-155501d8e238", "node_type": "1", "metadata": {"window": "Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue. ", "original_text": "And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan. "}, "hash": "155a2773164a7c37be31e17a351aefc30f71500e6d23949d19e0a49b1abfeab9", "class_name": "RelatedNodeInfo"}}, "text": "The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio. ", "start_char_idx": 784, "end_char_idx": 960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ff30789-82c1-4dc7-97d6-155501d8e238": {"__data__": {"id_": "9ff30789-82c1-4dc7-97d6-155501d8e238", "embedding": null, "metadata": {"window": "Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue. ", "original_text": "And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cf4d05f-5110-4f2f-bf38-346bda62acf1", "node_type": "1", "metadata": {"window": "Any update on factors driving Q2 to Q4, including the incremental oil price and \ncommodity pressure of th e last few months?  \n \n Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n", "original_text": "The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3eda06e32f042337398e4b03a9fef257e37c244ffb15bf9694c7047fc90f44b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "399ab943-3f94-4553-a526-21f726eaf999", "node_type": "1", "metadata": {"window": "Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter. ", "original_text": "And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults. "}, "hash": "591257e5a39ddf444718c7ff90d1d3a551aadfad4aa969f7df56ec8edf34cd24", "class_name": "RelatedNodeInfo"}}, "text": "And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan. ", "start_char_idx": 960, "end_char_idx": 1083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "399ab943-3f94-4553-a526-21f726eaf999": {"__data__": {"id_": "399ab943-3f94-4553-a526-21f726eaf999", "embedding": null, "metadata": {"window": "Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter. ", "original_text": "And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ff30789-82c1-4dc7-97d6-155501d8e238", "node_type": "1", "metadata": {"window": "Aaron Alt:   Good morning, Eric , it\u2019s Aaron.  Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue. ", "original_text": "And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0364d9ea47213f70718b55f473d8c07277793051ea34a70e6af6f472b16a4f89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "786d1aeb-ba78-44e4-84be-ec955f414f22", "node_type": "1", "metadata": {"window": "The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical. ", "original_text": "So, we were quite pleased with the results that we gave.  \n \n"}, "hash": "4dbf225ca794acdb63a2e3928f046e9d73f1baba3e18cf9002f525164bf2dc4d", "class_name": "RelatedNodeInfo"}}, "text": "And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults. ", "start_char_idx": 1083, "end_char_idx": 1192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "786d1aeb-ba78-44e4-84be-ec955f414f22": {"__data__": {"id_": "786d1aeb-ba78-44e4-84be-ec955f414f22", "embedding": null, "metadata": {"window": "The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical. ", "original_text": "So, we were quite pleased with the results that we gave.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "399ab943-3f94-4553-a526-21f726eaf999", "node_type": "1", "metadata": {"window": "Lo ok, we were really pleased to see Q1, the results slightly \nexceeding our external or rather our expectations.  The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter. ", "original_text": "And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1a75d614cc79bbfe88886957a0832c4d94929fff57c903f785b54d7300f7ab9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8594854d-94af-4727-bbc0-51d9ce86bfe7", "node_type": "1", "metadata": {"window": "And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n", "original_text": "And we do expect that to continue. "}, "hash": "d65d15ceeb6ae160a8a5ab4079b6b1ed8fea4e04c3e4da424a10e6e95b6cff0c", "class_name": "RelatedNodeInfo"}}, "text": "So, we were quite pleased with the results that we gave.  \n \n", "start_char_idx": 1192, "end_char_idx": 1253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8594854d-94af-4727-bbc0-51d9ce86bfe7": {"__data__": {"id_": "8594854d-94af-4727-bbc0-51d9ce86bfe7", "embedding": null, "metadata": {"window": "And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n", "original_text": "And we do expect that to continue. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "786d1aeb-ba78-44e4-84be-ec955f414f22", "node_type": "1", "metadata": {"window": "The results or result of the team doing what they \nhad planned to do , as well as being good managers and always looking for optimization  opportunities \nacross the portfolio.  And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical. ", "original_text": "So, we were quite pleased with the results that we gave.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e5b252a4ed9996127ac5802b5f5024fe811c57a5329727e6f90193e450299be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b998be1d-cafb-4629-b671-c67c4904fba0", "node_type": "1", "metadata": {"window": "And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right? ", "original_text": "You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter. "}, "hash": "7e6033a406313b2ae4aa875cc8cf0d5e81d166b87aaa4fbc437611e7f511a974", "class_name": "RelatedNodeInfo"}}, "text": "And we do expect that to continue. ", "start_char_idx": 1253, "end_char_idx": 1288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b998be1d-cafb-4629-b671-c67c4904fba0": {"__data__": {"id_": "b998be1d-cafb-4629-b671-c67c4904fba0", "embedding": null, "metadata": {"window": "And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right? ", "original_text": "You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8594854d-94af-4727-bbc0-51d9ce86bfe7", "node_type": "1", "metadata": {"window": "And so, they did what they were expected to on the first part or first part of the \nyear for the Medical Improvement Plan.  And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n", "original_text": "And we do expect that to continue. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5a12e4744449776aaba0725a200b468f13b5a4fbd0d810c3d65e32b194f3cae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ac8749-77d2-43e5-8f4c-aa810547cd28", "node_type": "1", "metadata": {"window": "So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about. ", "original_text": "We are not changing our guidance for the \nyear on Medical. "}, "hash": "82c697f13de67c1116896a24adc78b9c11e459a4f332e930db6e8b6ceb4e8566", "class_name": "RelatedNodeInfo"}}, "text": "You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter. ", "start_char_idx": 1288, "end_char_idx": 1409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ac8749-77d2-43e5-8f4c-aa810547cd28": {"__data__": {"id_": "34ac8749-77d2-43e5-8f4c-aa810547cd28", "embedding": null, "metadata": {"window": "So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about. ", "original_text": "We are not changing our guidance for the \nyear on Medical. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b998be1d-cafb-4629-b671-c67c4904fba0", "node_type": "1", "metadata": {"window": "And there were no notable one -time items, contrary to some \nearlier quarters that complicated the re sults.  So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right? ", "original_text": "You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be6cb339aec88d5ffdaa54406fa39095786b03a90e9b4847c8a2744e273c046c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29d7fd9c-bf37-46c2-abbd-927ad216cf63", "node_type": "1", "metadata": {"window": "And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand. ", "original_text": "I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n"}, "hash": "4b4622ae0942deb8534dbb7bc5cf81648d584b52be93eff1bffe7a9cbc74e015", "class_name": "RelatedNodeInfo"}}, "text": "We are not changing our guidance for the \nyear on Medical. ", "start_char_idx": 1409, "end_char_idx": 1468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29d7fd9c-bf37-46c2-abbd-927ad216cf63": {"__data__": {"id_": "29d7fd9c-bf37-46c2-abbd-927ad216cf63", "embedding": null, "metadata": {"window": "And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand. ", "original_text": "I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ac8749-77d2-43e5-8f4c-aa810547cd28", "node_type": "1", "metadata": {"window": "So, we were quite pleased with the results that we gave.  \n \n And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about. ", "original_text": "We are not changing our guidance for the \nyear on Medical. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "004512a321d9522331f2dd2ed35b048db4d918f5886151069272188655be67e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f5d2eb9-e671-4f94-ad52-244654fb75c2", "node_type": "1", "metadata": {"window": "You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization . ", "original_text": "And the plans also haven't changed, right? "}, "hash": "8119b57f4a2b847d5519694515959603493f92a5a139934a95c973d70c314b49", "class_name": "RelatedNodeInfo"}}, "text": "I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n", "start_char_idx": 1468, "end_char_idx": 1651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f5d2eb9-e671-4f94-ad52-244654fb75c2": {"__data__": {"id_": "5f5d2eb9-e671-4f94-ad52-244654fb75c2", "embedding": null, "metadata": {"window": "You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization . ", "original_text": "And the plans also haven't changed, right? ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29d7fd9c-bf37-46c2-abbd-927ad216cf63", "node_type": "1", "metadata": {"window": "And we do expect that to continue.  You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand. ", "original_text": "I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0201de25eb66256ad49c7573c3bcdb5efabe5566d04fd8b144b966d7b0b663fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75f5be47-1f29-4854-a124-06ec613e30e5", "node_type": "1", "metadata": {"window": "We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n", "original_text": "It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about. "}, "hash": "ecff3afc14c0b2dce71d0c90f7fd817fcd55f5b4992746ee0bcaae2e66a47e0a", "class_name": "RelatedNodeInfo"}}, "text": "And the plans also haven't changed, right? ", "start_char_idx": 1651, "end_char_idx": 1694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75f5be47-1f29-4854-a124-06ec613e30e5": {"__data__": {"id_": "75f5be47-1f29-4854-a124-06ec613e30e5", "embedding": null, "metadata": {"window": "We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n", "original_text": "It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f5d2eb9-e671-4f94-ad52-244654fb75c2", "node_type": "1", "metadata": {"window": "You will have noted from our guidance for the year that we do \nexpect slight continued improvement quarter over quarter.  We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization . ", "original_text": "And the plans also haven't changed, right? ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0c658730f40e0d38c524bb63cbd886885f921a20510e06707578b5c55f2d1a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13e4bcee-a11b-4cad-b3c8-10cac83184a6", "node_type": "1", "metadata": {"window": "I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah. ", "original_text": "Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand. "}, "hash": "136b72986063ba5b73cd687f46c57bdf65bb44a53f1dbe5e7201088bef617e05", "class_name": "RelatedNodeInfo"}}, "text": "It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about. ", "start_char_idx": 1694, "end_char_idx": 1842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13e4bcee-a11b-4cad-b3c8-10cac83184a6": {"__data__": {"id_": "13e4bcee-a11b-4cad-b3c8-10cac83184a6", "embedding": null, "metadata": {"window": "I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah. ", "original_text": "Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75f5be47-1f29-4854-a124-06ec613e30e5", "node_type": "1", "metadata": {"window": "We are not changing our guidance for the \nyear on Medical.  I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n", "original_text": "It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a82501dcc08e853e227f511d1e8279f8351b15ea32d269d6efd729cb63b6689b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68977a8d-9c34-4be6-8e1f-bf1c170d24b1", "node_type": "1", "metadata": {"window": "And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there. ", "original_text": "We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization . "}, "hash": "13d2a10cd02e6f32ffec216d6ddb8c599e4eb0847ac86a68ce7f9ddafb5f872a", "class_name": "RelatedNodeInfo"}}, "text": "Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand. ", "start_char_idx": 1842, "end_char_idx": 1990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68977a8d-9c34-4be6-8e1f-bf1c170d24b1": {"__data__": {"id_": "68977a8d-9c34-4be6-8e1f-bf1c170d24b1", "embedding": null, "metadata": {"window": "And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there. ", "original_text": "We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization . ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13e4bcee-a11b-4cad-b3c8-10cac83184a6", "node_type": "1", "metadata": {"window": "I want to emphasize  that we've taken a balanced approach and believe that the \n$400 million profit number for the year is the right target or the right guidance for that business.  \n And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah. ", "original_text": "Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e014d451ae49d91a0fc17146b6818815dbf6b5e34060adbd2bd02c044e9a8f7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "700536e1-780e-4695-a2ef-31c5361d980e", "node_type": "1", "metadata": {"window": "It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant. ", "original_text": "And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n"}, "hash": "d03ecb4485dcbef03a1441a2e20322b01b701634dc5d536ad09abaeaa452b401", "class_name": "RelatedNodeInfo"}}, "text": "We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization . ", "start_char_idx": 1990, "end_char_idx": 2130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "700536e1-780e-4695-a2ef-31c5361d980e": {"__data__": {"id_": "700536e1-780e-4695-a2ef-31c5361d980e", "embedding": null, "metadata": {"window": "It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant. ", "original_text": "And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68977a8d-9c34-4be6-8e1f-bf1c170d24b1", "node_type": "1", "metadata": {"window": "And the plans also haven't changed, right?  It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there. ", "original_text": "We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization . ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8ab4d9ab39caa873d7ef0113d0d6ae910fd4e75ec42d7f0a73eba9c0b18a9e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "955a1205-e270-4295-9d1b-e8fe4d0924e1", "node_type": "1", "metadata": {"window": "Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity. ", "original_text": "Jason Holler:   Yeah. "}, "hash": "8d8d00050db6841760b0ae740dd11d96223bff53dc4c32d2c0ae71297e780d45", "class_name": "RelatedNodeInfo"}}, "text": "And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n", "start_char_idx": 2130, "end_char_idx": 2212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "955a1205-e270-4295-9d1b-e8fe4d0924e1": {"__data__": {"id_": "955a1205-e270-4295-9d1b-e8fe4d0924e1", "embedding": null, "metadata": {"window": "Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity. ", "original_text": "Jason Holler:   Yeah. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "700536e1-780e-4695-a2ef-31c5361d980e", "node_type": "1", "metadata": {"window": "It's going to start with the continued execution of the \nMedical Improvement Plan, the inflation mitigation elements that we've been talking about.  Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant. ", "original_text": "And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2677476d892c10e0c9233fa66938eb62d2ec3e4f4150675f8e19f75a81de4a51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c1496fe-9d87-48ba-998a-14d8afc43552", "node_type": "1", "metadata": {"window": "We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that. ", "original_text": "Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there. "}, "hash": "f0fb2dc7ba1c2b52b2c0554551db27a49e6434f20f228d9f4f5cded8b704501d", "class_name": "RelatedNodeInfo"}}, "text": "Jason Holler:   Yeah. ", "start_char_idx": 2212, "end_char_idx": 2234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c1496fe-9d87-48ba-998a-14d8afc43552": {"__data__": {"id_": "2c1496fe-9d87-48ba-998a-14d8afc43552", "embedding": null, "metadata": {"window": "We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that. ", "original_text": "Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "955a1205-e270-4295-9d1b-e8fe4d0924e1", "node_type": "1", "metadata": {"window": "Jason \nhighlighted that we had hit 70% plus in the quarter as well, and they're going to continue to optimize  \nand grow the Cardinal Health Brand.  We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity. ", "original_text": "Jason Holler:   Yeah. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "540a9d66309c509c01c18ff0a0f34c45927c8f59387a1140c0ab6de1f002d960", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a53f2be6-0e9a-49df-8f6c-8a7621699b22", "node_type": "1", "metadata": {"window": "And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way. ", "original_text": "There was not anything significant. "}, "hash": "e5b4dace04f9e9e6061c7d3deb4cdd4fb99e150fd1f27835300d0fc61fef1c0d", "class_name": "RelatedNodeInfo"}}, "text": "Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there. ", "start_char_idx": 2234, "end_char_idx": 2371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a53f2be6-0e9a-49df-8f6c-8a7621699b22": {"__data__": {"id_": "a53f2be6-0e9a-49df-8f6c-8a7621699b22", "embedding": null, "metadata": {"window": "And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way. ", "original_text": "There was not anything significant. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c1496fe-9d87-48ba-998a-14d8afc43552", "node_type": "1", "metadata": {"window": "We're continuing to focus on driving more out of at-Home and \nthe other growth businesses as well as simplification and cost optimization .  And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that. ", "original_text": "Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ee1225d93024bf49a9dbf47b540acbadcaddbcdc906600fa25ff1eadab54279", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfaca6fc-83e1-4553-a39a-a0c6e92a80e8", "node_type": "1", "metadata": {"window": "Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets. ", "original_text": "So, I \nknow we've all been on this long journey as it relates to the impacts of commodity. "}, "hash": "39cd2ecb3ce5f43ac8b8073e8a057d0c0bec24277d7871ad0730dcb0de30ad3a", "class_name": "RelatedNodeInfo"}}, "text": "There was not anything significant. ", "start_char_idx": 2371, "end_char_idx": 2407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfaca6fc-83e1-4553-a39a-a0c6e92a80e8": {"__data__": {"id_": "bfaca6fc-83e1-4553-a39a-a0c6e92a80e8", "embedding": null, "metadata": {"window": "Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets. ", "original_text": "So, I \nknow we've all been on this long journey as it relates to the impacts of commodity. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a53f2be6-0e9a-49df-8f6c-8a7621699b22", "node_type": "1", "metadata": {"window": "And so overall, a great \nquarter and goo d expectations for the year to come.  \n \n Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way. ", "original_text": "There was not anything significant. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4906c238c4e6d1ebb1eeb1dfe4f6077fa2f9b3af96f2fd9f8cd20d5b914b96a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f35f29f-f0b5-46f3-99ad-0692359a8a74", "node_type": "1", "metadata": {"window": "Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change. ", "original_text": "So let me just \nspend a moment on that. "}, "hash": "42d5eb846b42d7bafbffd0f44e6006f0a75b8f132621dd19d2d398fdce30dba1", "class_name": "RelatedNodeInfo"}}, "text": "So, I \nknow we've all been on this long journey as it relates to the impacts of commodity. ", "start_char_idx": 2407, "end_char_idx": 2498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f35f29f-f0b5-46f3-99ad-0692359a8a74": {"__data__": {"id_": "6f35f29f-f0b5-46f3-99ad-0692359a8a74", "embedding": null, "metadata": {"window": "Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change. ", "original_text": "So let me just \nspend a moment on that. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfaca6fc-83e1-4553-a39a-a0c6e92a80e8", "node_type": "1", "metadata": {"window": "Jason Holler:   Yeah.  Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets. ", "original_text": "So, I \nknow we've all been on this long journey as it relates to the impacts of commodity. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1958d99745e718be1f8755888d7955bca92028c9e03ab225266a2a0509f26be1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c9693a0-3b0a-4534-9347-03899891f5d4", "node_type": "1", "metadata": {"window": "There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction. ", "original_text": "As I think about the commodity and just general inflation, let me answer the \nquestion that way. "}, "hash": "376f55bb724a8d26337f52571353dea224eab15cd4fb49e2c7c0575ac333fc47", "class_name": "RelatedNodeInfo"}}, "text": "So let me just \nspend a moment on that. ", "start_char_idx": 2498, "end_char_idx": 2538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c9693a0-3b0a-4534-9347-03899891f5d4": {"__data__": {"id_": "6c9693a0-3b0a-4534-9347-03899891f5d4", "embedding": null, "metadata": {"window": "There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction. ", "original_text": "As I think about the commodity and just general inflation, let me answer the \nquestion that way. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f35f29f-f0b5-46f3-99ad-0692359a8a74", "node_type": "1", "metadata": {"window": "Another thing I'd add, Eric, I think the component of your question was just \nasking about commodities and  if there's any impact there.  There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change. ", "original_text": "So let me just \nspend a moment on that. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e028000858fd164f8a3dc1d400516dd227a9d9edbccc1c296a8fa8fd765ffd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d266477f-00c9-4d45-aa1d-5f051ea2292f", "node_type": "1", "metadata": {"window": "So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters. ", "original_text": "I put our work into a couple of ke y buckets. "}, "hash": "ec9ffc34a89b547cc47f8e059a612de080bc5cd8cd2811ab2b435a89144af7f0", "class_name": "RelatedNodeInfo"}}, "text": "As I think about the commodity and just general inflation, let me answer the \nquestion that way. ", "start_char_idx": 2538, "end_char_idx": 2635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d266477f-00c9-4d45-aa1d-5f051ea2292f": {"__data__": {"id_": "d266477f-00c9-4d45-aa1d-5f051ea2292f", "embedding": null, "metadata": {"window": "So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters. ", "original_text": "I put our work into a couple of ke y buckets. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c9693a0-3b0a-4534-9347-03899891f5d4", "node_type": "1", "metadata": {"window": "There was not anything significant.  So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction. ", "original_text": "As I think about the commodity and just general inflation, let me answer the \nquestion that way. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdaac2ff1fda079808239d7220bf68733de84194bc16e300422235081e7ed126", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "786d7dd0-4205-4d5a-b5dc-46d50ee08398", "node_type": "1", "metadata": {"window": "So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n", "original_text": "The international freight piece is the \nonly compon ent that we've seen a meaningful change. "}, "hash": "13fc35d6225e501f1c2dca795bc8d3a8103866bb1c3286b7115756e064a5006d", "class_name": "RelatedNodeInfo"}}, "text": "I put our work into a couple of ke y buckets. ", "start_char_idx": 2635, "end_char_idx": 2681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "786d7dd0-4205-4d5a-b5dc-46d50ee08398": {"__data__": {"id_": "786d7dd0-4205-4d5a-b5dc-46d50ee08398", "embedding": null, "metadata": {"window": "So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n", "original_text": "The international freight piece is the \nonly compon ent that we've seen a meaningful change. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d266477f-00c9-4d45-aa1d-5f051ea2292f", "node_type": "1", "metadata": {"window": "So, I \nknow we've all been on this long journey as it relates to the impacts of commodity.  So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters. ", "original_text": "I put our work into a couple of ke y buckets. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d8b27d234aa7eefefbbab72d7c0be03ed87a8fcfb507289ab790bb6e276ce1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42cf2cae-c216-4c73-9365-c0d004b6136a", "node_type": "1", "metadata": {"window": "As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied . ", "original_text": "And of course,  that started about a year ago, \nand it was a dramatic reduction. "}, "hash": "ec726833d1f3fef41472e09d895863775f5e1091219ced03be0132947211650c", "class_name": "RelatedNodeInfo"}}, "text": "The international freight piece is the \nonly compon ent that we've seen a meaningful change. ", "start_char_idx": 2681, "end_char_idx": 2774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42cf2cae-c216-4c73-9365-c0d004b6136a": {"__data__": {"id_": "42cf2cae-c216-4c73-9365-c0d004b6136a", "embedding": null, "metadata": {"window": "As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied . ", "original_text": "And of course,  that started about a year ago, \nand it was a dramatic reduction. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "786d7dd0-4205-4d5a-b5dc-46d50ee08398", "node_type": "1", "metadata": {"window": "So let me just \nspend a moment on that.  As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n", "original_text": "The international freight piece is the \nonly compon ent that we've seen a meaningful change. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a3fe6ba542a9c90e5f1210c8ecc896c0b0bdbe5eb60693ca6cd18c4a7d2de2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a21edc9-1435-44b8-bb50-5864cf789caf", "node_type": "1", "metadata": {"window": "I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated. ", "original_text": "So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters. "}, "hash": "9c8b4239f4ff92bb7d096c6e3d6bd3e0ec7e6026569f0072b53668441e18e5b1", "class_name": "RelatedNodeInfo"}}, "text": "And of course,  that started about a year ago, \nand it was a dramatic reduction. ", "start_char_idx": 2774, "end_char_idx": 2855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a21edc9-1435-44b8-bb50-5864cf789caf": {"__data__": {"id_": "6a21edc9-1435-44b8-bb50-5864cf789caf", "embedding": null, "metadata": {"window": "I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated. ", "original_text": "So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42cf2cae-c216-4c73-9365-c0d004b6136a", "node_type": "1", "metadata": {"window": "As I think about the commodity and just general inflation, let me answer the \nquestion that way.  I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied . ", "original_text": "And of course,  that started about a year ago, \nand it was a dramatic reduction. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33e820c84e5f00aa98a908b3361742948f130c85518a532f892e6267a3e1b1ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "546146c8-1e78-4cd1-9522-432a75033b6b", "node_type": "1", "metadata": {"window": "The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n", "original_text": "So that is certainly a key \ncomponent of it.  \n \n"}, "hash": "0d9dfdb91c9e99e4766e214844d8a6c050512e932df064b8fe8c23f38bbaee68", "class_name": "RelatedNodeInfo"}}, "text": "So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters. ", "start_char_idx": 2855, "end_char_idx": 3102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "546146c8-1e78-4cd1-9522-432a75033b6b": {"__data__": {"id_": "546146c8-1e78-4cd1-9522-432a75033b6b", "embedding": null, "metadata": {"window": "The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n", "original_text": "So that is certainly a key \ncomponent of it.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a21edc9-1435-44b8-bb50-5864cf789caf", "node_type": "1", "metadata": {"window": "I put our work into a couple of ke y buckets.  The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated. ", "original_text": "So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4633a38222de1a657ec7435374323c00186b7e08ca484b9f7ca929fb9e938adf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58cea524-090a-495c-b890-45504db3aa53", "node_type": "1", "metadata": {"window": "And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise. ", "original_text": "What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied . "}, "hash": "4656ba795a99e170eac0595ad4d5abc5cfb5b3cba2ae0a1d1e0de914c8ba5ca0", "class_name": "RelatedNodeInfo"}}, "text": "So that is certainly a key \ncomponent of it.  \n \n", "start_char_idx": 3102, "end_char_idx": 3151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58cea524-090a-495c-b890-45504db3aa53": {"__data__": {"id_": "58cea524-090a-495c-b890-45504db3aa53", "embedding": null, "metadata": {"window": "And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise. ", "original_text": "What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied . ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "546146c8-1e78-4cd1-9522-432a75033b6b", "node_type": "1", "metadata": {"window": "The international freight piece is the \nonly compon ent that we've seen a meaningful change.  And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n", "original_text": "So that is certainly a key \ncomponent of it.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18a57ac5e07379369e0718cf1c4dc92963162f6d179ee2a1700f1a04e32d295f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec0863b1-4e57-4383-a724-2072c31bc2d3", "node_type": "1", "metadata": {"window": "So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "I would say that they are generally remain elevated. "}, "hash": "c6dd0377c0642a8788f31aad15b2143c59648ecbade85538e8edf88bf8fcaf24", "class_name": "RelatedNodeInfo"}}, "text": "What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied . ", "start_char_idx": 3151, "end_char_idx": 3401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec0863b1-4e57-4383-a724-2072c31bc2d3": {"__data__": {"id_": "ec0863b1-4e57-4383-a724-2072c31bc2d3", "embedding": null, "metadata": {"window": "So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "I would say that they are generally remain elevated. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58cea524-090a-495c-b890-45504db3aa53", "node_type": "1", "metadata": {"window": "And of course,  that started about a year ago, \nand it was a dramatic reduction.  So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise. ", "original_text": "What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied . ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9df17b49e063496514b71c81709daae8383e1aed04fab8de79e78c1f1b95cd5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "572c6b88-5b64-4d91-8083-a892403f2f15", "node_type": "1", "metadata": {"window": "So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n"}, "hash": "7a2abac5f3d5f539c846ba83056c5d7e267540f09411b59b1d7ed6bc5a96c212", "class_name": "RelatedNodeInfo"}}, "text": "I would say that they are generally remain elevated. ", "start_char_idx": 3401, "end_char_idx": 3454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "572c6b88-5b64-4d91-8083-a892403f2f15": {"__data__": {"id_": "572c6b88-5b64-4d91-8083-a892403f2f15", "embedding": null, "metadata": {"window": "So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec0863b1-4e57-4383-a724-2072c31bc2d3", "node_type": "1", "metadata": {"window": "So that reduction is as expected and given the elongated supply \nchain we had at that time, it took some time for that to work through and hit our P&L, but we're now \nseeing the more significan t benefits of that over the last couple of quarters.  So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "I would say that they are generally remain elevated. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5844723e3b22ef2bf0647b65455761bb6fed6891465fb5dd08529eb21c6301a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08c462fd-c57b-4624-9bab-284c0b0fec77", "node_type": "1", "metadata": {"window": "What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "So certainly noise. "}, "hash": "78e2933f433ad15cbb9422b94c73458e25214fceae66c9c251490b1c275a72fe", "class_name": "RelatedNodeInfo"}}, "text": "A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n", "start_char_idx": 3454, "end_char_idx": 3570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08c462fd-c57b-4624-9bab-284c0b0fec77": {"__data__": {"id_": "08c462fd-c57b-4624-9bab-284c0b0fec77", "embedding": null, "metadata": {"window": "What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "So certainly noise. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "572c6b88-5b64-4d91-8083-a892403f2f15", "node_type": "1", "metadata": {"window": "So that is certainly a key \ncomponent of it.  \n \n What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c432e273db8014845abf5ac99019df2b4050547f2d687cb05564a54d2e0e3bc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cfc6bf4-6e4f-4086-bcdc-fbb6c170f19a", "node_type": "1", "metadata": {"window": "I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "But how I think about it going forward and what my anticipation is, w e're just n ot "}, "hash": "b1a39244cb9090248fc64848efd0d9134a5effb35f402ebf4e758e5039938c00", "class_name": "RelatedNodeInfo"}}, "text": "So certainly noise. ", "start_char_idx": 3570, "end_char_idx": 3590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cfc6bf4-6e4f-4086-bcdc-fbb6c170f19a": {"__data__": {"id_": "1cfc6bf4-6e4f-4086-bcdc-fbb6c170f19a", "embedding": null, "metadata": {"window": "I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "But how I think about it going forward and what my anticipation is, w e're just n ot ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b23aaeb4-72c2-462d-8c96-16c55691043d", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83f1a426165d56484b73a3fa800f372692b447bc1466a3859f2b8c809a4d31d4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08c462fd-c57b-4624-9bab-284c0b0fec77", "node_type": "1", "metadata": {"window": "What I would say about all the other commodities or all the other inflation, specifically the commodity \nimpacts, whether it's the oil -based products, polypropylene, polyethylene or unwoven s and wovens \nand other types of inputs which are varied .  I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "So certainly noise. ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16d80e2433fc048bf926a8a44163cf8093d9f3201ffa439bb1e1fb19ef9c8678", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "099e1516-c617-416c-83d2-9eff5649bebb", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n", "original_text": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago. "}, "hash": "51e6568606bec3e4e66db145eacd5b42fb53ca52e078546c359451a4534215ee", "class_name": "RelatedNodeInfo"}}, "text": "But how I think about it going forward and what my anticipation is, w e're just n ot ", "start_char_idx": 3590, "end_char_idx": 3675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "099e1516-c617-416c-83d2-9eff5649bebb": {"__data__": {"id_": "099e1516-c617-416c-83d2-9eff5649bebb", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n", "original_text": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cfc6bf4-6e4f-4086-bcdc-fbb6c170f19a", "node_type": "1", "metadata": {"window": "I would say that they are generally remain elevated.  A little \nbit volatile here and there, but generally elevated and not real different than what we had anticipated. \n So certainly noise.  But how I think about it going forward and what my anticipation is, w e're just n ot ", "original_text": "But how I think about it going forward and what my anticipation is, w e're just n ot ", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "894ae239dbe4608380fe57be1f71c6e4bb972436ce800f7235ecd6411af1f766", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d732acb5-3f08-431b-934c-ae38151bd6f3", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n", "original_text": "So, there is volatility, no doubt there will always \nbe volatility. "}, "hash": "29771f9f5c2b2626dd58c4b1821ca1290115c1e085c7e181481c4d17f98f8893", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago. ", "start_char_idx": 0, "end_char_idx": 73, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d732acb5-3f08-431b-934c-ae38151bd6f3": {"__data__": {"id_": "d732acb5-3f08-431b-934c-ae38151bd6f3", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n", "original_text": "So, there is volatility, no doubt there will always \nbe volatility. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "099e1516-c617-416c-83d2-9eff5649bebb", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n", "original_text": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25bda937d54a651a834135108067b69bdc895602036f5eaec6b74c3be0ca1a07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "328bf653-c03a-499d-8668-fa37a8c00f47", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS. ", "original_text": "But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now. "}, "hash": "cf094299fc96fefe64c744c7d618d837830b37f2afdb10a38b40a64da9f5b292", "class_name": "RelatedNodeInfo"}}, "text": "So, there is volatility, no doubt there will always \nbe volatility. ", "start_char_idx": 73, "end_char_idx": 141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "328bf653-c03a-499d-8668-fa37a8c00f47": {"__data__": {"id_": "328bf653-c03a-499d-8668-fa37a8c00f47", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS. ", "original_text": "But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d732acb5-3f08-431b-934c-ae38151bd6f3", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n", "original_text": "So, there is volatility, no doubt there will always \nbe volatility. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c26ca20cf2f35dd6ec20f90977a13d9de38c4ccaa6e5c2c482ad531b23aaf26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f8e3dc3-2599-45d4-924f-94e54b73a616", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead. ", "original_text": "And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n"}, "hash": "6f180e728f3bfc339d1165e59875164e84d6a636015c49fa8e3e960fe3b5a6bd", "class_name": "RelatedNodeInfo"}}, "text": "But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now. ", "start_char_idx": 141, "end_char_idx": 245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f8e3dc3-2599-45d4-924f-94e54b73a616": {"__data__": {"id_": "5f8e3dc3-2599-45d4-924f-94e54b73a616", "embedding": null, "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead. ", "original_text": "And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "328bf653-c03a-499d-8668-fa37a8c00f47", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS. ", "original_text": "But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d03a7d88c547a8e1f078ccdd83698af1bcde8312847fc35b7b78b5736130e8fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c12f155-2639-4b88-9b5b-9fee55da5a08", "node_type": "1", "metadata": {"window": "So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n", "original_text": "Matt Sims:   The next question, please.  \n \n"}, "hash": "fea0c862587b9f6ab36089e918eb6dc470d0027194ffc153d6f3d71f0f099a5c", "class_name": "RelatedNodeInfo"}}, "text": "And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n", "start_char_idx": 245, "end_char_idx": 393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c12f155-2639-4b88-9b5b-9fee55da5a08": {"__data__": {"id_": "0c12f155-2639-4b88-9b5b-9fee55da5a08", "embedding": null, "metadata": {"window": "So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n", "original_text": "Matt Sims:   The next question, please.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f8e3dc3-2599-45d4-924f-94e54b73a616", "node_type": "1", "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead. ", "original_text": "And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c25e3f1ca9e81593ddd253758f02abd67ff872b0a2633a4562af6bdb5b9263c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0657404-80e7-4af7-a3d2-fe95e00121fc", "node_type": "1", "metadata": {"window": "But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great. ", "original_text": "Operator:  Kevin Caliendo, UBS. "}, "hash": "03c93ac66ed8c47382876cfec77d339572a07c1a0167f7f7f362ef729fcf8bef", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:   The next question, please.  \n \n", "start_char_idx": 393, "end_char_idx": 437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0657404-80e7-4af7-a3d2-fe95e00121fc": {"__data__": {"id_": "e0657404-80e7-4af7-a3d2-fe95e00121fc", "embedding": null, "metadata": {"window": "But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great. ", "original_text": "Operator:  Kevin Caliendo, UBS. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c12f155-2639-4b88-9b5b-9fee55da5a08", "node_type": "1", "metadata": {"window": "So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n", "original_text": "Matt Sims:   The next question, please.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "541d8b96c2f3603aa2f87b700e29c398b03c7b379d3d31cd3375ca49873be606", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f00c8034-83f4-4cd3-940e-3ba87d0077f8", "node_type": "1", "metadata": {"window": "And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks. ", "original_text": "Please go ahead. "}, "hash": "514ed9df727ba95b837c9621f177f0d175754f3a0626afe3b3c455a04e5007c1", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Kevin Caliendo, UBS. ", "start_char_idx": 437, "end_char_idx": 469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f00c8034-83f4-4cd3-940e-3ba87d0077f8": {"__data__": {"id_": "f00c8034-83f4-4cd3-940e-3ba87d0077f8", "embedding": null, "metadata": {"window": "And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks. ", "original_text": "Please go ahead. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0657404-80e7-4af7-a3d2-fe95e00121fc", "node_type": "1", "metadata": {"window": "But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great. ", "original_text": "Operator:  Kevin Caliendo, UBS. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c2ca80e360500a433bb263d22386a3458ad6859092fa6c7a2d4c8ef81ca8d07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29a9d8e6-674c-4bd3-8c83-7eef06d62eb4", "node_type": "1", "metadata": {"window": "Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected? ", "original_text": "Your line is open.  \n \n"}, "hash": "565aab8bd7d466a33d56d885514782e5bbcf387a6603dfd8ba1b12957f297b8d", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead. ", "start_char_idx": 469, "end_char_idx": 486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29a9d8e6-674c-4bd3-8c83-7eef06d62eb4": {"__data__": {"id_": "29a9d8e6-674c-4bd3-8c83-7eef06d62eb4", "embedding": null, "metadata": {"window": "Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected? ", "original_text": "Your line is open.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f00c8034-83f4-4cd3-940e-3ba87d0077f8", "node_type": "1", "metadata": {"window": "And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks. ", "original_text": "Please go ahead. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "804b8b8687619ab9aad6ddf7573c1a83cdba60af133fc497511491aa802429a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20938a40-e5e4-455b-a092-522001aa31f3", "node_type": "1", "metadata": {"window": "Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines? ", "original_text": "Kevin Caliendo:  Great. "}, "hash": "44899ef9ee15a13b2ce4d1c741812f86af7f34d8d64219c71f8bc767312da176", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n \n", "start_char_idx": 486, "end_char_idx": 509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20938a40-e5e4-455b-a092-522001aa31f3": {"__data__": {"id_": "20938a40-e5e4-455b-a092-522001aa31f3", "embedding": null, "metadata": {"window": "Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines? ", "original_text": "Kevin Caliendo:  Great. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29a9d8e6-674c-4bd3-8c83-7eef06d62eb4", "node_type": "1", "metadata": {"window": "Matt Sims:   The next question, please.  \n \n Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected? ", "original_text": "Your line is open.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3113a783120b479b4432510c5b40fbe37e6634765b17243ea2de6bdf3ec5711d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "455df7b1-c41e-4c59-bccb-ccb9e5b0c1d3", "node_type": "1", "metadata": {"window": "Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ? ", "original_text": "Thanks. "}, "hash": "e516933423ed9e82de7ced7e3a311feac27e6fe123f2a0ea0105465b0518e2f8", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo:  Great. ", "start_char_idx": 509, "end_char_idx": 533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "455df7b1-c41e-4c59-bccb-ccb9e5b0c1d3": {"__data__": {"id_": "455df7b1-c41e-4c59-bccb-ccb9e5b0c1d3", "embedding": null, "metadata": {"window": "Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ? ", "original_text": "Thanks. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20938a40-e5e4-455b-a092-522001aa31f3", "node_type": "1", "metadata": {"window": "Operator:  Kevin Caliendo, UBS.  Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines? ", "original_text": "Kevin Caliendo:  Great. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8c84fb2a79c439c6c551a6692855b359156f665ed319162e378ae67eade7dc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "621e82ff-f64f-402f-bbc4-5cf0858111d4", "node_type": "1", "metadata": {"window": "Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n", "original_text": "I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected? "}, "hash": "034a4122e26b9f7f5f9713eb987dab86b06bb749339c70fdcef9902732bbd0e7", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 533, "end_char_idx": 541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "621e82ff-f64f-402f-bbc4-5cf0858111d4": {"__data__": {"id_": "621e82ff-f64f-402f-bbc4-5cf0858111d4", "embedding": null, "metadata": {"window": "Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n", "original_text": "I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "455df7b1-c41e-4c59-bccb-ccb9e5b0c1d3", "node_type": "1", "metadata": {"window": "Please go ahead.  Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ? ", "original_text": "Thanks. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a44a72ca1647ab49cb6066bc8959d67b5d1618592b128cf2a469ab305ca02c55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "996ec2e8-034e-4588-83c7-2f69ae19e36c", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context. ", "original_text": "If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines? "}, "hash": "e1ec0956c36269b468f22a7baa0f44150d7942bab506a0fe3d9d7a4d00cbcf61", "class_name": "RelatedNodeInfo"}}, "text": "I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected? ", "start_char_idx": 541, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "996ec2e8-034e-4588-83c7-2f69ae19e36c": {"__data__": {"id_": "996ec2e8-034e-4588-83c7-2f69ae19e36c", "embedding": null, "metadata": {"window": "Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context. ", "original_text": "If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "621e82ff-f64f-402f-bbc4-5cf0858111d4", "node_type": "1", "metadata": {"window": "Your line is open.  \n \n Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n", "original_text": "I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41a0e44bc1c57e095c2cdd36240c3895638e2d5af47b70febe51b9532e5f722f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cd0122f-db5c-4204-a134-55b3ed6c4bee", "node_type": "1", "metadata": {"window": "Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business. ", "original_text": "Or maybe you can just break out where the benefits came from ? "}, "hash": "c1a82604c10d602a8a8e716ee47f0ff5d7effd0faf7f5433297d6fb193d6190e", "class_name": "RelatedNodeInfo"}}, "text": "If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines? ", "start_char_idx": 734, "end_char_idx": 927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cd0122f-db5c-4204-a134-55b3ed6c4bee": {"__data__": {"id_": "9cd0122f-db5c-4204-a134-55b3ed6c4bee", "embedding": null, "metadata": {"window": "Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business. ", "original_text": "Or maybe you can just break out where the benefits came from ? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "996ec2e8-034e-4588-83c7-2f69ae19e36c", "node_type": "1", "metadata": {"window": "Kevin Caliendo:  Great.  Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context. ", "original_text": "If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4538079098315750a7412da674cb7a8d8ce102b9c33c1f372d862a80b4a1392", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17a903d3-f986-47f9-8b45-9827881a5318", "node_type": "1", "metadata": {"window": "I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%. ", "original_text": "I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n"}, "hash": "38a1439069fdc2f620c577d35ec6878933d21068f32975a50cfc935bc1bc625f", "class_name": "RelatedNodeInfo"}}, "text": "Or maybe you can just break out where the benefits came from ? ", "start_char_idx": 927, "end_char_idx": 990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17a903d3-f986-47f9-8b45-9827881a5318": {"__data__": {"id_": "17a903d3-f986-47f9-8b45-9827881a5318", "embedding": null, "metadata": {"window": "I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%. ", "original_text": "I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cd0122f-db5c-4204-a134-55b3ed6c4bee", "node_type": "1", "metadata": {"window": "Thanks.  I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business. ", "original_text": "Or maybe you can just break out where the benefits came from ? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0947972dc9e82b799c9cf079de60d2322a5d40683d26a3a89a5e02a267f650cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aadc03bb-7622-47bd-94c1-6d423e812afb", "node_type": "1", "metadata": {"window": "If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors. ", "original_text": "Aaron Alt:  We're happy to provide a little more context. "}, "hash": "a737a33f816e7ee83d1c1c2bfd0d47cefadd245dcab8f3c37955c2f01f0ac531", "class_name": "RelatedNodeInfo"}}, "text": "I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n", "start_char_idx": 990, "end_char_idx": 1125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aadc03bb-7622-47bd-94c1-6d423e812afb": {"__data__": {"id_": "aadc03bb-7622-47bd-94c1-6d423e812afb", "embedding": null, "metadata": {"window": "If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors. ", "original_text": "Aaron Alt:  We're happy to provide a little more context. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17a903d3-f986-47f9-8b45-9827881a5318", "node_type": "1", "metadata": {"window": "I guess what we're trying to figure out is in the change in the Pharma \nguidance, how much of it was incrementally coming from the vaccine incremental versus what you \nhad originally expected?  If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%. ", "original_text": "I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b14c24342e60fb231214b35fb81743ff19b5448b82bb74379f324d080393638", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "517a627d-3723-4c3b-9b11-7e98b544a423", "node_type": "1", "metadata": {"window": "Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution. ", "original_text": "Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business. "}, "hash": "8c50db51a71a8e2da70eb4f124811a3af246e534f3ec962de924a44f513b7ab7", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  We're happy to provide a little more context. ", "start_char_idx": 1125, "end_char_idx": 1183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "517a627d-3723-4c3b-9b11-7e98b544a423": {"__data__": {"id_": "517a627d-3723-4c3b-9b11-7e98b544a423", "embedding": null, "metadata": {"window": "Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution. ", "original_text": "Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aadc03bb-7622-47bd-94c1-6d423e812afb", "node_type": "1", "metadata": {"window": "If you don't want to give us that number specifically, maybe explain there \nwas a five-basis  point improvement in the Pharma margin year over year, how much of that was \ncoming from vaccines?  Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors. ", "original_text": "Aaron Alt:  We're happy to provide a little more context. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "019d848cd416a8278e1e9eb5d59aa4ef784aaba90ab8588bf72ab463def2a316", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb9376c6-6ef8-44a4-b073-c516e9c1af51", "node_type": "1", "metadata": {"window": "I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher . ", "original_text": "And we did raise the guidance to \n7 to 9%. "}, "hash": "c0d3a10231fbb50c3a6e210b6532d3fdea571d1584407dfa18824141b6096d6a", "class_name": "RelatedNodeInfo"}}, "text": "Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business. ", "start_char_idx": 1183, "end_char_idx": 1299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb9376c6-6ef8-44a4-b073-c516e9c1af51": {"__data__": {"id_": "eb9376c6-6ef8-44a4-b073-c516e9c1af51", "embedding": null, "metadata": {"window": "I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher . ", "original_text": "And we did raise the guidance to \n7 to 9%. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "517a627d-3723-4c3b-9b11-7e98b544a423", "node_type": "1", "metadata": {"window": "Or maybe you can just break out where the benefits came from ?  I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution. ", "original_text": "Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e52d918831ac8d257521b8ea5662cad045f57e4989a966ac6b9fb9f600cda85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13cc2127-afa5-4a28-bb91-c1fc8662c967", "node_type": "1", "metadata": {"window": "Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.  ", "original_text": "And it was really a result of three factors. "}, "hash": "f491803a20b031e8fdc472305dcbc5633ab53dbee7facd4b7dcea16550f3f16a", "class_name": "RelatedNodeInfo"}}, "text": "And we did raise the guidance to \n7 to 9%. ", "start_char_idx": 1299, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13cc2127-afa5-4a28-bb91-c1fc8662c967": {"__data__": {"id_": "13cc2127-afa5-4a28-bb91-c1fc8662c967", "embedding": null, "metadata": {"window": "Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.  ", "original_text": "And it was really a result of three factors. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb9376c6-6ef8-44a4-b073-c516e9c1af51", "node_type": "1", "metadata": {"window": "I assume \nGLP-1s were negative on the margin, so someth ing had to be better on a year over year basis, I'd \nlove to explore that.  \n \n Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher . ", "original_text": "And we did raise the guidance to \n7 to 9%. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "881ceeeb98fbda4b06304037c8a8dc74615c12872bd77751f77f99eb75645fc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43af0314-ff41-40ef-82e1-e4dfbc5d6636", "node_type": "1", "metadata": {"window": "Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis. ", "original_text": "First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution. "}, "hash": "09d1f9943f132f55a1278e415f0513a18d71d64f844381557899b0d125012cfb", "class_name": "RelatedNodeInfo"}}, "text": "And it was really a result of three factors. ", "start_char_idx": 1342, "end_char_idx": 1387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43af0314-ff41-40ef-82e1-e4dfbc5d6636": {"__data__": {"id_": "43af0314-ff41-40ef-82e1-e4dfbc5d6636", "embedding": null, "metadata": {"window": "Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis. ", "original_text": "First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13cc2127-afa5-4a28-bb91-c1fc8662c967", "node_type": "1", "metadata": {"window": "Aaron Alt:  We're happy to provide a little more context.  Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.  ", "original_text": "And it was really a result of three factors. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc1c94c99dd08337a48e9145b538deb44ec5dcb5ff94da17a82a0b004d304b27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "967041a1-88a5-43fa-813b-f74f7f406860", "node_type": "1", "metadata": {"window": "And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n", "original_text": "And it was higher . "}, "hash": "fac5358f1b936258dca9bb8ef7ca519f091a4c14285f47bbfe0844690af04743", "class_name": "RelatedNodeInfo"}}, "text": "First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution. ", "start_char_idx": 1387, "end_char_idx": 1507, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "967041a1-88a5-43fa-813b-f74f7f406860": {"__data__": {"id_": "967041a1-88a5-43fa-813b-f74f7f406860", "embedding": null, "metadata": {"window": "And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n", "original_text": "And it was higher . ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43af0314-ff41-40ef-82e1-e4dfbc5d6636", "node_type": "1", "metadata": {"window": "Look, it was a strong start to the year,  and we \nremain very encouraged about the runway for the Pharma  business.  And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis. ", "original_text": "First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1cd35ce6a7a8636e405c777e4f6ea642bd1985926890f961e7b99cc7fd956c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68cd16dd-8176-40ee-b355-637e51f592ec", "node_type": "1", "metadata": {"window": "And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics. ", "original_text": "That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.  "}, "hash": "4ba12236d46b2aabbdf4197aa546700d9fea05b89ca20657224a2ffbd629e3f3", "class_name": "RelatedNodeInfo"}}, "text": "And it was higher . ", "start_char_idx": 1507, "end_char_idx": 1527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68cd16dd-8176-40ee-b355-637e51f592ec": {"__data__": {"id_": "68cd16dd-8176-40ee-b355-637e51f592ec", "embedding": null, "metadata": {"window": "And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics. ", "original_text": "That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.  ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "967041a1-88a5-43fa-813b-f74f7f406860", "node_type": "1", "metadata": {"window": "And we did raise the guidance to \n7 to 9%.  And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n", "original_text": "And it was higher . ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "714558aa20de23d72627a7113c8b4eca315fce693ee65d5e6b53a3780d0a258a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55b4e255-0a4d-423a-9198-6e8cf860d85c", "node_type": "1", "metadata": {"window": "First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business. ", "original_text": "Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis. "}, "hash": "78c06b8bee1a4c6c9308c3a70792a0f3a2ce94f213f1840778e3692f7961b6ab", "class_name": "RelatedNodeInfo"}}, "text": "That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.  ", "start_char_idx": 1527, "end_char_idx": 1745, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55b4e255-0a4d-423a-9198-6e8cf860d85c": {"__data__": {"id_": "55b4e255-0a4d-423a-9198-6e8cf860d85c", "embedding": null, "metadata": {"window": "First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business. ", "original_text": "Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68cd16dd-8176-40ee-b355-637e51f592ec", "node_type": "1", "metadata": {"window": "And it was really a result of three factors.  First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics. ", "original_text": "That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.  ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8545661dfce4988faa2034c50a995d2e352f09d5a372789c0628d30f0d16a9cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39096f86-f478-4e65-86c2-16ca0d246485", "node_type": "1", "metadata": {"window": "And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier. ", "original_text": "And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n"}, "hash": "c9161b5a38f5137cbd14c5668ad02da095acad0d9b88f88e800abd66e9439e45", "class_name": "RelatedNodeInfo"}}, "text": "Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis. ", "start_char_idx": 1745, "end_char_idx": 1974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39096f86-f478-4e65-86c2-16ca0d246485": {"__data__": {"id_": "39096f86-f478-4e65-86c2-16ca0d246485", "embedding": null, "metadata": {"window": "And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier. ", "original_text": "And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55b4e255-0a4d-423a-9198-6e8cf860d85c", "node_type": "1", "metadata": {"window": "First was just the strong Q1, and as Jason alluded \nto, we did have a contribution from the COVID vaccine distribution.  And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business. ", "original_text": "Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f730846c61586de8a343dd2e2559d6b9e4ec7685a9f95d3776a2ebb3841117cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be150bf5-4bce-4f51-885f-7cbaa5c03e40", "node_type": "1", "metadata": {"window": "That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right? ", "original_text": "We're expecting stability from the generics business, consistent market dynamics. "}, "hash": "00954d6e7fe0fdca0c262d3f272b045d65e801db96926eddc69f9131960b678f", "class_name": "RelatedNodeInfo"}}, "text": "And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n", "start_char_idx": 1974, "end_char_idx": 2123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be150bf5-4bce-4f51-885f-7cbaa5c03e40": {"__data__": {"id_": "be150bf5-4bce-4f51-885f-7cbaa5c03e40", "embedding": null, "metadata": {"window": "That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right? ", "original_text": "We're expecting stability from the generics business, consistent market dynamics. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39096f86-f478-4e65-86c2-16ca0d246485", "node_type": "1", "metadata": {"window": "And it was higher .  That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier. ", "original_text": "And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e88702ffbacd1c475343aa4e0eaf5c075c635e2d2dc2d6a94a5e59354aedb3fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9ebef97-2b25-47ad-8a78-0ea7b2d3a3ff", "node_type": "1", "metadata": {"window": "Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done. ", "original_text": "You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business. "}, "hash": "79925cba91150e722f3b4911b96cf88d209d2e94897abc6265a680767540d3e2", "class_name": "RelatedNodeInfo"}}, "text": "We're expecting stability from the generics business, consistent market dynamics. ", "start_char_idx": 2123, "end_char_idx": 2205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9ebef97-2b25-47ad-8a78-0ea7b2d3a3ff": {"__data__": {"id_": "d9ebef97-2b25-47ad-8a78-0ea7b2d3a3ff", "embedding": null, "metadata": {"window": "Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done. ", "original_text": "You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be150bf5-4bce-4f51-885f-7cbaa5c03e40", "node_type": "1", "metadata": {"window": "That \ncontribution was higher than what we had assumed in our original plan, just based on the timing of \nwhen the app rovals came through, and frankly, our team's ability to jump on it and execute the way \nthey did.   Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right? ", "original_text": "We're expecting stability from the generics business, consistent market dynamics. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbb9eb4b8793c13d114bb5612b3b26592de0e0da20c9c923c4abe6fad6a7a4cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0e71c6d-814c-44fa-88d1-5de81367573a", "node_type": "1", "metadata": {"window": "And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n", "original_text": "And Jason \nhighlighted that progress in his comments earlier. "}, "hash": "487fe4a5708febb616da31b510a1412315db709e188f4fd9836dfe89191a046e", "class_name": "RelatedNodeInfo"}}, "text": "You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business. ", "start_char_idx": 2205, "end_char_idx": 2306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0e71c6d-814c-44fa-88d1-5de81367573a": {"__data__": {"id_": "e0e71c6d-814c-44fa-88d1-5de81367573a", "embedding": null, "metadata": {"window": "And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n", "original_text": "And Jason \nhighlighted that progress in his comments earlier. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9ebef97-2b25-47ad-8a78-0ea7b2d3a3ff", "node_type": "1", "metadata": {"window": "Third element though is just the ongoing strength of the business , other than the COVID \nvaccines which is really consistent from an outlook perspective with the 4 to 6% guidance that we \ngave previously on a normalized  basis.  And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done. ", "original_text": "You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c877886264b6a0c6d993816972e45149e3311bc48a02cff002b2f6b0cfd7125", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c163d222-795d-4993-a489-e84569312913", "node_type": "1", "metadata": {"window": "We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley . ", "original_text": "And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right? "}, "hash": "cca389163f1a5344405c7129eb144e0c118894c8989c4e13241f4c30e5eb695c", "class_name": "RelatedNodeInfo"}}, "text": "And Jason \nhighlighted that progress in his comments earlier. ", "start_char_idx": 2306, "end_char_idx": 2368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c163d222-795d-4993-a489-e84569312913": {"__data__": {"id_": "c163d222-795d-4993-a489-e84569312913", "embedding": null, "metadata": {"window": "We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley . ", "original_text": "And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0e71c6d-814c-44fa-88d1-5de81367573a", "node_type": "1", "metadata": {"window": "And just to remind you on that, what we had guided \npreviously is that we expected low single -digit profit growth from the core  Pharma business.  \n We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n", "original_text": "And Jason \nhighlighted that progress in his comments earlier. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4216430cc925797b4a9f6bee6b98860bb26b7ad0763a8a72b5a8866500bd141a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0007bd4-df59-47bf-9e4c-2e349b92f941", "node_type": "1", "metadata": {"window": "You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n", "original_text": "And so, look, we \nare early in the year as we have done. "}, "hash": "cf5d078c0d65171d00384830770e4a8123c0ff443353c6ba114a65e75d07c628", "class_name": "RelatedNodeInfo"}}, "text": "And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right? ", "start_char_idx": 2368, "end_char_idx": 2506, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0007bd4-df59-47bf-9e4c-2e349b92f941": {"__data__": {"id_": "c0007bd4-df59-47bf-9e4c-2e349b92f941", "embedding": null, "metadata": {"window": "You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n", "original_text": "And so, look, we \nare early in the year as we have done. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c163d222-795d-4993-a489-e84569312913", "node_type": "1", "metadata": {"window": "We're expecting stability from the generics business, consistent market dynamics.  You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley . ", "original_text": "And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c96b7465edf93d900d689b5491cce136be0770e67f8bd057450ac0cf5fc85ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8066bc79-9428-4cb8-9602-150623a53439", "node_type": "1", "metadata": {"window": "And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks. ", "original_text": "We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n"}, "hash": "6da26339b47a8ccdf81e279b39b814df578b506aad48d6858d37b8b7684369b2", "class_name": "RelatedNodeInfo"}}, "text": "And so, look, we \nare early in the year as we have done. ", "start_char_idx": 2506, "end_char_idx": 2563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8066bc79-9428-4cb8-9602-150623a53439": {"__data__": {"id_": "8066bc79-9428-4cb8-9602-150623a53439", "embedding": null, "metadata": {"window": "And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks. ", "original_text": "We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0007bd4-df59-47bf-9e4c-2e349b92f941", "node_type": "1", "metadata": {"window": "You often hear us \nsay, we are expecting double -digit growth in the specialty and nuclear business.  And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n", "original_text": "And so, look, we \nare early in the year as we have done. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "006901a6a385157ab22cf6c2e8706a256fab456626bc6b5c7703a7158e964010", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7a47cf0-a027-4824-93bc-e52985ed983b", "node_type": "1", "metadata": {"window": "And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business. ", "original_text": "Operator:  The next question comes from Erin Wright, from Morgan Stanley . "}, "hash": "88832816ffca01ffadf90e8ae05ece9c7258a089ca306625367939b81e5cb7fe", "class_name": "RelatedNodeInfo"}}, "text": "We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n", "start_char_idx": 2563, "end_char_idx": 2684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7a47cf0-a027-4824-93bc-e52985ed983b": {"__data__": {"id_": "e7a47cf0-a027-4824-93bc-e52985ed983b", "embedding": null, "metadata": {"window": "And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business. ", "original_text": "Operator:  The next question comes from Erin Wright, from Morgan Stanley . ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8066bc79-9428-4cb8-9602-150623a53439", "node_type": "1", "metadata": {"window": "And Jason \nhighlighted that progress in his comments earlier.  And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks. ", "original_text": "We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e4c8243445970da3e9e377e22181fcee775207d285a15feb1547c819f915fc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48ea2aae-8278-442e-bea3-c8d524d98f5b", "node_type": "1", "metadata": {"window": "And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit. ", "original_text": "Please go ahead.  \n \n"}, "hash": "10aff60bf29bae920f42bab352c2c9efce3e3464894ecddcb694ffb590bb3227", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from Erin Wright, from Morgan Stanley . ", "start_char_idx": 2684, "end_char_idx": 2759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48ea2aae-8278-442e-bea3-c8d524d98f5b": {"__data__": {"id_": "48ea2aae-8278-442e-bea3-c8d524d98f5b", "embedding": null, "metadata": {"window": "And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit. ", "original_text": "Please go ahead.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7a47cf0-a027-4824-93bc-e52985ed983b", "node_type": "1", "metadata": {"window": "And importantly, we are expecting brand inflation \nmore in line with fiscal \u201822, not the modest benefit that we saw in fiscal \u201823, right?  And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business. ", "original_text": "Operator:  The next question comes from Erin Wright, from Morgan Stanley . ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbfbf145a26a2bc198d45e2fe0a94beaa3b741016cd32e70bb04557cfa0d24dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78732227-8bd4-4ab5-a37f-c829a90ec18d", "node_type": "1", "metadata": {"window": "We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment? ", "original_text": "Erin Wright:  Hi, thanks. "}, "hash": "27ce0b922969f31b7e135993c18af854e4b5a5eb7f061ea21702364c64ee0d5d", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 2759, "end_char_idx": 2780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78732227-8bd4-4ab5-a37f-c829a90ec18d": {"__data__": {"id_": "78732227-8bd4-4ab5-a37f-c829a90ec18d", "embedding": null, "metadata": {"window": "We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment? ", "original_text": "Erin Wright:  Hi, thanks. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48ea2aae-8278-442e-bea3-c8d524d98f5b", "node_type": "1", "metadata": {"window": "And so, look, we \nare early in the year as we have done.  We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit. ", "original_text": "Please go ahead.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfa4e11b1da9fb864a41a94af611f341251cd16ada35a06d4face0ce8b297719", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc58a25a-198c-4cea-b038-8cc60498d973", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics? ", "original_text": "Another question on the Pharma business. "}, "hash": "c9b315698aff2a9442bb9c9ea62ded5ad379a8dc8448bd47476918e7c058c8d3", "class_name": "RelatedNodeInfo"}}, "text": "Erin Wright:  Hi, thanks. ", "start_char_idx": 2780, "end_char_idx": 2806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc58a25a-198c-4cea-b038-8cc60498d973": {"__data__": {"id_": "cc58a25a-198c-4cea-b038-8cc60498d973", "embedding": null, "metadata": {"window": "Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics? ", "original_text": "Another question on the Pharma business. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78732227-8bd4-4ab5-a37f-c829a90ec18d", "node_type": "1", "metadata": {"window": "We'll continue to update as we push ahead, but we're pleased \nwith the results so far and the raise to the guidance.  \n \n Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment? ", "original_text": "Erin Wright:  Hi, thanks. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fc5ffabc908fb1e055a20fb2f222ab5b868658fc26bcd0002e53fb9e6a09dd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f6e784c-2b85-4f95-828a-f83f20669e5b", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment? ", "original_text": "You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit. "}, "hash": "6299d45e39f087395be879aeb7833b8c53c657eb67459829a7478918d9d1bd0d", "class_name": "RelatedNodeInfo"}}, "text": "Another question on the Pharma business. ", "start_char_idx": 2806, "end_char_idx": 2847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f6e784c-2b85-4f95-828a-f83f20669e5b": {"__data__": {"id_": "8f6e784c-2b85-4f95-828a-f83f20669e5b", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment? ", "original_text": "You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc58a25a-198c-4cea-b038-8cc60498d973", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from Erin Wright, from Morgan Stanley .  Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics? ", "original_text": "Another question on the Pharma business. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06944502788d70dd8e115314ec77f1f5c02b40b8bce01d8c6d263780dba3f008", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87fbc4bc-c813-42ff-9b49-123eb1abab35", "node_type": "1", "metadata": {"window": "Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar? ", "original_text": "I guess, can you speak to the generic \ndrug pricing environment? "}, "hash": "ddbe6a93c5a120b9e828b696611ca7a772b072c2e375dc72471713fb46f845a0", "class_name": "RelatedNodeInfo"}}, "text": "You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit. ", "start_char_idx": 2847, "end_char_idx": 2943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87fbc4bc-c813-42ff-9b49-123eb1abab35": {"__data__": {"id_": "87fbc4bc-c813-42ff-9b49-123eb1abab35", "embedding": null, "metadata": {"window": "Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar? ", "original_text": "I guess, can you speak to the generic \ndrug pricing environment? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f6e784c-2b85-4f95-828a-f83f20669e5b", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment? ", "original_text": "You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1377702f1ba1454c28e0207761284ca332f6e64320ce9cfd558a2959fdf60b29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a768d03-6136-4c78-bcb2-5d56a1114f44", "node_type": "1", "metadata": {"window": "Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n", "original_text": "Are you seeing easing deflationary dynamics across generics? "}, "hash": "716b6e105c2e5811ca100d14c874f57d67d6cf045851ee3e7f5ec495abc9b300", "class_name": "RelatedNodeInfo"}}, "text": "I guess, can you speak to the generic \ndrug pricing environment? ", "start_char_idx": 2943, "end_char_idx": 3008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a768d03-6136-4c78-bcb2-5d56a1114f44": {"__data__": {"id_": "9a768d03-6136-4c78-bcb2-5d56a1114f44", "embedding": null, "metadata": {"window": "Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n", "original_text": "Are you seeing easing deflationary dynamics across generics? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87fbc4bc-c813-42ff-9b49-123eb1abab35", "node_type": "1", "metadata": {"window": "Erin Wright:  Hi, thanks.  Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar? ", "original_text": "I guess, can you speak to the generic \ndrug pricing environment? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d16899d9b7935bd5c3eb702a94ffc487ed568b208014b333624b8563e23c46d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a37406fa-57af-4a8a-8336-fb7d776946bd", "node_type": "1", "metadata": {"window": "You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah. ", "original_text": "And how \nmaterial is that for you in terms of your guidance raised across that segment? "}, "hash": "516d4651fee8fe007989edc4813b48ee25ff79a686add95e5b039c21f2499e34", "class_name": "RelatedNodeInfo"}}, "text": "Are you seeing easing deflationary dynamics across generics? ", "start_char_idx": 3008, "end_char_idx": 3069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a37406fa-57af-4a8a-8336-fb7d776946bd": {"__data__": {"id_": "a37406fa-57af-4a8a-8336-fb7d776946bd", "embedding": null, "metadata": {"window": "You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah. ", "original_text": "And how \nmaterial is that for you in terms of your guidance raised across that segment? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a768d03-6136-4c78-bcb2-5d56a1114f44", "node_type": "1", "metadata": {"window": "Another question on the Pharma business.  You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n", "original_text": "Are you seeing easing deflationary dynamics across generics? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee1d680de4cb8e50f224e7b20a9bd95e92fde462fd361f66f8a8894b92c66838", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2210fdba-1ed3-46d0-bab0-d8113e95248c", "node_type": "1", "metadata": {"window": "I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin. ", "original_text": "And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar? "}, "hash": "953fc74b23160fed93e042be45f5c4a3aa22a8a476ecaf1d761d2f0731957ff1", "class_name": "RelatedNodeInfo"}}, "text": "And how \nmaterial is that for you in terms of your guidance raised across that segment? ", "start_char_idx": 3069, "end_char_idx": 3157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2210fdba-1ed3-46d0-bab0-d8113e95248c": {"__data__": {"id_": "2210fdba-1ed3-46d0-bab0-d8113e95248c", "embedding": null, "metadata": {"window": "I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin. ", "original_text": "And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a37406fa-57af-4a8a-8336-fb7d776946bd", "node_type": "1", "metadata": {"window": "You mentioned the consistent \ngenerics environment, but can you elaborate on that a little bit.  I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah. ", "original_text": "And how \nmaterial is that for you in terms of your guidance raised across that segment? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64f58209b3ef4db8fad5e114c0d9a0607c9292c464bae0c81a3ba3e9f2af31a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f7ebe58-202a-4399-8019-083272abde1c", "node_type": "1", "metadata": {"window": "Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages. ", "original_text": "Thanks.  \n \n"}, "hash": "340c6ccaa2839e4cf4269163e5fe345f514ee2f22bfbf297c3bf1df601d08f6b", "class_name": "RelatedNodeInfo"}}, "text": "And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar? ", "start_char_idx": 3157, "end_char_idx": 3304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f7ebe58-202a-4399-8019-083272abde1c": {"__data__": {"id_": "4f7ebe58-202a-4399-8019-083272abde1c", "embedding": null, "metadata": {"window": "Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages. ", "original_text": "Thanks.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2210fdba-1ed3-46d0-bab0-d8113e95248c", "node_type": "1", "metadata": {"window": "I guess, can you speak to the generic \ndrug pricing environment?  Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin. ", "original_text": "And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar? ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b98767f5b52ee4b790b34242bf0a91d75f53d8e5233ab15118b1ab179f51c335", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7181c93-d17b-4610-9d9b-4dcec91e7d63", "node_type": "1", "metadata": {"window": "And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market. ", "original_text": "Jason Holler:  Yeah. "}, "hash": "af612194af7c850657e63740980a9e48a59011c732900cc1ef6914c2b8f4d239", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 3304, "end_char_idx": 3316, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7181c93-d17b-4610-9d9b-4dcec91e7d63": {"__data__": {"id_": "b7181c93-d17b-4610-9d9b-4dcec91e7d63", "embedding": null, "metadata": {"window": "And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market. ", "original_text": "Jason Holler:  Yeah. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f7ebe58-202a-4399-8019-083272abde1c", "node_type": "1", "metadata": {"window": "Are you seeing easing deflationary dynamics across generics?  And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages. ", "original_text": "Thanks.  \n \n", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95cbb2ae5c02494f63f8a42668f1a5487b840651537ff2c0de29ddabfad82c4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4006e18d-cfa0-44c8-966a-d2d92d25fa27", "node_type": "1", "metadata": {"window": "And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "Thanks, Erin. "}, "hash": "224c93e0d8899b6038a5eac58e8a01083671e4a19e172c311a9a7791d4154b00", "class_name": "RelatedNodeInfo"}}, "text": "Jason Holler:  Yeah. ", "start_char_idx": 3316, "end_char_idx": 3337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4006e18d-cfa0-44c8-966a-d2d92d25fa27": {"__data__": {"id_": "4006e18d-cfa0-44c8-966a-d2d92d25fa27", "embedding": null, "metadata": {"window": "And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "Thanks, Erin. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7181c93-d17b-4610-9d9b-4dcec91e7d63", "node_type": "1", "metadata": {"window": "And how \nmaterial is that for you in terms of your guidance raised across that segment?  And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market. ", "original_text": "Jason Holler:  Yeah. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "328c4c10f7f4c39b2660a7c64c7735d52d300e806357761b4983488b1708d734", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95466834-b589-4cb1-b893-98f8b49f7e5f", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "It's very consistent to the prior messages. "}, "hash": "818bb720373811c2bde09fc9a084d868f8ecd1a07e371ff8514315a209dec9df", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Erin. ", "start_char_idx": 3337, "end_char_idx": 3351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95466834-b589-4cb1-b893-98f8b49f7e5f": {"__data__": {"id_": "95466834-b589-4cb1-b893-98f8b49f7e5f", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "It's very consistent to the prior messages. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4006e18d-cfa0-44c8-966a-d2d92d25fa27", "node_type": "1", "metadata": {"window": "And does consistent \nmean essentially a continuation of those favorable  pricing trends going for ward, I guess throughout \nthe rest of the ye ar?  Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "Thanks, Erin. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "390d5938f915aad86d57fbe5f48ff531199559480b5972792ad1ceec2038ec63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf81b24e-e5f8-46e0-a073-f17f237c607a", "node_type": "1", "metadata": {"window": "Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "So, we're not seeing \nany change in the underlying market. "}, "hash": "3f0f554b45dcfd3cccb5109edaa5bb2963a6220688e53c1bb811c4349ecd47a5", "class_name": "RelatedNodeInfo"}}, "text": "It's very consistent to the prior messages. ", "start_char_idx": 3351, "end_char_idx": 3395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf81b24e-e5f8-46e0-a073-f17f237c607a": {"__data__": {"id_": "bf81b24e-e5f8-46e0-a073-f17f237c607a", "embedding": null, "metadata": {"window": "Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "So, we're not seeing \nany change in the underlying market. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95466834-b589-4cb1-b893-98f8b49f7e5f", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "It's very consistent to the prior messages. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d2d34444fc41e3582fe9d3e5d797991987314ff0d19ae6f4a17d59b8325805f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6bce047-fbb7-4841-ae21-66b689ec6160", "node_type": "1", "metadata": {"window": "Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "And so, my comments are going to be very similar to what it's "}, "hash": "e4c33d62b1e39ed2268eda9d909997627ed56254a57654a0fa94aca1981a618a", "class_name": "RelatedNodeInfo"}}, "text": "So, we're not seeing \nany change in the underlying market. ", "start_char_idx": 3395, "end_char_idx": 3454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6bce047-fbb7-4841-ae21-66b689ec6160": {"__data__": {"id_": "d6bce047-fbb7-4841-ae21-66b689ec6160", "embedding": null, "metadata": {"window": "Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "And so, my comments are going to be very similar to what it's ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5e9f3f0943829f7dd7afb05e01167907fb9b510cda64a4b01cb14caef47b0b5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf81b24e-e5f8-46e0-a073-f17f237c607a", "node_type": "1", "metadata": {"window": "Jason Holler:  Yeah.  Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "So, we're not seeing \nany change in the underlying market. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69e89a9e091a26cb430b415858b67e36351df8ba10200bce90bca5c9524aae1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c939ec5-170a-4676-bbe0-c0bba0ded20a", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that. ", "original_text": " \nPage 11 of 16 \n \nbeen in the past. "}, "hash": "ddddedea4b2a4cc08debe3d089d58cf8512586230886f2b2c5556f879d25037c", "class_name": "RelatedNodeInfo"}}, "text": "And so, my comments are going to be very similar to what it's ", "start_char_idx": 3454, "end_char_idx": 3516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c939ec5-170a-4676-bbe0-c0bba0ded20a": {"__data__": {"id_": "1c939ec5-170a-4676-bbe0-c0bba0ded20a", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that. ", "original_text": " \nPage 11 of 16 \n \nbeen in the past. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6bce047-fbb7-4841-ae21-66b689ec6160", "node_type": "1", "metadata": {"window": "Thanks, Erin.  It's very consistent to the prior messages.  So, we're not seeing \nany change in the underlying market.  And so, my comments are going to be very similar to what it's ", "original_text": "And so, my comments are going to be very similar to what it's ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31ffe4ba77d667ae5f3ba08da413358ab25558d6db5a303f78ab2036964122b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "699003ef-f88f-4618-b07b-ca28343d9d3c", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced. ", "original_text": "So let me just start with just underlying utilization  continues to be strong. "}, "hash": "f0b5bf55b9fe168265c59b4ffb95dc256242ad8712bcbddbfb39265dfa6ae12c", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 16 \n \nbeen in the past. ", "start_char_idx": 0, "end_char_idx": 37, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "699003ef-f88f-4618-b07b-ca28343d9d3c": {"__data__": {"id_": "699003ef-f88f-4618-b07b-ca28343d9d3c", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced. ", "original_text": "So let me just start with just underlying utilization  continues to be strong. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c939ec5-170a-4676-bbe0-c0bba0ded20a", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that. ", "original_text": " \nPage 11 of 16 \n \nbeen in the past. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78eb1aceabbf43df62fe6ff4dff743ec11495a58da086633916f6a1bb129d0a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd1c4a9b-6d53-49ee-8a1d-501d0cf393a8", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces. ", "original_text": "We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that. "}, "hash": "31d9bb659a1c4c40bbb9037be5553293f8fdcc38b6495b493b8521c2e780a923", "class_name": "RelatedNodeInfo"}}, "text": "So let me just start with just underlying utilization  continues to be strong. ", "start_char_idx": 37, "end_char_idx": 116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd1c4a9b-6d53-49ee-8a1d-501d0cf393a8": {"__data__": {"id_": "cd1c4a9b-6d53-49ee-8a1d-501d0cf393a8", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces. ", "original_text": "We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "699003ef-f88f-4618-b07b-ca28343d9d3c", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced. ", "original_text": "So let me just start with just underlying utilization  continues to be strong. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddf1e7b65220c9dd69e663c7e9115f87f95e67e977318276e204edb7ea6dfc3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce74601f-674c-42c2-b27d-a1bdf933b726", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis. ", "original_text": "So , volume is \nabsolutely a key component of that. "}, "hash": "01c8aa5943f8802926487452d2809feba998d13967e5b01156386547610bf454", "class_name": "RelatedNodeInfo"}}, "text": "We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that. ", "start_char_idx": 116, "end_char_idx": 305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce74601f-674c-42c2-b27d-a1bdf933b726": {"__data__": {"id_": "ce74601f-674c-42c2-b27d-a1bdf933b726", "embedding": null, "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis. ", "original_text": "So , volume is \nabsolutely a key component of that. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd1c4a9b-6d53-49ee-8a1d-501d0cf393a8", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces. ", "original_text": "We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36208dcb7a01c88eaf50b8f59b2c7966033782bd797c806f77f081a7ac89338a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53a49faf-27ed-46b4-a607-bbc59a1cf487", "node_type": "1", "metadata": {"window": "So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture. ", "original_text": "The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced. "}, "hash": "06e9ae2f4411cb6edf686b8776069dac354704c57d77fdf919b6ad3f6bc48e85", "class_name": "RelatedNodeInfo"}}, "text": "So , volume is \nabsolutely a key component of that. ", "start_char_idx": 305, "end_char_idx": 357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53a49faf-27ed-46b4-a607-bbc59a1cf487": {"__data__": {"id_": "53a49faf-27ed-46b4-a607-bbc59a1cf487", "embedding": null, "metadata": {"window": "So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture. ", "original_text": "The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce74601f-674c-42c2-b27d-a1bdf933b726", "node_type": "1", "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis. ", "original_text": "So , volume is \nabsolutely a key component of that. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7eed6298caa3f84c78924fc68ebf2cf5f39c0502638addcecdfda27cd169a16b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fdb80c3-d6b5-4b36-93f4-c92de4d63715", "node_type": "1", "metadata": {"window": "We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost. ", "original_text": "So overall, as in the past, I'm \nnot going to break apart all the different pieces. "}, "hash": "27216b7279eaad6d453da7410051edf8866730be33eaf287ac227bede2a905e6", "class_name": "RelatedNodeInfo"}}, "text": "The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced. ", "start_char_idx": 357, "end_char_idx": 497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fdb80c3-d6b5-4b36-93f4-c92de4d63715": {"__data__": {"id_": "7fdb80c3-d6b5-4b36-93f4-c92de4d63715", "embedding": null, "metadata": {"window": "We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost. ", "original_text": "So overall, as in the past, I'm \nnot going to break apart all the different pieces. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53a49faf-27ed-46b4-a607-bbc59a1cf487", "node_type": "1", "metadata": {"window": "So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture. ", "original_text": "The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f0cf7c7dcf0e697f58ebfb37086d8d96a75a39039bd432bd369b5eea39fc6c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc9df0ca-e063-46e6-874a-b85e954ba787", "node_type": "1", "metadata": {"window": "So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well. ", "original_text": "We think it's best to look at them on a net basis. "}, "hash": "77e2ad61f949781a7b66caca4ec077bbb4dc1ef80c1c799e50d3b5780e9dc7cf", "class_name": "RelatedNodeInfo"}}, "text": "So overall, as in the past, I'm \nnot going to break apart all the different pieces. ", "start_char_idx": 497, "end_char_idx": 581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc9df0ca-e063-46e6-874a-b85e954ba787": {"__data__": {"id_": "fc9df0ca-e063-46e6-874a-b85e954ba787", "embedding": null, "metadata": {"window": "So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well. ", "original_text": "We think it's best to look at them on a net basis. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fdb80c3-d6b5-4b36-93f4-c92de4d63715", "node_type": "1", "metadata": {"window": "We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost. ", "original_text": "So overall, as in the past, I'm \nnot going to break apart all the different pieces. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "868ca7d6f2a82b1cbbd70fc3f072ed22dcf454920defe87f94e5693ba73726b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d43269c2-3149-4737-9d7a-6e6c21aacb7d", "node_type": "1", "metadata": {"window": "The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers. ", "original_text": "And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture. "}, "hash": "2f15a69e60c0c1f5fca342aee77a480c6b50b26f4bf817ef7d1dbaf72c75f161", "class_name": "RelatedNodeInfo"}}, "text": "We think it's best to look at them on a net basis. ", "start_char_idx": 581, "end_char_idx": 632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d43269c2-3149-4737-9d7a-6e6c21aacb7d": {"__data__": {"id_": "d43269c2-3149-4737-9d7a-6e6c21aacb7d", "embedding": null, "metadata": {"window": "The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers. ", "original_text": "And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc9df0ca-e063-46e6-874a-b85e954ba787", "node_type": "1", "metadata": {"window": "So , volume is \nabsolutely a key component of that.  The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well. ", "original_text": "We think it's best to look at them on a net basis. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86a58a8ed732c1b633bd38f343df786f1b4fb25d169ecc94bea4dc657ec18fed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc43e3da-6701-433b-9863-ae01e7d29f63", "node_type": "1", "metadata": {"window": "So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n", "original_text": "So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost. "}, "hash": "18818b00b9040b7a31f92db3f85a34b3e94a9316768b3c354ea27c2e2762414d", "class_name": "RelatedNodeInfo"}}, "text": "And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture. ", "start_char_idx": 632, "end_char_idx": 762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc43e3da-6701-433b-9863-ae01e7d29f63": {"__data__": {"id_": "fc43e3da-6701-433b-9863-ae01e7d29f63", "embedding": null, "metadata": {"window": "So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n", "original_text": "So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d43269c2-3149-4737-9d7a-6e6c21aacb7d", "node_type": "1", "metadata": {"window": "The consistent market dynamics that Aaron just referenced again \nis an indication that the buy and sell side continues to be very balanced.  So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers. ", "original_text": "And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea3b7456c9b32ea615f18803084909beb6372454ea7ede57e67f561bd14df08f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c055758b-d566-4759-8edd-b8eb195721de", "node_type": "1", "metadata": {"window": "We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well. "}, "hash": "da816318db37fee7c2212a55ced603ec52cb1ff35ffca3c09b8d64b885f039b8", "class_name": "RelatedNodeInfo"}}, "text": "So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost. ", "start_char_idx": 762, "end_char_idx": 871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c055758b-d566-4759-8edd-b8eb195721de": {"__data__": {"id_": "c055758b-d566-4759-8edd-b8eb195721de", "embedding": null, "metadata": {"window": "We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc43e3da-6701-433b-9863-ae01e7d29f63", "node_type": "1", "metadata": {"window": "So overall, as in the past, I'm \nnot going to break apart all the different pieces.  We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n", "original_text": "So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be7b5bd444da0fa42772caec35d63b142eb0acb702b0a80bf25d8bee935aac6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be6ee68a-a32f-4091-88ce-4825c02cdf8e", "node_type": "1", "metadata": {"window": "And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank. ", "original_text": "So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers. "}, "hash": "da5d1c5a6066a8d227ee8d08300e3d0fd596a258e71c6e9134110b9320360a21", "class_name": "RelatedNodeInfo"}}, "text": "But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well. ", "start_char_idx": 871, "end_char_idx": 991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be6ee68a-a32f-4091-88ce-4825c02cdf8e": {"__data__": {"id_": "be6ee68a-a32f-4091-88ce-4825c02cdf8e", "embedding": null, "metadata": {"window": "And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank. ", "original_text": "So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c055758b-d566-4759-8edd-b8eb195721de", "node_type": "1", "metadata": {"window": "We think it's best to look at them on a net basis.  And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b333701b0a689c53a799066c67687cb2ca8bd27fe028614207245b422ac0fbff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c47ff9b-dd7b-4d0a-bcf0-3b22647bdafd", "node_type": "1", "metadata": {"window": "So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n", "original_text": "So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n"}, "hash": "1260681ee45cf4bbca7a32175759d9b7629cbbed540517f56bb5e0a505594b3a", "class_name": "RelatedNodeInfo"}}, "text": "So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers. ", "start_char_idx": 991, "end_char_idx": 1117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c47ff9b-dd7b-4d0a-bcf0-3b22647bdafd": {"__data__": {"id_": "3c47ff9b-dd7b-4d0a-bcf0-3b22647bdafd", "embedding": null, "metadata": {"window": "So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n", "original_text": "So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be6ee68a-a32f-4091-88ce-4825c02cdf8e", "node_type": "1", "metadata": {"window": "And \nwithin that, what I will say though is we continue to have very strong performance with our Red Oak \nsourcing joint venture.  So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank. ", "original_text": "So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2bc95ce111a55ab00c0ac780a19c6d1a80bc6c8814ee27b1da49528eda91b70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3321af62-383c-48f4-8fe7-2f328bc06084", "node_type": "1", "metadata": {"window": "But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah. ", "original_text": "Matt Sims:  Next question, please.  \n \n"}, "hash": "714c82fd43a046c6e6d5c1af3f13a99b61ba0e52e015afea250bf90e6e1a6def", "class_name": "RelatedNodeInfo"}}, "text": "So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n", "start_char_idx": 1117, "end_char_idx": 1358, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3321af62-383c-48f4-8fe7-2f328bc06084": {"__data__": {"id_": "3321af62-383c-48f4-8fe7-2f328bc06084", "embedding": null, "metadata": {"window": "But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah. ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c47ff9b-dd7b-4d0a-bcf0-3b22647bdafd", "node_type": "1", "metadata": {"window": "So, we continue to have that team very focused on the dual mandate of a \ncourse, driving down the best cost.  But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n", "original_text": "So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6faf28de5f217a3cb57a39500c5262386ff6c1e59053834b32c25f46a0c7134", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea11c094-3d47-4057-ab77-5e063e72460d", "node_type": "1", "metadata": {"window": "So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions. ", "original_text": "Operator:  George Hill of Deutsche Bank. "}, "hash": "e226022e0a938efd114762df3740c0bca9ec96143554a0c1b3fde0b1646347eb", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:  Next question, please.  \n \n", "start_char_idx": 1358, "end_char_idx": 1397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea11c094-3d47-4057-ab77-5e063e72460d": {"__data__": {"id_": "ea11c094-3d47-4057-ab77-5e063e72460d", "embedding": null, "metadata": {"window": "So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions. ", "original_text": "Operator:  George Hill of Deutsche Bank. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3321af62-383c-48f4-8fe7-2f328bc06084", "node_type": "1", "metadata": {"window": "But also,  as important and their mandate is to ensure that service \nlevels are optimized  as much as possible as well.  So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah. ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da9c08de1e8abab875bfd9008c31db142a0148dad24e786cd0324e5e95a2d120", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2342e942-9e24-4823-946d-5e80bc419d26", "node_type": "1", "metadata": {"window": "So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness. ", "original_text": "Please go ahead , your line is open.  \n \n"}, "hash": "b575d95e71aa5d9414b294ee696dabf367634f668802bf2a82a502586e5fbd48", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  George Hill of Deutsche Bank. ", "start_char_idx": 1397, "end_char_idx": 1438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2342e942-9e24-4823-946d-5e80bc419d26": {"__data__": {"id_": "2342e942-9e24-4823-946d-5e80bc419d26", "embedding": null, "metadata": {"window": "So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness. ", "original_text": "Please go ahead , your line is open.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea11c094-3d47-4057-ab77-5e063e72460d", "node_type": "1", "metadata": {"window": "So, we feel very good about their progress, both in \ncontrolling cos ts, but also in driving great service for our customers.  So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions. ", "original_text": "Operator:  George Hill of Deutsche Bank. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d404cf8f76405956ff77a6d8ac769099ea69ba33b6cd706fb3a5ff817b880ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11262282-f56f-4ba4-a6ad-70d83638ec96", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak . ", "original_text": "George Hill:  Yeah. "}, "hash": "4ae9d628d2c50aee70115c108dd091725a48181f779bfb543f8de40aa8468aa2", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead , your line is open.  \n \n", "start_char_idx": 1438, "end_char_idx": 1479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11262282-f56f-4ba4-a6ad-70d83638ec96": {"__data__": {"id_": "11262282-f56f-4ba4-a6ad-70d83638ec96", "embedding": null, "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak . ", "original_text": "George Hill:  Yeah. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2342e942-9e24-4823-946d-5e80bc419d26", "node_type": "1", "metadata": {"window": "So again, those should be very \nsimilar words we've said in the past, so that's why we use the phrase consistent market dynamics \nbecause we're not seeing any significant change in the underlying dynam ics of this part of our \nbusiness.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness. ", "original_text": "Please go ahead , your line is open.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecc98dad38cfbd18283802fedec7a8380b9222b494f2d0cd46258ddb6c7eed6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f480935-93bb-4cae-8254-7bb8864493ae", "node_type": "1", "metadata": {"window": "Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed. ", "original_text": "Good morning,  guys,  and thanks for taking the questions. "}, "hash": "1188fea9921d054501dc94466523d1b3eca05acbc5e4b935ce1197d6e094ccc9", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Yeah. ", "start_char_idx": 1479, "end_char_idx": 1499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f480935-93bb-4cae-8254-7bb8864493ae": {"__data__": {"id_": "9f480935-93bb-4cae-8254-7bb8864493ae", "embedding": null, "metadata": {"window": "Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed. ", "original_text": "Good morning,  guys,  and thanks for taking the questions. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11262282-f56f-4ba4-a6ad-70d83638ec96", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak . ", "original_text": "George Hill:  Yeah. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fdfc1e1f5bb1a4e0132ded26e0721532c21eaa31bb7f79e2144270fde28ee730", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2e4fc83-2273-41a2-8b62-ba27d2633adb", "node_type": "1", "metadata": {"window": "Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side. ", "original_text": "I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness. "}, "hash": "ff42cd028c36e12879bd59e461a277884cd36a312ad50d39151b5d1b29762907", "class_name": "RelatedNodeInfo"}}, "text": "Good morning,  guys,  and thanks for taking the questions. ", "start_char_idx": 1499, "end_char_idx": 1558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2e4fc83-2273-41a2-8b62-ba27d2633adb": {"__data__": {"id_": "b2e4fc83-2273-41a2-8b62-ba27d2633adb", "embedding": null, "metadata": {"window": "Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side. ", "original_text": "I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f480935-93bb-4cae-8254-7bb8864493ae", "node_type": "1", "metadata": {"window": "Operator:  George Hill of Deutsche Bank.  Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed. ", "original_text": "Good morning,  guys,  and thanks for taking the questions. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cd1f8372b67d07bb8b1598cbb426cd48e4dffcdda398a9a3e43d41f08ca36de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f89556c-9bdb-40be-878f-4724fd884ac7", "node_type": "1", "metadata": {"window": "George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance? ", "original_text": "You guys called out Red Oak . "}, "hash": "997468c0aae6a88e1d98a8177c93c66a2aa3bbb5016795facc7115d43a9a5040", "class_name": "RelatedNodeInfo"}}, "text": "I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness. ", "start_char_idx": 1558, "end_char_idx": 1697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f89556c-9bdb-40be-878f-4724fd884ac7": {"__data__": {"id_": "9f89556c-9bdb-40be-878f-4724fd884ac7", "embedding": null, "metadata": {"window": "George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance? ", "original_text": "You guys called out Red Oak . ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2e4fc83-2273-41a2-8b62-ba27d2633adb", "node_type": "1", "metadata": {"window": "Please go ahead , your line is open.  \n \n George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side. ", "original_text": "I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c92cadc444895531cd0aa38afd3f05d8accdba31a4cd5a3284ae4e9b200062a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d40b2cf2-6e65-4f61-b6ff-1ed12be7bc59", "node_type": "1", "metadata": {"window": "Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n", "original_text": "GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed. "}, "hash": "9b695acc924cbf461abe410b182ebf682e862c3910a271985cd2590d12d23d6d", "class_name": "RelatedNodeInfo"}}, "text": "You guys called out Red Oak . ", "start_char_idx": 1697, "end_char_idx": 1727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d40b2cf2-6e65-4f61-b6ff-1ed12be7bc59": {"__data__": {"id_": "d40b2cf2-6e65-4f61-b6ff-1ed12be7bc59", "embedding": null, "metadata": {"window": "Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n", "original_text": "GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f89556c-9bdb-40be-878f-4724fd884ac7", "node_type": "1", "metadata": {"window": "George Hill:  Yeah.  Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance? ", "original_text": "You guys called out Red Oak . ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "191b85fc387749803429ac4e396c89455e348c0c6888cb35120a3d90be7e9c58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80a67ed4-e145-4f6b-b342-e457b612ec53", "node_type": "1", "metadata": {"window": "I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah. ", "original_text": "I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side. "}, "hash": "b9e89ca39bdc55fece9d433a439efab355ceeb69b9b670bb1860588a19b3adb5", "class_name": "RelatedNodeInfo"}}, "text": "GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed. ", "start_char_idx": 1727, "end_char_idx": 1821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80a67ed4-e145-4f6b-b342-e457b612ec53": {"__data__": {"id_": "80a67ed4-e145-4f6b-b342-e457b612ec53", "embedding": null, "metadata": {"window": "I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah. ", "original_text": "I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d40b2cf2-6e65-4f61-b6ff-1ed12be7bc59", "node_type": "1", "metadata": {"window": "Good morning,  guys,  and thanks for taking the questions.  I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n", "original_text": "GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d77f9e8035cedfefbf04533d8011ae45df6d94d4feff7d33e800199860ba9c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "113af8a7-666b-4f51-8948-253c8567d273", "node_type": "1", "metadata": {"window": "You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George. ", "original_text": "Are you seeing like increased rebates for purchasing compliance or supply \ncompliance? "}, "hash": "3c65b017bb7e0565f1d58f4dc511a2794030de357ec4bf2f01dbf44aeca3441a", "class_name": "RelatedNodeInfo"}}, "text": "I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side. ", "start_char_idx": 1821, "end_char_idx": 1924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "113af8a7-666b-4f51-8948-253c8567d273": {"__data__": {"id_": "113af8a7-666b-4f51-8948-253c8567d273", "embedding": null, "metadata": {"window": "You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George. ", "original_text": "Are you seeing like increased rebates for purchasing compliance or supply \ncompliance? ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80a67ed4-e145-4f6b-b342-e457b612ec53", "node_type": "1", "metadata": {"window": "I think like a lot of the \nother people on the line here, I'm really intrigued by what seems to be going on in the generic drug \nbusiness.  You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah. ", "original_text": "I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "158554ac69e900801472582ea8454747e82e35eb5f265a1912cddcd734bf805f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd6fd90b-3fc8-47c7-876c-5b9b9384dccb", "node_type": "1", "metadata": {"window": "GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract. ", "original_text": "Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n"}, "hash": "d4bbccc89b17d4cba543495b1aa151742b0866ad66514dc3c3a48a1fb0b78710", "class_name": "RelatedNodeInfo"}}, "text": "Are you seeing like increased rebates for purchasing compliance or supply \ncompliance? ", "start_char_idx": 1924, "end_char_idx": 2011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd6fd90b-3fc8-47c7-876c-5b9b9384dccb": {"__data__": {"id_": "bd6fd90b-3fc8-47c7-876c-5b9b9384dccb", "embedding": null, "metadata": {"window": "GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract. ", "original_text": "Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "113af8a7-666b-4f51-8948-253c8567d273", "node_type": "1", "metadata": {"window": "You guys called out Red Oak .  GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George. ", "original_text": "Are you seeing like increased rebates for purchasing compliance or supply \ncompliance? ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff7e7e42b31365b506a38aa693c40ae8a660d6f880e75a5485964f2e001218d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f333fb26-42d3-485f-870f-3ecc2a41843f", "node_type": "1", "metadata": {"window": "I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving. ", "original_text": "Jason Holler:  Yeah. "}, "hash": "efccb5da9067e859ab2be1fbd9b4e44173e5255e899885f0b3922dc40e0b872b", "class_name": "RelatedNodeInfo"}}, "text": "Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n", "start_char_idx": 2011, "end_char_idx": 2179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f333fb26-42d3-485f-870f-3ecc2a41843f": {"__data__": {"id_": "f333fb26-42d3-485f-870f-3ecc2a41843f", "embedding": null, "metadata": {"window": "I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving. ", "original_text": "Jason Holler:  Yeah. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd6fd90b-3fc8-47c7-876c-5b9b9384dccb", "node_type": "1", "metadata": {"window": "GLP-1s were really strong in the quarter, but they have to be \nsignificantly margin dilut ed.  I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract. ", "original_text": "Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3590a3a975e878b323bba48da50434d30f2744774497c98f3b17303d09469313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c06a753-5d19-45e3-912e-e116f45757a5", "node_type": "1", "metadata": {"window": "Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange. ", "original_text": "So, it's a fair question, George. "}, "hash": "82aaf6a788549d3f32d45736f35d13dc9bb636e4039c32a706c8f1fe980bae62", "class_name": "RelatedNodeInfo"}}, "text": "Jason Holler:  Yeah. ", "start_char_idx": 2179, "end_char_idx": 2200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c06a753-5d19-45e3-912e-e116f45757a5": {"__data__": {"id_": "1c06a753-5d19-45e3-912e-e116f45757a5", "embedding": null, "metadata": {"window": "Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange. ", "original_text": "So, it's a fair question, George. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f333fb26-42d3-485f-870f-3ecc2a41843f", "node_type": "1", "metadata": {"window": "I guess Jason, I'd love if you could talk about like, if anything's changing \non the contracting side.  Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving. ", "original_text": "Jason Holler:  Yeah. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ec3b1c16ca1068eed9286be0a368dac7549477aa963067b49ee9e86cbc9a63d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeaa8dc0-6f43-4f09-8675-84085213cc9b", "node_type": "1", "metadata": {"window": "Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey . ", "original_text": "And there's always going to be an evolution, \ncustomer to customer contract to contract. "}, "hash": "1890b59cb0107d6aa559e1ffe3a46a7d40a59d2825b7a5699431b14178b828ae", "class_name": "RelatedNodeInfo"}}, "text": "So, it's a fair question, George. ", "start_char_idx": 2200, "end_char_idx": 2234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aeaa8dc0-6f43-4f09-8675-84085213cc9b": {"__data__": {"id_": "aeaa8dc0-6f43-4f09-8675-84085213cc9b", "embedding": null, "metadata": {"window": "Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey . ", "original_text": "And there's always going to be an evolution, \ncustomer to customer contract to contract. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c06a753-5d19-45e3-912e-e116f45757a5", "node_type": "1", "metadata": {"window": "Are you seeing like increased rebates for purchasing compliance or supply \ncompliance?  Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange. ", "original_text": "So, it's a fair question, George. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d512e8feef3792c1c7b6bbd43c5485f289213a45727d277830c9ac983ed37281", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09094806-702b-4188-bfbd-97ebde770adc", "node_type": "1", "metadata": {"window": "Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive. ", "original_text": "The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving. "}, "hash": "3f33229cf20a1d427e60b849b87c38718d94e928cc7d2188d2e24ff9dbd707ff", "class_name": "RelatedNodeInfo"}}, "text": "And there's always going to be an evolution, \ncustomer to customer contract to contract. ", "start_char_idx": 2234, "end_char_idx": 2323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09094806-702b-4188-bfbd-97ebde770adc": {"__data__": {"id_": "09094806-702b-4188-bfbd-97ebde770adc", "embedding": null, "metadata": {"window": "Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive. ", "original_text": "The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aeaa8dc0-6f43-4f09-8675-84085213cc9b", "node_type": "1", "metadata": {"window": "Just kind of interest ed, any more color  that you can provide on what's going on in the \ngeneric drug space as it relates to profitability would be super helpful.  \n \n Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey . ", "original_text": "And there's always going to be an evolution, \ncustomer to customer contract to contract. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e691e0ba2ff20c6514c7381bad665d39cc3234ed4b2764272091c6548eb8e057", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5aa481b-30d9-4ae7-9f81-325f2a98c7d9", "node_type": "1", "metadata": {"window": "So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars. ", "original_text": "And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange. "}, "hash": "a814e6e3254d3ac9d918f1f7a89067c9a1b84eef5bb91f4828d8b6bc97735660", "class_name": "RelatedNodeInfo"}}, "text": "The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving. ", "start_char_idx": 2323, "end_char_idx": 2436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5aa481b-30d9-4ae7-9f81-325f2a98c7d9": {"__data__": {"id_": "d5aa481b-30d9-4ae7-9f81-325f2a98c7d9", "embedding": null, "metadata": {"window": "So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars. ", "original_text": "And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09094806-702b-4188-bfbd-97ebde770adc", "node_type": "1", "metadata": {"window": "Jason Holler:  Yeah.  So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive. ", "original_text": "The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810403263190706fb32bdac65f7368e5d96d6ce17e03bce14d141dc54c499301", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97adcd77-faa6-4bb7-83cf-af9957c77252", "node_type": "1", "metadata": {"window": "And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day. ", "original_text": "So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey . "}, "hash": "2c7fcea17cd59553367355b457ffb3c29f352771c58191377e045fdc2724413e", "class_name": "RelatedNodeInfo"}}, "text": "And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange. ", "start_char_idx": 2436, "end_char_idx": 2581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97adcd77-faa6-4bb7-83cf-af9957c77252": {"__data__": {"id_": "97adcd77-faa6-4bb7-83cf-af9957c77252", "embedding": null, "metadata": {"window": "And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day. ", "original_text": "So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey . ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5aa481b-30d9-4ae7-9f81-325f2a98c7d9", "node_type": "1", "metadata": {"window": "So, it's a fair question, George.  And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars. ", "original_text": "And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4bfee50028c312f72190c822214e9716208e816eec4ca41ef697f4a5f357d112", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4afc0e2d-9eee-487a-9d56-ab5bbb583290", "node_type": "1", "metadata": {"window": "The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us. ", "original_text": "So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive. "}, "hash": "c1419cb35ec67f24b0b9b92cdb3d55e9d061f1b57f2ca47f6d464777370c850f", "class_name": "RelatedNodeInfo"}}, "text": "So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey . ", "start_char_idx": 2581, "end_char_idx": 2737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4afc0e2d-9eee-487a-9d56-ab5bbb583290": {"__data__": {"id_": "4afc0e2d-9eee-487a-9d56-ab5bbb583290", "embedding": null, "metadata": {"window": "The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us. ", "original_text": "So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97adcd77-faa6-4bb7-83cf-af9957c77252", "node_type": "1", "metadata": {"window": "And there's always going to be an evolution, \ncustomer to customer contract to contract.  The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day. ", "original_text": "So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey . ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d28fa612a3bb1263bc0129a40404bfd342b5c63de64ff3f2a9b541ba488820a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e0f80d2-0ce1-40f4-a12a-a2aa55ca0161", "node_type": "1", "metadata": {"window": "And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us. ", "original_text": "I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars. "}, "hash": "51fa28a24a71bbada7f3522916d3d88b3bc441e6380ee8d1cf8e115e40dab907", "class_name": "RelatedNodeInfo"}}, "text": "So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive. ", "start_char_idx": 2737, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e0f80d2-0ce1-40f4-a12a-a2aa55ca0161": {"__data__": {"id_": "5e0f80d2-0ce1-40f4-a12a-a2aa55ca0161", "embedding": null, "metadata": {"window": "And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us. ", "original_text": "I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4afc0e2d-9eee-487a-9d56-ab5bbb583290", "node_type": "1", "metadata": {"window": "The balance of brand versus generic, and then within \nbrand and within generic, the mix always is ever evolving.  And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us. ", "original_text": "So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a4a6a7ba9a479898d13ae6239e6882ee83e4ee22a1120cbaf067a86232e5e1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b31a00d8-5eab-41e3-a139-c5bf5b2b855c", "node_type": "1", "metadata": {"window": "So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry. ", "original_text": "And I \neven jo ked about this at investor day. "}, "hash": "84010fa18cc355b0b1ef48325b27a1830316ee4f8234d7eab3242d97fe67eec9", "class_name": "RelatedNodeInfo"}}, "text": "I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars. ", "start_char_idx": 2829, "end_char_idx": 2985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b31a00d8-5eab-41e3-a139-c5bf5b2b855c": {"__data__": {"id_": "b31a00d8-5eab-41e3-a139-c5bf5b2b855c", "embedding": null, "metadata": {"window": "So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry. ", "original_text": "And I \neven jo ked about this at investor day. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e0f80d2-0ce1-40f4-a12a-a2aa55ca0161", "node_type": "1", "metadata": {"window": "And so over time, I would  expect there to \nbe more and more separation between some of these elements as the weighting of the products \nchange.  So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us. ", "original_text": "I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c201631d22f08a33e8588bc29b50398c0335576a1acde4e50a7c98f90ca0bed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9f94bf5-b11d-48ee-8f8d-103b669de36e", "node_type": "1", "metadata": {"window": "So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n", "original_text": "I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us. "}, "hash": "a60d06d59e79f1a88ba7e14d332aee2d4941c8ab1c1e8c10aedb520fd2e790fd", "class_name": "RelatedNodeInfo"}}, "text": "And I \neven jo ked about this at investor day. ", "start_char_idx": 2985, "end_char_idx": 3032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9f94bf5-b11d-48ee-8f8d-103b669de36e": {"__data__": {"id_": "b9f94bf5-b11d-48ee-8f8d-103b669de36e", "embedding": null, "metadata": {"window": "So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n", "original_text": "I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b31a00d8-5eab-41e3-a139-c5bf5b2b855c", "node_type": "1", "metadata": {"window": "So even though this volume has been dramatic for the GLP -1s, it's also been over a pretty \nshort period of time and probably still early in this journey .  So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry. ", "original_text": "And I \neven jo ked about this at investor day. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "810974619ac1b93e0b273ba996ed12eca48b6339cdc056f6c5937e74cada3ec0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a3d95d8-896d-4228-b350-849fa741709d", "node_type": "1", "metadata": {"window": "I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities . ", "original_text": "And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us. "}, "hash": "0349812111ac965438569a17689e40c21de7b00d1700b9b78b37b9da76e569ad", "class_name": "RelatedNodeInfo"}}, "text": "I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us. ", "start_char_idx": 3032, "end_char_idx": 3176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a3d95d8-896d-4228-b350-849fa741709d": {"__data__": {"id_": "6a3d95d8-896d-4228-b350-849fa741709d", "embedding": null, "metadata": {"window": "I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities . ", "original_text": "And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9f94bf5-b11d-48ee-8f8d-103b669de36e", "node_type": "1", "metadata": {"window": "So, you used the phrase, and I think it was \nused earlier as significantly margin dilutive.  I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n", "original_text": "I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e2467d3b0948362d21421a89ecb5452ae356fa9bb09d4f136cd2e6a99602b45e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46a75768-c5b9-412d-aae6-3e252901cdbd", "node_type": "1", "metadata": {"window": "And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric. ", "original_text": "It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry. "}, "hash": "3f4061fd4f8c9b20588732f4d5862ab531268110bf6772c10b5d7adba0ecfe25", "class_name": "RelatedNodeInfo"}}, "text": "And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us. ", "start_char_idx": 3176, "end_char_idx": 3371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46a75768-c5b9-412d-aae6-3e252901cdbd": {"__data__": {"id_": "46a75768-c5b9-412d-aae6-3e252901cdbd", "embedding": null, "metadata": {"window": "And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric. ", "original_text": "It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a3d95d8-896d-4228-b350-849fa741709d", "node_type": "1", "metadata": {"window": "I'm sure we've never said words like that because it's very \nrare you hear us talking about margin rate, which you hear us talking about is margin dollars.  And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities . ", "original_text": "And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "059361a53e747734d05bae47efc126204497337fdfcee13dc03d96a6a1f26a33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba3b6543-b923-4852-9442-fafdd7439910", "node_type": "1", "metadata": {"window": "I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n"}, "hash": "856f00a3914974171bd4c1a4da698eba09ac578dee174edf74203c6bd0e49dde", "class_name": "RelatedNodeInfo"}}, "text": "It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry. ", "start_char_idx": 3371, "end_char_idx": 3503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba3b6543-b923-4852-9442-fafdd7439910": {"__data__": {"id_": "ba3b6543-b923-4852-9442-fafdd7439910", "embedding": null, "metadata": {"window": "I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46a75768-c5b9-412d-aae6-3e252901cdbd", "node_type": "1", "metadata": {"window": "And I \neven jo ked about this at investor day.  I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric. ", "original_text": "It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd556bf6ef44bc966c6a81b733beabab8d2338b607773931b0960e993e7ebed2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f237f9d-90b6-4d10-b3db-e73d3ddfc70f", "node_type": "1", "metadata": {"window": "And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities . "}, "hash": "a6861676052a48ddba99d8f722a3cd3685898cf67a23bdbdbc5cd658092c50ef", "class_name": "RelatedNodeInfo"}}, "text": "What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n", "start_char_idx": 3503, "end_char_idx": 3603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f237f9d-90b6-4d10-b3db-e73d3ddfc70f": {"__data__": {"id_": "5f237f9d-90b6-4d10-b3db-e73d3ddfc70f", "embedding": null, "metadata": {"window": "And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities . ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba3b6543-b923-4852-9442-fafdd7439910", "node_type": "1", "metadata": {"window": "I'm not sure I've ever said the words out loud in my career \nabout the margin rate not being the most important or a significant metric for us.  And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16f3d3702f93acf58a6d5f112a77e68f9e01d7e0bd26f2ec7e15cd8071fc9b5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaf65bf2-f10b-4a08-aa19-967198e4c243", "node_type": "1", "metadata": {"window": "It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric. "}, "hash": "a952d1ad925dfe9007eb875586b6267529f4d492cca619bffc1844d445eee257", "class_name": "RelatedNodeInfo"}}, "text": "Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities . ", "start_char_idx": 3603, "end_char_idx": 3760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaf65bf2-f10b-4a08-aa19-967198e4c243": {"__data__": {"id_": "aaf65bf2-f10b-4a08-aa19-967198e4c243", "embedding": null, "metadata": {"window": "It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f237f9d-90b6-4d10-b3db-e73d3ddfc70f", "node_type": "1", "metadata": {"window": "And it's because of \nproducts like the GL P-1s, products that are incredibly important to that underlying patient, which \nmeans it's important to our customers, which means it's important to us.  It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities . ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c96a1b919d9e4aa57e98cf05bb6bdf462c0ba55f7559a536beb16cf143e0dd73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8356eade-38df-478a-b718-56bdda1d3e76", "node_type": "1", "metadata": {"window": "What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "There's just lots of different ways in which you can create economic value on a particular "}, "hash": "e5897e0260670d514c00c0653903e8377696005ed5d82828b22075d17e4fc315", "class_name": "RelatedNodeInfo"}}, "text": "Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric. ", "start_char_idx": 3760, "end_char_idx": 3920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8356eade-38df-478a-b718-56bdda1d3e76": {"__data__": {"id_": "8356eade-38df-478a-b718-56bdda1d3e76", "embedding": null, "metadata": {"window": "What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "There's just lots of different ways in which you can create economic value on a particular ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "67bee7a21cc22078844b8f5e2f6ed73880726da6c7ce766265d7f48b25987f82", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaf65bf2-f10b-4a08-aa19-967198e4c243", "node_type": "1", "metadata": {"window": "It is not the most profitable \nclass of products for us today, but it's important for our patients and im portant for the industry.  What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "220176b805ff2eb14228fcbc388d9b7f89f69d97cc4f87f7c7980a17c4376dce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc94666e-47dc-4a27-b6a4-270b3778a208", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic. ", "original_text": " \nPage 12 of 16 \n \ntransaction, particular product. "}, "hash": "d4204c2d5888598e964b276d3f888e7c41271c8243292901a8c7479da44be5ec", "class_name": "RelatedNodeInfo"}}, "text": "There's just lots of different ways in which you can create economic value on a particular ", "start_char_idx": 3920, "end_char_idx": 4011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc94666e-47dc-4a27-b6a4-270b3778a208": {"__data__": {"id_": "cc94666e-47dc-4a27-b6a4-270b3778a208", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic. ", "original_text": " \nPage 12 of 16 \n \ntransaction, particular product. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8356eade-38df-478a-b718-56bdda1d3e76", "node_type": "1", "metadata": {"window": "What \nwe value more than anything else is innovation in the distribution channel in the industry.  \n Innovation brings good things for us, maybe not in the short term, and maybe not for every single \nproduct, but innovation ultimately brings opportunities .  Whether it's services , or whether it's when \nthese products become other opportunities to contract , or other opportunities over time for them to go \ngeneric.  There's just lots of different ways in which you can create economic value on a particular ", "original_text": "There's just lots of different ways in which you can create economic value on a particular ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5d8e05723b734040736b4bb621f5a5788a147f7f855b7cb8ff129c620db1844", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ff1d61e-5d83-427f-b0b7-2afb7d088783", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer. ", "original_text": "And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings. "}, "hash": "882038e7397e7a8f10df2d5bfbef3f324315b785884f6cb96794c249ea8258b5", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 16 \n \ntransaction, particular product. ", "start_char_idx": 0, "end_char_idx": 52, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ff1d61e-5d83-427f-b0b7-2afb7d088783": {"__data__": {"id_": "2ff1d61e-5d83-427f-b0b7-2afb7d088783", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer. ", "original_text": "And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc94666e-47dc-4a27-b6a4-270b3778a208", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic. ", "original_text": " \nPage 12 of 16 \n \ntransaction, particular product. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "659e9d84e8e4aeb564e6d0aa0bf0ea3ea657bcc46c08059b0d3e6dfb85b42bef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cce5109-7a50-4691-b52c-904e6e282431", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time. ", "original_text": "And so, we're not going to talk about it from earnings \nperspective. "}, "hash": "204cc74b3d87b4db58322c5bbd898ecb5c452c6ac65a19db67fb5b28287e0fff", "class_name": "RelatedNodeInfo"}}, "text": "And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings. ", "start_char_idx": 52, "end_char_idx": 166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cce5109-7a50-4691-b52c-904e6e282431": {"__data__": {"id_": "1cce5109-7a50-4691-b52c-904e6e282431", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time. ", "original_text": "And so, we're not going to talk about it from earnings \nperspective. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ff1d61e-5d83-427f-b0b7-2afb7d088783", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer. ", "original_text": "And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a87965e5c439e90d94cb3420383e35f3c20b9fc2df0886ffcac17b2684b1a76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50c68992-bb30-4399-9f4e-f97c35670105", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say. ", "original_text": "Contracting, back to your original question will continue to evolve underneath that \ndynamic. "}, "hash": "83d47d0e43936943fd8aa650878010f469cde10d27e9e0c6b7c84fa2ba381653", "class_name": "RelatedNodeInfo"}}, "text": "And so, we're not going to talk about it from earnings \nperspective. ", "start_char_idx": 166, "end_char_idx": 235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50c68992-bb30-4399-9f4e-f97c35670105": {"__data__": {"id_": "50c68992-bb30-4399-9f4e-f97c35670105", "embedding": null, "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say. ", "original_text": "Contracting, back to your original question will continue to evolve underneath that \ndynamic. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cce5109-7a50-4691-b52c-904e6e282431", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time. ", "original_text": "And so, we're not going to talk about it from earnings \nperspective. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4db8cf027564cfec8c32359f082e10398a2f1534a48008fb84b7159ad0a5fb05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5481a2ff-5514-4c28-acfc-f49760d55d89", "node_type": "1", "metadata": {"window": "And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry. ", "original_text": "But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer. "}, "hash": "21bddd765f63d7bbb992df87e8a9c9b17f06a16215186443ab147a6246363f17", "class_name": "RelatedNodeInfo"}}, "text": "Contracting, back to your original question will continue to evolve underneath that \ndynamic. ", "start_char_idx": 235, "end_char_idx": 329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5481a2ff-5514-4c28-acfc-f49760d55d89": {"__data__": {"id_": "5481a2ff-5514-4c28-acfc-f49760d55d89", "embedding": null, "metadata": {"window": "And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry. ", "original_text": "But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50c68992-bb30-4399-9f4e-f97c35670105", "node_type": "1", "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say. ", "original_text": "Contracting, back to your original question will continue to evolve underneath that \ndynamic. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d4cb31f23c2d0e53fe01e6dcd9fef31c13a1a8f9b815538bcae112dfa585416", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "638a7d12-160b-42a3-8130-448532ee41c7", "node_type": "1", "metadata": {"window": "And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard. ", "original_text": "And so that needs to evolve over time as \nthose concentratio ns evolve over time. "}, "hash": "e7f56f1194580cbb6d43f86be3e7c6cc8e3b52868b59626df3b2916c1ba758ee", "class_name": "RelatedNodeInfo"}}, "text": "But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer. ", "start_char_idx": 329, "end_char_idx": 478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "638a7d12-160b-42a3-8130-448532ee41c7": {"__data__": {"id_": "638a7d12-160b-42a3-8130-448532ee41c7", "embedding": null, "metadata": {"window": "And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard. ", "original_text": "And so that needs to evolve over time as \nthose concentratio ns evolve over time. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5481a2ff-5514-4c28-acfc-f49760d55d89", "node_type": "1", "metadata": {"window": "And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry. ", "original_text": "But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ad39db9b403df5a2623cd9c1f134511d84e016b8a9f34819d40ff15d48c144c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9324571b-d160-4ca3-842c-ceb6729ce6ac", "node_type": "1", "metadata": {"window": "Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n", "original_text": "But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say. "}, "hash": "fb493c8a535d504668824887f2ac2870272778aeae69bb80b6a65c1151bccfae", "class_name": "RelatedNodeInfo"}}, "text": "And so that needs to evolve over time as \nthose concentratio ns evolve over time. ", "start_char_idx": 478, "end_char_idx": 560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9324571b-d160-4ca3-842c-ceb6729ce6ac": {"__data__": {"id_": "9324571b-d160-4ca3-842c-ceb6729ce6ac", "embedding": null, "metadata": {"window": "Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n", "original_text": "But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "638a7d12-160b-42a3-8130-448532ee41c7", "node_type": "1", "metadata": {"window": "And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard. ", "original_text": "And so that needs to evolve over time as \nthose concentratio ns evolve over time. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51b5841c94d943163c4d583e41cfceab37f1ed1a5fe1a10efcfa3cd83eb36e4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23bfd213-0cd5-4722-81c0-d771496f0ea9", "node_type": "1", "metadata": {"window": "But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore. ", "original_text": "But \nit's not the first time that there's been a mix change in her industry. "}, "hash": "8111f864aa8244d594602c8ab41950267ef8f377f78c6633ec233f812242ea7c", "class_name": "RelatedNodeInfo"}}, "text": "But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say. ", "start_char_idx": 560, "end_char_idx": 720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23bfd213-0cd5-4722-81c0-d771496f0ea9": {"__data__": {"id_": "23bfd213-0cd5-4722-81c0-d771496f0ea9", "embedding": null, "metadata": {"window": "But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore. ", "original_text": "But \nit's not the first time that there's been a mix change in her industry. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9324571b-d160-4ca3-842c-ceb6729ce6ac", "node_type": "1", "metadata": {"window": "Contracting, back to your original question will continue to evolve underneath that \ndynamic.  But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n", "original_text": "But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf661c8eba5f1c16cc5716940825c3bf328964d52a3f23054c17b13b858d197c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c8e4889-5fd5-4d93-a2c3-7ed34540d24e", "node_type": "1", "metadata": {"window": "And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n", "original_text": "And so, our model's proven to be \nresilient in that regard. "}, "hash": "dd97f88c961c0f7d4fd83e8b8016210ddcbf5400cba2b3314cb1bbe2db7910b4", "class_name": "RelatedNodeInfo"}}, "text": "But \nit's not the first time that there's been a mix change in her industry. ", "start_char_idx": 720, "end_char_idx": 797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c8e4889-5fd5-4d93-a2c3-7ed34540d24e": {"__data__": {"id_": "9c8e4889-5fd5-4d93-a2c3-7ed34540d24e", "embedding": null, "metadata": {"window": "And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n", "original_text": "And so, our model's proven to be \nresilient in that regard. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23bfd213-0cd5-4722-81c0-d771496f0ea9", "node_type": "1", "metadata": {"window": "But ultimately, we are well protected customer by customer in certain corridors to ensure \nthat we don' t flip upside down on a particular customer.  And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore. ", "original_text": "But \nit's not the first time that there's been a mix change in her industry. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f05378d09dd5f4bdce82e5369074728c33415fc2ece28454d4b71c16c1d1607f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf00d338-e0d1-49cc-9011-29848d723b7d", "node_type": "1", "metadata": {"window": "But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys. ", "original_text": "So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n"}, "hash": "5c0b6595c36a0b3fe048dfed8ae8dacb931f48219558c3dc138e23b27969ccfe", "class_name": "RelatedNodeInfo"}}, "text": "And so, our model's proven to be \nresilient in that regard. ", "start_char_idx": 797, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf00d338-e0d1-49cc-9011-29848d723b7d": {"__data__": {"id_": "cf00d338-e0d1-49cc-9011-29848d723b7d", "embedding": null, "metadata": {"window": "But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys. ", "original_text": "So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c8e4889-5fd5-4d93-a2c3-7ed34540d24e", "node_type": "1", "metadata": {"window": "And so that needs to evolve over time as \nthose concentratio ns evolve over time.  But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n", "original_text": "And so, our model's proven to be \nresilient in that regard. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f502e8e7b09b9cf92e27cc415d4d703428137c9e4db4d83a3425c549e05bd2f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3adc3cfe-7fe5-4a6c-a43d-c8b0fb2a1f4c", "node_type": "1", "metadata": {"window": "But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year. ", "original_text": "Operator:  The next question comes from Elizabeth Anderson of Evercore. "}, "hash": "9db2f778c61a5bf839dfc5d8227ef447febed5f05d63570abcec654faf6f0f71", "class_name": "RelatedNodeInfo"}}, "text": "So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n", "start_char_idx": 857, "end_char_idx": 1031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3adc3cfe-7fe5-4a6c-a43d-c8b0fb2a1f4c": {"__data__": {"id_": "3adc3cfe-7fe5-4a6c-a43d-c8b0fb2a1f4c", "embedding": null, "metadata": {"window": "But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year. ", "original_text": "Operator:  The next question comes from Elizabeth Anderson of Evercore. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf00d338-e0d1-49cc-9011-29848d723b7d", "node_type": "1", "metadata": {"window": "But our model has proven very, very resilient over the years \nand decades because this is the latest mix challenge that there is, or mixed change I should say.  But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys. ", "original_text": "So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3fd4d0d5b530ca8bcea597584d2065db8dc2f86a483021b1df1bf28c598f81f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad339732-2922-411c-bcce-8cc142dac9c2", "node_type": "1", "metadata": {"window": "And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year. ", "original_text": "Please go ahead.  \n \n"}, "hash": "9a0a421c5d7446b2b9789ac941f4314b957bbcc9115e8fe5fcdf46bfc34eb47f", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from Elizabeth Anderson of Evercore. ", "start_char_idx": 1031, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad339732-2922-411c-bcce-8cc142dac9c2": {"__data__": {"id_": "ad339732-2922-411c-bcce-8cc142dac9c2", "embedding": null, "metadata": {"window": "And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year. ", "original_text": "Please go ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3adc3cfe-7fe5-4a6c-a43d-c8b0fb2a1f4c", "node_type": "1", "metadata": {"window": "But \nit's not the first time that there's been a mix change in her industry.  And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year. ", "original_text": "Operator:  The next question comes from Elizabeth Anderson of Evercore. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a03662aae259c4b48876aa7c274330e21bd669c4a4465d2c8efedc9505437897", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "214030a8-cf2b-438d-b0e6-b1e77b1f9fa9", "node_type": "1", "metadata": {"window": "So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year? ", "original_text": "Elizabeth Anderson:  Hi guys. "}, "hash": "ca40b4e6169a280140fa3ac1eed2d02070831a7c011aa0d5bba67d77db56bfa9", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1103, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "214030a8-cf2b-438d-b0e6-b1e77b1f9fa9": {"__data__": {"id_": "214030a8-cf2b-438d-b0e6-b1e77b1f9fa9", "embedding": null, "metadata": {"window": "So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year? ", "original_text": "Elizabeth Anderson:  Hi guys. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad339732-2922-411c-bcce-8cc142dac9c2", "node_type": "1", "metadata": {"window": "And so, our model's proven to be \nresilient in that regard.  So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year. ", "original_text": "Please go ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b195327116e16a6a0d655ff2d0236af73301bf5b82e3dd92de11fabddcca588", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c803a89-8126-40a4-9cc4-4c60fb0a53a3", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n", "original_text": "Thanks for the questions or the comments about sort of the pacing of \nthe year. "}, "hash": "9d43f80d307a28ec3af28ea623f5a0966cf274de160e5093bd6c8568327e742c", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson:  Hi guys. ", "start_char_idx": 1124, "end_char_idx": 1154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c803a89-8126-40a4-9cc4-4c60fb0a53a3": {"__data__": {"id_": "5c803a89-8126-40a4-9cc4-4c60fb0a53a3", "embedding": null, "metadata": {"window": "Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n", "original_text": "Thanks for the questions or the comments about sort of the pacing of \nthe year. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "214030a8-cf2b-438d-b0e6-b1e77b1f9fa9", "node_type": "1", "metadata": {"window": "So, it's unique in different product, but it's not unique in terms of impacts and \ninfluences that a particular product category has on the pharma distribution industry.  \n \n Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year? ", "original_text": "Elizabeth Anderson:  Hi guys. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f4d8d7370ece5b9c5cfd772a6f350d3a6d99d89904a63f3671921d4cb45b51f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b467962b-2099-4631-b981-b4260c8c07a7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry. ", "original_text": "One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year. "}, "hash": "76a488419b755f2f85d108c5546b4e658bc6526476b62eb7cb8e3dda228d13b7", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the questions or the comments about sort of the pacing of \nthe year. ", "start_char_idx": 1154, "end_char_idx": 1234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b467962b-2099-4631-b981-b4260c8c07a7": {"__data__": {"id_": "b467962b-2099-4631-b981-b4260c8c07a7", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry. ", "original_text": "One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c803a89-8126-40a4-9cc4-4c60fb0a53a3", "node_type": "1", "metadata": {"window": "Operator:  The next question comes from Elizabeth Anderson of Evercore.  Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n", "original_text": "Thanks for the questions or the comments about sort of the pacing of \nthe year. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c991f1fe96605c377e084529dc3bce47c84cbc1dc17a726624b90c17bd48df2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09f35abc-e4cb-4609-b42c-89eb36181829", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller. ", "original_text": "Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year? "}, "hash": "ec624dcbafa775cca0bd8070595150ac590b8a43b7c30c47409040d0f1bb5bb2", "class_name": "RelatedNodeInfo"}}, "text": "One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year. ", "start_char_idx": 1234, "end_char_idx": 1394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09f35abc-e4cb-4609-b42c-89eb36181829": {"__data__": {"id_": "09f35abc-e4cb-4609-b42c-89eb36181829", "embedding": null, "metadata": {"window": "Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller. ", "original_text": "Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year? ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b467962b-2099-4631-b981-b4260c8c07a7", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry. ", "original_text": "One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7ac5910fbef96af63a181cbccd05018f4dda32d929d363eef52ad83a88fe3ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b4e3f56-b119-47e2-8d06-d3114a6de375", "node_type": "1", "metadata": {"window": "Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi. ", "original_text": "Because obvio usly you had \na [inaudible] . \n \n"}, "hash": "12a8180510d0c3c5d3666c98b4c6772106a69d07f3dc47328c94bf0b132d87ab", "class_name": "RelatedNodeInfo"}}, "text": "Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year? ", "start_char_idx": 1394, "end_char_idx": 1509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b4e3f56-b119-47e2-8d06-d3114a6de375": {"__data__": {"id_": "3b4e3f56-b119-47e2-8d06-d3114a6de375", "embedding": null, "metadata": {"window": "Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi. ", "original_text": "Because obvio usly you had \na [inaudible] . \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09f35abc-e4cb-4609-b42c-89eb36181829", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  Hi guys.  Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller. ", "original_text": "Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year? ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "718f6df5cbf6c4862f25ca0a567c5b4216205758dd74506dcee54c93886e9a84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03b46db9-8fd5-490e-81f0-fed98b7d3208", "node_type": "1", "metadata": {"window": "One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n", "original_text": "Operator:  Sorry. "}, "hash": "608718204cb1be5ae9a01a9c7a1e7d26f9b0473c63af671abe36a3228bc3f369", "class_name": "RelatedNodeInfo"}}, "text": "Because obvio usly you had \na [inaudible] . \n \n", "start_char_idx": 1509, "end_char_idx": 1556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03b46db9-8fd5-490e-81f0-fed98b7d3208": {"__data__": {"id_": "03b46db9-8fd5-490e-81f0-fed98b7d3208", "embedding": null, "metadata": {"window": "One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n", "original_text": "Operator:  Sorry. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b4e3f56-b119-47e2-8d06-d3114a6de375", "node_type": "1", "metadata": {"window": "Thanks for the questions or the comments about sort of the pacing of \nthe year.  One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi. ", "original_text": "Because obvio usly you had \na [inaudible] . \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df63f88585bcc5f3d625bb66a05b4a9e167fe2b53d71e2f5f13a445e2ba141a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f647980e-7b8f-4e9c-b352-91665710f286", "node_type": "1", "metadata": {"window": "Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question. ", "original_text": "I think we lost we lost the previous caller. "}, "hash": "1bb8cd95c7fef9cd0ee69ee0159bb60e91247c5cef080ad79fd9049014f3545f", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Sorry. ", "start_char_idx": 1556, "end_char_idx": 1574, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f647980e-7b8f-4e9c-b352-91665710f286": {"__data__": {"id_": "f647980e-7b8f-4e9c-b352-91665710f286", "embedding": null, "metadata": {"window": "Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question. ", "original_text": "I think we lost we lost the previous caller. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03b46db9-8fd5-490e-81f0-fed98b7d3208", "node_type": "1", "metadata": {"window": "One thing I was just kind of , I heard what you said about calling out the inflation and how \nthat doesn't quite flow through the same way as it did last year.  Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n", "original_text": "Operator:  Sorry. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad49622c56c56baa0bdcf3c633b9b1f2b58d5ce57d912f593b6cd58683d6dfac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ff35655-a5be-4839-ba99-dc7acb23d689", "node_type": "1", "metadata": {"window": "Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here. ", "original_text": "And we'll move on to the next question \nfrom Daniel Grosslight from Citi. "}, "hash": "6019c282f185cff45481708b597c66c3e2b2b029dab2df36dc09ef9994d96eb6", "class_name": "RelatedNodeInfo"}}, "text": "I think we lost we lost the previous caller. ", "start_char_idx": 1574, "end_char_idx": 1619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ff35655-a5be-4839-ba99-dc7acb23d689": {"__data__": {"id_": "2ff35655-a5be-4839-ba99-dc7acb23d689", "embedding": null, "metadata": {"window": "Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here. ", "original_text": "And we'll move on to the next question \nfrom Daniel Grosslight from Citi. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f647980e-7b8f-4e9c-b352-91665710f286", "node_type": "1", "metadata": {"window": "Can you speak to how you're thinking \nabout sort of the first half of the year versus the second half of the year?  Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question. ", "original_text": "I think we lost we lost the previous caller. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8fd016f4fc6a6a20f2ee254795d66e9692917c3c027b0801601a3f0b74b6110", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d56965c-1e71-4782-beed-dae97fa2bddb", "node_type": "1", "metadata": {"window": "Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season. ", "original_text": "Please go ahead.  \n \n"}, "hash": "2b50c3db1bcb3d17277c4c1d5171b61884f222d2db8070596d0ac59273e90ea9", "class_name": "RelatedNodeInfo"}}, "text": "And we'll move on to the next question \nfrom Daniel Grosslight from Citi. ", "start_char_idx": 1619, "end_char_idx": 1693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d56965c-1e71-4782-beed-dae97fa2bddb": {"__data__": {"id_": "6d56965c-1e71-4782-beed-dae97fa2bddb", "embedding": null, "metadata": {"window": "Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season. ", "original_text": "Please go ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ff35655-a5be-4839-ba99-dc7acb23d689", "node_type": "1", "metadata": {"window": "Because obvio usly you had \na [inaudible] . \n \n Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here. ", "original_text": "And we'll move on to the next question \nfrom Daniel Grosslight from Citi. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8e42bf816ca25ccb53236eb1e97d7eedef9cd474270de4992fb9db6e63299fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87cf121a-c6a3-42cc-94ed-ada7253986bc", "node_type": "1", "metadata": {"window": "I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest? ", "original_text": "Daniel Grosslight:  Hi, thanks for taking the question. "}, "hash": "d5ec04b267540eb28e2c5173b6a70b25350ba299d0333a0c1bec2dd367a52bf1", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1103, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87cf121a-c6a3-42cc-94ed-ada7253986bc": {"__data__": {"id_": "87cf121a-c6a3-42cc-94ed-ada7253986bc", "embedding": null, "metadata": {"window": "I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest? ", "original_text": "Daniel Grosslight:  Hi, thanks for taking the question. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d56965c-1e71-4782-beed-dae97fa2bddb", "node_type": "1", "metadata": {"window": "Operator:  Sorry.  I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season. ", "original_text": "Please go ahead.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c770a86ffb32234a5a8070ec4980f015c15a3daa01b52c8d453d6ff7fcc0b16d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0361ad4-3005-49a8-ad16-775c242a39f8", "node_type": "1", "metadata": {"window": "And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance? ", "original_text": "Maybe we'll go back to the COVID vaccine for a \nsecond here. "}, "hash": "dd2563cecf8a237833154f5a957fc57d45621e7c27c083fa57234aec16a99994", "class_name": "RelatedNodeInfo"}}, "text": "Daniel Grosslight:  Hi, thanks for taking the question. ", "start_char_idx": 1714, "end_char_idx": 1770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0361ad4-3005-49a8-ad16-775c242a39f8": {"__data__": {"id_": "a0361ad4-3005-49a8-ad16-775c242a39f8", "embedding": null, "metadata": {"window": "And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance? ", "original_text": "Maybe we'll go back to the COVID vaccine for a \nsecond here. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87cf121a-c6a3-42cc-94ed-ada7253986bc", "node_type": "1", "metadata": {"window": "I think we lost we lost the previous caller.  And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest? ", "original_text": "Daniel Grosslight:  Hi, thanks for taking the question. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f5121b57d542f9ac500151a10af197d345a2d062f01baec68d9d5beb0f221cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b375a85-699c-4459-b096-84e3cbd91bdb", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here. ", "original_text": "You mentioned that you're seeing stocking of vaccine ahead of the winter season. "}, "hash": "9740bfc6cc71788eca813abccf9ca934189f5de17979746701e830577584c899", "class_name": "RelatedNodeInfo"}}, "text": "Maybe we'll go back to the COVID vaccine for a \nsecond here. ", "start_char_idx": 1770, "end_char_idx": 1831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b375a85-699c-4459-b096-84e3cbd91bdb": {"__data__": {"id_": "3b375a85-699c-4459-b096-84e3cbd91bdb", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here. ", "original_text": "You mentioned that you're seeing stocking of vaccine ahead of the winter season. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0361ad4-3005-49a8-ad16-775c242a39f8", "node_type": "1", "metadata": {"window": "And we'll move on to the next question \nfrom Daniel Grosslight from Citi.  Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance? ", "original_text": "Maybe we'll go back to the COVID vaccine for a \nsecond here. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abd359c85c12900fea5d3164dd94430eafd1c210948e586857ea4af51d7b8264", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72daba6b-87a7-4bde-8491-c54f50e922b6", "node_type": "1", "metadata": {"window": "Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n", "original_text": "Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest? "}, "hash": "d0064253377ca2d9ad94dd9c8d2b3f7bc9ac931807454195fc04d4cf0fb7b77c", "class_name": "RelatedNodeInfo"}}, "text": "You mentioned that you're seeing stocking of vaccine ahead of the winter season. ", "start_char_idx": 1831, "end_char_idx": 1912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72daba6b-87a7-4bde-8491-c54f50e922b6": {"__data__": {"id_": "72daba6b-87a7-4bde-8491-c54f50e922b6", "embedding": null, "metadata": {"window": "Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n", "original_text": "Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest? ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b375a85-699c-4459-b096-84e3cbd91bdb", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here. ", "original_text": "You mentioned that you're seeing stocking of vaccine ahead of the winter season. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa4de1e4a4d8b761dc3c63a68f92ba0c93c33c53fb2d4069e201bed17c041cbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e5e85aa-92ce-44ac-bba1-915658d2fcf2", "node_type": "1", "metadata": {"window": "Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question. ", "original_text": "And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance? "}, "hash": "06e19b4565904d2595b37f358f0ddd7aeccfaf42ababba467214467fc62e8388", "class_name": "RelatedNodeInfo"}}, "text": "Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest? ", "start_char_idx": 1912, "end_char_idx": 2024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e5e85aa-92ce-44ac-bba1-915658d2fcf2": {"__data__": {"id_": "2e5e85aa-92ce-44ac-bba1-915658d2fcf2", "embedding": null, "metadata": {"window": "Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question. ", "original_text": "And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance? ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72daba6b-87a7-4bde-8491-c54f50e922b6", "node_type": "1", "metadata": {"window": "Daniel Grosslight:  Hi, thanks for taking the question.  Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n", "original_text": "Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest? ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "259fb2de43821e47281e1046ea148972daa2c54c3c3614f9ed22dd80b1313184", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c09b2ec9-2ccf-4670-9862-07eb2e79780f", "node_type": "1", "metadata": {"window": "You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one. ", "original_text": "And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here. "}, "hash": "c306d427cda1ad6d1ead1953c91b1b5a82c9cefb7a4e254397f1fc81ad257ba0", "class_name": "RelatedNodeInfo"}}, "text": "And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance? ", "start_char_idx": 2024, "end_char_idx": 2169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c09b2ec9-2ccf-4670-9862-07eb2e79780f": {"__data__": {"id_": "c09b2ec9-2ccf-4670-9862-07eb2e79780f", "embedding": null, "metadata": {"window": "You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one. ", "original_text": "And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e5e85aa-92ce-44ac-bba1-915658d2fcf2", "node_type": "1", "metadata": {"window": "Maybe we'll go back to the COVID vaccine for a \nsecond here.  You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question. ", "original_text": "And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance? ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "508ab0711ea28402748010efa3151da87cdbb575e652288f385ae7ef0828dd6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63f5b437-f2b9-4fb9-8b4a-89151ed64a60", "node_type": "1", "metadata": {"window": "Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these. ", "original_text": "I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n"}, "hash": "e470c7f961cf2cb0a57ce7cb737ccc4ca6b96b6ff77fcb36e586d3d4f76dce84", "class_name": "RelatedNodeInfo"}}, "text": "And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here. ", "start_char_idx": 2169, "end_char_idx": 2295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63f5b437-f2b9-4fb9-8b4a-89151ed64a60": {"__data__": {"id_": "63f5b437-f2b9-4fb9-8b4a-89151ed64a60", "embedding": null, "metadata": {"window": "Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these. ", "original_text": "I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c09b2ec9-2ccf-4670-9862-07eb2e79780f", "node_type": "1", "metadata": {"window": "You mentioned that you're seeing stocking of vaccine ahead of the winter season.  Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one. ", "original_text": "And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da6b484369c5865c9d71a6103282494c9563e27f8e8b80c8454a11fe5b54ac0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbe20fe2-e589-4eeb-bea5-de9063f78be3", "node_type": "1", "metadata": {"window": "And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint. ", "original_text": "Jason Holler:   Well, you're getting all the value out of your one question. "}, "hash": "730c1422849a3813b592a554476ff2bb7ebfe15fae5c92b70a45a3fdbe9c10d4", "class_name": "RelatedNodeInfo"}}, "text": "I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n", "start_char_idx": 2295, "end_char_idx": 2505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbe20fe2-e589-4eeb-bea5-de9063f78be3": {"__data__": {"id_": "cbe20fe2-e589-4eeb-bea5-de9063f78be3", "embedding": null, "metadata": {"window": "And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint. ", "original_text": "Jason Holler:   Well, you're getting all the value out of your one question. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63f5b437-f2b9-4fb9-8b4a-89151ed64a60", "node_type": "1", "metadata": {"window": "Are \nyou also taking more share in vaccine distribution than perhaps your overal l market share would \nsuggest?  And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these. ", "original_text": "I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "783e3ec0eeaa63c36e88538ab938ca16ac2acbc6c5e457c03089b42fbe753a04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e09b1724-5a30-4e4c-a3ce-30344f0ccbe1", "node_type": "1", "metadata": {"window": "And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n", "original_text": "So let me see if I can touch \non each one. "}, "hash": "86f11ce58f78a558fd1d102945dd4ac58f2f02c419c21f140c3ffc5f950efc13", "class_name": "RelatedNodeInfo"}}, "text": "Jason Holler:   Well, you're getting all the value out of your one question. ", "start_char_idx": 2505, "end_char_idx": 2582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e09b1724-5a30-4e4c-a3ce-30344f0ccbe1": {"__data__": {"id_": "e09b1724-5a30-4e4c-a3ce-30344f0ccbe1", "embedding": null, "metadata": {"window": "And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n", "original_text": "So let me see if I can touch \non each one. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbe20fe2-e589-4eeb-bea5-de9063f78be3", "node_type": "1", "metadata": {"window": "And then as we think about therapeutics moving into the commercial channel in a couple \nmonths here, how is that factored in into your guidance?  And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint. ", "original_text": "Jason Holler:   Well, you're getting all the value out of your one question. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aca0bc74bd306b00e70a557bd8447361ba81df3b6482196a72c7da52ce971adc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efd87e23-ac0b-4736-9f02-27900adfaa93", "node_type": "1", "metadata": {"window": "I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share? ", "original_text": "I think there's some connectivity between these. "}, "hash": "e607cbf186f9afe7e666e6a47b4d534945cc16e2557d49b30dfd2d8264fa04a7", "class_name": "RelatedNodeInfo"}}, "text": "So let me see if I can touch \non each one. ", "start_char_idx": 2582, "end_char_idx": 2625, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efd87e23-ac0b-4736-9f02-27900adfaa93": {"__data__": {"id_": "efd87e23-ac0b-4736-9f02-27900adfaa93", "embedding": null, "metadata": {"window": "I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share? ", "original_text": "I think there's some connectivity between these. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e09b1724-5a30-4e4c-a3ce-30344f0ccbe1", "node_type": "1", "metadata": {"window": "And then lastly, you've been operating well \nabove your longer -term Pharma EBIT guidance of 4 to 6% for a few quarters here.  I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n", "original_text": "So let me see if I can touch \non each one. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25a67c74be260e6be1a401abc765b01687a38e2fa99219de3d570cbc7c2a4c6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f967f9c-b809-41ce-9629-1ee1c7f32fc7", "node_type": "1", "metadata": {"window": "Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have. ", "original_text": "So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint. "}, "hash": "db7c576355bbd3dfd391866a56bbdaec013907b2eb753f65a179f9dff698e91c", "class_name": "RelatedNodeInfo"}}, "text": "I think there's some connectivity between these. ", "start_char_idx": 2625, "end_char_idx": 2674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f967f9c-b809-41ce-9629-1ee1c7f32fc7": {"__data__": {"id_": "9f967f9c-b809-41ce-9629-1ee1c7f32fc7", "embedding": null, "metadata": {"window": "Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have. ", "original_text": "So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efd87e23-ac0b-4736-9f02-27900adfaa93", "node_type": "1", "metadata": {"window": "I'm curious if \nthere's been any change to how you're thinking longer term about the business and some of the \nsecular tailwinds that might be driving growth higher than your longer term  4 to 6% guidance.  \n \n Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share? ", "original_text": "I think there's some connectivity between these. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e1fae0b2397fa5c9f5876e420379067c93ed0f68e375d138d62384d5e3d8416", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51d3f4c4-2761-4c95-953b-6b0504f892fe", "node_type": "1", "metadata": {"window": "So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers. ", "original_text": "So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n"}, "hash": "ae4af38a844d95a5b91e16e6df74d145faf939affd64cdc7459fd507b8379af9", "class_name": "RelatedNodeInfo"}}, "text": "So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint. ", "start_char_idx": 2674, "end_char_idx": 2804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51d3f4c4-2761-4c95-953b-6b0504f892fe": {"__data__": {"id_": "51d3f4c4-2761-4c95-953b-6b0504f892fe", "embedding": null, "metadata": {"window": "So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers. ", "original_text": "So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f967f9c-b809-41ce-9629-1ee1c7f32fc7", "node_type": "1", "metadata": {"window": "Jason Holler:   Well, you're getting all the value out of your one question.  So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have. ", "original_text": "So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f04e2e5d53f4301f5934f272622391655020548de52ce3b3147594df710376a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d923c704-3b02-4952-8267-8d8f89819fa9", "node_type": "1", "metadata": {"window": "I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n", "original_text": "So, the real question is, are our customers getting more than their fair share? "}, "hash": "09d1424f397ab8b71b05e4c7d7ba327c0878d64d770c7d51c6c0a9c659cc0649", "class_name": "RelatedNodeInfo"}}, "text": "So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n", "start_char_idx": 2804, "end_char_idx": 2931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d923c704-3b02-4952-8267-8d8f89819fa9": {"__data__": {"id_": "d923c704-3b02-4952-8267-8d8f89819fa9", "embedding": null, "metadata": {"window": "I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n", "original_text": "So, the real question is, are our customers getting more than their fair share? ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51d3f4c4-2761-4c95-953b-6b0504f892fe", "node_type": "1", "metadata": {"window": "So let me see if I can touch \non each one.  I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers. ", "original_text": "So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99793ce9b26f1fddcecab414ce1dc3db6316464c4716439549f3189159edace9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5714c10e-21b0-4d50-b75c-4e97a09ffe0d", "node_type": "1", "metadata": {"window": "So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics. ", "original_text": "And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have. "}, "hash": "91304b7ab22ef0b84a31b6e00a1fc38844a34075a7d6dcfd2a83dcad56bfa404", "class_name": "RelatedNodeInfo"}}, "text": "So, the real question is, are our customers getting more than their fair share? ", "start_char_idx": 2931, "end_char_idx": 3011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5714c10e-21b0-4d50-b75c-4e97a09ffe0d": {"__data__": {"id_": "5714c10e-21b0-4d50-b75c-4e97a09ffe0d", "embedding": null, "metadata": {"window": "So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics. ", "original_text": "And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d923c704-3b02-4952-8267-8d8f89819fa9", "node_type": "1", "metadata": {"window": "I think there's some connectivity between these.  So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n", "original_text": "So, the real question is, are our customers getting more than their fair share? ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e116cd6debe803c4bd7c769aa88bdc17fe9ea4c5d633be589c5e0706fbd88fc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28a53c50-3252-4107-8a39-b259bc402ad2", "node_type": "1", "metadata": {"window": "So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout . ", "original_text": "We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers. "}, "hash": "fd40cae2db32986e6bdac282d76acd75a0011f3f5f932d13f65a32a4e6c499af", "class_name": "RelatedNodeInfo"}}, "text": "And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have. ", "start_char_idx": 3011, "end_char_idx": 3147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28a53c50-3252-4107-8a39-b259bc402ad2": {"__data__": {"id_": "28a53c50-3252-4107-8a39-b259bc402ad2", "embedding": null, "metadata": {"window": "So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout . ", "original_text": "We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5714c10e-21b0-4d50-b75c-4e97a09ffe0d", "node_type": "1", "metadata": {"window": "So overall for vaccines, I think the best \nway to think about vaccine distribution is more about it from the customer standpoint.  So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics. ", "original_text": "And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a283393cfbecc440e2438feafb9baa8803a1085807401eea0c09f27ee9ae6baf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff873239-8c85-4801-a49f-2784e686b8cf", "node_type": "1", "metadata": {"window": "So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile . ", "original_text": "But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n"}, "hash": "e2ed74c77124dd4a4d67efe26fd0778259c5230df83671889fe90fad76d4bfdf", "class_name": "RelatedNodeInfo"}}, "text": "We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers. ", "start_char_idx": 3147, "end_char_idx": 3281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff873239-8c85-4801-a49f-2784e686b8cf": {"__data__": {"id_": "ff873239-8c85-4801-a49f-2784e686b8cf", "embedding": null, "metadata": {"window": "So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile . ", "original_text": "But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28a53c50-3252-4107-8a39-b259bc402ad2", "node_type": "1", "metadata": {"window": "So, I think what \nyou'll see is that COVID -19 vaccines, like other vaccines, typically will follow the distribution network. \n So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout . ", "original_text": "We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6faf56ef7e892bef0c5ba37fffe897ca70648ae7ff571cf659b8f149671bcef2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2353576b-1b19-4c83-9336-3ae18bd22669", "node_type": "1", "metadata": {"window": "And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "I think your second element of that question was on the COVID therapeutics. "}, "hash": "a9625385596502bb79c068733a11d83cc16db80d96cf062239878bc59645fee5", "class_name": "RelatedNodeInfo"}}, "text": "But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n", "start_char_idx": 3281, "end_char_idx": 3428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2353576b-1b19-4c83-9336-3ae18bd22669": {"__data__": {"id_": "2353576b-1b19-4c83-9336-3ae18bd22669", "embedding": null, "metadata": {"window": "And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "I think your second element of that question was on the COVID therapeutics. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff873239-8c85-4801-a49f-2784e686b8cf", "node_type": "1", "metadata": {"window": "So, the real question is, are our customers getting more than their fair share?  And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile . ", "original_text": "But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d34317437cf35ffa0e0f49b14a8930a9b632288698a821943eadd9510cc0a2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c728dd1-197c-4249-a4c9-13418b0c7930", "node_type": "1", "metadata": {"window": "We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "How I think about that , \nis a little bit differently than vaccines in terms of just the rollout . "}, "hash": "aaaf082c1048dde42ea90579903051afa5ba3ed35adebb18692c52d78695a57e", "class_name": "RelatedNodeInfo"}}, "text": "I think your second element of that question was on the COVID therapeutics. ", "start_char_idx": 3428, "end_char_idx": 3504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c728dd1-197c-4249-a4c9-13418b0c7930": {"__data__": {"id_": "3c728dd1-197c-4249-a4c9-13418b0c7930", "embedding": null, "metadata": {"window": "We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "How I think about that , \nis a little bit differently than vaccines in terms of just the rollout . ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2353576b-1b19-4c83-9336-3ae18bd22669", "node_type": "1", "metadata": {"window": "And I don't necessarily \nwant to talk about them from that perspective other than to say we are very happy with the customers \nwe have.  We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "I think your second element of that question was on the COVID therapeutics. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be807c5ef0baf785e34a914daf3dab3a24e70b1191e5a5ae5a68f0dbd1d1f8ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "708f468b-5f20-4f35-b744-5c4947365e85", "node_type": "1", "metadata": {"window": "But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile . "}, "hash": "d26443d0c1fb8474f08d53d03142837b48b05acbbe85ff8306616055aef3264d", "class_name": "RelatedNodeInfo"}}, "text": "How I think about that , \nis a little bit differently than vaccines in terms of just the rollout . ", "start_char_idx": 3504, "end_char_idx": 3603, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "708f468b-5f20-4f35-b744-5c4947365e85": {"__data__": {"id_": "708f468b-5f20-4f35-b744-5c4947365e85", "embedding": null, "metadata": {"window": "But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile . ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c728dd1-197c-4249-a4c9-13418b0c7930", "node_type": "1", "metadata": {"window": "We've often used a phrase for other situations about \u2018winning with the winners \u2019 and we feel \nvery well aligned with great customers.  But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "How I think about that , \nis a little bit differently than vaccines in terms of just the rollout . ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c3584652dc27c0d723fc6f12038273f85ed60985aa138c13dd10a79e3420713", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12f244c7-b4c8-4591-92db-e234ae20f1ab", "node_type": "1", "metadata": {"window": "I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , "}, "hash": "6fea4bc482f4c4eb3e4d8a1f5537c67de24379498568d1abada5065c31cac93c", "class_name": "RelatedNodeInfo"}}, "text": "Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile . ", "start_char_idx": 3603, "end_char_idx": 3730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12f244c7-b4c8-4591-92db-e234ae20f1ab": {"__data__": {"id_": "12f244c7-b4c8-4591-92db-e234ae20f1ab", "embedding": null, "metadata": {"window": "I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e72e370e7755a94f0e2a605e5eff78b1a0bdbb78faced1dd3916e49f10af903", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "708f468b-5f20-4f35-b744-5c4947365e85", "node_type": "1", "metadata": {"window": "But I think that's how you should think about it in that it most \nlikely the vast majority of the volume will follow the distribution network.  \n \n I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile . ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ed8bc7cfd05ac52fa189f714bc90c7b3c0aa70b8e54ae89f7d90044fe8fe52d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1272e0d5-ad63-41f1-b752-672ba5e877bc", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right? ", "original_text": " \nPage 13 of 16 \n \nthat was part of our response as well.  "}, "hash": "b18dce18abd83fa53b3cb9ec5266cae569392bc91cc4aa1c4b6d78473c50eda8", "class_name": "RelatedNodeInfo"}}, "text": "When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "start_char_idx": 3730, "end_char_idx": 3838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1272e0d5-ad63-41f1-b752-672ba5e877bc": {"__data__": {"id_": "1272e0d5-ad63-41f1-b752-672ba5e877bc", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right? ", "original_text": " \nPage 13 of 16 \n \nthat was part of our response as well.  ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12f244c7-b4c8-4591-92db-e234ae20f1ab", "node_type": "1", "metadata": {"window": "I think your second element of that question was on the COVID therapeutics.  How I think about that , \nis a little bit differently than vaccines in terms of just the rollout .  Where the vaccines were a bit of an \nobsolete old product, new product type of situation where all that government stockpile .  When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "original_text": "When we \nwere asked about vaccines nearly a year ago, when it was first communicated to be commercialized , ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69e83b56adbf3e4793a3e3e64eac7455ea1a8000ef1426591a62a80e389cad8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87385dc5-8fdf-4ba5-a8e1-ec8d0fce3e86", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.  ", "original_text": "We didn't know the FDA approval date. "}, "hash": "36facd475482ae6c1ab20271b407cf8e80b60e0cb12b6a6c93ff5f4ce9f1e0c7", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 16 \n \nthat was part of our response as well.  ", "start_char_idx": 0, "end_char_idx": 59, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87385dc5-8fdf-4ba5-a8e1-ec8d0fce3e86": {"__data__": {"id_": "87385dc5-8fdf-4ba5-a8e1-ec8d0fce3e86", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.  ", "original_text": "We didn't know the FDA approval date. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1272e0d5-ad63-41f1-b752-672ba5e877bc", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right? ", "original_text": " \nPage 13 of 16 \n \nthat was part of our response as well.  ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dafeb9d434112d52ec4346fe7c1d9e82b9936e2046503d8ffbddf4aaab569a00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca273c70-c370-48df-9e19-4f590bde4ef5", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n", "original_text": "We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n"}, "hash": "25c15ea61418a9f58363b22fed2677b52a4c2148c49941570b21aed9afb6855f", "class_name": "RelatedNodeInfo"}}, "text": "We didn't know the FDA approval date. ", "start_char_idx": 59, "end_char_idx": 97, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca273c70-c370-48df-9e19-4f590bde4ef5": {"__data__": {"id_": "ca273c70-c370-48df-9e19-4f590bde4ef5", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n", "original_text": "We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87385dc5-8fdf-4ba5-a8e1-ec8d0fce3e86", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.  ", "original_text": "We didn't know the FDA approval date. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea6d09cb1effeddaed884fb0cff3734b7eab5909179aa0bce0010aaa80d58287", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "926518c7-8c1c-4db1-a534-c70cb3d6dc64", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook. ", "original_text": "As it relates to therapeutics, we don't have that same challenge, right? "}, "hash": "5508105b08c7637a306d5a0cf01fe0fc7929dbcda9ac5422f80865c5f137b67d", "class_name": "RelatedNodeInfo"}}, "text": "We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n", "start_char_idx": 97, "end_char_idx": 267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "926518c7-8c1c-4db1-a534-c70cb3d6dc64": {"__data__": {"id_": "926518c7-8c1c-4db1-a534-c70cb3d6dc64", "embedding": null, "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook. ", "original_text": "As it relates to therapeutics, we don't have that same challenge, right? ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca273c70-c370-48df-9e19-4f590bde4ef5", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n", "original_text": "We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06d745b8f9170f8e469a37e01b09a12833cc6355759931cf77140ddf7ed801c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15060017-62f5-40c9-9eb3-df02b14ec11e", "node_type": "1", "metadata": {"window": "We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual. ", "original_text": "There's a lot of product out \nthere still, and the rollout will be slower.  "}, "hash": "b751f519d9f2d2cf06e98df62a936a1ecbe6f64bf90f3a1066789849ba57cd0e", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to therapeutics, we don't have that same challenge, right? ", "start_char_idx": 267, "end_char_idx": 340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15060017-62f5-40c9-9eb3-df02b14ec11e": {"__data__": {"id_": "15060017-62f5-40c9-9eb3-df02b14ec11e", "embedding": null, "metadata": {"window": "We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual. ", "original_text": "There's a lot of product out \nthere still, and the rollout will be slower.  ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "926518c7-8c1c-4db1-a534-c70cb3d6dc64", "node_type": "1", "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook. ", "original_text": "As it relates to therapeutics, we don't have that same challenge, right? ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6886c25cacb600e06d735a446e52fcc2a4848ae48cd459960bc071e69fb9151", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a451365-5623-442a-a46f-e8b5ef404b87", "node_type": "1", "metadata": {"window": "We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation . ", "original_text": "And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n"}, "hash": "073bc47d99a71fb29b038250846b310c63137b5522799988164d5e3b2cc74d46", "class_name": "RelatedNodeInfo"}}, "text": "There's a lot of product out \nthere still, and the rollout will be slower.  ", "start_char_idx": 340, "end_char_idx": 416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a451365-5623-442a-a46f-e8b5ef404b87": {"__data__": {"id_": "2a451365-5623-442a-a46f-e8b5ef404b87", "embedding": null, "metadata": {"window": "We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation . ", "original_text": "And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15060017-62f5-40c9-9eb3-df02b14ec11e", "node_type": "1", "metadata": {"window": "We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual. ", "original_text": "There's a lot of product out \nthere still, and the rollout will be slower.  ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbd6b99638bd1a71f715065aa926a4f3e58c0ca1d94b4cac51ebafc1825c5f33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bff655f1-6e78-4dec-82de-fc3c89643730", "node_type": "1", "metadata": {"window": "As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation. ", "original_text": "And then the last question is on the long -term growth outlook. "}, "hash": "4339a16e76bfe631ff6c49b5afa99030f0c45cd2e20b9b833db52e7578f69ff6", "class_name": "RelatedNodeInfo"}}, "text": "And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n", "start_char_idx": 416, "end_char_idx": 657, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bff655f1-6e78-4dec-82de-fc3c89643730": {"__data__": {"id_": "bff655f1-6e78-4dec-82de-fc3c89643730", "embedding": null, "metadata": {"window": "As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation. ", "original_text": "And then the last question is on the long -term growth outlook. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a451365-5623-442a-a46f-e8b5ef404b87", "node_type": "1", "metadata": {"window": "We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation . ", "original_text": "And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc5f9a63d360b38fd28f69a8cb580e45cc02d809621f70008240e3735727f7e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "194a8d75-5d46-4443-9d9c-2d2d5837ae70", "node_type": "1", "metadata": {"window": "There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n", "original_text": "I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual. "}, "hash": "921ef147ea38800be5518e9be051d76f37f4947d8a8048a11c0205bfdb05906f", "class_name": "RelatedNodeInfo"}}, "text": "And then the last question is on the long -term growth outlook. ", "start_char_idx": 657, "end_char_idx": 721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "194a8d75-5d46-4443-9d9c-2d2d5837ae70": {"__data__": {"id_": "194a8d75-5d46-4443-9d9c-2d2d5837ae70", "embedding": null, "metadata": {"window": "There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n", "original_text": "I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bff655f1-6e78-4dec-82de-fc3c89643730", "node_type": "1", "metadata": {"window": "As it relates to therapeutics, we don't have that same challenge, right?  There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation. ", "original_text": "And then the last question is on the long -term growth outlook. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45a695543ac838560304a7d6ed8728a8ed7649370802feb58fe6091199468b52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a4cca4c-5311-4544-96af-088c898971f1", "node_type": "1", "metadata": {"window": "And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time? ", "original_text": "Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation . "}, "hash": "c65d1dd616bc3bdcd3e0173a01c3907b73c716b8f6e6c0196ebf98b5b8f954f2", "class_name": "RelatedNodeInfo"}}, "text": "I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual. ", "start_char_idx": 721, "end_char_idx": 901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a4cca4c-5311-4544-96af-088c898971f1": {"__data__": {"id_": "4a4cca4c-5311-4544-96af-088c898971f1", "embedding": null, "metadata": {"window": "And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time? ", "original_text": "Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation . ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "194a8d75-5d46-4443-9d9c-2d2d5837ae70", "node_type": "1", "metadata": {"window": "There's a lot of product out \nthere still, and the rollout will be slower.   And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n", "original_text": "I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79554fa984502a0ffc54ed5afbc09ce688b5216b7bb5e5f1b75b917cbb558c90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbe90d1d-20ad-441c-a6c6-b4619c248246", "node_type": "1", "metadata": {"window": "And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity? ", "original_text": "We like innovation. "}, "hash": "28c5b7f606a1f15359ab9826471588c5f2ff7fc1c1c5ee66a448592f5a93fb28", "class_name": "RelatedNodeInfo"}}, "text": "Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation . ", "start_char_idx": 901, "end_char_idx": 978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbe90d1d-20ad-441c-a6c6-b4619c248246": {"__data__": {"id_": "cbe90d1d-20ad-441c-a6c6-b4619c248246", "embedding": null, "metadata": {"window": "And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity? ", "original_text": "We like innovation. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a4cca4c-5311-4544-96af-088c898971f1", "node_type": "1", "metadata": {"window": "And you're talking about an oral solid type of brand product, \nwhich typically does not carry the same type of specialization  necessary in the distribution channel \nthat does drive higher -margin products , like our specialty products.  \n \n And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time? ", "original_text": "Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation . ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c02053fbee3f90ff157f89fa6600434948bf8b484aaffdc9cbcd7ae92e8cdd07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "782a08f0-9139-45ab-b322-166dded77e6b", "node_type": "1", "metadata": {"window": "I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy? ", "original_text": "It provides us new opportunities and new growth as an enterprise.  \n"}, "hash": "df6f72f764a7238c817822a5bcbab01a1eaffd374f47890bec0f9bc2cae45e48", "class_name": "RelatedNodeInfo"}}, "text": "We like innovation. ", "start_char_idx": 978, "end_char_idx": 998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "782a08f0-9139-45ab-b322-166dded77e6b": {"__data__": {"id_": "782a08f0-9139-45ab-b322-166dded77e6b", "embedding": null, "metadata": {"window": "I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy? ", "original_text": "It provides us new opportunities and new growth as an enterprise.  \n", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbe90d1d-20ad-441c-a6c6-b4619c248246", "node_type": "1", "metadata": {"window": "And then the last question is on the long -term growth outlook.  I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity? ", "original_text": "We like innovation. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a045111b1836f7f9c8b907ad0673a511647ba87d923e93f615faa0fcf52b556", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3b01afe-41a5-42f8-9f68-75f00c06b562", "node_type": "1", "metadata": {"window": "Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future? ", "original_text": "And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time? "}, "hash": "7f14b3851315ec168d0dc02b440faab21d2885c7714ae4d79f9b57e81d8f495d", "class_name": "RelatedNodeInfo"}}, "text": "It provides us new opportunities and new growth as an enterprise.  \n", "start_char_idx": 998, "end_char_idx": 1066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3b01afe-41a5-42f8-9f68-75f00c06b562": {"__data__": {"id_": "a3b01afe-41a5-42f8-9f68-75f00c06b562", "embedding": null, "metadata": {"window": "Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future? ", "original_text": "And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time? ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "782a08f0-9139-45ab-b322-166dded77e6b", "node_type": "1", "metadata": {"window": "I think one of the key messages that is \nbehind your question and behind how we think about it, and it's partly why we're calling out those \nelements that may be a little unusual.  Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy? ", "original_text": "It provides us new opportunities and new growth as an enterprise.  \n", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4468b6bda0cdbcb083f3ba6d1c45ff9b554585a7a6b5cbb06c4cecd16154acc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "229971eb-7602-473c-99ce-4ad5c36d9327", "node_type": "1", "metadata": {"window": "We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure. ", "original_text": "Is that a continued opportunity? "}, "hash": "8b6c5f7eafce34fdf8f1bdf2c6a53351749645d8bf5de54243d4868457b69524", "class_name": "RelatedNodeInfo"}}, "text": "And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time? ", "start_char_idx": 1066, "end_char_idx": 1188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "229971eb-7602-473c-99ce-4ad5c36d9327": {"__data__": {"id_": "229971eb-7602-473c-99ce-4ad5c36d9327", "embedding": null, "metadata": {"window": "We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure. ", "original_text": "Is that a continued opportunity? ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3b01afe-41a5-42f8-9f68-75f00c06b562", "node_type": "1", "metadata": {"window": "Again, just lik e with GLP -1s, COVID vaccines another form of \ninnovation .  We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future? ", "original_text": "And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time? ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c06230b3cf0dad7171b144a979709d490a558a51631a307d059301aad5d8d16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf91b05e-2441-48bf-8129-12eb38cad558", "node_type": "1", "metadata": {"window": "It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A. ", "original_text": "Is it lumpy? "}, "hash": "08cde74f165d8b8533eab0f7e2277e9956da7eb3306bee6af7a0fb6f58a3dbf5", "class_name": "RelatedNodeInfo"}}, "text": "Is that a continued opportunity? ", "start_char_idx": 1188, "end_char_idx": 1221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf91b05e-2441-48bf-8129-12eb38cad558": {"__data__": {"id_": "cf91b05e-2441-48bf-8129-12eb38cad558", "embedding": null, "metadata": {"window": "It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A. ", "original_text": "Is it lumpy? ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "229971eb-7602-473c-99ce-4ad5c36d9327", "node_type": "1", "metadata": {"window": "We like innovation.  It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure. ", "original_text": "Is that a continued opportunity? ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77801fd02d0a567e49623cc9aeca43a3d2bcd4bb52ce597935da2c8d0c4b07e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78e52c02-d77a-417c-96e0-09fa23e9b5d7", "node_type": "1", "metadata": {"window": "And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments . ", "original_text": "Is this year maybe higher or lower \nthan what that volume will be in the future? "}, "hash": "2449cc3d9bdb737fa78f65471e0aed253f5dc44fca59920d0916395f534d11f7", "class_name": "RelatedNodeInfo"}}, "text": "Is it lumpy? ", "start_char_idx": 1221, "end_char_idx": 1234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78e52c02-d77a-417c-96e0-09fa23e9b5d7": {"__data__": {"id_": "78e52c02-d77a-417c-96e0-09fa23e9b5d7", "embedding": null, "metadata": {"window": "And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments . ", "original_text": "Is this year maybe higher or lower \nthan what that volume will be in the future? ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf91b05e-2441-48bf-8129-12eb38cad558", "node_type": "1", "metadata": {"window": "It provides us new opportunities and new growth as an enterprise.  \n And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A. ", "original_text": "Is it lumpy? ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8de657cdbf589b27ae57bf47db753f90c907e4a085cca33ccb6f058cc68998a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80e14891-54dc-49f0-9623-5e186376bdb8", "node_type": "1", "metadata": {"window": "Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter. ", "original_text": "Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure. "}, "hash": "75fd98981a2d9c67d08bfa3aac9f1b61ba29f494d99684a448e60e625ad8c1e1", "class_name": "RelatedNodeInfo"}}, "text": "Is this year maybe higher or lower \nthan what that volume will be in the future? ", "start_char_idx": 1234, "end_char_idx": 1315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80e14891-54dc-49f0-9623-5e186376bdb8": {"__data__": {"id_": "80e14891-54dc-49f0-9623-5e186376bdb8", "embedding": null, "metadata": {"window": "Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter. ", "original_text": "Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78e52c02-d77a-417c-96e0-09fa23e9b5d7", "node_type": "1", "metadata": {"window": "And so, part of the answer to this question is, well, how did these innovative products evolve and \ntransition over time?  Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments . ", "original_text": "Is this year maybe higher or lower \nthan what that volume will be in the future? ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa3d80bca6b406259a0386cdb4d255caec3ddf272d0dab30ec0bea4977140466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d1ff400-bb1e-4920-bbc1-e6bd44feb9ee", "node_type": "1", "metadata": {"window": "Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team . ", "original_text": "One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A. "}, "hash": "6edd87b04cde6a3c45248afbc9b9b0b3db349db11f659702233b72cb522e2acb", "class_name": "RelatedNodeInfo"}}, "text": "Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure. ", "start_char_idx": 1315, "end_char_idx": 1489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d1ff400-bb1e-4920-bbc1-e6bd44feb9ee": {"__data__": {"id_": "4d1ff400-bb1e-4920-bbc1-e6bd44feb9ee", "embedding": null, "metadata": {"window": "Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team . ", "original_text": "One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80e14891-54dc-49f0-9623-5e186376bdb8", "node_type": "1", "metadata": {"window": "Is that a continued opportunity?  Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter. ", "original_text": "Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "31f3efd20447295b4b1adf2ef0278dad346ea8ebfae74909eb7897498ab66edc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be61aa6b-0ef8-4307-bd49-4d158255e689", "node_type": "1", "metadata": {"window": "Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel. ", "original_text": "I made the comment about the \noperating leverage in my comments . "}, "hash": "350c65ca9a7a8ebec9948c80c991378ffcf706e2279da47f8d5a1dd983e621dd", "class_name": "RelatedNodeInfo"}}, "text": "One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A. ", "start_char_idx": 1489, "end_char_idx": 1649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be61aa6b-0ef8-4307-bd49-4d158255e689": {"__data__": {"id_": "be61aa6b-0ef8-4307-bd49-4d158255e689", "embedding": null, "metadata": {"window": "Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel. ", "original_text": "I made the comment about the \noperating leverage in my comments . ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d1ff400-bb1e-4920-bbc1-e6bd44feb9ee", "node_type": "1", "metadata": {"window": "Is it lumpy?  Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team . ", "original_text": "One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d97b62810b5106fc190ef9d31d16883e91204244e8d2914f69b0b35cb43b6e24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fd6ea3a-dae3-4bfb-b3f9-0d1de18ba732", "node_type": "1", "metadata": {"window": "Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity. ", "original_text": "That's what I'm getting at, is that we were able to execute very \nefficiently this quarter. "}, "hash": "843faa9323d2fd195a1831a350745e1751ed843d405d432fc729c79c555b2119", "class_name": "RelatedNodeInfo"}}, "text": "I made the comment about the \noperating leverage in my comments . ", "start_char_idx": 1649, "end_char_idx": 1715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fd6ea3a-dae3-4bfb-b3f9-0d1de18ba732": {"__data__": {"id_": "2fd6ea3a-dae3-4bfb-b3f9-0d1de18ba732", "embedding": null, "metadata": {"window": "Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity. ", "original_text": "That's what I'm getting at, is that we were able to execute very \nefficiently this quarter. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be61aa6b-0ef8-4307-bd49-4d158255e689", "node_type": "1", "metadata": {"window": "Is this year maybe higher or lower \nthan what that volume will be in the future?  Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel. ", "original_text": "I made the comment about the \noperating leverage in my comments . ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "99c95294d5ccd1c4916a40171399e012c11605ae93c46f82a05ba86986c6980d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d19764c8-8206-41e2-8bf7-73588bc21027", "node_type": "1", "metadata": {"window": "One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target. ", "original_text": "And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team . "}, "hash": "479a45600248558b2977395f5f332da0b059822bf5c9449fec4ef0c4f5de6ccf", "class_name": "RelatedNodeInfo"}}, "text": "That's what I'm getting at, is that we were able to execute very \nefficiently this quarter. ", "start_char_idx": 1715, "end_char_idx": 1807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d19764c8-8206-41e2-8bf7-73588bc21027": {"__data__": {"id_": "d19764c8-8206-41e2-8bf7-73588bc21027", "embedding": null, "metadata": {"window": "One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target. ", "original_text": "And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team . ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fd6ea3a-dae3-4bfb-b3f9-0d1de18ba732", "node_type": "1", "metadata": {"window": "Those are all ha rd questions to answer, but what we saw \nhere is a bit of an influx of innovation that we've been able to benefit from while using the same \ninfrastructure.  One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity. ", "original_text": "That's what I'm getting at, is that we were able to execute very \nefficiently this quarter. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "537133e9bd0a97dd14787da0f78d63496276f548438528578b35f8fc9f9df7cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55a67ace-2d32-4802-aab2-1cb8cda854c1", "node_type": "1", "metadata": {"window": "I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.  ", "original_text": "That's an \nefficient use of o ur distribution channel. "}, "hash": "cba9c9584136091fb0b30615edd12dadf54766168595ceb0cf377e6fe86c4b02", "class_name": "RelatedNodeInfo"}}, "text": "And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team . ", "start_char_idx": 1807, "end_char_idx": 2075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55a67ace-2d32-4802-aab2-1cb8cda854c1": {"__data__": {"id_": "55a67ace-2d32-4802-aab2-1cb8cda854c1", "embedding": null, "metadata": {"window": "I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.  ", "original_text": "That's an \nefficient use of o ur distribution channel. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d19764c8-8206-41e2-8bf7-73588bc21027", "node_type": "1", "metadata": {"window": "One thing that's really important to highlight about our performance this quarter , is that \nwe had really nice gross margin growth, and we had very flat SG&A.  I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target. ", "original_text": "And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team . ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d3262461b84d59d9dc49dc5d8495d5cad7fd5ff616d8b84e1ef755e7c70d239", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5eb3977e-2dc3-493d-ac16-70e758e14a7b", "node_type": "1", "metadata": {"window": "That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term. ", "original_text": "And as we get more opportunities like that, then there's some \nopportunity. "}, "hash": "5bc82e5e7800100b3a0a745f23e72408adbc8edc4ba29af05bfeb54ef1ce4495", "class_name": "RelatedNodeInfo"}}, "text": "That's an \nefficient use of o ur distribution channel. ", "start_char_idx": 2075, "end_char_idx": 2130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5eb3977e-2dc3-493d-ac16-70e758e14a7b": {"__data__": {"id_": "5eb3977e-2dc3-493d-ac16-70e758e14a7b", "embedding": null, "metadata": {"window": "That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term. ", "original_text": "And as we get more opportunities like that, then there's some \nopportunity. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55a67ace-2d32-4802-aab2-1cb8cda854c1", "node_type": "1", "metadata": {"window": "I made the comment about the \noperating leverage in my comments .  That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.  ", "original_text": "That's an \nefficient use of o ur distribution channel. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b3283d7e542ff5684e0e0cab307cc611bc83c0cc01a904755ec11ea55f821f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2beb8f2-5f59-479a-a0b1-c8694b616873", "node_type": "1", "metadata": {"window": "And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth. ", "original_text": "But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target. "}, "hash": "ee7b729539f67c725d206e9a84ddc52e3a3178c62dbc46a678567d3fc04ae70c", "class_name": "RelatedNodeInfo"}}, "text": "And as we get more opportunities like that, then there's some \nopportunity. ", "start_char_idx": 2130, "end_char_idx": 2206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2beb8f2-5f59-479a-a0b1-c8694b616873": {"__data__": {"id_": "d2beb8f2-5f59-479a-a0b1-c8694b616873", "embedding": null, "metadata": {"window": "And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth. ", "original_text": "But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5eb3977e-2dc3-493d-ac16-70e758e14a7b", "node_type": "1", "metadata": {"window": "That's what I'm getting at, is that we were able to execute very \nefficiently this quarter.  And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term. ", "original_text": "And as we get more opportunities like that, then there's some \nopportunity. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "803d9dd14205d6c703e689044a91622cdd5929126aba3b5101c1e7beb7e10d50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44f81ce5-efef-41e5-81cd-82a8a55c9aee", "node_type": "1", "metadata": {"window": "That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range. ", "original_text": "And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.  "}, "hash": "9c59046a2a94d13c663f5f61b5bca2c94c1606313ce009e635849dd85507dce9", "class_name": "RelatedNodeInfo"}}, "text": "But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target. ", "start_char_idx": 2206, "end_char_idx": 2424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44f81ce5-efef-41e5-81cd-82a8a55c9aee": {"__data__": {"id_": "44f81ce5-efef-41e5-81cd-82a8a55c9aee", "embedding": null, "metadata": {"window": "That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range. ", "original_text": "And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.  ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2beb8f2-5f59-479a-a0b1-c8694b616873", "node_type": "1", "metadata": {"window": "And whether we're talking about vaccines or other products, having that gross \nmargin because it's an incremental product category for us because of course we did not participate \nin that volume last year, but we're able to leverage the same capacity, the same team .  That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth. ", "original_text": "But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9a8366e226653c902a64dda275156ed720986a029b50e5873d6db58cc175559", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02f026d4-78d3-4a23-a9b4-d2119d7afd86", "node_type": "1", "metadata": {"window": "And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n", "original_text": "That's not the same level of strength \nthat we have indicated we should be thinking about long -term. "}, "hash": "b5e33620b3758f201d9d4889336a927185ce3836bf1ed202e1208868edc6ba89", "class_name": "RelatedNodeInfo"}}, "text": "And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.  ", "start_char_idx": 2424, "end_char_idx": 2564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02f026d4-78d3-4a23-a9b4-d2119d7afd86": {"__data__": {"id_": "02f026d4-78d3-4a23-a9b4-d2119d7afd86", "embedding": null, "metadata": {"window": "And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n", "original_text": "That's not the same level of strength \nthat we have indicated we should be thinking about long -term. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44f81ce5-efef-41e5-81cd-82a8a55c9aee", "node_type": "1", "metadata": {"window": "That's an \nefficient use of o ur distribution channel.  And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range. ", "original_text": "And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.  ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e7431d07c9a4d2af72d821ccc7e541c5c5f33f3c439e87993046c4fd1855e75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b1a9bb6-d0d4-433a-8a50-8c56e4d73014", "node_type": "1", "metadata": {"window": "But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is. ", "original_text": "It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth. "}, "hash": "4c2ed1564822ba29d6466c93f9418e0ba39cb4216e82ad04cc67051ceae262d8", "class_name": "RelatedNodeInfo"}}, "text": "That's not the same level of strength \nthat we have indicated we should be thinking about long -term. ", "start_char_idx": 2564, "end_char_idx": 2666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b1a9bb6-d0d4-433a-8a50-8c56e4d73014": {"__data__": {"id_": "3b1a9bb6-d0d4-433a-8a50-8c56e4d73014", "embedding": null, "metadata": {"window": "But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is. ", "original_text": "It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02f026d4-78d3-4a23-a9b4-d2119d7afd86", "node_type": "1", "metadata": {"window": "And as we get more opportunities like that, then there's some \nopportunity.  But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n", "original_text": "That's not the same level of strength \nthat we have indicated we should be thinking about long -term. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19b5e3f8e080e9d17833072deb94b737fba2fd29133ce0c0452cd104e0e9087b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e69a96f6-94b0-4a43-a182-b40f785ec731", "node_type": "1", "metadata": {"window": "And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n", "original_text": "We'd expect that cor e growth to still be in that 4 to 6% range. "}, "hash": "fdc9208cda6d5b8701cd52aebb3b20d0b3d6ad269524c9120905d8075a5dbace", "class_name": "RelatedNodeInfo"}}, "text": "It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth. ", "start_char_idx": 2666, "end_char_idx": 2844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e69a96f6-94b0-4a43-a182-b40f785ec731": {"__data__": {"id_": "e69a96f6-94b0-4a43-a182-b40f785ec731", "embedding": null, "metadata": {"window": "And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n", "original_text": "We'd expect that cor e growth to still be in that 4 to 6% range. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b1a9bb6-d0d4-433a-8a50-8c56e4d73014", "node_type": "1", "metadata": {"window": "But one of the key things that Aaron highlighted in a number of his comments, whether \nit's his comments or his answers to the question , is that our underlying growth, we feel very good \nabout that long -term target.  And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is. ", "original_text": "It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44f7c9add6201fe6c81418fb64a2c6e1ffa868c9aedf682427a1722b3a03f310", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5ff8eae-28ef-4267-9e36-b17b7bfd5660", "node_type": "1", "metadata": {"window": "That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance. ", "original_text": "But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n"}, "hash": "c11d42c147bbecae8c24dab33f7575d82f0488be4774966d56be85215a91f74f", "class_name": "RelatedNodeInfo"}}, "text": "We'd expect that cor e growth to still be in that 4 to 6% range. ", "start_char_idx": 2844, "end_char_idx": 2909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5ff8eae-28ef-4267-9e36-b17b7bfd5660": {"__data__": {"id_": "b5ff8eae-28ef-4267-9e36-b17b7bfd5660", "embedding": null, "metadata": {"window": "That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance. ", "original_text": "But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e69a96f6-94b0-4a43-a182-b40f785ec731", "node_type": "1", "metadata": {"window": "And a lot of what we've seen here was the Q1 over performance, both \nfrom vaccines, but also just the core utilization  being very strong.   That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n", "original_text": "We'd expect that cor e growth to still be in that 4 to 6% range. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40584b9029c2d01fd7bb369974aa74f4ef965010e6b937bf2d7603da188242be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e146c1e2-49e5-41bb-8e27-165c5ecdca18", "node_type": "1", "metadata": {"window": "It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is. "}, "hash": "694282fd493f898ab730358544e8070476c1b3c8786ee4b9c9dab67a9bae2127", "class_name": "RelatedNodeInfo"}}, "text": "But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n", "start_char_idx": 2909, "end_char_idx": 3037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e146c1e2-49e5-41bb-8e27-165c5ecdca18": {"__data__": {"id_": "e146c1e2-49e5-41bb-8e27-165c5ecdca18", "embedding": null, "metadata": {"window": "It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5ff8eae-28ef-4267-9e36-b17b7bfd5660", "node_type": "1", "metadata": {"window": "That's not the same level of strength \nthat we have indicated we should be thinking about long -term.  It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance. ", "original_text": "But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d95564f36a7ede76a776b51a9d5ad89e47bcd00256fcae8de02bc5bbfa3fbb75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04c66a11-62ed-474b-a435-e5245e186c78", "node_type": "1", "metadata": {"window": "We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n"}, "hash": "dc7ad8c61f07e93a655888ef61a5a567a36a11e499b4b283088472545d8d2724", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is. ", "start_char_idx": 3037, "end_char_idx": 3166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04c66a11-62ed-474b-a435-e5245e186c78": {"__data__": {"id_": "04c66a11-62ed-474b-a435-e5245e186c78", "embedding": null, "metadata": {"window": "We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e146c1e2-49e5-41bb-8e27-165c5ecdca18", "node_type": "1", "metadata": {"window": "It's an opportunity for us, but that's not \nwhat we're expecting at this point in time, and it's not what we're guiding for the balance of the year in \nterms of the core growth.  We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "feec2e440a951eb289a5bb4c0def7032d61f0299c7907772a7b88f453915e1cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cafc0d5-b293-43b7-9d64-f0d8be04d702", "node_type": "1", "metadata": {"window": "But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance. "}, "hash": "0ed8539333895f278d8b16957b65d166ae9daa1dab460c1ae6b3c263f0a91110", "class_name": "RelatedNodeInfo"}}, "text": "Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n", "start_char_idx": 3166, "end_char_idx": 3374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cafc0d5-b293-43b7-9d64-f0d8be04d702": {"__data__": {"id_": "4cafc0d5-b293-43b7-9d64-f0d8be04d702", "embedding": null, "metadata": {"window": "But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04c66a11-62ed-474b-a435-e5245e186c78", "node_type": "1", "metadata": {"window": "We'd expect that cor e growth to still be in that 4 to 6% range.  But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d32363f85eb7be75fb5cf0a5090f69bc2cc17fadb02dd108e5a079c9dda4994", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05ebb30e-bc30-4e4c-890f-12c1ecf5948f", "node_type": "1", "metadata": {"window": "Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "We're not making changes to a long -term guidance as we \nsit here today.  "}, "hash": "0a639dac3fe170b3d1044d380dc64301598b6fbc7363620a4c02e0aa432e6d7e", "class_name": "RelatedNodeInfo"}}, "text": "While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance. ", "start_char_idx": 3374, "end_char_idx": 3717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05ebb30e-bc30-4e4c-890f-12c1ecf5948f": {"__data__": {"id_": "05ebb30e-bc30-4e4c-890f-12c1ecf5948f", "embedding": null, "metadata": {"window": "Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "We're not making changes to a long -term guidance as we \nsit here today.  ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f9d142eb6e74e60fd76e8b318c30943bd02bdf428c4281c59610c29b78bb2c6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cafc0d5-b293-43b7-9d64-f0d8be04d702", "node_type": "1", "metadata": {"window": "But again, \ninnovation can create some opportunities for us that's hard to see right now, but we're not planning \nfor that.  \n \n Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance. ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e18a7935fb6cb9e82b7619385c324b9a5f4ad9700a8235fb70d9111c75fd94ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b99c1ed9-a701-43e2-80e5-3f3f9ee5be4a", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen. ", "original_text": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is. "}, "hash": "7469cb379c046a61d5636f41ca5aa5cfabcd07820e7b817dfb3b796ef78e862a", "class_name": "RelatedNodeInfo"}}, "text": "We're not making changes to a long -term guidance as we \nsit here today.  ", "start_char_idx": 3717, "end_char_idx": 3791, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b99c1ed9-a701-43e2-80e5-3f3f9ee5be4a": {"__data__": {"id_": "b99c1ed9-a701-43e2-80e5-3f3f9ee5be4a", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen. ", "original_text": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05ebb30e-bc30-4e4c-890f-12c1ecf5948f", "node_type": "1", "metadata": {"window": "Aaron Alt:   So maybe if I can just wrap a bow around that from a guidance perspective, just to \nreiterate what our guidance is.  Look for the , as we sit here today, the Medical segment guidance is \n$400 million of profit for this year, and we've talked about that extensively , leading to $650 million of \nprofit in fiscal year \u201826. \n \n While we are pleased with the progress on Pharma one quarter into the year and are raising our \nguidance for this year for  Pharma, the 7 to 9% profit growth, our longer -term algorithm remains the 4 \nto 6% profit growth that we had called out at our Investor Day, leading to 12 to 14% adjusted EPS \ngrowth long -term as our overall guidance.  We're not making changes to a long -term guidance as we \nsit here today.  ", "original_text": "We're not making changes to a long -term guidance as we \nsit here today.  ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e49da6657bdba1cfc70c2b008e068d4749f020c0fdbc6ccb985a67f70430f66d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1c4b83a-316e-48c5-9766-7debb6f8f90c", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n", "original_text": "And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations. "}, "hash": "7f8e780d2418ca7b78382bce5397d4f648303dd5db6d1b50a9ba46a4619e10b8", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is. ", "start_char_idx": 0, "end_char_idx": 182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1c4b83a-316e-48c5-9766-7debb6f8f90c": {"__data__": {"id_": "d1c4b83a-316e-48c5-9766-7debb6f8f90c", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n", "original_text": "And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b99c1ed9-a701-43e2-80e5-3f3f9ee5be4a", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen. ", "original_text": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0b02b80b96e624f41c43e2e4cc358f64858a3edf7c6edec2d1a4b0058c6c84f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e959cef-1a2c-4077-9b3b-b2ed556f5e73", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah. ", "original_text": "And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n"}, "hash": "308ce7c66a85b70dfa938646c79ee193ea6856624de2c038d311efa8604875d5", "class_name": "RelatedNodeInfo"}}, "text": "And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations. ", "start_char_idx": 182, "end_char_idx": 363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e959cef-1a2c-4077-9b3b-b2ed556f5e73": {"__data__": {"id_": "1e959cef-1a2c-4077-9b3b-b2ed556f5e73", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah. ", "original_text": "And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1c4b83a-316e-48c5-9766-7debb6f8f90c", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n", "original_text": "And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7edac914d276b92e04b42b2c75ce344a18ebb7413868956eb59e46ba34f5fc20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27896f18-4086-4e15-bed2-1476423fd20a", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question. ", "original_text": "Operator:   The next question comes from Charles Rhyee from TD Cowen. "}, "hash": "96e3e46dcb79be469ce6710a3b19637d21ddacbde588e52e758b6edcc22651d4", "class_name": "RelatedNodeInfo"}}, "text": "And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n", "start_char_idx": 363, "end_char_idx": 591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27896f18-4086-4e15-bed2-1476423fd20a": {"__data__": {"id_": "27896f18-4086-4e15-bed2-1476423fd20a", "embedding": null, "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question. ", "original_text": "Operator:   The next question comes from Charles Rhyee from TD Cowen. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e959cef-1a2c-4077-9b3b-b2ed556f5e73", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah. ", "original_text": "And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f5bf1ebd4682eebd34e025742b5b116271aeb3fe812e95fb01d841d4df6af60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c27c5bb-ffdc-4b3c-8681-617e652dde21", "node_type": "1", "metadata": {"window": "And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices. ", "original_text": "Please go ahead.  \n \n"}, "hash": "e9aafdf2f31ba84f9ab4c3ae1cbc07b4c5dc4a6af11f8715c4185def2bccdf01", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   The next question comes from Charles Rhyee from TD Cowen. ", "start_char_idx": 591, "end_char_idx": 661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c27c5bb-ffdc-4b3c-8681-617e652dde21": {"__data__": {"id_": "5c27c5bb-ffdc-4b3c-8681-617e652dde21", "embedding": null, "metadata": {"window": "And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices. ", "original_text": "Please go ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27896f18-4086-4e15-bed2-1476423fd20a", "node_type": "1", "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question. ", "original_text": "Operator:   The next question comes from Charles Rhyee from TD Cowen. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6afc6f74f9db5d4235343e717918e3007e5db33f8b56bf083e9355899919fb54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3899c379-7c5e-4a8e-adb2-2819fbd92581", "node_type": "1", "metadata": {"window": "And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n", "original_text": "Charles Rhyee:  Yeah. "}, "hash": "7eb03f110933bafbf49d2dd0c1ee3d319825070f936b4f0a9f12e2c6722761aa", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 661, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3899c379-7c5e-4a8e-adb2-2819fbd92581": {"__data__": {"id_": "3899c379-7c5e-4a8e-adb2-2819fbd92581", "embedding": null, "metadata": {"window": "And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n", "original_text": "Charles Rhyee:  Yeah. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c27c5bb-ffdc-4b3c-8681-617e652dde21", "node_type": "1", "metadata": {"window": "And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices. ", "original_text": "Please go ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba3128b20564c25f4ba192a701efe689f36beb79e29781abfbf660115aadf4cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c90bf52a-b6c7-4189-8375-4e05fe2103ea", "node_type": "1", "metadata": {"window": "Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point? ", "original_text": "Thanks for taking the question. "}, "hash": "e1b730e047b086dce7284d41f13a4a8958e8d9475455b580bcb41bc3b1ca2968", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Yeah. ", "start_char_idx": 682, "end_char_idx": 704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c90bf52a-b6c7-4189-8375-4e05fe2103ea": {"__data__": {"id_": "c90bf52a-b6c7-4189-8375-4e05fe2103ea", "embedding": null, "metadata": {"window": "Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point? ", "original_text": "Thanks for taking the question. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3899c379-7c5e-4a8e-adb2-2819fbd92581", "node_type": "1", "metadata": {"window": "And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n", "original_text": "Charles Rhyee:  Yeah. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "14e1a9f0df1fc60a799fccefeffca734ddd95057539e9c6d7d27fb5206ca4d81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d3e216d-8b94-4fd1-9567-ca752aa01033", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n", "original_text": "Jason, I wanted to follow up on your \ncomments on commodity prices. "}, "hash": "32e96eb550fa0afb21d06dbbbfc39062c287faa3a84100bc3e92005e9066c7b4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 704, "end_char_idx": 736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d3e216d-8b94-4fd1-9567-ca752aa01033": {"__data__": {"id_": "5d3e216d-8b94-4fd1-9567-ca752aa01033", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n", "original_text": "Jason, I wanted to follow up on your \ncomments on commodity prices. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c90bf52a-b6c7-4189-8375-4e05fe2103ea", "node_type": "1", "metadata": {"window": "Operator:   The next question comes from Charles Rhyee from TD Cowen.  Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point? ", "original_text": "Thanks for taking the question. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb560ac74e65e2dd842e822f9dbbf338322b3e2378d5b4647576ccad3ec8068e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48874496-3d53-45dd-a662-d8a56e81d9b3", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah. ", "original_text": "And you said that you're seeing less volatility in pricing than before. \n"}, "hash": "91851a3d81244cf3ac7f7bdb73c322af26b3a697c7a02f5ed2fa4c373dc7fb79", "class_name": "RelatedNodeInfo"}}, "text": "Jason, I wanted to follow up on your \ncomments on commodity prices. ", "start_char_idx": 736, "end_char_idx": 804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48874496-3d53-45dd-a662-d8a56e81d9b3": {"__data__": {"id_": "48874496-3d53-45dd-a662-d8a56e81d9b3", "embedding": null, "metadata": {"window": "Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah. ", "original_text": "And you said that you're seeing less volatility in pricing than before. \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d3e216d-8b94-4fd1-9567-ca752aa01033", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n", "original_text": "Jason, I wanted to follow up on your \ncomments on commodity prices. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "deffe881a752bfc25d3f4f991f9b4ddea2f3d8da50120786edde9d2cde168f31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48951eaa-bbfd-4a2f-9a02-9b10f1a22b66", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question. ", "original_text": "Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point? "}, "hash": "2d098c001fb5bd5af90dcba34c512a368b92f1ee529c48a677cf3e9d85e7ea0f", "class_name": "RelatedNodeInfo"}}, "text": "And you said that you're seeing less volatility in pricing than before. \n", "start_char_idx": 804, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48951eaa-bbfd-4a2f-9a02-9b10f1a22b66": {"__data__": {"id_": "48951eaa-bbfd-4a2f-9a02-9b10f1a22b66", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question. ", "original_text": "Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point? ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48874496-3d53-45dd-a662-d8a56e81d9b3", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yeah.  Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah. ", "original_text": "And you said that you're seeing less volatility in pricing than before. \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbac9bb53752ff9e4888075a5af7e2b17b4b344ddfcede7109e08d8162da4de8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a77d7a9e-8235-48e2-ab24-cc1c99b7bfda", "node_type": "1", "metadata": {"window": "Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy. ", "original_text": "Thanks.  \n \n"}, "hash": "b1533d13c51230ccdd830dce8fded48c974da8437c41622941af90efe8b6a8a6", "class_name": "RelatedNodeInfo"}}, "text": "Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point? ", "start_char_idx": 877, "end_char_idx": 1156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a77d7a9e-8235-48e2-ab24-cc1c99b7bfda": {"__data__": {"id_": "a77d7a9e-8235-48e2-ab24-cc1c99b7bfda", "embedding": null, "metadata": {"window": "Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy. ", "original_text": "Thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48951eaa-bbfd-4a2f-9a02-9b10f1a22b66", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question. ", "original_text": "Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point? ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df82a233fb0310aeb03ada7780f158883317cfe3108939a7d250125774b5a6dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4f4f05b-67cf-41fc-bef3-ec6509eb2fb8", "node_type": "1", "metadata": {"window": "And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based. ", "original_text": "Jason Holler:  Yeah. "}, "hash": "deafe818e78445d0753e4ec3e4e4d1fca93ca2b4025bb2900bed7d308100237a", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1156, "end_char_idx": 1168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4f4f05b-67cf-41fc-bef3-ec6509eb2fb8": {"__data__": {"id_": "c4f4f05b-67cf-41fc-bef3-ec6509eb2fb8", "embedding": null, "metadata": {"window": "And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based. ", "original_text": "Jason Holler:  Yeah. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a77d7a9e-8235-48e2-ab24-cc1c99b7bfda", "node_type": "1", "metadata": {"window": "Jason, I wanted to follow up on your \ncomments on commodity prices.  And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy. ", "original_text": "Thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98eaefaffa3968013b1788fa820e0874f96261d428fa27b0b0c8f484d7e6d5d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31cc06f2-a77e-4def-85b2-8714bd06f27e", "node_type": "1", "metadata": {"window": "Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue . ", "original_text": "No, that's a great question. "}, "hash": "609f8dbdcd8039bcf8642d0f3c8fd331647c381989d2a3a3e89380db562186e6", "class_name": "RelatedNodeInfo"}}, "text": "Jason Holler:  Yeah. ", "start_char_idx": 1168, "end_char_idx": 1189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31cc06f2-a77e-4def-85b2-8714bd06f27e": {"__data__": {"id_": "31cc06f2-a77e-4def-85b2-8714bd06f27e", "embedding": null, "metadata": {"window": "Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue . ", "original_text": "No, that's a great question. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4f4f05b-67cf-41fc-bef3-ec6509eb2fb8", "node_type": "1", "metadata": {"window": "And you said that you're seeing less volatility in pricing than before. \n Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based. ", "original_text": "Jason Holler:  Yeah. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6acb1db63cbd152f4c0ffd39b32a373bc40081f0ab4c1df029276942ed2fad53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45478c8f-fe90-42dc-b8c3-319e5552af26", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil. ", "original_text": "So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy. "}, "hash": "f5bae2f8e263c5569b4401e552b8397a14483c32165036696ffe63eb166fe5c8", "class_name": "RelatedNodeInfo"}}, "text": "No, that's a great question. ", "start_char_idx": 1189, "end_char_idx": 1218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45478c8f-fe90-42dc-b8c3-319e5552af26": {"__data__": {"id_": "45478c8f-fe90-42dc-b8c3-319e5552af26", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil. ", "original_text": "So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31cc06f2-a77e-4def-85b2-8714bd06f27e", "node_type": "1", "metadata": {"window": "Would you say that, when you look at sort of the increase in oil over the past six months or so, would \nyou say that's within your expectations of volatility, or would you might expect to see that get reflected \ninto freight, and/or some of your other input costs at some point?  Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue . ", "original_text": "No, that's a great question. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf3d6f6d7d6fdff7dcee1c4de503daa6569b731eeb588527e7eea965befd8cc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8bfda88-5c4e-4a8b-9411-fc9af0cd31cb", "node_type": "1", "metadata": {"window": "Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band. ", "original_text": "But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based. "}, "hash": "d0cb23b8ff6654dbf9ae9f20756a8fd2d99976c41e9a511d95852c96a7b5eeaa", "class_name": "RelatedNodeInfo"}}, "text": "So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy. ", "start_char_idx": 1218, "end_char_idx": 1413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8bfda88-5c4e-4a8b-9411-fc9af0cd31cb": {"__data__": {"id_": "b8bfda88-5c4e-4a8b-9411-fc9af0cd31cb", "embedding": null, "metadata": {"window": "Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band. ", "original_text": "But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45478c8f-fe90-42dc-b8c3-319e5552af26", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil. ", "original_text": "So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72e40d3a88cc858ffab4de2fc18b17dd0a7d2535e5b7ff7bd89f5e7739c5448d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73bee685-65b5-4df4-a11e-ecf148d36018", "node_type": "1", "metadata": {"window": "No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right? ", "original_text": "So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue . "}, "hash": "06bfd3b72a501df4e1e3c9f360a22efc96e5038baf854120ca34008b6af472fb", "class_name": "RelatedNodeInfo"}}, "text": "But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based. ", "start_char_idx": 1413, "end_char_idx": 1521, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73bee685-65b5-4df4-a11e-ecf148d36018": {"__data__": {"id_": "73bee685-65b5-4df4-a11e-ecf148d36018", "embedding": null, "metadata": {"window": "No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right? ", "original_text": "So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue . ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8bfda88-5c4e-4a8b-9411-fc9af0cd31cb", "node_type": "1", "metadata": {"window": "Jason Holler:  Yeah.  No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band. ", "original_text": "But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08af59f801f94528ced991e49ff86073711c4f0a9d2c36e9a4d3d00bdc103834", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df2d8b83-9c8c-421a-b2a1-d594304bc59f", "node_type": "1", "metadata": {"window": "So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were. ", "original_text": "Because we don't buy \noil, we buy p roducts that contain oil. "}, "hash": "ebab7ea61019fc3dffc15c5a2f7e874ae965b0b3ef738fb4873647f05a888b52", "class_name": "RelatedNodeInfo"}}, "text": "So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue . ", "start_char_idx": 1521, "end_char_idx": 1654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df2d8b83-9c8c-421a-b2a1-d594304bc59f": {"__data__": {"id_": "df2d8b83-9c8c-421a-b2a1-d594304bc59f", "embedding": null, "metadata": {"window": "So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were. ", "original_text": "Because we don't buy \noil, we buy p roducts that contain oil. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73bee685-65b5-4df4-a11e-ecf148d36018", "node_type": "1", "metadata": {"window": "No, that's a great question.  So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right? ", "original_text": "So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue . ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "430562da1a90e3d8a32ad454e1c94a3aa77a101a0c27265c5f124e79306d0484", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7909bb20-0226-4c6f-851b-19d57ce46157", "node_type": "1", "metadata": {"window": "But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities. ", "original_text": "And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band. "}, "hash": "7f80bf5a40d79170ee72ba7aa9e99c3fa92b93b800d03077102ecbbdafc004ef", "class_name": "RelatedNodeInfo"}}, "text": "Because we don't buy \noil, we buy p roducts that contain oil. ", "start_char_idx": 1654, "end_char_idx": 1716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7909bb20-0226-4c6f-851b-19d57ce46157": {"__data__": {"id_": "7909bb20-0226-4c6f-851b-19d57ce46157", "embedding": null, "metadata": {"window": "But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities. ", "original_text": "And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df2d8b83-9c8c-421a-b2a1-d594304bc59f", "node_type": "1", "metadata": {"window": "So, when I step back and think about 18 months \nago, what the root issue was, of course we had the international freight that was driving up the cost of \neverything in a multiple that was crazy.  But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were. ", "original_text": "Because we don't buy \noil, we buy p roducts that contain oil. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59b8debeac9153406e816286e600a7c1facd0236a389546581ae3dab73735154", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "019b842c-8d0c-40ee-aef6-2bcede4da6d2", "node_type": "1", "metadata": {"window": "So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right? ", "original_text": "So, it did get outside \nthat band, right? "}, "hash": "1ed4c74e8d313d573cd6fb53ae459394eba960993ba0ec3dd6fec8e45eab5004", "class_name": "RelatedNodeInfo"}}, "text": "And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band. ", "start_char_idx": 1716, "end_char_idx": 1863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "019b842c-8d0c-40ee-aef6-2bcede4da6d2": {"__data__": {"id_": "019b842c-8d0c-40ee-aef6-2bcede4da6d2", "embedding": null, "metadata": {"window": "So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right? ", "original_text": "So, it did get outside \nthat band, right? ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7909bb20-0226-4c6f-851b-19d57ce46157", "node_type": "1", "metadata": {"window": "But you also had these other commodities that were , okay, so \nthere's some commodities that are oil based.  So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities. ", "original_text": "And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd85f0ba540d9362a07006c8712100780e111e467003fd387c135d5faa761be8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d4a4a10-e809-4d33-a32c-52f2d5351a4e", "node_type": "1", "metadata": {"window": "Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time. ", "original_text": "Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were. "}, "hash": "1d43c2f596da7f043115a88fb398c95d79413fdc86b83b465709b0edf387ff95", "class_name": "RelatedNodeInfo"}}, "text": "So, it did get outside \nthat band, right? ", "start_char_idx": 1863, "end_char_idx": 1905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d4a4a10-e809-4d33-a32c-52f2d5351a4e": {"__data__": {"id_": "9d4a4a10-e809-4d33-a32c-52f2d5351a4e", "embedding": null, "metadata": {"window": "Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time. ", "original_text": "Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "019b842c-8d0c-40ee-aef6-2bcede4da6d2", "node_type": "1", "metadata": {"window": "So, you had the oil input cost, but then you had the \nsupply demand factors going on too that I think over -emphasized  that issue .  Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right? ", "original_text": "So, it did get outside \nthat band, right? ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98aefcc0d6e5f0d30cf0968b73238e37e03c8598b9624f794e53dabeaea5d286", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74f3163c-20ea-461d-a520-c5b593c61572", "node_type": "1", "metadata": {"window": "And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n", "original_text": "So, you had a bit of a \nexponential increase in a number of commodities. "}, "hash": "e9d65d8315a7d43138c077382be26246ac14bd43ed44232404a93a7ce5576fbf", "class_name": "RelatedNodeInfo"}}, "text": "Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were. ", "start_char_idx": 1905, "end_char_idx": 2064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74f3163c-20ea-461d-a520-c5b593c61572": {"__data__": {"id_": "74f3163c-20ea-461d-a520-c5b593c61572", "embedding": null, "metadata": {"window": "And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n", "original_text": "So, you had a bit of a \nexponential increase in a number of commodities. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d4a4a10-e809-4d33-a32c-52f2d5351a4e", "node_type": "1", "metadata": {"window": "Because we don't buy \noil, we buy p roducts that contain oil.  And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time. ", "original_text": "Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e5c39e60edac2f90ef539f16ff438a247b3696326af5709d4bdbb5be0bd5d12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71b5adca-c6b9-4146-a1d3-74208c105684", "node_type": "1", "metadata": {"window": "So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds. ", "original_text": "So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right? "}, "hash": "db22a1f22a46f3531762b3285c6c6fe7e86fb140008f34ee22ea8a02975e95b0", "class_name": "RelatedNodeInfo"}}, "text": "So, you had a bit of a \nexponential increase in a number of commodities. ", "start_char_idx": 2064, "end_char_idx": 2137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71b5adca-c6b9-4146-a1d3-74208c105684": {"__data__": {"id_": "71b5adca-c6b9-4146-a1d3-74208c105684", "embedding": null, "metadata": {"window": "So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds. ", "original_text": "So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right? ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74f3163c-20ea-461d-a520-c5b593c61572", "node_type": "1", "metadata": {"window": "And so, as oil goes up and down, that's often absorbed within the \nsupply chain in a normal steady state unless it gets outside of a certain band.  So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n", "original_text": "So, you had a bit of a \nexponential increase in a number of commodities. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdfbc363d46cda89c3478f1d80b24be04a9f463cacd0ab9ea2d73e0431bc73ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c57529f4-164a-456e-b3c5-8730c62f6544", "node_type": "1", "metadata": {"window": "Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this. ", "original_text": "It's a \ngeneral economy not being as hot as it was at that point in time. "}, "hash": "6df46be734bd9e3ef46dcbcd7ce3341fd396ae5676f6de7c50addde238483584", "class_name": "RelatedNodeInfo"}}, "text": "So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right? ", "start_char_idx": 2137, "end_char_idx": 2277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c57529f4-164a-456e-b3c5-8730c62f6544": {"__data__": {"id_": "c57529f4-164a-456e-b3c5-8730c62f6544", "embedding": null, "metadata": {"window": "Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this. ", "original_text": "It's a \ngeneral economy not being as hot as it was at that point in time. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71b5adca-c6b9-4146-a1d3-74208c105684", "node_type": "1", "metadata": {"window": "So, it did get outside \nthat band, right?  Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds. ", "original_text": "So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right? ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "743e6514362eca3475b6181e9c7d4fb94f8847df7e595ccaf75574c90c9e7015", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26a6fc68-9ab3-4109-b893-ae809dc39fcb", "node_type": "1", "metadata": {"window": "So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n", "original_text": "When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n"}, "hash": "126ac768c2fe8590ca154dac46c07a46388a84d4373a4870d1e8f4aa57c9d374", "class_name": "RelatedNodeInfo"}}, "text": "It's a \ngeneral economy not being as hot as it was at that point in time. ", "start_char_idx": 2277, "end_char_idx": 2351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26a6fc68-9ab3-4109-b893-ae809dc39fcb": {"__data__": {"id_": "26a6fc68-9ab3-4109-b893-ae809dc39fcb", "embedding": null, "metadata": {"window": "So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n", "original_text": "When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c57529f4-164a-456e-b3c5-8730c62f6544", "node_type": "1", "metadata": {"window": "Oil went above a $100 per barrel, and then you had other demand factors that were \ndriving those commodity costs well beyond what the input cost impacts were.  So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this. ", "original_text": "It's a \ngeneral economy not being as hot as it was at that point in time. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5dd1c263723a30e9bd975b08d4e195f0def7a18467e3d1fea878d5360009285a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4628a38-87e4-46aa-8d94-df503d2e2579", "node_type": "1", "metadata": {"window": "So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect. ", "original_text": "So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds. "}, "hash": "e292c8571acf6eeb3580cc80a223d94b684fd0fc1d85be3c6f99d3cb5daabd2a", "class_name": "RelatedNodeInfo"}}, "text": "When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n", "start_char_idx": 2351, "end_char_idx": 2586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4628a38-87e4-46aa-8d94-df503d2e2579": {"__data__": {"id_": "e4628a38-87e4-46aa-8d94-df503d2e2579", "embedding": null, "metadata": {"window": "So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect. ", "original_text": "So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26a6fc68-9ab3-4109-b893-ae809dc39fcb", "node_type": "1", "metadata": {"window": "So, you had a bit of a \nexponential increase in a number of commodities.  So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n", "original_text": "When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1da2897f2eaa5b6fc84d554c4a45edd3e42f302d01fd53806ea9e709089d418a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33a8536f-b091-42e6-97e0-7d81919b0148", "node_type": "1", "metadata": {"window": "It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n", "original_text": "So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this. "}, "hash": "faa4be75312420730140e68142f205e5d7eb268841668433549199d4d7c90546", "class_name": "RelatedNodeInfo"}}, "text": "So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds. ", "start_char_idx": 2586, "end_char_idx": 2705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33a8536f-b091-42e6-97e0-7d81919b0148": {"__data__": {"id_": "33a8536f-b091-42e6-97e0-7d81919b0148", "embedding": null, "metadata": {"window": "It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n", "original_text": "So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4628a38-87e4-46aa-8d94-df503d2e2579", "node_type": "1", "metadata": {"window": "So today, given that we're in a much more muted \ndemand environment , as a broad industry because this is way outside of healthcare, right?  It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect. ", "original_text": "So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d931701337fe26b553ca8b119e0e8bdd7ef98f0e84e1513230fdbb55765d5b62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cbd91bd-a31a-4df9-9f31-d68f72e9f7af", "node_type": "1", "metadata": {"window": "When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n"}, "hash": "cfeb1455078c9db1674cf20714fafb0299bfb58ec56db79150f3a09f666f411d", "class_name": "RelatedNodeInfo"}}, "text": "So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this. ", "start_char_idx": 2705, "end_char_idx": 2882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cbd91bd-a31a-4df9-9f31-d68f72e9f7af": {"__data__": {"id_": "8cbd91bd-a31a-4df9-9f31-d68f72e9f7af", "embedding": null, "metadata": {"window": "When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33a8536f-b091-42e6-97e0-7d81919b0148", "node_type": "1", "metadata": {"window": "It's a \ngeneral economy not being as hot as it was at that point in time.  When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n", "original_text": "So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41db21e87e1e33e2293c222278022a43271d07ff844295a4aa6fd5637ec10db5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a561e606-362d-48a9-9f70-349d35ee4b1c", "node_type": "1", "metadata": {"window": "So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America. ", "original_text": "Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect. "}, "hash": "b8216ab5005e7e526ca6080485f6481e2e1670c075e71c849227e527d07cf414", "class_name": "RelatedNodeInfo"}}, "text": "I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n", "start_char_idx": 2882, "end_char_idx": 3060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a561e606-362d-48a9-9f70-349d35ee4b1c": {"__data__": {"id_": "a561e606-362d-48a9-9f70-349d35ee4b1c", "embedding": null, "metadata": {"window": "So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America. ", "original_text": "Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cbd91bd-a31a-4df9-9f31-d68f72e9f7af", "node_type": "1", "metadata": {"window": "When you see these types of input \ncosts going up and down, it goes back to a bit more of a normal model, which is they're not being \nexaggerated and multiplied, they're just flowing through in a much more normalized , steady state.  \n So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f465ea366c8fa379d7ec73e15b2ac726673b5286f924c781ba61b2db638066a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7059de0b-4077-4e95-9bf5-91763a89c657", "node_type": "1", "metadata": {"window": "So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n"}, "hash": "aee2eb5e18a22aa3fb45c73e1ce17e814bd68aba5aa312ad4058080e3b0fb093", "class_name": "RelatedNodeInfo"}}, "text": "Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect. ", "start_char_idx": 3060, "end_char_idx": 3227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7059de0b-4077-4e95-9bf5-91763a89c657": {"__data__": {"id_": "7059de0b-4077-4e95-9bf5-91763a89c657", "embedding": null, "metadata": {"window": "So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a561e606-362d-48a9-9f70-349d35ee4b1c", "node_type": "1", "metadata": {"window": "So that's the reason why that I would not expect this under this current environment to get outside of \nnormal bounds.  So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America. ", "original_text": "Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "004bc240b4de2d6df4d167bb9352864f7d26c391fe37cd4247f2139fa71f57e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cdbd0d9-ea26-4645-a1f6-5c01220aa5f4", "node_type": "1", "metadata": {"window": "I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "Matt Sims:  Next question, please.  \n \n"}, "hash": "c3bbbf14413cd4a37a2ebdad8f15b21e006027814f0f7ac18fa18f4f15ea375a", "class_name": "RelatedNodeInfo"}}, "text": "It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n", "start_char_idx": 3227, "end_char_idx": 3505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cdbd0d9-ea26-4645-a1f6-5c01220aa5f4": {"__data__": {"id_": "9cdbd0d9-ea26-4645-a1f6-5c01220aa5f4", "embedding": null, "metadata": {"window": "I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7059de0b-4077-4e95-9bf5-91763a89c657", "node_type": "1", "metadata": {"window": "So, if you see the input costs going up and you see a heated economic environment \nthat can further compound that impact, that's when we need to start worrying more about this.  I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bcb78e4e4259a2684c70cb2df6acc26933a2211ce25b2620bef0192cf659e806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7da2179f-f433-4f53-80d4-d6d8887df9d3", "node_type": "1", "metadata": {"window": "Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "Operator:  The next question comes from Allen Lutz from Bank of America. "}, "hash": "cee3dfb25eb1dbc6218d9eca6a11c0cd4d082cdeddfb527bb563b1adbd6f720e", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:  Next question, please.  \n \n", "start_char_idx": 3505, "end_char_idx": 3544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7da2179f-f433-4f53-80d4-d6d8887df9d3": {"__data__": {"id_": "7da2179f-f433-4f53-80d4-d6d8887df9d3", "embedding": null, "metadata": {"window": "Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "Operator:  The next question comes from Allen Lutz from Bank of America. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cdbd0d9-ea26-4645-a1f6-5c01220aa5f4", "node_type": "1", "metadata": {"window": "I know \nthe importance of this will certainly be day to day, we certainly spend a lo t of time on this, but we'll \ncontinue to provide any insight that we see going forward.  \n \n Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94ff3bf511a916cb28c1eb0049269cdd660546a955767ae00e8164c3be1f401a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a910e62-e8bc-458c-b0f0-78301eaf21ba", "node_type": "1", "metadata": {"window": "It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "Please go ahead.  "}, "hash": "769dad4497b36bac1e0bd2ec1226a0828a2a8f0d6fb863e265780fac50600496", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  The next question comes from Allen Lutz from Bank of America. ", "start_char_idx": 3544, "end_char_idx": 3617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a910e62-e8bc-458c-b0f0-78301eaf21ba": {"__data__": {"id_": "3a910e62-e8bc-458c-b0f0-78301eaf21ba", "embedding": null, "metadata": {"window": "It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "Please go ahead.  ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff3c7d2e12eb13b43610cf4cedce6d47f43c6647e0dfc50432e97037f78726a1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7da2179f-f433-4f53-80d4-d6d8887df9d3", "node_type": "1", "metadata": {"window": "Of course, when we get into the very significant changes, that's the changes to our contracting \nstructure that we've put into place that's never going to be perfect.  It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "Operator:  The next question comes from Allen Lutz from Bank of America. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac00c864b02a0c7ec25768062b08e60e9f89b8a4f1f461d724eb793c978dc192", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7029c1e-46b6-4902-aed1-7ade1f589656", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q. ", "original_text": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions. "}, "hash": "99d87c61c131ef57e93bc9bbc5903311e1897e817e19699b03461c0102942941", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  ", "start_char_idx": 661, "end_char_idx": 679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7029c1e-46b6-4902-aed1-7ade1f589656": {"__data__": {"id_": "a7029c1e-46b6-4902-aed1-7ade1f589656", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q. ", "original_text": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a910e62-e8bc-458c-b0f0-78301eaf21ba", "node_type": "1", "metadata": {"window": "It's never going to be a one for one \noffset, but it's meant to really be active and impact ful when you have those more extraordinary types \nof impacts that really kind of compound these items like I just referenced, and not just the normal \ntypes of more muted movements.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  The next question comes from Allen Lutz from Bank of America.  Please go ahead.  ", "original_text": "Please go ahead.  ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82eeb8c7dd3f1338926991b7363f81da250ad429ff8202aa1674d90a82809cca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fad4e3a0-4495-46a3-ad02-7f64eecfd922", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half? ", "original_text": "I want to go after the Pharma \nmargin dynamic a little bit differently. "}, "hash": "fef554a1aeb67e57e376f0ff6185729f2a457f59ba497c6f4232825bc667a0c6", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions. ", "start_char_idx": 0, "end_char_idx": 86, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fad4e3a0-4495-46a3-ad02-7f64eecfd922": {"__data__": {"id_": "fad4e3a0-4495-46a3-ad02-7f64eecfd922", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half? ", "original_text": "I want to go after the Pharma \nmargin dynamic a little bit differently. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7029c1e-46b6-4902-aed1-7ade1f589656", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q. ", "original_text": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23ba8984fdec40466202e5266fd54cfdd6e8b3fd2ad13203362fa7dc3ef1c62a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d3e38ce-1105-4282-b245-307ad127dc2e", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there. ", "original_text": "So, they were up five b ps year -over-year. "}, "hash": "58ec0458d9c0836e0cf1f988ae5ea71e83db07c088e4239b4e8dc2f980781251", "class_name": "RelatedNodeInfo"}}, "text": "I want to go after the Pharma \nmargin dynamic a little bit differently. ", "start_char_idx": 86, "end_char_idx": 158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d3e38ce-1105-4282-b245-307ad127dc2e": {"__data__": {"id_": "2d3e38ce-1105-4282-b245-307ad127dc2e", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there. ", "original_text": "So, they were up five b ps year -over-year. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fad4e3a0-4495-46a3-ad02-7f64eecfd922", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half? ", "original_text": "I want to go after the Pharma \nmargin dynamic a little bit differently. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a722fa4db737deb7a85e9e5cc04c2b59a0c8e1285dcb191477cf4f6a04c77ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1b3a3be-d940-4924-9728-e4fbb5561528", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n", "original_text": "It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q. "}, "hash": "6250fdf291681ced51dc36698ecc2d177112f887d3a814c98cb358c06e99c444", "class_name": "RelatedNodeInfo"}}, "text": "So, they were up five b ps year -over-year. ", "start_char_idx": 158, "end_char_idx": 202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1b3a3be-d940-4924-9728-e4fbb5561528": {"__data__": {"id_": "b1b3a3be-d940-4924-9728-e4fbb5561528", "embedding": null, "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n", "original_text": "It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d3e38ce-1105-4282-b245-307ad127dc2e", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there. ", "original_text": "So, they were up five b ps year -over-year. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43630c14c55f9c7d9ec2861f0c4ce7a780ced6b9f8ef2598e193c6d6d9b30b5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f691a9f-5acb-41fc-a361-59925ee2fb99", "node_type": "1", "metadata": {"window": "I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness. ", "original_text": "So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half? "}, "hash": "c49487eed8ede3b33a300b009b808a57579b63c73c6c3713bb3bd7fda3d58432", "class_name": "RelatedNodeInfo"}}, "text": "It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q. ", "start_char_idx": 202, "end_char_idx": 274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f691a9f-5acb-41fc-a361-59925ee2fb99": {"__data__": {"id_": "6f691a9f-5acb-41fc-a361-59925ee2fb99", "embedding": null, "metadata": {"window": "I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness. ", "original_text": "So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half? ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1b3a3be-d940-4924-9728-e4fbb5561528", "node_type": "1", "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n", "original_text": "It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a924a530284dce702be93d51f096c269a6c087678d992d5d8097eb4b8d0a3f1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b31f1e96-7b32-4735-b759-23af5f8f1a8c", "node_type": "1", "metadata": {"window": "So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2. ", "original_text": "Just trying to get a sense of the \nseasonal ity there. "}, "hash": "5d5d67ea86babd6b0230c6f1ddcd5164766f65d34e080013e69f8f9d11427911", "class_name": "RelatedNodeInfo"}}, "text": "So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half? ", "start_char_idx": 274, "end_char_idx": 499, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b31f1e96-7b32-4735-b759-23af5f8f1a8c": {"__data__": {"id_": "b31f1e96-7b32-4735-b759-23af5f8f1a8c", "embedding": null, "metadata": {"window": "So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2. ", "original_text": "Just trying to get a sense of the \nseasonal ity there. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f691a9f-5acb-41fc-a361-59925ee2fb99", "node_type": "1", "metadata": {"window": "I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness. ", "original_text": "So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half? ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94f5a6c285a9b720e9cd89fd79939cbe175ed4ad1ed52382d2f2a3ae83ddca35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c9a9d51-2e63-4a50-bd5a-34fb1208c942", "node_type": "1", "metadata": {"window": "It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right? ", "original_text": "Thanks.  \n \n"}, "hash": "2ecf46236e7f5d4e35456f9fa5703e081cdf0d7ab1dafcf92ac4f91b18cc21b8", "class_name": "RelatedNodeInfo"}}, "text": "Just trying to get a sense of the \nseasonal ity there. ", "start_char_idx": 499, "end_char_idx": 554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c9a9d51-2e63-4a50-bd5a-34fb1208c942": {"__data__": {"id_": "8c9a9d51-2e63-4a50-bd5a-34fb1208c942", "embedding": null, "metadata": {"window": "It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right? ", "original_text": "Thanks.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b31f1e96-7b32-4735-b759-23af5f8f1a8c", "node_type": "1", "metadata": {"window": "So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2. ", "original_text": "Just trying to get a sense of the \nseasonal ity there. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63e25a6713bf65705263232dbdd5a3533641c7501ea6bbdd82c8caf85d3b6941", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31e680df-fe9d-4eaf-9a8a-be9756214d5f", "node_type": "1", "metadata": {"window": "So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen. ", "original_text": "Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness. "}, "hash": "9bc0bc07437c4cc7d95dae9206c056489354961ecf76ad1ca2a765a4999354ad", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 554, "end_char_idx": 566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31e680df-fe9d-4eaf-9a8a-be9756214d5f": {"__data__": {"id_": "31e680df-fe9d-4eaf-9a8a-be9756214d5f", "embedding": null, "metadata": {"window": "So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen. ", "original_text": "Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c9a9d51-2e63-4a50-bd5a-34fb1208c942", "node_type": "1", "metadata": {"window": "It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q.  So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right? ", "original_text": "Thanks.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a240326d6bbef936fbbc7bd8f71363df0b7503de594aff47f78b10e470917867", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3b25bdb-d4cd-4e85-bbf6-a5e2af6188ee", "node_type": "1", "metadata": {"window": "Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n", "original_text": "We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2. "}, "hash": "f4b0ebbe128d9fdeb35c092ed5e10eb76c1bee4b055f3b5b2a302fcbc2dc1517", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness. ", "start_char_idx": 566, "end_char_idx": 671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3b25bdb-d4cd-4e85-bbf6-a5e2af6188ee": {"__data__": {"id_": "c3b25bdb-d4cd-4e85-bbf6-a5e2af6188ee", "embedding": null, "metadata": {"window": "Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n", "original_text": "We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31e680df-fe9d-4eaf-9a8a-be9756214d5f", "node_type": "1", "metadata": {"window": "So, is the right way to think about the margin growth \nin the Pharma segment year -over-year is, it could peak or the growth could peak in 2Q and then kind \nof more of a normalized  lower -margin trajectory in the back half?  Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen. ", "original_text": "Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5d683300697ad56d9cbdd122405afe5b1e534948954361180f474b91ea62c23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3efad347-7819-4eb8-a77b-623d63f115cd", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore. ", "original_text": "Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right? "}, "hash": "26e4ee5aa16f4692f19b700b3bc32da8b366657ead26ee243bf940ed940fa14b", "class_name": "RelatedNodeInfo"}}, "text": "We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2. ", "start_char_idx": 671, "end_char_idx": 829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3efad347-7819-4eb8-a77b-623d63f115cd": {"__data__": {"id_": "3efad347-7819-4eb8-a77b-623d63f115cd", "embedding": null, "metadata": {"window": "Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore. ", "original_text": "Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right? ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3b25bdb-d4cd-4e85-bbf6-a5e2af6188ee", "node_type": "1", "metadata": {"window": "Just trying to get a sense of the \nseasonal ity there.  Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n", "original_text": "We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f5a80d05f08a88abb72deed492bc879f88a96ce4add9d7bd1351fb0ff262bc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5975424-58ba-47e9-9de9-f49dafe6055d", "node_type": "1", "metadata": {"window": "Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n", "original_text": "And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen. "}, "hash": "7f3c1d682f38a018d2a128aea421f179c323aa9d9b0dbe3a9b8b79103baf7bb5", "class_name": "RelatedNodeInfo"}}, "text": "Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right? ", "start_char_idx": 829, "end_char_idx": 1026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5975424-58ba-47e9-9de9-f49dafe6055d": {"__data__": {"id_": "e5975424-58ba-47e9-9de9-f49dafe6055d", "embedding": null, "metadata": {"window": "Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n", "original_text": "And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3efad347-7819-4eb8-a77b-623d63f115cd", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore. ", "original_text": "Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right? ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "136eccb8403de255e9226bf080f8c14758800e05ab7b8f45e90e4bdfbc786b4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "640b2608-428b-43e4-95fa-3e454d03d012", "node_type": "1", "metadata": {"window": "We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys. ", "original_text": "That's how we're offering \nup today.  \n  \n"}, "hash": "602b150304f307d661d0ac70453a3ac1fedd7bc99573decbde3a64b1abb96fd5", "class_name": "RelatedNodeInfo"}}, "text": "And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen. ", "start_char_idx": 1026, "end_char_idx": 1134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "640b2608-428b-43e4-95fa-3e454d03d012": {"__data__": {"id_": "640b2608-428b-43e4-95fa-3e454d03d012", "embedding": null, "metadata": {"window": "We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys. ", "original_text": "That's how we're offering \nup today.  \n  \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5975424-58ba-47e9-9de9-f49dafe6055d", "node_type": "1", "metadata": {"window": "Aaron Alt:   We really haven't provided quarterly guidance at the margin level for the Pharma \nbusiness.  We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n", "original_text": "And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fa45ff7b0a9b9e60ada8aeb771bbb2a7a145cd740794f6f6f079ea0ea6149cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af642033-ece5-43ad-b9c1-7e0df55c9223", "node_type": "1", "metadata": {"window": "Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before. ", "original_text": "Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore. "}, "hash": "b434a88f8cdb1acc4fbede0943cb49a2f9588e4a1a509a9c69a5230945d16ecb", "class_name": "RelatedNodeInfo"}}, "text": "That's how we're offering \nup today.  \n  \n", "start_char_idx": 1134, "end_char_idx": 1176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af642033-ece5-43ad-b9c1-7e0df55c9223": {"__data__": {"id_": "af642033-ece5-43ad-b9c1-7e0df55c9223", "embedding": null, "metadata": {"window": "Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before. ", "original_text": "Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "640b2608-428b-43e4-95fa-3e454d03d012", "node_type": "1", "metadata": {"window": "We were , we leaned in a bit in describing the impact to Q1 from the COVID vaccine \ndistribution, as well as Jason's comments around the expectations for Q2.  Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys. ", "original_text": "That's how we're offering \nup today.  \n  \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76f2af9abb9c04b420e7add35ac9b732e8cd35dc5e3394621d44ee1c4c182dde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc971faa-edbd-4f9f-812a-a32fb8406efc", "node_type": "1", "metadata": {"window": "And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n", "original_text": "Please go \nahead.  \n \n"}, "hash": "1f67c4d755b3bb03bfc6a291b1a1e21c4b44577fad82018b1946b81183334cc9", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore. ", "start_char_idx": 1176, "end_char_idx": 1263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc971faa-edbd-4f9f-812a-a32fb8406efc": {"__data__": {"id_": "bc971faa-edbd-4f9f-812a-a32fb8406efc", "embedding": null, "metadata": {"window": "And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n", "original_text": "Please go \nahead.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af642033-ece5-43ad-b9c1-7e0df55c9223", "node_type": "1", "metadata": {"window": "Beyond that, I think you \njust need to take into account what we typically say about our business, which is fir st that we expect \nthe consistent market dynamics from a generic perspective, right?  And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before. ", "original_text": "Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a90a8b89fd86103285ac469656be8dc4987fd770ffb0172781e2dd73952377b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da3a77cf-1d9b-4805-bd75-ba86bcb8c25a", "node_type": "1", "metadata": {"window": "That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n", "original_text": "Elizabeth Anderson:  Hi guys. "}, "hash": "95c6f48bc11af26f2bcd678dd62a5d01132fad20c85440acd6b9b4ceb857739e", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n \n", "start_char_idx": 1263, "end_char_idx": 1285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da3a77cf-1d9b-4805-bd75-ba86bcb8c25a": {"__data__": {"id_": "da3a77cf-1d9b-4805-bd75-ba86bcb8c25a", "embedding": null, "metadata": {"window": "That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n", "original_text": "Elizabeth Anderson:  Hi guys. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc971faa-edbd-4f9f-812a-a32fb8406efc", "node_type": "1", "metadata": {"window": "And we are not assuming some of \nthe benefits from a brand p erspective in Q3 that we have previously seen.  That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n", "original_text": "Please go \nahead.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "431a3d78a8c33471aefaa5e9a58c7b94fa2acf5a09bf91c52b4204ba5f0e9b16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "deaa8826-5ae5-45bb-89c6-f98173f21705", "node_type": "1", "metadata": {"window": "Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n", "original_text": "Apologies about the audio issues before. "}, "hash": "8332789571e0478054f327f2e31543b6669576cb642d901baa8fd331f3f83931", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson:  Hi guys. ", "start_char_idx": 1285, "end_char_idx": 1315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "deaa8826-5ae5-45bb-89c6-f98173f21705": {"__data__": {"id_": "deaa8826-5ae5-45bb-89c6-f98173f21705", "embedding": null, "metadata": {"window": "Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n", "original_text": "Apologies about the audio issues before. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da3a77cf-1d9b-4805-bd75-ba86bcb8c25a", "node_type": "1", "metadata": {"window": "That's how we're offering \nup today.  \n  \n Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n", "original_text": "Elizabeth Anderson:  Hi guys. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a95e328c89b9f46d4f6ef53916b00c377e91159306debbd7ba5904b9f415594", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86d362ed-791e-49cf-a093-02a4527ac3ae", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count? ", "original_text": "My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n"}, "hash": "abefab9233bf32e2a661b1a1f35208784528a814c1841aea3d2adc47ec8cb99e", "class_name": "RelatedNodeInfo"}}, "text": "Apologies about the audio issues before. ", "start_char_idx": 1315, "end_char_idx": 1356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86d362ed-791e-49cf-a093-02a4527ac3ae": {"__data__": {"id_": "86d362ed-791e-49cf-a093-02a4527ac3ae", "embedding": null, "metadata": {"window": "Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count? ", "original_text": "My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "deaa8826-5ae5-45bb-89c6-f98173f21705", "node_type": "1", "metadata": {"window": "Operator:   We'll now take our final question today from Elizabeth Anderson, Evercore.  Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n", "original_text": "Apologies about the audio issues before. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "975dd2b82fbd478baaa5c959e1446b178dd3bc4854799df663894a13333c46f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d10e7129-0103-4679-a2cc-937244baac97", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.  ", "original_text": "Operator:  And it seems we have lost her again.  \n \n"}, "hash": "a2738fec56767c97b95694fd2d6dd781035b4964bcbf63ecd07b4732b76bb700", "class_name": "RelatedNodeInfo"}}, "text": "My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n", "start_char_idx": 1356, "end_char_idx": 1664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d10e7129-0103-4679-a2cc-937244baac97": {"__data__": {"id_": "d10e7129-0103-4679-a2cc-937244baac97", "embedding": null, "metadata": {"window": "Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.  ", "original_text": "Operator:  And it seems we have lost her again.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86d362ed-791e-49cf-a093-02a4527ac3ae", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n \n Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count? ", "original_text": "My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d27779af920c7ec48f6e90f3d0aaff0d570b9a902b4901285b2fa8324834e2b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7575a8e9-2da1-4a26-8cef-fbd4ee40663d", "node_type": "1", "metadata": {"window": "Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate. ", "original_text": "Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n"}, "hash": "f207aba980c2620df87f3ddbba2d7a6ba3ec2043c279d1a7ace18b012ae7757f", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  And it seems we have lost her again.  \n \n", "start_char_idx": 1664, "end_char_idx": 1716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7575a8e9-2da1-4a26-8cef-fbd4ee40663d": {"__data__": {"id_": "7575a8e9-2da1-4a26-8cef-fbd4ee40663d", "embedding": null, "metadata": {"window": "Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate. ", "original_text": "Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d10e7129-0103-4679-a2cc-937244baac97", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  Hi guys.  Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.  ", "original_text": "Operator:  And it seems we have lost her again.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02b55656112164e117b71a5ad80157ccedc1e9a3db6c959487f2cf4c41410ace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1813762-52ea-4e31-84f2-a3d2a84519ab", "node_type": "1", "metadata": {"window": "My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with. ", "original_text": "The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count? "}, "hash": "d4136dcb605ad199e8f809cef768205005f57425311e9c6219f566578920db65", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n", "start_char_idx": 1716, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1813762-52ea-4e31-84f2-a3d2a84519ab": {"__data__": {"id_": "f1813762-52ea-4e31-84f2-a3d2a84519ab", "embedding": null, "metadata": {"window": "My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with. ", "original_text": "The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count? ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7575a8e9-2da1-4a26-8cef-fbd4ee40663d", "node_type": "1", "metadata": {"window": "Apologies about the audio issues before.  My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate. ", "original_text": "Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e4a9c962a49e4171e75dbc46e12ca40931b3cf0ee236b9cf5610216831d4c99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d834534d-f83d-4082-b583-f452d20ae81e", "node_type": "1", "metadata": {"window": "Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n", "original_text": "And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.  "}, "hash": "d269a520fe471ddd2a81c05b9480d837f946e330678c3f071a58b343544df41d", "class_name": "RelatedNodeInfo"}}, "text": "The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count? ", "start_char_idx": 1823, "end_char_idx": 1956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d834534d-f83d-4082-b583-f452d20ae81e": {"__data__": {"id_": "d834534d-f83d-4082-b583-f452d20ae81e", "embedding": null, "metadata": {"window": "Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n", "original_text": "And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.  ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1813762-52ea-4e31-84f2-a3d2a84519ab", "node_type": "1", "metadata": {"window": "My question was just on the \nnon-operating items, it seems like both on interest expense and maybe on the share count based on \nthe ASR that you talked about and the interest expense in the first quarter, tha t there's a little bit of \nconservatism int that number, in both of those numbers [inaudible] . \n \n Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with. ", "original_text": "The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count? ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "083b9394cf43eff1c1c2a10582af4bc11136a9a6ae84969ca5b7576ad9496c8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb458a9f-48a6-4968-a6bb-02e7079ac6a1", "node_type": "1", "metadata": {"window": "Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824. ", "original_text": "We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate. "}, "hash": "bb521dbd6bd06b9340bcc845d5806a636cd9f36f5d8c697de5c321e38dc844b7", "class_name": "RelatedNodeInfo"}}, "text": "And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.  ", "start_char_idx": 1956, "end_char_idx": 2178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb458a9f-48a6-4968-a6bb-02e7079ac6a1": {"__data__": {"id_": "fb458a9f-48a6-4968-a6bb-02e7079ac6a1", "embedding": null, "metadata": {"window": "Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824. ", "original_text": "We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d834534d-f83d-4082-b583-f452d20ae81e", "node_type": "1", "metadata": {"window": "Operator:  And it seems we have lost her again.  \n \n Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n", "original_text": "And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.  ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b99d3038ec3eded3652607ddaed20ff26964322d8191feb5133db3ff656b4474", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d52bbcb8-4020-4cf5-9659-329e6544bb21", "node_type": "1", "metadata": {"window": "The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward. ", "original_text": "We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with. "}, "hash": "b6580a437c175838c5acd5c45b938c094c025109c2b0c42120bfc0187252c3df", "class_name": "RelatedNodeInfo"}}, "text": "We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate. ", "start_char_idx": 2178, "end_char_idx": 2273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d52bbcb8-4020-4cf5-9659-329e6544bb21": {"__data__": {"id_": "d52bbcb8-4020-4cf5-9659-329e6544bb21", "embedding": null, "metadata": {"window": "The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward. ", "original_text": "We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb458a9f-48a6-4968-a6bb-02e7079ac6a1", "node_type": "1", "metadata": {"window": "Aaron Alt:  I'm going to attempt to answer the , I'll answer the question I think she was seeking to ask. \n The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824. ", "original_text": "We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c667fa48e5adc565b0829e1de5d5f223944943b61d57fcdbac5b4940992eff18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82dc824a-1e3e-4457-8007-95e695fc0d4f", "node_type": "1", "metadata": {"window": "And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n", "original_text": "And \nthat's just driven by the good stewardship , previously.  \n \n"}, "hash": "875e4aec0377c70c3aaaad9ed4570b135578b1dad75574fa141cab98f6dd6909", "class_name": "RelatedNodeInfo"}}, "text": "We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with. ", "start_char_idx": 2273, "end_char_idx": 2421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82dc824a-1e3e-4457-8007-95e695fc0d4f": {"__data__": {"id_": "82dc824a-1e3e-4457-8007-95e695fc0d4f", "embedding": null, "metadata": {"window": "And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n", "original_text": "And \nthat's just driven by the good stewardship , previously.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d52bbcb8-4020-4cf5-9659-329e6544bb21", "node_type": "1", "metadata": {"window": "The question from what I heard was interest and  other, are  we being conservative as well as what's \ngoing on with our share count?  And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward. ", "original_text": "We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2219dd209fd44ec6e238541f390ca6f48074d409773da2704eb945f462fb759f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7887a02d-97ea-4a53-947a-c8c145ef75fc", "node_type": "1", "metadata": {"window": "We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase. ", "original_text": "We do have a maturity coming at the end of fiscal \u201824. "}, "hash": "cbdd35018627866a856f24438489c1ed83cab830304fd600aff4b58c495e3b96", "class_name": "RelatedNodeInfo"}}, "text": "And \nthat's just driven by the good stewardship , previously.  \n \n", "start_char_idx": 2421, "end_char_idx": 2487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7887a02d-97ea-4a53-947a-c8c145ef75fc": {"__data__": {"id_": "7887a02d-97ea-4a53-947a-c8c145ef75fc", "embedding": null, "metadata": {"window": "We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase. ", "original_text": "We do have a maturity coming at the end of fiscal \u201824. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82dc824a-1e3e-4457-8007-95e695fc0d4f", "node_type": "1", "metadata": {"window": "And I guess I would offer the following:  we were pleased to see \ncontinued benefit in the quarter from I &O driven by the fact that we have such high cash balances \nand the return we're receiving on those cash balances.   We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n", "original_text": "And \nthat's just driven by the good stewardship , previously.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eeb9a3a4e3c68f238e5bca1fdb2a011b5c37b048930f2043f6a7585119097647", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3681391-1c6d-413f-bcee-75b26e53f3ce", "node_type": "1", "metadata": {"window": "We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824. ", "original_text": "It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward. "}, "hash": "216b25ca4cf9747fd3455f444796d1120fc724a3b071d0f8866d35bcceb52545", "class_name": "RelatedNodeInfo"}}, "text": "We do have a maturity coming at the end of fiscal \u201824. ", "start_char_idx": 2487, "end_char_idx": 2542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3681391-1c6d-413f-bcee-75b26e53f3ce": {"__data__": {"id_": "b3681391-1c6d-413f-bcee-75b26e53f3ce", "embedding": null, "metadata": {"window": "We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824. ", "original_text": "It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7887a02d-97ea-4a53-947a-c8c145ef75fc", "node_type": "1", "metadata": {"window": "We are of course also benefiting in the quarter \nfrom the fact that we are largely fixed rate.  We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase. ", "original_text": "We do have a maturity coming at the end of fiscal \u201824. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e8ea8ec095c0e925b390331c527c44fb44760b537dca394f02abc1dcd503065", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2555354-2bd9-48ef-9317-73332a7b5620", "node_type": "1", "metadata": {"window": "And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter. ", "original_text": "And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n"}, "hash": "d8318235ae0f638787384bbfb0cf25afff4735eff67c9c2a882ad10a257329f7", "class_name": "RelatedNodeInfo"}}, "text": "It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward. ", "start_char_idx": 2542, "end_char_idx": 2705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2555354-2bd9-48ef-9317-73332a7b5620": {"__data__": {"id_": "b2555354-2bd9-48ef-9317-73332a7b5620", "embedding": null, "metadata": {"window": "And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter. ", "original_text": "And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3681391-1c6d-413f-bcee-75b26e53f3ce", "node_type": "1", "metadata": {"window": "We have been now for several quarters and so we haven't \nbeen exposed to the interest rate increases that some other companies may be dealing with.  And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824. ", "original_text": "It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d14dae1c0d7a0be5f7ab5ae464374eb251d31a23f70e63718e23e43bc55fe5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb25bb20-4a4c-406a-9551-8d0a27303a76", "node_type": "1", "metadata": {"window": "We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today. ", "original_text": "With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase. "}, "hash": "00f9fde095d6e6c871471c144c1d0998d7c2743172965c0f644e67f854abde64", "class_name": "RelatedNodeInfo"}}, "text": "And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n", "start_char_idx": 2705, "end_char_idx": 2829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb25bb20-4a4c-406a-9551-8d0a27303a76": {"__data__": {"id_": "cb25bb20-4a4c-406a-9551-8d0a27303a76", "embedding": null, "metadata": {"window": "We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today. ", "original_text": "With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2555354-2bd9-48ef-9317-73332a7b5620", "node_type": "1", "metadata": {"window": "And \nthat's just driven by the good stewardship , previously.  \n \n We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter. ", "original_text": "And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab0e633b2a63dc6a4792f4a12593bbd0a9b348f0bf126dc4c1735b432d175744", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a16f2f2b-f2d4-425c-9f43-964e9c84c538", "node_type": "1", "metadata": {"window": "It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram. ", "original_text": "We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824. "}, "hash": "dfccee7f1d51ee6a8cd72658f30088b74c58ac4d239c8cd990e45c9e1dc452db", "class_name": "RelatedNodeInfo"}}, "text": "With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase. ", "start_char_idx": 2829, "end_char_idx": 3013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a16f2f2b-f2d4-425c-9f43-964e9c84c538": {"__data__": {"id_": "a16f2f2b-f2d4-425c-9f43-964e9c84c538", "embedding": null, "metadata": {"window": "It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram. ", "original_text": "We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb25bb20-4a4c-406a-9551-8d0a27303a76", "node_type": "1", "metadata": {"window": "We do have a maturity coming at the end of fiscal \u201824.  It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today. ", "original_text": "With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5dd9c62299616dce8ceec126d7a778d72e63f19712fcc599e1be828065582c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b70e87b7-b0f9-4241-86de-5600e18060d7", "node_type": "1", "metadata": {"window": "And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "We completed that in the first quarter. "}, "hash": "95c0a1f27e9c97aafb8f4571a78047b177b76f088c11094d2304eb6391655990", "class_name": "RelatedNodeInfo"}}, "text": "We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824. ", "start_char_idx": 3013, "end_char_idx": 3168, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b70e87b7-b0f9-4241-86de-5600e18060d7": {"__data__": {"id_": "b70e87b7-b0f9-4241-86de-5600e18060d7", "embedding": null, "metadata": {"window": "And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "We completed that in the first quarter. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a16f2f2b-f2d4-425c-9f43-964e9c84c538", "node_type": "1", "metadata": {"window": "It's about $750 million from recollection, and \nwe've commented that we're likely to refinance that, haven't commented on the timing of that as we \ncarry forward.  And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram. ", "original_text": "We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32fac1a3bb5da9670cc9251ef71f61ec8968cb99bdfde0678732c715a6bf0578", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46d87dfb-c8a8-46aa-80e3-1ce5a832f0d0", "node_type": "1", "metadata": {"window": "With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "That is the share \nrepurchase we're talking about today. "}, "hash": "aefe376b1a0088e5314453398ca9244bf25928ded444fd973fac6f18ccd74a94", "class_name": "RelatedNodeInfo"}}, "text": "We completed that in the first quarter. ", "start_char_idx": 3168, "end_char_idx": 3208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46d87dfb-c8a8-46aa-80e3-1ce5a832f0d0": {"__data__": {"id_": "46d87dfb-c8a8-46aa-80e3-1ce5a832f0d0", "embedding": null, "metadata": {"window": "With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "That is the share \nrepurchase we're talking about today. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b70e87b7-b0f9-4241-86de-5600e18060d7", "node_type": "1", "metadata": {"window": "And so, we believe the updated guide we've provided on I &O reflects the benefits and \nthe various trade -offs in that.  \n \n With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "We completed that in the first quarter. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e90d183aa95ca7dd414255a1e07ccc25812ea84ccea648e39cff651f2636df8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "769e8b4d-3d17-4374-9474-70d10cdc7e0c", "node_type": "1", "metadata": {"window": "We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "And our guide reflects the impact of the completion of that \nshare repurchase prog ram. "}, "hash": "bb4894f3c671c38b08cc14fbfe25f8b6331867033181a378b8f09ae10d245223", "class_name": "RelatedNodeInfo"}}, "text": "That is the share \nrepurchase we're talking about today. ", "start_char_idx": 3208, "end_char_idx": 3265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "769e8b4d-3d17-4374-9474-70d10cdc7e0c": {"__data__": {"id_": "769e8b4d-3d17-4374-9474-70d10cdc7e0c", "embedding": null, "metadata": {"window": "We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "And our guide reflects the impact of the completion of that \nshare repurchase prog ram. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46d87dfb-c8a8-46aa-80e3-1ce5a832f0d0", "node_type": "1", "metadata": {"window": "With respect to the share count, I do think it's important to call out that as we have consistently said, \nwe don't guide for share count changes beyond the baseline share repurchase.  We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "That is the share \nrepurchase we're talking about today. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b16acf1b4648817339affaaba1ef8e344688c4ce364e33cdc3a9321a3b0a19e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e109b82a-c71f-43b5-b670-d055f676b615", "node_type": "1", "metadata": {"window": "We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "It does not reflect any other changes to share repurchase over the course "}, "hash": "fd1f8309bdd2163005f55df790a3822b7f4a2d3c42a8fd9103542a2d1cf93c57", "class_name": "RelatedNodeInfo"}}, "text": "And our guide reflects the impact of the completion of that \nshare repurchase prog ram. ", "start_char_idx": 3265, "end_char_idx": 3353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e109b82a-c71f-43b5-b670-d055f676b615": {"__data__": {"id_": "e109b82a-c71f-43b5-b670-d055f676b615", "embedding": null, "metadata": {"window": "We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "It does not reflect any other changes to share repurchase over the course ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65bd923bcfe9b905fe0167c030c6b7d6f2d65f219632447ddf794c626b7b49e5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "769e8b4d-3d17-4374-9474-70d10cdc7e0c", "node_type": "1", "metadata": {"window": "We made a \ncommitment at fiscal , during our Investor Day in June that our baseline share repurchase was going \nto be $500 million during fiscal year \u201824.  We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "And our guide reflects the impact of the completion of that \nshare repurchase prog ram. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9f7382c7d8b525171f6f84d6d5f6ed6cdaa630d4ed1d406b48b1d3b9c2878f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c432851-3e9f-45cd-b27b-03c583c5f70d", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out. ", "original_text": " \nPage 16 of 16 \n \nof year. "}, "hash": "cddcdb470cc21b310494b270858b8deff65363a9df6e1d03d3c22c3ba1687940", "class_name": "RelatedNodeInfo"}}, "text": "It does not reflect any other changes to share repurchase over the course ", "start_char_idx": 3353, "end_char_idx": 3427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c432851-3e9f-45cd-b27b-03c583c5f70d": {"__data__": {"id_": "8c432851-3e9f-45cd-b27b-03c583c5f70d", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out. ", "original_text": " \nPage 16 of 16 \n \nof year. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e109b82a-c71f-43b5-b670-d055f676b615", "node_type": "1", "metadata": {"window": "We completed that in the first quarter.  That is the share \nrepurchase we're talking about today.  And our guide reflects the impact of the completion of that \nshare repurchase prog ram.  It does not reflect any other changes to share repurchase over the course ", "original_text": "It does not reflect any other changes to share repurchase over the course ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3de53f5563512bc9646f44a7c55e6ac0808d7049367d38d87c52e2f3c7d2aa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64a3aa68-4b8a-446d-ad5d-429b930d98c2", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing. ", "original_text": "As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating. "}, "hash": "0886427346682ad065f88ee60e0001b7a1324e8e2a22ebd79be875678b9420ef", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 16 of 16 \n \nof year. ", "start_char_idx": 0, "end_char_idx": 28, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64a3aa68-4b8a-446d-ad5d-429b930d98c2": {"__data__": {"id_": "64a3aa68-4b8a-446d-ad5d-429b930d98c2", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing. ", "original_text": "As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c432851-3e9f-45cd-b27b-03c583c5f70d", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out. ", "original_text": " \nPage 16 of 16 \n \nof year. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64fd9dd3ef1a90bfb8688c846d1658e1de7bd67d051c250f00d0a400fc18ed0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9287e502-a19e-462a-aaf2-196c7f400063", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n", "original_text": "And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n"}, "hash": "808227e06b706c2f531e5382c4202f7b074c716cc6c2b89265b7bffbc85950db", "class_name": "RelatedNodeInfo"}}, "text": "As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating. ", "start_char_idx": 28, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9287e502-a19e-462a-aaf2-196c7f400063": {"__data__": {"id_": "9287e502-a19e-462a-aaf2-196c7f400063", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n", "original_text": "And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64a3aa68-4b8a-446d-ad5d-429b930d98c2", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing. ", "original_text": "As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "431fd48c5360c3843082fc400befb36d36aad64b5a059a3677710f26b1cfd04b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b852de42-13c5-49fc-b62b-bf34adbeaa1b", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you. ", "original_text": "And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out. "}, "hash": "8579da6402d6536b6415004a108208fa615936b459ff7063eff45033a35b58f3", "class_name": "RelatedNodeInfo"}}, "text": "And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n", "start_char_idx": 318, "end_char_idx": 528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b852de42-13c5-49fc-b62b-bf34adbeaa1b": {"__data__": {"id_": "b852de42-13c5-49fc-b62b-bf34adbeaa1b", "embedding": null, "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you. ", "original_text": "And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9287e502-a19e-462a-aaf2-196c7f400063", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n", "original_text": "And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e7a0634a394dfcb214a304799891be1ce6cb4fb2be04a83eb53d29ea119789c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06f714f1-eed8-4137-856c-5a67e25e4a78", "node_type": "1", "metadata": {"window": "As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session. ", "original_text": "And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing. "}, "hash": "32770e92aa13ceaf1e6315885c0afafd10713895d5e79bb236c5ecb6a503f8a2", "class_name": "RelatedNodeInfo"}}, "text": "And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out. ", "start_char_idx": 528, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06f714f1-eed8-4137-856c-5a67e25e4a78": {"__data__": {"id_": "06f714f1-eed8-4137-856c-5a67e25e4a78", "embedding": null, "metadata": {"window": "As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session. ", "original_text": "And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b852de42-13c5-49fc-b62b-bf34adbeaa1b", "node_type": "1", "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you. ", "original_text": "And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba4194083275941249c08dfbe2105667c92c6008f6332892107ebd9109a988e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afb3c28e-6c2a-4eda-a47c-f57d0cf99567", "node_type": "1", "metadata": {"window": "And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks. ", "original_text": "I think that's \nwhere Elizabeth was going.  \n \n"}, "hash": "0fbeddec586c8924d77deace7b94ac3baac8c755a715345e26eba0bacd5fd8c4", "class_name": "RelatedNodeInfo"}}, "text": "And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing. ", "start_char_idx": 789, "end_char_idx": 910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afb3c28e-6c2a-4eda-a47c-f57d0cf99567": {"__data__": {"id_": "afb3c28e-6c2a-4eda-a47c-f57d0cf99567", "embedding": null, "metadata": {"window": "And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks. ", "original_text": "I think that's \nwhere Elizabeth was going.  \n \n", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06f714f1-eed8-4137-856c-5a67e25e4a78", "node_type": "1", "metadata": {"window": "As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session. ", "original_text": "And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a971cef2c9c155008fd117dd9809b6ee1c90bb325356ca1cbb84c19e308e048", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d408aaab-b50d-495f-a590-c0fa0cb9c935", "node_type": "1", "metadata": {"window": "And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n", "original_text": "Operator:  Thank you. "}, "hash": "1ca8663b09d11912b48fcb5f031eea31033bf1b84913226196da15f73703e855", "class_name": "RelatedNodeInfo"}}, "text": "I think that's \nwhere Elizabeth was going.  \n \n", "start_char_idx": 910, "end_char_idx": 957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d408aaab-b50d-495f-a590-c0fa0cb9c935": {"__data__": {"id_": "d408aaab-b50d-495f-a590-c0fa0cb9c935", "embedding": null, "metadata": {"window": "And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n", "original_text": "Operator:  Thank you. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afb3c28e-6c2a-4eda-a47c-f57d0cf99567", "node_type": "1", "metadata": {"window": "And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks. ", "original_text": "I think that's \nwhere Elizabeth was going.  \n \n", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62749a5b6fe54c5458bda30eac6d41d97f28c86c79bbd7d8b154ac778fce5676", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1cd5011-2c55-4ef7-9652-14e650f7f589", "node_type": "1", "metadata": {"window": "And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.  ", "original_text": "With this, we conclude today's question and answer session. "}, "hash": "687c72de012642692015cda8a265ad350b43eef312c3b673151e80428ef575dd", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you. ", "start_char_idx": 957, "end_char_idx": 979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1cd5011-2c55-4ef7-9652-14e650f7f589": {"__data__": {"id_": "e1cd5011-2c55-4ef7-9652-14e650f7f589", "embedding": null, "metadata": {"window": "And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.  ", "original_text": "With this, we conclude today's question and answer session. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d408aaab-b50d-495f-a590-c0fa0cb9c935", "node_type": "1", "metadata": {"window": "And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out.  And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n", "original_text": "Operator:  Thank you. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "880f62262dea5452a2f211d3466f3e35dd194160db097160912b6a1c2e7b2332", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06323d27-3ae8-4e2b-837a-e904558265ab", "node_type": "1", "metadata": {"window": "I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year . ", "original_text": "And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks. "}, "hash": "9716878311d959b2f15ac29294e51b86f4d25b1872a881141ed03f31b2cd7b3d", "class_name": "RelatedNodeInfo"}}, "text": "With this, we conclude today's question and answer session. ", "start_char_idx": 979, "end_char_idx": 1039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06323d27-3ae8-4e2b-837a-e904558265ab": {"__data__": {"id_": "06323d27-3ae8-4e2b-837a-e904558265ab", "embedding": null, "metadata": {"window": "I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year . ", "original_text": "And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1cd5011-2c55-4ef7-9652-14e650f7f589", "node_type": "1", "metadata": {"window": "And then  to also consider further \nopportunistic share of purchase in due time as we assess how the year is performing.  I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.  ", "original_text": "With this, we conclude today's question and answer session. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7bde7d79df56d43c9e3963a827e4c7c0cc06753e37d63fb354171dd2ccfabb68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecba36fc-4483-4cc3-99b3-c4348d20c1d7", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter . ", "original_text": "Over to you, sir.  \n \n"}, "hash": "3097f84ec696d70c14d34176cdad9c1106506d65dff8bcf00f95d35119a566bc", "class_name": "RelatedNodeInfo"}}, "text": "And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks. ", "start_char_idx": 1039, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecba36fc-4483-4cc3-99b3-c4348d20c1d7": {"__data__": {"id_": "ecba36fc-4483-4cc3-99b3-c4348d20c1d7", "embedding": null, "metadata": {"window": "Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter . ", "original_text": "Over to you, sir.  \n \n", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06323d27-3ae8-4e2b-837a-e904558265ab", "node_type": "1", "metadata": {"window": "I think that's \nwhere Elizabeth was going.  \n \n Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year . ", "original_text": "And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41d225549055b17fd0c6456349ab96a4f3d82fb5a224772cdb42fd840724bf55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cba35f2-266b-4494-9214-f087d593161b", "node_type": "1", "metadata": {"window": "With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year. ", "original_text": "Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.  "}, "hash": "331b48cfeab431631fc098926613303e7e3cda9ee2f2f47e4c36c3070a7aba7d", "class_name": "RelatedNodeInfo"}}, "text": "Over to you, sir.  \n \n", "start_char_idx": 1140, "end_char_idx": 1162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cba35f2-266b-4494-9214-f087d593161b": {"__data__": {"id_": "7cba35f2-266b-4494-9214-f087d593161b", "embedding": null, "metadata": {"window": "With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year. ", "original_text": "Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.  ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecba36fc-4483-4cc3-99b3-c4348d20c1d7", "node_type": "1", "metadata": {"window": "Operator:  Thank you.  With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter . ", "original_text": "Over to you, sir.  \n \n", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c3d076b9d2368327c5c32fa00351b8c258fc754d8fc1cc69a2dc72d3cb590e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e024f7e-1029-4a2b-b09a-24363507a2b0", "node_type": "1", "metadata": {"window": "And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n", "original_text": "As we said a few times, it  was \na great start to the year . "}, "hash": "2b1269dcea3ce22d849071a6494ae821e57f4039211e17a78abb9df5de32eec3", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.  ", "start_char_idx": 1162, "end_char_idx": 1238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e024f7e-1029-4a2b-b09a-24363507a2b0": {"__data__": {"id_": "4e024f7e-1029-4a2b-b09a-24363507a2b0", "embedding": null, "metadata": {"window": "And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n", "original_text": "As we said a few times, it  was \na great start to the year . ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cba35f2-266b-4494-9214-f087d593161b", "node_type": "1", "metadata": {"window": "With this, we conclude today's question and answer session.  And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year. ", "original_text": "Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.  ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e991ef498ec018835016a43b08d609c9d3fecb62c29fd2d02c1e46efd3323c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a74870ff-05ce-45e8-8033-1cf859781911", "node_type": "1", "metadata": {"window": "Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you. ", "original_text": "We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter . "}, "hash": "d21b79ce592a54411137120e4ec2cc09236fd5e2c9e1584687f0a9d1b206e446", "class_name": "RelatedNodeInfo"}}, "text": "As we said a few times, it  was \na great start to the year . ", "start_char_idx": 1238, "end_char_idx": 1299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a74870ff-05ce-45e8-8033-1cf859781911": {"__data__": {"id_": "a74870ff-05ce-45e8-8033-1cf859781911", "embedding": null, "metadata": {"window": "Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you. ", "original_text": "We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter . ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e024f7e-1029-4a2b-b09a-24363507a2b0", "node_type": "1", "metadata": {"window": "And now I'd like \nto hand the call back over to Jason Holl ar for any additional or closing remarks.  Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n", "original_text": "As we said a few times, it  was \na great start to the year . ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c053954c899fc1dce94c40c58916b5c1912d67c8c72642e9f392172697770ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17441337-d7f6-412a-882c-3b675b9e43a7", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call. ", "original_text": "We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year. "}, "hash": "e82e56d9e232e211eca80efa245e2286aa3c85149f07bcbd7884f6a5917cc149", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter . ", "start_char_idx": 1299, "end_char_idx": 1440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17441337-d7f6-412a-882c-3b675b9e43a7": {"__data__": {"id_": "17441337-d7f6-412a-882c-3b675b9e43a7", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call. ", "original_text": "We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a74870ff-05ce-45e8-8033-1cf859781911", "node_type": "1", "metadata": {"window": "Over to you, sir.  \n \n Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you. ", "original_text": "We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter . ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c1b20ef0583bb71342af7748963c2caee438e0be1b952c24ad0802c8f03f298", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "950fa927-f93d-4793-9972-08c99a3fa4a4", "node_type": "1", "metadata": {"window": "As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation. ", "original_text": "And w ith that, thank you and \nhave a great day.  \n \n"}, "hash": "e63bfddc58c2b525c789194f37cb1d90a0303058caf06563afb0398b3e9b1db5", "class_name": "RelatedNodeInfo"}}, "text": "We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year. ", "start_char_idx": 1440, "end_char_idx": 1553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "950fa927-f93d-4793-9972-08c99a3fa4a4": {"__data__": {"id_": "950fa927-f93d-4793-9972-08c99a3fa4a4", "embedding": null, "metadata": {"window": "As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation. ", "original_text": "And w ith that, thank you and \nhave a great day.  \n \n", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17441337-d7f6-412a-882c-3b675b9e43a7", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, t hanks again  everyone  for joining us this morning.   As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call. ", "original_text": "We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40e8855b5f26a0beeaabf40f174b4ecaf1eeed88a67dd2f919b873635573aeb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31f313ba-1782-4f2d-8689-5c97af2e0781", "node_type": "1", "metadata": {"window": "We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "Operator: Thank you. "}, "hash": "3270209a7d38324eae418f6ee89c98fd2a90ecd70a7d3e4e9ad4b6528fc4d30e", "class_name": "RelatedNodeInfo"}}, "text": "And w ith that, thank you and \nhave a great day.  \n \n", "start_char_idx": 1553, "end_char_idx": 1606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31f313ba-1782-4f2d-8689-5c97af2e0781": {"__data__": {"id_": "31f313ba-1782-4f2d-8689-5c97af2e0781", "embedding": null, "metadata": {"window": "We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "Operator: Thank you. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "950fa927-f93d-4793-9972-08c99a3fa4a4", "node_type": "1", "metadata": {"window": "As we said a few times, it  was \na great start to the year .  We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation. ", "original_text": "And w ith that, thank you and \nhave a great day.  \n \n", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbc3bb87460a4b914fc509004f5c952f2cab16ce77aebb8cac8260b87876e7da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a42881f-6057-48cc-9b81-e60cda732d61", "node_type": "1", "metadata": {"window": "We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "This concludes today's conference call. "}, "hash": "10e2dfffe6ca890f7f831252f5b95ca808847063a174f241bc5b0b6a34732960", "class_name": "RelatedNodeInfo"}}, "text": "Operator: Thank you. ", "start_char_idx": 1606, "end_char_idx": 1627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a42881f-6057-48cc-9b81-e60cda732d61": {"__data__": {"id_": "2a42881f-6057-48cc-9b81-e60cda732d61", "embedding": null, "metadata": {"window": "We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "This concludes today's conference call. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31f313ba-1782-4f2d-8689-5c97af2e0781", "node_type": "1", "metadata": {"window": "We\u2019re pleased with our broad -based performance and to be in the position \nwe are today to raise our guidance after just the first quarter .  We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "Operator: Thank you. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ffacf8dd8a799adb97450002ed857802fd92aead5b8fd37c81b0c99dbed2829f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe903f66-e7cf-4aff-9eb3-c1adb5b39d1d", "node_type": "1", "metadata": {"window": "And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "Thank you for your participation. "}, "hash": "0ed2dbf4e7682ea82ab8241016d1c89f54847549ac5be442923668990c3245f3", "class_name": "RelatedNodeInfo"}}, "text": "This concludes today's conference call. ", "start_char_idx": 1627, "end_char_idx": 1667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe903f66-e7cf-4aff-9eb3-c1adb5b39d1d": {"__data__": {"id_": "fe903f66-e7cf-4aff-9eb3-c1adb5b39d1d", "embedding": null, "metadata": {"window": "And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "Thank you for your participation. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a42881f-6057-48cc-9b81-e60cda732d61", "node_type": "1", "metadata": {"window": "We look forward to certainly continuing \nto update you on our progress against these  plans throughout the year.  And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "This concludes today's conference call. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7231a5f0ad48dbfc643a8bfeddb6d643d3fc50ee09632dab3d98f464f00d6a81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57619ab6-002c-4dca-b2d7-81cdd3066fb6", "node_type": "1", "metadata": {"window": "Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "Ladies \nand gentlemen, you may now disconnect.  "}, "hash": "6f4277dcb9600f2f102f52510c74598bc6874e727465caa4aea89f7f67e9d021", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your participation. ", "start_char_idx": 1667, "end_char_idx": 1701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57619ab6-002c-4dca-b2d7-81cdd3066fb6": {"__data__": {"id_": "57619ab6-002c-4dca-b2d7-81cdd3066fb6", "embedding": null, "metadata": {"window": "Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "Ladies \nand gentlemen, you may now disconnect.  ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08430c94350405ad5b7b61eefc79bdeb49499c54c4c9d605a21d9c2f14376455", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe903f66-e7cf-4aff-9eb3-c1adb5b39d1d", "node_type": "1", "metadata": {"window": "And w ith that, thank you and \nhave a great day.  \n \n Operator: Thank you.  This concludes today's conference call.  Thank you for your participation.  Ladies \nand gentlemen, you may now disconnect.  ", "original_text": "Thank you for your participation. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e48f56f09d2c0f646be425fc3c1cb5af06ce09a5c578aea927646d34d016149", "class_name": "RelatedNodeInfo"}}, "text": "Ladies \nand gentlemen, you may now disconnect.  ", "start_char_idx": 1701, "end_char_idx": 1749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"2f3848ba-87c2-4cf3-bec3-a58ce48756f5": {"doc_hash": "4630dd88447c295317fa30a062a00f33b0e62c599b6b8db5bbdda5406a3c4628", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "5f1611e9-b0b7-497d-8587-38b687e4c16f": {"doc_hash": "9ddce99cb6e84941c5a8680018f2f0958945b1f21cc360d5836bbdf1e9d3e91f", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "dcffea4e-3a3b-4f13-bb07-fea3d5fa5cca": {"doc_hash": "39120f9355f9ce77a74d56af0b55e9622560ff45ff801ab7fbd4a4e947040e51", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "bcd385bf-05b9-4530-97b3-d4e9653e412a": {"doc_hash": "b4f614ce7f1c50fae351da097ebec814fd820002bcbda2f4aeb35f43436b50bd", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "707073c4-694c-4cc2-8c16-e702670bd52d": {"doc_hash": "e875536974ce980340f52fe5a071b64c70821289a6e851e1321a883024d60eee", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "b2cab5b5-45c2-4a2a-80bb-8b66827cf027": {"doc_hash": "6219e4c27c806ea20bacc5ede148fc9d7979b70090e825ddddef8a994d04c070", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "64b09bd3-f490-4575-b265-80123928d632": {"doc_hash": "66a27f8d4b0368c5928db3485b02151c31412df4d722a3a79b5cff2c5f236590", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "0d10be3c-6c31-4230-a2fe-ab5abee3e967": {"doc_hash": "08b9eef2d9f7fc5616591b1ed9a12d413e8b8360b111bd385d11de6e09ec4092", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "d8e176be-be9e-4371-8ac4-98e42bb5c85b": {"doc_hash": "e60314fcbf8cc87b78fda506c3565958425971b6d1f716cc6b24579ca1cdc358", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "e4eb8b3f-c0b9-4e3d-92f7-d6b455e163ed": {"doc_hash": "c9977dfd7d8dfb184af388e84bc91ecbb62cd6516e38fbd7b1052f6a3a027a37", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "a66c1c2b-18c7-4204-a865-9f801a233763": {"doc_hash": "d699919832b6c6b11a9273a5fda3687859f97ca06371fa1bd4f4d571c8f17fd4", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "4d325935-288b-447a-a567-ceee3243fc3f": {"doc_hash": "55f18f830571aaac35ceaae29b7f0fe3197194ae0baa6ffb0121f9208dbe72be", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "430136dc-7592-45d5-a5f1-81a32baacf4d": {"doc_hash": "b6ce05e43de3c830c59d86808751cf0a72d0e2bb90f393e2e078e5f534abc016", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "c49c955a-a7b2-4393-bc2d-f40dbc9d1ae3": {"doc_hash": "00d7ee267f96ca3682a09187c750e563240a549fc21d89fc568ac855bc26ac71", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "da683bb3-78ba-47b5-8b40-1544be9a80ce": {"doc_hash": "061d4cea6c6fda33e2fa9e8b5cd8866a9b99f26a53767a16e7640b8cbdee9e46", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "a784b4ff-917a-4ae3-8082-99a3a57f2796": {"doc_hash": "80de391e48e7038783da1785d22a622a65db9640058771f5bf0b0e066ea4b445", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "2a5ef303-ead0-43cf-aa73-ff98de7b4037": {"doc_hash": "5a4cf2f145234e8501ed13f36cfbbd93fb3ccdd5832d86b5de4f69d2a4dc9a4b", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "22e5a2e8-7bf2-4d8b-b533-c775a503f4d4": {"doc_hash": "275011c519c03c42242972afaad3dab00447b83028fecb9f467bcf0070ca88cb", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "559c2658-489e-4c95-afe6-3916de83fd21": {"doc_hash": "510faa5fab0ba39077671574a9fcedc01e118357ccba8123c7e429b15d6d064c", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "104b78be-f357-4138-be65-cb60299cfe2f": {"doc_hash": "552efa1fdb6680758ae101c51380ec688fda4bee8989194db5ef50cc04630d5c", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "11bbd84b-e055-4fe8-84c3-bfc3cbd74662": {"doc_hash": "5b020da6e589b55447a4ef8e615807bc707580166ca165781847c020d7149f22", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "c06ed333-1d18-4899-99a6-66d71c16abba": {"doc_hash": "0b2c73294ebd3b241a3adaa5e211e1c1e2206ebffdb9f302175d18ce9bf0bcdf", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "cd899c7d-260c-4210-a106-ff77e937ebd9": {"doc_hash": "d25ee6f5487eb06c82c7ed6dd0ef4c6e5e6ea1da49503393c6e496859a6f241c", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "b65047a4-bc49-43e7-9795-cc23108d2a41": {"doc_hash": "f025746029f795ede475fc1599e6940fca4d5c0538da5f49349161bf0455948f", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "3f272b30-e7ce-4a88-ba29-c0136d061553": {"doc_hash": "98e3041dd24b5043c2b5d607b188e99c6958a07e8a348b121e3a24c9a21fd193", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "dfe36bbf-fdcb-4553-83d9-89ce516ca686": {"doc_hash": "10545cb0e513bf4dd39e2bed7bae87988073a6a73a045b756c6c0991ed925652", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "d0241e82-2271-462e-a7c9-01a7fb1f0c19": {"doc_hash": "c086f01d04f6ee9fd5b3646f3b84e0125eda7e4df6dce2654f10416f07c80385", "ref_doc_id": "babee6b7-56fc-4416-b788-8fe24ee564b8"}, "2eff0640-d37d-49b7-a034-eeb3d178da57": {"doc_hash": "1583086b02890933d19f53a5f9cfbb42c4768668c1b4085e914f737ba5fabf18", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "91ac8485-2a92-49bf-8598-d42ae10ec432": {"doc_hash": "e764024645ea85d4d5f604a8d8286d51b2fe0177405caadcdb5e1b623b911d08", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "c024bbe4-4675-4a63-98e3-669c3dc47be2": {"doc_hash": "0de6a1e9a9432d5e9bd14d2f2527acc0927eddff7851ed7a3dde532f1814930f", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "cea8529f-202c-46f8-bdb0-e672303070c2": {"doc_hash": "febfbf79fcb28c8177230111dce747cf5aa2925ade86a27d01cce6c6d5558337", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "6e7ba431-2d7d-4216-986f-d31e30346df6": {"doc_hash": "b744d1f9d4c0d599c97402f6454b25da1368574d25e342531480e7cad1ca4944", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "b7491cae-aa47-4636-991a-33b51848fabf": {"doc_hash": "ba917821df9fd1d6032c4eb5b59c2d9f72a8ed03f14f321ff5e0b21db624227e", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "bd42a543-3b7a-4f29-bf14-4650a67d49c4": {"doc_hash": "28d1fb35d17140b21adada2fd0eedd4372110d93d9c917afdb23a568a3d5f000", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "6fe2dba7-3027-4559-a434-dff0bcd53a7f": {"doc_hash": "db0c75e1b9bf85919314855e6c36ff38dd24695c2d0a53dc2bad6b0f3650325c", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "802c7326-d786-4cc8-9a29-cf8f7bb19911": {"doc_hash": "2f3d4424dcdd379d3eda21dab6a73f221cc578bd2067949ca0688bec3a413ab4", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "b39de5ee-4909-4fce-aa50-04b3a9c26994": {"doc_hash": "7f062d2461635c8f8fba737b4a6d24d75cba9d685033fa7f54ce2d2acf61ac42", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "5abd2e9b-ee5f-410c-b843-dd2b0a894008": {"doc_hash": "8222c1e71778d5fad069987f25016787c2e1d7a037188321c71410ba759775ad", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "fc7085a0-9f01-4206-9d9e-14c64c058b41": {"doc_hash": "6f3dde836b20cfd7e52fe78ea4bc9dd7e5cde215c448c43bfb859781ce94a794", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "5462e242-7fcb-4df3-8309-918001d368c2": {"doc_hash": "681fc5e018b4b996759a725ef4a24e2676501f53aec8447ca022c0c9a27ac2d1", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "f6753711-5613-41de-9cea-4cfe8bf5967d": {"doc_hash": "661ef59811cb300e08f9336b9e6d7b9f3486180975150c229762670d6980f40c", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "17d8a14c-0d72-4db4-b987-3b8132ffa3bd": {"doc_hash": "bd7f073f812b878893477eef2c883ef88529700053dd46d69c8b38bb421e9b04", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "3f56653e-2858-4236-82ec-2e19c33f073e": {"doc_hash": "11994d335fe03e6e3b7eaaa51ed35198134025d0072a854b7a797ed75990f545", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "a110531d-5719-4ae5-b2f7-eb21980eb3d0": {"doc_hash": "7e4f74dd67f35c98c1652389afe0e3386c7b6d138c1a26e5eae45b695b373e09", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "97a72503-efee-4ce0-8428-ac7b3b90aedb": {"doc_hash": "1baad2d5682ea37e39a5bebdd83298e02bd2f6ca871f126c327aa64b81d057b7", "ref_doc_id": "d4643389-38cf-4b2f-a529-2f3c5812eb28"}, "e501a3dc-97b6-4017-84bb-0a1fabf685a0": {"doc_hash": "c21046bee6d55ac73db79b1dea53ff2385888a3707e5985d8c16bbb6b809fff7", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "fcb059ba-3d8f-4b8b-b810-2f205f0e5f28": {"doc_hash": "e449d8eec4aab059066acc47d058a6203d690e7e668bbe7395be1382ca71b4eb", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "0cc45b94-9872-4294-9364-ade1929264d7": {"doc_hash": "78bbecf491c4706f502c07ee5aee7facd32841cd49a4a35dfa835fbd1b781d1d", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "057eea99-543a-457a-8d89-d2ba1288d020": {"doc_hash": "2fb6b562326e6ecf26a1d2bf8a51e922ec345b5ce5abb9cc686ecf47f42b1275", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "6b94e48c-0e4a-43d7-b695-9b2430f064c4": {"doc_hash": "dc0104155218a27f55ba0167df554a41095c7ec2edc72cc9e669388934270fce", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "2188e672-3a2e-4767-b0a0-d2c46018894d": {"doc_hash": "666c3aaecd1ba9a9e3f4d4dbb15406b9692401c81af0177eae590a756acaef99", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "829b4a27-8e83-45dc-bcda-92995da0b123": {"doc_hash": "6171e2a4c1a96d6539cb817c109e2d0c6e18b577e25d90b456c249795c249955", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "b9921e69-0254-49d4-80f0-2779626411de": {"doc_hash": "90e504b5365f3b90b3e85d139104b6988e94ec5cb8c214fd7f05f46d5cd3a52d", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "928b4b7e-8e46-4f00-b80f-0560ed8d6117": {"doc_hash": "702a3a77d320b85439448b478f6023507dbb29626a37ce380b26e87afcb1d11b", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "5687b4e6-690b-476f-b452-b69f91744a49": {"doc_hash": "3576fbde6a67a64104acdb94d6485f800f94ad0362f9adfa92cd9733bb481cd9", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "4c0c84f3-fc7a-4e05-b0e2-5717e9136abc": {"doc_hash": "342eccada66bb2da6716c1b7e4052ed5856400e4f9a95bf63e5a4b6a07f16d96", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "db9d432f-eedd-4f9b-87cd-9dd4f2c74b32": {"doc_hash": "e33e667c47541bbf5aed64a7c7b72ad42ece28765969b9cee45f8eae11c75864", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "4dcb295d-29cb-4592-8eba-455f2466d333": {"doc_hash": "4324f3641cc68a9d2af15bb81e195febcbe31a049be14a4110aada9aa05b8ff1", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "205c1063-0549-4925-bd35-77f196dfb391": {"doc_hash": "7d68d5ae048e9b12fbdc44b8a207b3e8e3a92dc0b570a5773c95b3d2dcaf7e24", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "32a7a169-1e47-4874-89a1-96bbecfd49ef": {"doc_hash": "e2a53b46d4a4393529901cc3577fe3e723f4aac97b110833079a3cbbf6429201", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "c5987a61-8d3d-4af7-87d3-5c573e3a85de": {"doc_hash": "0522b86e25454b0697c930263e0f5b22c1f05383e4b321b9d708c5589d13f42b", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "919ecf47-b3f3-4017-b13c-1243f4b7e148": {"doc_hash": "4d566c5e2fd3bdee5df2324822feacd31ef872a5fc2fe835e41ff5cf2409d9ed", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "4a872749-9e06-46ee-bbb5-701df2fceab0": {"doc_hash": "21f66bb218afefc2262c248280649e1931326bd7b5ab4593fa8f541f571bec2d", "ref_doc_id": "5b9a20ff-5a2b-4338-adda-f070b3e8f645"}, "55f51ea6-54d3-4d49-9a53-d678083ddec5": {"doc_hash": "c91b4315bf7d60e83d0d5726f723be6a745f4cb20f8a9c4b3141316cd0c4bcc6", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "77fbd534-60f5-45d2-ac10-cda069dc5c64": {"doc_hash": "6bc68f2ef86b564db761819d1bbac289e1050e56d36140c1ca138b390835163f", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "5a4ac9a1-683a-4339-882c-e44e8185e831": {"doc_hash": "0a926846f1d5da950230b04996ae77e4923991b4764dcedea9465c8a732c9efd", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "874cac7f-2c4b-41c2-bef6-18eb519119d8": {"doc_hash": "50ace052b03ccd7eed1239943c245d2af664e267f7a200d8207d63a8e2923319", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "5ae05320-5489-4436-b35e-e8bff9486dd5": {"doc_hash": "7adca0d1e4c4c7e4492235ecc04297e1702f49be9c403d09b50d131e3027cf38", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "e07d468c-235b-4496-9170-fa9665351dd5": {"doc_hash": "e6926731fa73e35eb95bab81b6e9a12d9116a9100d127d0c790ea331fd3f4b33", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "17c8732f-eb80-4700-98db-df9248430876": {"doc_hash": "6d3743a5da5c492de7605de02855da9b5bd8fb4e9f4b4f9a9aa0b8ddd075047c", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "1bf0fae0-0b22-4291-854e-a94a8da484b3": {"doc_hash": "1163f4703eb26c21d37e49dc921e58597fc1477b0a5f19b0649af83230ef4d9d", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "5f88f2da-8b9b-42d0-bdd6-c417b303449b": {"doc_hash": "fae16f8f616e7249ac456681f883dc5b680665b33f01703712497ba3911e47c0", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "6f27c981-74b0-42a6-a24c-65957aa1ab22": {"doc_hash": "d409429fecf7ae65ac20e936f8a286c04ac7f8bcea591d80c2d1d500e3330fb3", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "fc4febb9-7397-42ef-bd13-d9d3e6d80442": {"doc_hash": "b1d55eaf17c2e695a817a80497c7e4234f1b9fadecc4f1a1d65dc8d71e81b2ff", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "703cc76a-f348-4b59-acac-befb17fa8751": {"doc_hash": "68134093d897fa80439d7253cb7ef7e61c73d9c1da57d2ff8c04166c359debe5", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "07a05c2b-abc2-4435-b3fb-fd7edc4f4388": {"doc_hash": "6d1381c034bdc49de968168244ac2c5d4d689146f852d8f871b2a10394a94087", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "af05461d-b1c8-411b-bd76-a49c360dbdbc": {"doc_hash": "d98f49d6d4152d2ce8e74afa4ff66c24f32f8ea2fe159f6910983d36518db991", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "f4b893b8-b5aa-4c30-aebe-9bc005703481": {"doc_hash": "d778bfee3c1704f85c046de8ce467526d61b8bd343850b5b1ecd3684b1570a3d", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "e3dec6d5-e9ee-4dfc-8557-2dca7ec3ad19": {"doc_hash": "594a354ddf5776f806cac0c8c34eb09104de037171cda96f6c7648514bea9db9", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "fb82fb8f-1ec7-45c7-9570-ae0bc7968cad": {"doc_hash": "a6f4faf085ff83dc4700b7820d9823deee1e57e290a7fa5f662d74ebb91ec3ab", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "6bb13edc-7714-466d-b454-3988e2f8e6c7": {"doc_hash": "ad4ef9b5ae6de37362e71c409b5eec5eb13602d5716a39ad27d816d6e3795176", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "229c7720-91f7-4d1b-a030-c5fdc6865767": {"doc_hash": "0a25cb15abbfdfbf9bad1b86a68d3b658a06d350d3eeb71c9bc04282ff210939", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "28c868cf-96b6-44a7-a548-ea2ee14f7b93": {"doc_hash": "8070e4c6f13a7b5cfb96e4cdeeebc0cbe26ea2e73ccbd678fc14c279a5978c54", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "7f15a560-06f7-440d-9af5-4879293c57ec": {"doc_hash": "41352204fb52e6651ea43e6f663f2de8c2a155bdc419aa7d7643ad392f142298", "ref_doc_id": "21f040d2-eb1c-4e95-a858-ee913e6d5f56"}, "63de44cc-ebb5-4ed3-99f8-4f73cee2f0ee": {"doc_hash": "93ec584aee6faafd51de815459a0f90b25c60faa44459198cd218886ee204aa2", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "37971da2-8838-4c6e-9742-40d468b42c34": {"doc_hash": "99e1d4b01200e5bcc0ce35cbe47292f8128bb98655cc4aefbd9b0dd1fd6294d9", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "6ac4250a-30e8-4e90-94ef-2e7e86cfc5f7": {"doc_hash": "12dbdda09948bfb3dc1abc201b9323332f7afc3ff71fde2ee92f4778a8479e17", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "b4ecdd8e-b7d5-4032-b8eb-71eb91c60c82": {"doc_hash": "28e7b2a40853db4ca4c8a1c6db7bffb43309c712a8149f8e32f4b7d250b1b0bf", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "dead4661-a24d-4345-9a77-1ffcde33f512": {"doc_hash": "beb7775ec50d3cfdebf334a1f5000b27b06bf80a759631085a2c6c4e7b36441c", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "35f6a5ff-398a-49c9-8535-6083d62d66e5": {"doc_hash": "d19862b9500e690c4f64e8c56f55d51139b636a12c0d40763da687d210c353df", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "670c18d8-1d5c-4140-8369-3753da40c908": {"doc_hash": "f2ed25301a0db1ae152fd3c5c552fde75a952ae0b6a52536af34f5ac3b8e8c3f", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "403d8ee1-980b-4732-b14e-18ccb77c7dec": {"doc_hash": "a13fe78f046362665824f75acc4af67165e69088a387ccee0d6ad15c3918275c", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "eb89fbe7-4b93-483f-9b36-1f1bf358a509": {"doc_hash": "340970a69d95b4485bd1f3fb731ef9112f517f5cd653dea9faa1c491cf81d9be", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "506f6454-72e4-45c3-8e81-59009d0ae286": {"doc_hash": "2dff489dd15d731bba76b7c256eb400d1913b67dc746c6a8b89da185655649b1", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "4b07b5ae-c82e-4091-914a-cd3171b6636c": {"doc_hash": "a8f5ecd02be91ac671647378046e950cd1fbc3cdbd589e7a79e602c993ab6c25", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "0f490209-183e-4ae4-80d0-c57ef81aa8d0": {"doc_hash": "ea0c46b58969e678afa52b6ecab2aaf3c14f9a2a526d8173adeacaadd0c75f0a", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "14c74394-8e52-411c-8d4e-2e6bbdf48f63": {"doc_hash": "c4f03a1ebb282ef957a47f12a77b3f0dd4fa9e521a5c7e3d6ed1d741b76406d7", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "54cd75b9-632e-4184-9c8a-cb08dad080c2": {"doc_hash": "fcef4e3a74daab3090c7b71e72615ba86539f2e008cf8eda67bfbd962469e9d9", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "0613dd19-cf56-4ce4-a613-6f664e7ca53e": {"doc_hash": "309e7d31bada4dc8773ad4704957e60f8e3c5319ddc580865a346fcd4f392df5", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "66ddbf86-6c11-4e14-8313-db4f02bb67c2": {"doc_hash": "566c1922719a6f360413bb25faa6e709d8279174c2496ec2a7dd380952300300", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "7ee855b9-d5a9-45ba-a037-cdf945452157": {"doc_hash": "e28046c8f818befc1a37481db68eb175f7efd6cf7e4b432dee5935ad854f2809", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "3a3afda5-e6c8-4011-b7d6-45bd9080c33f": {"doc_hash": "5dd7ffca5482debff1c077035e0160afed12d4bb544a4a05c4c8f1fc8d017f16", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "91100f83-3111-42b8-a325-bc9f0377c6db": {"doc_hash": "58a96f06250cc809faee9ac7b5332561050ccfe1f7af394c80c80e7ef674dc04", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "0957c6d3-3aad-4e92-8add-e82e704aeb45": {"doc_hash": "ab04b75e4feacd5f476d14f863070006b0a55946a55cdb263df05a932a75b64c", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "3f0719b0-e391-46bb-b1ea-49c324d4bc6c": {"doc_hash": "eb0ba6ca69dfcf6be7a2618da29b1b72c8ac0283d847641ebbd9fa20add880b3", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "c6a09db3-8c70-4526-82b4-9e7ca3ac7b87": {"doc_hash": "060bc1fa4f15f7dda23eb730540680d210c33140a4e93df7fa883289cb105ccf", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "03768f15-3584-4a27-8683-30ffc33e7f1c": {"doc_hash": "a5af47dbc4fbd90010f134edbcf313797e67f54eb88498d78701a8d6a63e63ce", "ref_doc_id": "6320064a-bf30-48fd-9ed3-5e691f4bbe49"}, "433df34d-f9a1-41bd-80df-fb076c7f5aa2": {"doc_hash": "964e1deac5912f6507d6506012a4d23b83d8e8be37dfbe36b336b3669508e328", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "259a6bec-f3aa-46cd-aa86-da932892be4a": {"doc_hash": "a7931e10b763314efd6fe3943ce03f9856e49744594594afb42b5d2a7620f1bc", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "ba57c2e0-2acb-48fe-97dd-fe5cc7744d4c": {"doc_hash": "08621c53a87607462fb7f5e4ce43d148ab5e68079140b405284cc6e9a623e4f7", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "b5855f92-07e3-4e75-810a-ef3eb95d66b8": {"doc_hash": "38bab65c2780a22c0a43e3429f696310a83c4f542da1a808b797924b78620933", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "82c0ffa5-c95d-414b-9121-eba592c313e1": {"doc_hash": "49fde1c0ea83aad0c230549cdf72ffcb58f1f299e80b7025fbe65b2339d8420e", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "3d3b84d2-e476-49ac-a95d-5717572cc4c6": {"doc_hash": "d515757d6c470ce81013cbeb38a0252debf33270228761f709cd6acc5a1d7bc0", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "987d0f58-6d97-46c6-959d-25cee92604f9": {"doc_hash": "3e88cb38ec5a700572364f9ebce3163fcebbd77105b99664161c162a0af04cb3", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "d41e161d-399e-4626-9bee-9ea52c48c27f": {"doc_hash": "bcdc4a5c0ed2b4bbe1abfe4b086e3c9e3a252ac25dbe9e20db2439e8dd41d715", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "e80597aa-9e1c-42b9-b5b6-27b3cf8bf1b3": {"doc_hash": "0475392bcf9672267078342ab31c217eafe738843014b912df969fa84eecba49", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "cbaed71a-c55a-4db4-9c02-07f888c0b672": {"doc_hash": "4d0d658ae7ac55a4381e23e16d56b654006ef0547123875ca86c512ae9f5116f", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "7620a6b0-a7d7-43ca-b49f-15efcc5090c4": {"doc_hash": "0b30a34581bf8561777e0fb9039771eb3f7a8e0ff352dd2d59e2bed8c4818f53", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "674a1216-def1-40e3-9178-ddded5dd495f": {"doc_hash": "2eef94c3af0f448310b672aeda3d00670576a8ad836fdd3f8eced724c8ab4157", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "8aed07d5-6f44-44e7-8690-776eca66cf7d": {"doc_hash": "ed4a53d269fb38f91a84b7718a4b80c598aafbfd91c4048c542b7949807d4c17", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "64151535-cae5-4520-9c42-e79335b03085": {"doc_hash": "12a34c5d43c08c8dbe9cb9d8f888ba926739284cfbbedf91b1073be8acb3c349", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "c50ca827-ec1a-4ab0-b260-b409a95d07e2": {"doc_hash": "01c886147f0eb9cd734ac9411874f34d5170f7cf3638533c69cec5aaf987e75e", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "c9f34189-4675-4830-a241-6ff1997997b5": {"doc_hash": "4db918aa4d421ee37a80901b0e98d6d198ebf5e2604433e85ea0799db8355f21", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "12eaa204-30d1-4e69-9809-be8bc8370287": {"doc_hash": "3504cbf2025b9f9f1bcd14fad42768a7439c28af536a5b46fb9a2ba2508ec96c", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "29e9e2bb-296c-401b-b6c5-78eb0cf545dc": {"doc_hash": "d36ef18e78553a9929dbc2bbe1453b6653afebe55c655c1ea0e3ba904ab11195", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "16a532d1-2ae6-4a8f-b415-495d6499eeb4": {"doc_hash": "d0d389e597c1fa0c489d07c6321bbb81fa9ba43ac8191208a06edd6286c20600", "ref_doc_id": "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea"}, "f47c276b-7ed4-4c03-afbd-c44d6f3b3e0f": {"doc_hash": "d4cbfc9736cd05608b6506f7a00498b8568d29628cc5c9b9443c33ef474bbd59", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "c4ccdd39-b07e-47b5-9222-24b76e75193c": {"doc_hash": "22aa9e8879ea3fbdde01180a671ff1aafc30a4ab935d481877ddc1cc97ee5b97", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "b9c26e02-7e37-4a15-879e-df74f7f16213": {"doc_hash": "6e91592ea05e9bf99df55c68b24aacb5daa543b6bac9ae77a4cd3c487f78320c", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "61a74da0-10d0-4a63-936d-a7080e4253fa": {"doc_hash": "0fd409b2b6a763f5ce73dcd8aafbedb9b9e828d28046586272982c9d3236464d", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "97272ba8-52d1-4a30-bc77-68a21cb752fa": {"doc_hash": "aa95ca057619783421b39daab46b69dfc22ed7740a2870f511bbc35263624ecb", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "fca99689-82b0-408d-ae4d-92b11cbe1c2d": {"doc_hash": "2ef3c74d68675283e59e8ed00d4033c8237a17843d3edbf03f12c2273b466236", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "d67b270a-86d5-4dfc-82de-1bdad334b5b9": {"doc_hash": "f2f0e52f0d3190a344c27aa8f68ce8cb756de8c32aecec0408469e3b45a1e1f1", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "b04a9e00-da7a-495a-92dd-9dc1bf5eed75": {"doc_hash": "31390752f39466d40d9faeca4392cb938ccb62d8a03b90e86bcc75be791128a1", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "f6baff83-eeff-481c-a0b0-95941e3762e0": {"doc_hash": "922fdc1e27cba78a689d48d864aefec498478ee2b241032fc94a9791958b3332", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "2585e936-646f-4524-a65d-42f3fb6a5360": {"doc_hash": "0cdae54f35e68dbe8298f34464e803660260cfdae209c073185b4f4d6bd520b8", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "f812cd30-4871-4c56-8fae-d92a39890bd8": {"doc_hash": "f49542b170a12fc768a39975e41a6e282e768aa04701a5157c1f305fb312302b", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "6546a90b-4ac0-4de0-9591-147e3a7ed7dc": {"doc_hash": "a2223ba9bf3d47715b3f4f07296bd5cdc00801a44c800e2174077007e806014f", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "c1ff3de7-a095-40b9-9ab3-8f77734e026e": {"doc_hash": "1df1d1c908d875b6bd0fcfa4ab31922d57c202d8092100065b748a02890d0445", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "10fc315d-854d-44bb-884a-ec26c8945056": {"doc_hash": "2ac733ac77030285fafbc485cf8169c9caf21913ddddd18885efd602ba9a1b9f", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "0261c168-aac4-4881-a5d3-bbd6b030ed3f": {"doc_hash": "14706a2beffe89a06e3634fe73b12cbbb10061c47c43ae4aa94ba3f128532247", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "921d67b3-8555-427e-8532-87c00ccd3139": {"doc_hash": "c248143ad1792631875303708af9adb9bd794a784dca3ec5425ba57f5889f5da", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "0837afd4-266a-46e2-b41b-d2a0a8956c68": {"doc_hash": "5b703aec9dcf6cf73c0b13ddc81f3b963b34995e8e3d0190bb769bb19935fec6", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "2116156e-bcb2-4af8-935f-ae697c652cf6": {"doc_hash": "a8dbc2970b73b0202abf3f8400754add62c6b34a5689e6f32562cdf9b5da2c6d", "ref_doc_id": "33477d9f-24c3-496c-9932-7d3b3369370d"}, "2820eaec-c762-4334-9280-0d5891773c28": {"doc_hash": "3de4de63dabe3b152db21016b474100127a6943b94eb4a3aef2199cf842d0762", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "95df35be-101b-420b-8b33-c231008cd303": {"doc_hash": "a44b8538e8cf01b107cf23d7ae85920e9619381af5a700797176fa54407f8b40", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "66c20b87-fe56-4041-9aef-458a80089c56": {"doc_hash": "e5cfcc6d2a035262f8357f13c79715ae8a8145627f0c7712693254a7da22500e", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "7265d2f4-2732-424b-84ab-186996e39401": {"doc_hash": "0dff0eca7f5ab1dbfb2b41481f22c14e1e8cec774b2c2c08c30d08835bd92cdf", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "e704df97-bc24-457a-9fa9-de3a1074cbb6": {"doc_hash": "b9d0eb2ced92f19e58911e665ca1132dfdfc344a86315cc1abad8bb86dc73b70", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "03e01d84-f932-412d-bfbb-85d5a33cf84c": {"doc_hash": "bf75c07582af4a5847e89e1268cd748fb1069056af42c77682164d8416cb21ae", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "9ede66f6-f888-475b-a0ef-d82c7cf557f9": {"doc_hash": "ed9013f628b7732a0da73a9145fa3e154bcff066e5bc1e183099f95a7d685cdd", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "fcae312b-b09e-487b-b9d0-c8235d8f648a": {"doc_hash": "a8c8c0de4b3028c6fc43b2601b43a4b2e3390a610552f33754cf97c3ec103f87", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "3587cc60-d459-4628-ad59-47f8bf955558": {"doc_hash": "21f57dfb98ba287e5e7ef2c45a35b465eea9e1bee7b2c4455c880d1a93635982", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "d5eefcf5-c930-44cf-8295-c12e221adf7b": {"doc_hash": "f0e676720245a04d828c363da4686de28c8996dc385c499eb3f22d3b974d43db", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "4cddde3a-cbe1-47a4-b606-831a3df043ed": {"doc_hash": "1da3fbc574247d7c5c4ad57c8ed1b4c39e134280b8f585f54144370e0ce928cd", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "50e8ad10-e52b-4093-a275-a3f6e4ff7445": {"doc_hash": "40dc8a560403b0be1e0cf6d22c694c39949e833fc7aec220845a296b2a36322d", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "cbd82db0-e328-4aba-b8cb-b7247b7e4c39": {"doc_hash": "15a7d79778da150e8993328a1a3a08ba49cddcaf0bc7a24322641df8f83adfbb", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "5ecae08a-396c-4732-be4b-f54f58d778ab": {"doc_hash": "b7dd69b6052d285a2c5ff1b995665907083de3f6c7f2840391ec10015e390a4f", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "91b3091e-8172-48d2-9d44-e6a2c01c7cf6": {"doc_hash": "e30d4d2a10bedaac5c707ad152b934ba9c0502e381b92cfc6daa7b30bf83a2c5", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "eb35b404-79ca-4b6d-b3ed-59efb0d36840": {"doc_hash": "7f54d55e7e06839e79c1c3587023d34d43a8d6076d96fc3df484867bb8644eb9", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "66a9d1f8-8b33-4ffa-ae8e-d32312e8a0f6": {"doc_hash": "e3da3a9b86d2abba8a7c7e750af1eab2763e52ac8617780a331bea55aa469877", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "2fcb0ee8-5445-4dbf-931e-76873dbfc399": {"doc_hash": "bdf6b85074456f5c22fa18be27a2985db914ac127e7672572a899ad09b68fd75", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "3e6521b2-2e3e-414d-bd9f-fe4fece21eab": {"doc_hash": "2bc83297fcd0d302133e2b730ffd6b9d22b448a00d855007d13ee88373971f2c", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "3e95b822-6e7e-434b-b60b-1f03a5a3f4a0": {"doc_hash": "5cf45d8c7c20406f6d71791f2019701f2f96e66e520e1abf5bb6217fa13a6a92", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "ff993a18-95aa-45f9-8bc2-cf4e2b14373c": {"doc_hash": "70d85f8b625f5ebb36b1885d5cb139a13a537be14a9231124196b3c95ac3915d", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "b6e0e0d4-337d-41f4-bafa-679b3c5e2847": {"doc_hash": "c6885338e0d6bd4ec50bd0dc4ef0d8a6c81db0cd68c637457bf9b20f03337d59", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "fbfdb949-d191-4ea3-9948-d17856b3cc9b": {"doc_hash": "c66eba775c8b7ba8f232c5bc7cf7ad3c9569d891db71f49888e672d890cf4fe7", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "845f05b8-5180-4277-b73a-1390fed5ec55": {"doc_hash": "96f3a9db8c40ef0807528f13336621909025f2635580da6a3fd77a4629fe0cd0", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "66f41d19-0e04-47c4-8bdb-bb68e581bb7f": {"doc_hash": "61478b12f106ae48116947eb59d0871b4e24288e29cae5d2623f1e2d98a35043", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "23cbf49e-cc9f-4978-9e3e-dfd30cea3bc2": {"doc_hash": "e4559b2ed47c5a127f812223492a1534bd8e92553cdc62560e04444e77cf5a8a", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "88aba52c-0ce1-4d38-8699-d75daf831d5f": {"doc_hash": "2b72b90e1ba40961bacd8d211c47b2af791c5e70cb04ac416cc00fd4b55a209f", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "aeaab8b4-c04c-4ae4-8ca9-4909fdd5ab86": {"doc_hash": "c685c4aa56d80be3ecfaa64407a6276ac6a36bae6e4adf7cbebd5445140ccff3", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "733f079b-d6ae-49e8-bae0-e2870b3c7624": {"doc_hash": "68159282904605ccb27394152db3df34b52d9dbd6f548df5b9634351c9ca084f", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "c2852579-9f63-4a47-abb0-64b0bffba9a4": {"doc_hash": "f44cfb362bdd3c848754e87791660e54381361364bd86358e5c794de550e2dce", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "b444d533-9a36-41f7-902e-354afc854ee9": {"doc_hash": "df32eda07509e0970fcec7f3473f419e554431cf75f35e1cb8200f31c53d5f33", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "1169e367-416d-4bcb-9a0e-ef7392ac2b8d": {"doc_hash": "b0a8da46a02b6cbc5994abf17b4e40dcff94b2d30f43fb84595e94c557cd0071", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "7e54aa47-997d-4b6b-9ea6-67fc06413c95": {"doc_hash": "75ff9943bf955707bffc75beb213906ce869ef021afd3a27e1d288d0b4a0d806", "ref_doc_id": "a67c6fde-3741-4839-b762-38a12ca39ac5"}, "82962c72-87c5-487b-956b-c956734d978c": {"doc_hash": "171f9b27bf86eccd4e8c2ed67dda05e4496f26c6bc3006305585b8301f890432", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "34d28b23-6e5a-4aac-aaed-660f644d746d": {"doc_hash": "65d78ac96026be33672a8d869dddf9440c90d9e3b95ecfc9660ccd2935e1d48c", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "7eb52375-febd-4b5e-8c88-c8015f94b926": {"doc_hash": "e3b4395568cdc86992b70c39e84844e3fba1ac62c97f16ee9b42c5d244489759", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "9d8c2712-6ea4-432e-9e02-b4ec24de6648": {"doc_hash": "128c3153b83d98286663d09751e8670515ee8e598f363061f742084bbb16545b", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "338f6738-7751-48fa-acea-fade553f5375": {"doc_hash": "32ed14e5a09b5d52e7835b1d53371c071775f64ee1a6e1285dc912b63569bf17", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "34ea1318-93fc-4ed3-b306-1eee90bfa3d3": {"doc_hash": "641c8f58ea15ea350ec0696318e4b54fbd5fcf27a1dd0999d654110fda201eca", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "6831192f-ed4e-4331-b978-884ab35ac9e6": {"doc_hash": "33f34396223573595e2d98bc9ad93aa8f53d40e4d63b7b267a5861cd4761f964", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "e7bcf9f7-f3f4-4018-b4dd-d84a015d719f": {"doc_hash": "9466165ac87205831e90fff9801fbd17a8dd310b26cb078bdccc37179ad50dfb", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "f067dcaa-d79f-4e00-9236-c9d76f7cc4cb": {"doc_hash": "74807729c39c13921da80e42c088f72a1d2497b298e15a1cf656102dc0a52f41", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "54769bbb-c65a-4360-9d0a-55b803a567a5": {"doc_hash": "03fca7bbb5d8971f6ab12fcb2defe63036bcb8a4825366beba080f37f2480195", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "d094a9b2-7d3c-433f-89ac-188a39fd4a01": {"doc_hash": "b79646671640c82cba2bf373f006dbaa24eb7c44d7bb97e81010a9e074259f08", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "2cf4d05f-5110-4f2f-bf38-346bda62acf1": {"doc_hash": "3eda06e32f042337398e4b03a9fef257e37c244ffb15bf9694c7047fc90f44b0", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "9ff30789-82c1-4dc7-97d6-155501d8e238": {"doc_hash": "0364d9ea47213f70718b55f473d8c07277793051ea34a70e6af6f472b16a4f89", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "399ab943-3f94-4553-a526-21f726eaf999": {"doc_hash": "d1a75d614cc79bbfe88886957a0832c4d94929fff57c903f785b54d7300f7ab9", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "786d1aeb-ba78-44e4-84be-ec955f414f22": {"doc_hash": "4e5b252a4ed9996127ac5802b5f5024fe811c57a5329727e6f90193e450299be", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "8594854d-94af-4727-bbc0-51d9ce86bfe7": {"doc_hash": "d5a12e4744449776aaba0725a200b468f13b5a4fbd0d810c3d65e32b194f3cae", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "b998be1d-cafb-4629-b671-c67c4904fba0": {"doc_hash": "be6cb339aec88d5ffdaa54406fa39095786b03a90e9b4847c8a2744e273c046c", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "34ac8749-77d2-43e5-8f4c-aa810547cd28": {"doc_hash": "004512a321d9522331f2dd2ed35b048db4d918f5886151069272188655be67e7", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "29d7fd9c-bf37-46c2-abbd-927ad216cf63": {"doc_hash": "0201de25eb66256ad49c7573c3bcdb5efabe5566d04fd8b144b966d7b0b663fc", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "5f5d2eb9-e671-4f94-ad52-244654fb75c2": {"doc_hash": "f0c658730f40e0d38c524bb63cbd886885f921a20510e06707578b5c55f2d1a3", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "75f5be47-1f29-4854-a124-06ec613e30e5": {"doc_hash": "a82501dcc08e853e227f511d1e8279f8351b15ea32d269d6efd729cb63b6689b", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "13e4bcee-a11b-4cad-b3c8-10cac83184a6": {"doc_hash": "e014d451ae49d91a0fc17146b6818815dbf6b5e34060adbd2bd02c044e9a8f7c", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "68977a8d-9c34-4be6-8e1f-bf1c170d24b1": {"doc_hash": "e8ab4d9ab39caa873d7ef0113d0d6ae910fd4e75ec42d7f0a73eba9c0b18a9e0", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "700536e1-780e-4695-a2ef-31c5361d980e": {"doc_hash": "2677476d892c10e0c9233fa66938eb62d2ec3e4f4150675f8e19f75a81de4a51", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "955a1205-e270-4295-9d1b-e8fe4d0924e1": {"doc_hash": "540a9d66309c509c01c18ff0a0f34c45927c8f59387a1140c0ab6de1f002d960", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "2c1496fe-9d87-48ba-998a-14d8afc43552": {"doc_hash": "0ee1225d93024bf49a9dbf47b540acbadcaddbcdc906600fa25ff1eadab54279", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "a53f2be6-0e9a-49df-8f6c-8a7621699b22": {"doc_hash": "4906c238c4e6d1ebb1eeb1dfe4f6077fa2f9b3af96f2fd9f8cd20d5b914b96a4", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "bfaca6fc-83e1-4553-a39a-a0c6e92a80e8": {"doc_hash": "1958d99745e718be1f8755888d7955bca92028c9e03ab225266a2a0509f26be1", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "6f35f29f-f0b5-46f3-99ad-0692359a8a74": {"doc_hash": "0e028000858fd164f8a3dc1d400516dd227a9d9edbccc1c296a8fa8fd765ffd3", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "6c9693a0-3b0a-4534-9347-03899891f5d4": {"doc_hash": "cdaac2ff1fda079808239d7220bf68733de84194bc16e300422235081e7ed126", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "d266477f-00c9-4d45-aa1d-5f051ea2292f": {"doc_hash": "0d8b27d234aa7eefefbbab72d7c0be03ed87a8fcfb507289ab790bb6e276ce1a", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "786d7dd0-4205-4d5a-b5dc-46d50ee08398": {"doc_hash": "6a3fe6ba542a9c90e5f1210c8ecc896c0b0bdbe5eb60693ca6cd18c4a7d2de2e", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "42cf2cae-c216-4c73-9365-c0d004b6136a": {"doc_hash": "33e820c84e5f00aa98a908b3361742948f130c85518a532f892e6267a3e1b1ef", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "6a21edc9-1435-44b8-bb50-5864cf789caf": {"doc_hash": "4633a38222de1a657ec7435374323c00186b7e08ca484b9f7ca929fb9e938adf", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "546146c8-1e78-4cd1-9522-432a75033b6b": {"doc_hash": "18a57ac5e07379369e0718cf1c4dc92963162f6d179ee2a1700f1a04e32d295f", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "58cea524-090a-495c-b890-45504db3aa53": {"doc_hash": "9df17b49e063496514b71c81709daae8383e1aed04fab8de79e78c1f1b95cd5c", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "ec0863b1-4e57-4383-a724-2072c31bc2d3": {"doc_hash": "d5844723e3b22ef2bf0647b65455761bb6fed6891465fb5dd08529eb21c6301a", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "572c6b88-5b64-4d91-8083-a892403f2f15": {"doc_hash": "c432e273db8014845abf5ac99019df2b4050547f2d687cb05564a54d2e0e3bc7", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "08c462fd-c57b-4624-9bab-284c0b0fec77": {"doc_hash": "16d80e2433fc048bf926a8a44163cf8093d9f3201ffa439bb1e1fb19ef9c8678", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "1cfc6bf4-6e4f-4086-bcdc-fbb6c170f19a": {"doc_hash": "894ae239dbe4608380fe57be1f71c6e4bb972436ce800f7235ecd6411af1f766", "ref_doc_id": "b23aaeb4-72c2-462d-8c96-16c55691043d"}, "099e1516-c617-416c-83d2-9eff5649bebb": {"doc_hash": "25bda937d54a651a834135108067b69bdc895602036f5eaec6b74c3be0ca1a07", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "d732acb5-3f08-431b-934c-ae38151bd6f3": {"doc_hash": "8c26ca20cf2f35dd6ec20f90977a13d9de38c4ccaa6e5c2c482ad531b23aaf26", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "328bf653-c03a-499d-8668-fa37a8c00f47": {"doc_hash": "d03a7d88c547a8e1f078ccdd83698af1bcde8312847fc35b7b78b5736130e8fa", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "5f8e3dc3-2599-45d4-924f-94e54b73a616": {"doc_hash": "9c25e3f1ca9e81593ddd253758f02abd67ff872b0a2633a4562af6bdb5b9263c", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "0c12f155-2639-4b88-9b5b-9fee55da5a08": {"doc_hash": "541d8b96c2f3603aa2f87b700e29c398b03c7b379d3d31cd3375ca49873be606", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "e0657404-80e7-4af7-a3d2-fe95e00121fc": {"doc_hash": "6c2ca80e360500a433bb263d22386a3458ad6859092fa6c7a2d4c8ef81ca8d07", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "f00c8034-83f4-4cd3-940e-3ba87d0077f8": {"doc_hash": "804b8b8687619ab9aad6ddf7573c1a83cdba60af133fc497511491aa802429a3", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "29a9d8e6-674c-4bd3-8c83-7eef06d62eb4": {"doc_hash": "3113a783120b479b4432510c5b40fbe37e6634765b17243ea2de6bdf3ec5711d", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "20938a40-e5e4-455b-a092-522001aa31f3": {"doc_hash": "d8c84fb2a79c439c6c551a6692855b359156f665ed319162e378ae67eade7dc7", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "455df7b1-c41e-4c59-bccb-ccb9e5b0c1d3": {"doc_hash": "a44a72ca1647ab49cb6066bc8959d67b5d1618592b128cf2a469ab305ca02c55", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "621e82ff-f64f-402f-bbc4-5cf0858111d4": {"doc_hash": "41a0e44bc1c57e095c2cdd36240c3895638e2d5af47b70febe51b9532e5f722f", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "996ec2e8-034e-4588-83c7-2f69ae19e36c": {"doc_hash": "e4538079098315750a7412da674cb7a8d8ce102b9c33c1f372d862a80b4a1392", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "9cd0122f-db5c-4204-a134-55b3ed6c4bee": {"doc_hash": "0947972dc9e82b799c9cf079de60d2322a5d40683d26a3a89a5e02a267f650cd", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "17a903d3-f986-47f9-8b45-9827881a5318": {"doc_hash": "3b14c24342e60fb231214b35fb81743ff19b5448b82bb74379f324d080393638", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "aadc03bb-7622-47bd-94c1-6d423e812afb": {"doc_hash": "019d848cd416a8278e1e9eb5d59aa4ef784aaba90ab8588bf72ab463def2a316", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "517a627d-3723-4c3b-9b11-7e98b544a423": {"doc_hash": "7e52d918831ac8d257521b8ea5662cad045f57e4989a966ac6b9fb9f600cda85", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "eb9376c6-6ef8-44a4-b073-c516e9c1af51": {"doc_hash": "881ceeeb98fbda4b06304037c8a8dc74615c12872bd77751f77f99eb75645fc6", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "13cc2127-afa5-4a28-bb91-c1fc8662c967": {"doc_hash": "cc1c94c99dd08337a48e9145b538deb44ec5dcb5ff94da17a82a0b004d304b27", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "43af0314-ff41-40ef-82e1-e4dfbc5d6636": {"doc_hash": "e1cd35ce6a7a8636e405c777e4f6ea642bd1985926890f961e7b99cc7fd956c7", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "967041a1-88a5-43fa-813b-f74f7f406860": {"doc_hash": "714558aa20de23d72627a7113c8b4eca315fce693ee65d5e6b53a3780d0a258a", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "68cd16dd-8176-40ee-b355-637e51f592ec": {"doc_hash": "8545661dfce4988faa2034c50a995d2e352f09d5a372789c0628d30f0d16a9cd", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "55b4e255-0a4d-423a-9198-6e8cf860d85c": {"doc_hash": "f730846c61586de8a343dd2e2559d6b9e4ec7685a9f95d3776a2ebb3841117cb", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "39096f86-f478-4e65-86c2-16ca0d246485": {"doc_hash": "e88702ffbacd1c475343aa4e0eaf5c075c635e2d2dc2d6a94a5e59354aedb3fd", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "be150bf5-4bce-4f51-885f-7cbaa5c03e40": {"doc_hash": "fbb9eb4b8793c13d114bb5612b3b26592de0e0da20c9c923c4abe6fad6a7a4cf", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "d9ebef97-2b25-47ad-8a78-0ea7b2d3a3ff": {"doc_hash": "1c877886264b6a0c6d993816972e45149e3311bc48a02cff002b2f6b0cfd7125", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "e0e71c6d-814c-44fa-88d1-5de81367573a": {"doc_hash": "4216430cc925797b4a9f6bee6b98860bb26b7ad0763a8a72b5a8866500bd141a", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "c163d222-795d-4993-a489-e84569312913": {"doc_hash": "0c96b7465edf93d900d689b5491cce136be0770e67f8bd057450ac0cf5fc85ec", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "c0007bd4-df59-47bf-9e4c-2e349b92f941": {"doc_hash": "006901a6a385157ab22cf6c2e8706a256fab456626bc6b5c7703a7158e964010", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "8066bc79-9428-4cb8-9602-150623a53439": {"doc_hash": "6e4c8243445970da3e9e377e22181fcee775207d285a15feb1547c819f915fc6", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "e7a47cf0-a027-4824-93bc-e52985ed983b": {"doc_hash": "fbfbf145a26a2bc198d45e2fe0a94beaa3b741016cd32e70bb04557cfa0d24dc", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "48ea2aae-8278-442e-bea3-c8d524d98f5b": {"doc_hash": "dfa4e11b1da9fb864a41a94af611f341251cd16ada35a06d4face0ce8b297719", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "78732227-8bd4-4ab5-a37f-c829a90ec18d": {"doc_hash": "7fc5ffabc908fb1e055a20fb2f222ab5b868658fc26bcd0002e53fb9e6a09dd7", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "cc58a25a-198c-4cea-b038-8cc60498d973": {"doc_hash": "06944502788d70dd8e115314ec77f1f5c02b40b8bce01d8c6d263780dba3f008", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "8f6e784c-2b85-4f95-828a-f83f20669e5b": {"doc_hash": "1377702f1ba1454c28e0207761284ca332f6e64320ce9cfd558a2959fdf60b29", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "87fbc4bc-c813-42ff-9b49-123eb1abab35": {"doc_hash": "7d16899d9b7935bd5c3eb702a94ffc487ed568b208014b333624b8563e23c46d", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "9a768d03-6136-4c78-bcb2-5d56a1114f44": {"doc_hash": "ee1d680de4cb8e50f224e7b20a9bd95e92fde462fd361f66f8a8894b92c66838", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "a37406fa-57af-4a8a-8336-fb7d776946bd": {"doc_hash": "64f58209b3ef4db8fad5e114c0d9a0607c9292c464bae0c81a3ba3e9f2af31a4", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "2210fdba-1ed3-46d0-bab0-d8113e95248c": {"doc_hash": "b98767f5b52ee4b790b34242bf0a91d75f53d8e5233ab15118b1ab179f51c335", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "4f7ebe58-202a-4399-8019-083272abde1c": {"doc_hash": "95cbb2ae5c02494f63f8a42668f1a5487b840651537ff2c0de29ddabfad82c4a", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "b7181c93-d17b-4610-9d9b-4dcec91e7d63": {"doc_hash": "328c4c10f7f4c39b2660a7c64c7735d52d300e806357761b4983488b1708d734", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "4006e18d-cfa0-44c8-966a-d2d92d25fa27": {"doc_hash": "390d5938f915aad86d57fbe5f48ff531199559480b5972792ad1ceec2038ec63", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "95466834-b589-4cb1-b893-98f8b49f7e5f": {"doc_hash": "0d2d34444fc41e3582fe9d3e5d797991987314ff0d19ae6f4a17d59b8325805f", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "bf81b24e-e5f8-46e0-a073-f17f237c607a": {"doc_hash": "d69e89a9e091a26cb430b415858b67e36351df8ba10200bce90bca5c9524aae1", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "d6bce047-fbb7-4841-ae21-66b689ec6160": {"doc_hash": "31ffe4ba77d667ae5f3ba08da413358ab25558d6db5a303f78ab2036964122b0", "ref_doc_id": "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc"}, "1c939ec5-170a-4676-bbe0-c0bba0ded20a": {"doc_hash": "78eb1aceabbf43df62fe6ff4dff743ec11495a58da086633916f6a1bb129d0a7", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "699003ef-f88f-4618-b07b-ca28343d9d3c": {"doc_hash": "ddf1e7b65220c9dd69e663c7e9115f87f95e67e977318276e204edb7ea6dfc3a", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "cd1c4a9b-6d53-49ee-8a1d-501d0cf393a8": {"doc_hash": "36208dcb7a01c88eaf50b8f59b2c7966033782bd797c806f77f081a7ac89338a", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "ce74601f-674c-42c2-b27d-a1bdf933b726": {"doc_hash": "7eed6298caa3f84c78924fc68ebf2cf5f39c0502638addcecdfda27cd169a16b", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "53a49faf-27ed-46b4-a607-bbc59a1cf487": {"doc_hash": "3f0cf7c7dcf0e697f58ebfb37086d8d96a75a39039bd432bd369b5eea39fc6c2", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "7fdb80c3-d6b5-4b36-93f4-c92de4d63715": {"doc_hash": "868ca7d6f2a82b1cbbd70fc3f072ed22dcf454920defe87f94e5693ba73726b2", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "fc9df0ca-e063-46e6-874a-b85e954ba787": {"doc_hash": "86a58a8ed732c1b633bd38f343df786f1b4fb25d169ecc94bea4dc657ec18fed", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "d43269c2-3149-4737-9d7a-6e6c21aacb7d": {"doc_hash": "ea3b7456c9b32ea615f18803084909beb6372454ea7ede57e67f561bd14df08f", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "fc43e3da-6701-433b-9863-ae01e7d29f63": {"doc_hash": "be7b5bd444da0fa42772caec35d63b142eb0acb702b0a80bf25d8bee935aac6c", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "c055758b-d566-4759-8edd-b8eb195721de": {"doc_hash": "b333701b0a689c53a799066c67687cb2ca8bd27fe028614207245b422ac0fbff", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "be6ee68a-a32f-4091-88ce-4825c02cdf8e": {"doc_hash": "d2bc95ce111a55ab00c0ac780a19c6d1a80bc6c8814ee27b1da49528eda91b70", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "3c47ff9b-dd7b-4d0a-bcf0-3b22647bdafd": {"doc_hash": "d6faf28de5f217a3cb57a39500c5262386ff6c1e59053834b32c25f46a0c7134", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "3321af62-383c-48f4-8fe7-2f328bc06084": {"doc_hash": "da9c08de1e8abab875bfd9008c31db142a0148dad24e786cd0324e5e95a2d120", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "ea11c094-3d47-4057-ab77-5e063e72460d": {"doc_hash": "1d404cf8f76405956ff77a6d8ac769099ea69ba33b6cd706fb3a5ff817b880ca", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "2342e942-9e24-4823-946d-5e80bc419d26": {"doc_hash": "ecc98dad38cfbd18283802fedec7a8380b9222b494f2d0cd46258ddb6c7eed6c", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "11262282-f56f-4ba4-a6ad-70d83638ec96": {"doc_hash": "fdfc1e1f5bb1a4e0132ded26e0721532c21eaa31bb7f79e2144270fde28ee730", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "9f480935-93bb-4cae-8254-7bb8864493ae": {"doc_hash": "6cd1f8372b67d07bb8b1598cbb426cd48e4dffcdda398a9a3e43d41f08ca36de", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "b2e4fc83-2273-41a2-8b62-ba27d2633adb": {"doc_hash": "c92cadc444895531cd0aa38afd3f05d8accdba31a4cd5a3284ae4e9b200062a8", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "9f89556c-9bdb-40be-878f-4724fd884ac7": {"doc_hash": "191b85fc387749803429ac4e396c89455e348c0c6888cb35120a3d90be7e9c58", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "d40b2cf2-6e65-4f61-b6ff-1ed12be7bc59": {"doc_hash": "8d77f9e8035cedfefbf04533d8011ae45df6d94d4feff7d33e800199860ba9c8", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "80a67ed4-e145-4f6b-b342-e457b612ec53": {"doc_hash": "158554ac69e900801472582ea8454747e82e35eb5f265a1912cddcd734bf805f", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "113af8a7-666b-4f51-8948-253c8567d273": {"doc_hash": "ff7e7e42b31365b506a38aa693c40ae8a660d6f880e75a5485964f2e001218d7", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "bd6fd90b-3fc8-47c7-876c-5b9b9384dccb": {"doc_hash": "3590a3a975e878b323bba48da50434d30f2744774497c98f3b17303d09469313", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "f333fb26-42d3-485f-870f-3ecc2a41843f": {"doc_hash": "7ec3b1c16ca1068eed9286be0a368dac7549477aa963067b49ee9e86cbc9a63d", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "1c06a753-5d19-45e3-912e-e116f45757a5": {"doc_hash": "d512e8feef3792c1c7b6bbd43c5485f289213a45727d277830c9ac983ed37281", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "aeaa8dc0-6f43-4f09-8675-84085213cc9b": {"doc_hash": "e691e0ba2ff20c6514c7381bad665d39cc3234ed4b2764272091c6548eb8e057", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "09094806-702b-4188-bfbd-97ebde770adc": {"doc_hash": "810403263190706fb32bdac65f7368e5d96d6ce17e03bce14d141dc54c499301", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "d5aa481b-30d9-4ae7-9f81-325f2a98c7d9": {"doc_hash": "4bfee50028c312f72190c822214e9716208e816eec4ca41ef697f4a5f357d112", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "97adcd77-faa6-4bb7-83cf-af9957c77252": {"doc_hash": "d28fa612a3bb1263bc0129a40404bfd342b5c63de64ff3f2a9b541ba488820a9", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "4afc0e2d-9eee-487a-9d56-ab5bbb583290": {"doc_hash": "6a4a6a7ba9a479898d13ae6239e6882ee83e4ee22a1120cbaf067a86232e5e1e", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "5e0f80d2-0ce1-40f4-a12a-a2aa55ca0161": {"doc_hash": "7c201631d22f08a33e8588bc29b50398c0335576a1acde4e50a7c98f90ca0bed", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "b31a00d8-5eab-41e3-a139-c5bf5b2b855c": {"doc_hash": "810974619ac1b93e0b273ba996ed12eca48b6339cdc056f6c5937e74cada3ec0", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "b9f94bf5-b11d-48ee-8f8d-103b669de36e": {"doc_hash": "e2467d3b0948362d21421a89ecb5452ae356fa9bb09d4f136cd2e6a99602b45e", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "6a3d95d8-896d-4228-b350-849fa741709d": {"doc_hash": "059361a53e747734d05bae47efc126204497337fdfcee13dc03d96a6a1f26a33", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "46a75768-c5b9-412d-aae6-3e252901cdbd": {"doc_hash": "bd556bf6ef44bc966c6a81b733beabab8d2338b607773931b0960e993e7ebed2", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "ba3b6543-b923-4852-9442-fafdd7439910": {"doc_hash": "16f3d3702f93acf58a6d5f112a77e68f9e01d7e0bd26f2ec7e15cd8071fc9b5e", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "5f237f9d-90b6-4d10-b3db-e73d3ddfc70f": {"doc_hash": "c96a1b919d9e4aa57e98cf05bb6bdf462c0ba55f7559a536beb16cf143e0dd73", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "aaf65bf2-f10b-4a08-aa19-967198e4c243": {"doc_hash": "220176b805ff2eb14228fcbc388d9b7f89f69d97cc4f87f7c7980a17c4376dce", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "8356eade-38df-478a-b718-56bdda1d3e76": {"doc_hash": "d5d8e05723b734040736b4bb621f5a5788a147f7f855b7cb8ff129c620db1844", "ref_doc_id": "152c004b-fd48-4cac-90ab-f0ad3c88c7da"}, "cc94666e-47dc-4a27-b6a4-270b3778a208": {"doc_hash": "659e9d84e8e4aeb564e6d0aa0bf0ea3ea657bcc46c08059b0d3e6dfb85b42bef", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "2ff1d61e-5d83-427f-b0b7-2afb7d088783": {"doc_hash": "5a87965e5c439e90d94cb3420383e35f3c20b9fc2df0886ffcac17b2684b1a76", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "1cce5109-7a50-4691-b52c-904e6e282431": {"doc_hash": "4db8cf027564cfec8c32359f082e10398a2f1534a48008fb84b7159ad0a5fb05", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "50c68992-bb30-4399-9f4e-f97c35670105": {"doc_hash": "3d4cb31f23c2d0e53fe01e6dcd9fef31c13a1a8f9b815538bcae112dfa585416", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "5481a2ff-5514-4c28-acfc-f49760d55d89": {"doc_hash": "8ad39db9b403df5a2623cd9c1f134511d84e016b8a9f34819d40ff15d48c144c", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "638a7d12-160b-42a3-8130-448532ee41c7": {"doc_hash": "51b5841c94d943163c4d583e41cfceab37f1ed1a5fe1a10efcfa3cd83eb36e4b", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "9324571b-d160-4ca3-842c-ceb6729ce6ac": {"doc_hash": "cf661c8eba5f1c16cc5716940825c3bf328964d52a3f23054c17b13b858d197c", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "23bfd213-0cd5-4722-81c0-d771496f0ea9": {"doc_hash": "f05378d09dd5f4bdce82e5369074728c33415fc2ece28454d4b71c16c1d1607f", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "9c8e4889-5fd5-4d93-a2c3-7ed34540d24e": {"doc_hash": "f502e8e7b09b9cf92e27cc415d4d703428137c9e4db4d83a3425c549e05bd2f3", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "cf00d338-e0d1-49cc-9011-29848d723b7d": {"doc_hash": "a3fd4d0d5b530ca8bcea597584d2065db8dc2f86a483021b1df1bf28c598f81f", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "3adc3cfe-7fe5-4a6c-a43d-c8b0fb2a1f4c": {"doc_hash": "a03662aae259c4b48876aa7c274330e21bd669c4a4465d2c8efedc9505437897", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "ad339732-2922-411c-bcce-8cc142dac9c2": {"doc_hash": "6b195327116e16a6a0d655ff2d0236af73301bf5b82e3dd92de11fabddcca588", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "214030a8-cf2b-438d-b0e6-b1e77b1f9fa9": {"doc_hash": "0f4d8d7370ece5b9c5cfd772a6f350d3a6d99d89904a63f3671921d4cb45b51f", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "5c803a89-8126-40a4-9cc4-4c60fb0a53a3": {"doc_hash": "3c991f1fe96605c377e084529dc3bce47c84cbc1dc17a726624b90c17bd48df2", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "b467962b-2099-4631-b981-b4260c8c07a7": {"doc_hash": "a7ac5910fbef96af63a181cbccd05018f4dda32d929d363eef52ad83a88fe3ad", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "09f35abc-e4cb-4609-b42c-89eb36181829": {"doc_hash": "718f6df5cbf6c4862f25ca0a567c5b4216205758dd74506dcee54c93886e9a84", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "3b4e3f56-b119-47e2-8d06-d3114a6de375": {"doc_hash": "df63f88585bcc5f3d625bb66a05b4a9e167fe2b53d71e2f5f13a445e2ba141a1", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "03b46db9-8fd5-490e-81f0-fed98b7d3208": {"doc_hash": "ad49622c56c56baa0bdcf3c633b9b1f2b58d5ce57d912f593b6cd58683d6dfac", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "f647980e-7b8f-4e9c-b352-91665710f286": {"doc_hash": "f8fd016f4fc6a6a20f2ee254795d66e9692917c3c027b0801601a3f0b74b6110", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "2ff35655-a5be-4839-ba99-dc7acb23d689": {"doc_hash": "d8e42bf816ca25ccb53236eb1e97d7eedef9cd474270de4992fb9db6e63299fd", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "6d56965c-1e71-4782-beed-dae97fa2bddb": {"doc_hash": "c770a86ffb32234a5a8070ec4980f015c15a3daa01b52c8d453d6ff7fcc0b16d", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "87cf121a-c6a3-42cc-94ed-ada7253986bc": {"doc_hash": "6f5121b57d542f9ac500151a10af197d345a2d062f01baec68d9d5beb0f221cb", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "a0361ad4-3005-49a8-ad16-775c242a39f8": {"doc_hash": "abd359c85c12900fea5d3164dd94430eafd1c210948e586857ea4af51d7b8264", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "3b375a85-699c-4459-b096-84e3cbd91bdb": {"doc_hash": "aa4de1e4a4d8b761dc3c63a68f92ba0c93c33c53fb2d4069e201bed17c041cbc", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "72daba6b-87a7-4bde-8491-c54f50e922b6": {"doc_hash": "259fb2de43821e47281e1046ea148972daa2c54c3c3614f9ed22dd80b1313184", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "2e5e85aa-92ce-44ac-bba1-915658d2fcf2": {"doc_hash": "508ab0711ea28402748010efa3151da87cdbb575e652288f385ae7ef0828dd6c", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "c09b2ec9-2ccf-4670-9862-07eb2e79780f": {"doc_hash": "da6b484369c5865c9d71a6103282494c9563e27f8e8b80c8454a11fe5b54ac0b", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "63f5b437-f2b9-4fb9-8b4a-89151ed64a60": {"doc_hash": "783e3ec0eeaa63c36e88538ab938ca16ac2acbc6c5e457c03089b42fbe753a04", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "cbe20fe2-e589-4eeb-bea5-de9063f78be3": {"doc_hash": "aca0bc74bd306b00e70a557bd8447361ba81df3b6482196a72c7da52ce971adc", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "e09b1724-5a30-4e4c-a3ce-30344f0ccbe1": {"doc_hash": "25a67c74be260e6be1a401abc765b01687a38e2fa99219de3d570cbc7c2a4c6f", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "efd87e23-ac0b-4736-9f02-27900adfaa93": {"doc_hash": "9e1fae0b2397fa5c9f5876e420379067c93ed0f68e375d138d62384d5e3d8416", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "9f967f9c-b809-41ce-9629-1ee1c7f32fc7": {"doc_hash": "0f04e2e5d53f4301f5934f272622391655020548de52ce3b3147594df710376a", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "51d3f4c4-2761-4c95-953b-6b0504f892fe": {"doc_hash": "99793ce9b26f1fddcecab414ce1dc3db6316464c4716439549f3189159edace9", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "d923c704-3b02-4952-8267-8d8f89819fa9": {"doc_hash": "e116cd6debe803c4bd7c769aa88bdc17fe9ea4c5d633be589c5e0706fbd88fc6", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "5714c10e-21b0-4d50-b75c-4e97a09ffe0d": {"doc_hash": "a283393cfbecc440e2438feafb9baa8803a1085807401eea0c09f27ee9ae6baf", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "28a53c50-3252-4107-8a39-b259bc402ad2": {"doc_hash": "6faf56ef7e892bef0c5ba37fffe897ca70648ae7ff571cf659b8f149671bcef2", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "ff873239-8c85-4801-a49f-2784e686b8cf": {"doc_hash": "2d34317437cf35ffa0e0f49b14a8930a9b632288698a821943eadd9510cc0a2e", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "2353576b-1b19-4c83-9336-3ae18bd22669": {"doc_hash": "be807c5ef0baf785e34a914daf3dab3a24e70b1191e5a5ae5a68f0dbd1d1f8ae", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "3c728dd1-197c-4249-a4c9-13418b0c7930": {"doc_hash": "4c3584652dc27c0d723fc6f12038273f85ed60985aa138c13dd10a79e3420713", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "708f468b-5f20-4f35-b744-5c4947365e85": {"doc_hash": "4ed8bc7cfd05ac52fa189f714bc90c7b3c0aa70b8e54ae89f7d90044fe8fe52d", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "12f244c7-b4c8-4591-92db-e234ae20f1ab": {"doc_hash": "69e83b56adbf3e4793a3e3e64eac7455ea1a8000ef1426591a62a80e389cad8f", "ref_doc_id": "edac5a20-4fd7-4741-8d71-049d72c7c91c"}, "1272e0d5-ad63-41f1-b752-672ba5e877bc": {"doc_hash": "dafeb9d434112d52ec4346fe7c1d9e82b9936e2046503d8ffbddf4aaab569a00", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "87385dc5-8fdf-4ba5-a8e1-ec8d0fce3e86": {"doc_hash": "ea6d09cb1effeddaed884fb0cff3734b7eab5909179aa0bce0010aaa80d58287", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "ca273c70-c370-48df-9e19-4f590bde4ef5": {"doc_hash": "06d745b8f9170f8e469a37e01b09a12833cc6355759931cf77140ddf7ed801c8", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "926518c7-8c1c-4db1-a534-c70cb3d6dc64": {"doc_hash": "a6886c25cacb600e06d735a446e52fcc2a4848ae48cd459960bc071e69fb9151", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "15060017-62f5-40c9-9eb3-df02b14ec11e": {"doc_hash": "dbd6b99638bd1a71f715065aa926a4f3e58c0ca1d94b4cac51ebafc1825c5f33", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "2a451365-5623-442a-a46f-e8b5ef404b87": {"doc_hash": "fc5f9a63d360b38fd28f69a8cb580e45cc02d809621f70008240e3735727f7e0", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "bff655f1-6e78-4dec-82de-fc3c89643730": {"doc_hash": "45a695543ac838560304a7d6ed8728a8ed7649370802feb58fe6091199468b52", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "194a8d75-5d46-4443-9d9c-2d2d5837ae70": {"doc_hash": "79554fa984502a0ffc54ed5afbc09ce688b5216b7bb5e5f1b75b917cbb558c90", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "4a4cca4c-5311-4544-96af-088c898971f1": {"doc_hash": "c02053fbee3f90ff157f89fa6600434948bf8b484aaffdc9cbcd7ae92e8cdd07", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "cbe90d1d-20ad-441c-a6c6-b4619c248246": {"doc_hash": "1a045111b1836f7f9c8b907ad0673a511647ba87d923e93f615faa0fcf52b556", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "782a08f0-9139-45ab-b322-166dded77e6b": {"doc_hash": "4468b6bda0cdbcb083f3ba6d1c45ff9b554585a7a6b5cbb06c4cecd16154acc6", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "a3b01afe-41a5-42f8-9f68-75f00c06b562": {"doc_hash": "5c06230b3cf0dad7171b144a979709d490a558a51631a307d059301aad5d8d16", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "229971eb-7602-473c-99ce-4ad5c36d9327": {"doc_hash": "77801fd02d0a567e49623cc9aeca43a3d2bcd4bb52ce597935da2c8d0c4b07e5", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "cf91b05e-2441-48bf-8129-12eb38cad558": {"doc_hash": "8de657cdbf589b27ae57bf47db753f90c907e4a085cca33ccb6f058cc68998a0", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "78e52c02-d77a-417c-96e0-09fa23e9b5d7": {"doc_hash": "fa3d80bca6b406259a0386cdb4d255caec3ddf272d0dab30ec0bea4977140466", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "80e14891-54dc-49f0-9623-5e186376bdb8": {"doc_hash": "31f3efd20447295b4b1adf2ef0278dad346ea8ebfae74909eb7897498ab66edc", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "4d1ff400-bb1e-4920-bbc1-e6bd44feb9ee": {"doc_hash": "d97b62810b5106fc190ef9d31d16883e91204244e8d2914f69b0b35cb43b6e24", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "be61aa6b-0ef8-4307-bd49-4d158255e689": {"doc_hash": "99c95294d5ccd1c4916a40171399e012c11605ae93c46f82a05ba86986c6980d", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "2fd6ea3a-dae3-4bfb-b3f9-0d1de18ba732": {"doc_hash": "537133e9bd0a97dd14787da0f78d63496276f548438528578b35f8fc9f9df7cc", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "d19764c8-8206-41e2-8bf7-73588bc21027": {"doc_hash": "1d3262461b84d59d9dc49dc5d8495d5cad7fd5ff616d8b84e1ef755e7c70d239", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "55a67ace-2d32-4802-aab2-1cb8cda854c1": {"doc_hash": "6b3283d7e542ff5684e0e0cab307cc611bc83c0cc01a904755ec11ea55f821f1", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "5eb3977e-2dc3-493d-ac16-70e758e14a7b": {"doc_hash": "803d9dd14205d6c703e689044a91622cdd5929126aba3b5101c1e7beb7e10d50", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "d2beb8f2-5f59-479a-a0b1-c8694b616873": {"doc_hash": "f9a8366e226653c902a64dda275156ed720986a029b50e5873d6db58cc175559", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "44f81ce5-efef-41e5-81cd-82a8a55c9aee": {"doc_hash": "8e7431d07c9a4d2af72d821ccc7e541c5c5f33f3c439e87993046c4fd1855e75", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "02f026d4-78d3-4a23-a9b4-d2119d7afd86": {"doc_hash": "19b5e3f8e080e9d17833072deb94b737fba2fd29133ce0c0452cd104e0e9087b", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "3b1a9bb6-d0d4-433a-8a50-8c56e4d73014": {"doc_hash": "44f7c9add6201fe6c81418fb64a2c6e1ffa868c9aedf682427a1722b3a03f310", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "e69a96f6-94b0-4a43-a182-b40f785ec731": {"doc_hash": "40584b9029c2d01fd7bb369974aa74f4ef965010e6b937bf2d7603da188242be", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "b5ff8eae-28ef-4267-9e36-b17b7bfd5660": {"doc_hash": "d95564f36a7ede76a776b51a9d5ad89e47bcd00256fcae8de02bc5bbfa3fbb75", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "e146c1e2-49e5-41bb-8e27-165c5ecdca18": {"doc_hash": "feec2e440a951eb289a5bb4c0def7032d61f0299c7907772a7b88f453915e1cf", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "04c66a11-62ed-474b-a435-e5245e186c78": {"doc_hash": "1d32363f85eb7be75fb5cf0a5090f69bc2cc17fadb02dd108e5a079c9dda4994", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "4cafc0d5-b293-43b7-9d64-f0d8be04d702": {"doc_hash": "e18a7935fb6cb9e82b7619385c324b9a5f4ad9700a8235fb70d9111c75fd94ce", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "05ebb30e-bc30-4e4c-890f-12c1ecf5948f": {"doc_hash": "e49da6657bdba1cfc70c2b008e068d4749f020c0fdbc6ccb985a67f70430f66d", "ref_doc_id": "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20"}, "b99c1ed9-a701-43e2-80e5-3f3f9ee5be4a": {"doc_hash": "d0b02b80b96e624f41c43e2e4cc358f64858a3edf7c6edec2d1a4b0058c6c84f", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "d1c4b83a-316e-48c5-9766-7debb6f8f90c": {"doc_hash": "7edac914d276b92e04b42b2c75ce344a18ebb7413868956eb59e46ba34f5fc20", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "1e959cef-1a2c-4077-9b3b-b2ed556f5e73": {"doc_hash": "4f5bf1ebd4682eebd34e025742b5b116271aeb3fe812e95fb01d841d4df6af60", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "27896f18-4086-4e15-bed2-1476423fd20a": {"doc_hash": "6afc6f74f9db5d4235343e717918e3007e5db33f8b56bf083e9355899919fb54", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "5c27c5bb-ffdc-4b3c-8681-617e652dde21": {"doc_hash": "ba3128b20564c25f4ba192a701efe689f36beb79e29781abfbf660115aadf4cc", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "3899c379-7c5e-4a8e-adb2-2819fbd92581": {"doc_hash": "14e1a9f0df1fc60a799fccefeffca734ddd95057539e9c6d7d27fb5206ca4d81", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "c90bf52a-b6c7-4189-8375-4e05fe2103ea": {"doc_hash": "fb560ac74e65e2dd842e822f9dbbf338322b3e2378d5b4647576ccad3ec8068e", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "5d3e216d-8b94-4fd1-9567-ca752aa01033": {"doc_hash": "deffe881a752bfc25d3f4f991f9b4ddea2f3d8da50120786edde9d2cde168f31", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "48874496-3d53-45dd-a662-d8a56e81d9b3": {"doc_hash": "cbac9bb53752ff9e4888075a5af7e2b17b4b344ddfcede7109e08d8162da4de8", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "48951eaa-bbfd-4a2f-9a02-9b10f1a22b66": {"doc_hash": "df82a233fb0310aeb03ada7780f158883317cfe3108939a7d250125774b5a6dc", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "a77d7a9e-8235-48e2-ab24-cc1c99b7bfda": {"doc_hash": "98eaefaffa3968013b1788fa820e0874f96261d428fa27b0b0c8f484d7e6d5d8", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "c4f4f05b-67cf-41fc-bef3-ec6509eb2fb8": {"doc_hash": "6acb1db63cbd152f4c0ffd39b32a373bc40081f0ab4c1df029276942ed2fad53", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "31cc06f2-a77e-4def-85b2-8714bd06f27e": {"doc_hash": "cf3d6f6d7d6fdff7dcee1c4de503daa6569b731eeb588527e7eea965befd8cc2", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "45478c8f-fe90-42dc-b8c3-319e5552af26": {"doc_hash": "72e40d3a88cc858ffab4de2fc18b17dd0a7d2535e5b7ff7bd89f5e7739c5448d", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "b8bfda88-5c4e-4a8b-9411-fc9af0cd31cb": {"doc_hash": "08af59f801f94528ced991e49ff86073711c4f0a9d2c36e9a4d3d00bdc103834", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "73bee685-65b5-4df4-a11e-ecf148d36018": {"doc_hash": "430562da1a90e3d8a32ad454e1c94a3aa77a101a0c27265c5f124e79306d0484", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "df2d8b83-9c8c-421a-b2a1-d594304bc59f": {"doc_hash": "59b8debeac9153406e816286e600a7c1facd0236a389546581ae3dab73735154", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "7909bb20-0226-4c6f-851b-19d57ce46157": {"doc_hash": "bd85f0ba540d9362a07006c8712100780e111e467003fd387c135d5faa761be8", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "019b842c-8d0c-40ee-aef6-2bcede4da6d2": {"doc_hash": "98aefcc0d6e5f0d30cf0968b73238e37e03c8598b9624f794e53dabeaea5d286", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "9d4a4a10-e809-4d33-a32c-52f2d5351a4e": {"doc_hash": "1e5c39e60edac2f90ef539f16ff438a247b3696326af5709d4bdbb5be0bd5d12", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "74f3163c-20ea-461d-a520-c5b593c61572": {"doc_hash": "bdfbc363d46cda89c3478f1d80b24be04a9f463cacd0ab9ea2d73e0431bc73ee", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "71b5adca-c6b9-4146-a1d3-74208c105684": {"doc_hash": "743e6514362eca3475b6181e9c7d4fb94f8847df7e595ccaf75574c90c9e7015", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "c57529f4-164a-456e-b3c5-8730c62f6544": {"doc_hash": "5dd1c263723a30e9bd975b08d4e195f0def7a18467e3d1fea878d5360009285a", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "26a6fc68-9ab3-4109-b893-ae809dc39fcb": {"doc_hash": "1da2897f2eaa5b6fc84d554c4a45edd3e42f302d01fd53806ea9e709089d418a", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "e4628a38-87e4-46aa-8d94-df503d2e2579": {"doc_hash": "d931701337fe26b553ca8b119e0e8bdd7ef98f0e84e1513230fdbb55765d5b62", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "33a8536f-b091-42e6-97e0-7d81919b0148": {"doc_hash": "41db21e87e1e33e2293c222278022a43271d07ff844295a4aa6fd5637ec10db5", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "8cbd91bd-a31a-4df9-9f31-d68f72e9f7af": {"doc_hash": "7f465ea366c8fa379d7ec73e15b2ac726673b5286f924c781ba61b2db638066a", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "a561e606-362d-48a9-9f70-349d35ee4b1c": {"doc_hash": "004bc240b4de2d6df4d167bb9352864f7d26c391fe37cd4247f2139fa71f57e7", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "7059de0b-4077-4e95-9bf5-91763a89c657": {"doc_hash": "bcb78e4e4259a2684c70cb2df6acc26933a2211ce25b2620bef0192cf659e806", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "9cdbd0d9-ea26-4645-a1f6-5c01220aa5f4": {"doc_hash": "94ff3bf511a916cb28c1eb0049269cdd660546a955767ae00e8164c3be1f401a", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "7da2179f-f433-4f53-80d4-d6d8887df9d3": {"doc_hash": "ac00c864b02a0c7ec25768062b08e60e9f89b8a4f1f461d724eb793c978dc192", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "3a910e62-e8bc-458c-b0f0-78301eaf21ba": {"doc_hash": "82eeb8c7dd3f1338926991b7363f81da250ad429ff8202aa1674d90a82809cca", "ref_doc_id": "f4cc41fd-611c-43a0-800d-a4568f6d2480"}, "a7029c1e-46b6-4902-aed1-7ade1f589656": {"doc_hash": "23ba8984fdec40466202e5266fd54cfdd6e8b3fd2ad13203362fa7dc3ef1c62a", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "fad4e3a0-4495-46a3-ad02-7f64eecfd922": {"doc_hash": "3a722fa4db737deb7a85e9e5cc04c2b59a0c8e1285dcb191477cf4f6a04c77ea", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "2d3e38ce-1105-4282-b245-307ad127dc2e": {"doc_hash": "43630c14c55f9c7d9ec2861f0c4ce7a780ced6b9f8ef2598e193c6d6d9b30b5f", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "b1b3a3be-d940-4924-9728-e4fbb5561528": {"doc_hash": "a924a530284dce702be93d51f096c269a6c087678d992d5d8097eb4b8d0a3f1c", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "6f691a9f-5acb-41fc-a361-59925ee2fb99": {"doc_hash": "94f5a6c285a9b720e9cd89fd79939cbe175ed4ad1ed52382d2f2a3ae83ddca35", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "b31f1e96-7b32-4735-b759-23af5f8f1a8c": {"doc_hash": "63e25a6713bf65705263232dbdd5a3533641c7501ea6bbdd82c8caf85d3b6941", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "8c9a9d51-2e63-4a50-bd5a-34fb1208c942": {"doc_hash": "a240326d6bbef936fbbc7bd8f71363df0b7503de594aff47f78b10e470917867", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "31e680df-fe9d-4eaf-9a8a-be9756214d5f": {"doc_hash": "a5d683300697ad56d9cbdd122405afe5b1e534948954361180f474b91ea62c23", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "c3b25bdb-d4cd-4e85-bbf6-a5e2af6188ee": {"doc_hash": "9f5a80d05f08a88abb72deed492bc879f88a96ce4add9d7bd1351fb0ff262bc1", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "3efad347-7819-4eb8-a77b-623d63f115cd": {"doc_hash": "136eccb8403de255e9226bf080f8c14758800e05ab7b8f45e90e4bdfbc786b4b", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "e5975424-58ba-47e9-9de9-f49dafe6055d": {"doc_hash": "0fa45ff7b0a9b9e60ada8aeb771bbb2a7a145cd740794f6f6f079ea0ea6149cc", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "640b2608-428b-43e4-95fa-3e454d03d012": {"doc_hash": "76f2af9abb9c04b420e7add35ac9b732e8cd35dc5e3394621d44ee1c4c182dde", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "af642033-ece5-43ad-b9c1-7e0df55c9223": {"doc_hash": "0a90a8b89fd86103285ac469656be8dc4987fd770ffb0172781e2dd73952377b", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "bc971faa-edbd-4f9f-812a-a32fb8406efc": {"doc_hash": "431a3d78a8c33471aefaa5e9a58c7b94fa2acf5a09bf91c52b4204ba5f0e9b16", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "da3a77cf-1d9b-4805-bd75-ba86bcb8c25a": {"doc_hash": "1a95e328c89b9f46d4f6ef53916b00c377e91159306debbd7ba5904b9f415594", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "deaa8826-5ae5-45bb-89c6-f98173f21705": {"doc_hash": "975dd2b82fbd478baaa5c959e1446b178dd3bc4854799df663894a13333c46f1", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "86d362ed-791e-49cf-a093-02a4527ac3ae": {"doc_hash": "d27779af920c7ec48f6e90f3d0aaff0d570b9a902b4901285b2fa8324834e2b8", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "d10e7129-0103-4679-a2cc-937244baac97": {"doc_hash": "02b55656112164e117b71a5ad80157ccedc1e9a3db6c959487f2cf4c41410ace", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "7575a8e9-2da1-4a26-8cef-fbd4ee40663d": {"doc_hash": "4e4a9c962a49e4171e75dbc46e12ca40931b3cf0ee236b9cf5610216831d4c99", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "f1813762-52ea-4e31-84f2-a3d2a84519ab": {"doc_hash": "083b9394cf43eff1c1c2a10582af4bc11136a9a6ae84969ca5b7576ad9496c8d", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "d834534d-f83d-4082-b583-f452d20ae81e": {"doc_hash": "b99d3038ec3eded3652607ddaed20ff26964322d8191feb5133db3ff656b4474", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "fb458a9f-48a6-4968-a6bb-02e7079ac6a1": {"doc_hash": "c667fa48e5adc565b0829e1de5d5f223944943b61d57fcdbac5b4940992eff18", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "d52bbcb8-4020-4cf5-9659-329e6544bb21": {"doc_hash": "2219dd209fd44ec6e238541f390ca6f48074d409773da2704eb945f462fb759f", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "82dc824a-1e3e-4457-8007-95e695fc0d4f": {"doc_hash": "eeb9a3a4e3c68f238e5bca1fdb2a011b5c37b048930f2043f6a7585119097647", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "7887a02d-97ea-4a53-947a-c8c145ef75fc": {"doc_hash": "5e8ea8ec095c0e925b390331c527c44fb44760b537dca394f02abc1dcd503065", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "b3681391-1c6d-413f-bcee-75b26e53f3ce": {"doc_hash": "4d14dae1c0d7a0be5f7ab5ae464374eb251d31a23f70e63718e23e43bc55fe5b", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "b2555354-2bd9-48ef-9317-73332a7b5620": {"doc_hash": "ab0e633b2a63dc6a4792f4a12593bbd0a9b348f0bf126dc4c1735b432d175744", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "cb25bb20-4a4c-406a-9551-8d0a27303a76": {"doc_hash": "e5dd9c62299616dce8ceec126d7a778d72e63f19712fcc599e1be828065582c9", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "a16f2f2b-f2d4-425c-9f43-964e9c84c538": {"doc_hash": "32fac1a3bb5da9670cc9251ef71f61ec8968cb99bdfde0678732c715a6bf0578", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "b70e87b7-b0f9-4241-86de-5600e18060d7": {"doc_hash": "e90d183aa95ca7dd414255a1e07ccc25812ea84ccea648e39cff651f2636df8d", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "46d87dfb-c8a8-46aa-80e3-1ce5a832f0d0": {"doc_hash": "7b16acf1b4648817339affaaba1ef8e344688c4ce364e33cdc3a9321a3b0a19e", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "769e8b4d-3d17-4374-9474-70d10cdc7e0c": {"doc_hash": "c9f7382c7d8b525171f6f84d6d5f6ed6cdaa630d4ed1d406b48b1d3b9c2878f0", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "e109b82a-c71f-43b5-b670-d055f676b615": {"doc_hash": "a3de53f5563512bc9646f44a7c55e6ac0808d7049367d38d87c52e2f3c7d2aa1", "ref_doc_id": "a5029d12-6ba1-4600-87e4-6defbf5e44b6"}, "8c432851-3e9f-45cd-b27b-03c583c5f70d": {"doc_hash": "64fd9dd3ef1a90bfb8688c846d1658e1de7bd67d051c250f00d0a400fc18ed0f", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "64a3aa68-4b8a-446d-ad5d-429b930d98c2": {"doc_hash": "431fd48c5360c3843082fc400befb36d36aad64b5a059a3677710f26b1cfd04b", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "9287e502-a19e-462a-aaf2-196c7f400063": {"doc_hash": "5e7a0634a394dfcb214a304799891be1ce6cb4fb2be04a83eb53d29ea119789c", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "b852de42-13c5-49fc-b62b-bf34adbeaa1b": {"doc_hash": "ba4194083275941249c08dfbe2105667c92c6008f6332892107ebd9109a988e2", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "06f714f1-eed8-4137-856c-5a67e25e4a78": {"doc_hash": "7a971cef2c9c155008fd117dd9809b6ee1c90bb325356ca1cbb84c19e308e048", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "afb3c28e-6c2a-4eda-a47c-f57d0cf99567": {"doc_hash": "62749a5b6fe54c5458bda30eac6d41d97f28c86c79bbd7d8b154ac778fce5676", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "d408aaab-b50d-495f-a590-c0fa0cb9c935": {"doc_hash": "880f62262dea5452a2f211d3466f3e35dd194160db097160912b6a1c2e7b2332", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "e1cd5011-2c55-4ef7-9652-14e650f7f589": {"doc_hash": "7bde7d79df56d43c9e3963a827e4c7c0cc06753e37d63fb354171dd2ccfabb68", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "06323d27-3ae8-4e2b-837a-e904558265ab": {"doc_hash": "41d225549055b17fd0c6456349ab96a4f3d82fb5a224772cdb42fd840724bf55", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "ecba36fc-4483-4cc3-99b3-c4348d20c1d7": {"doc_hash": "8c3d076b9d2368327c5c32fa00351b8c258fc754d8fc1cc69a2dc72d3cb590e4", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "7cba35f2-266b-4494-9214-f087d593161b": {"doc_hash": "1e991ef498ec018835016a43b08d609c9d3fecb62c29fd2d02c1e46efd3323c1", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "4e024f7e-1029-4a2b-b09a-24363507a2b0": {"doc_hash": "3c053954c899fc1dce94c40c58916b5c1912d67c8c72642e9f392172697770ed", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "a74870ff-05ce-45e8-8033-1cf859781911": {"doc_hash": "7c1b20ef0583bb71342af7748963c2caee438e0be1b952c24ad0802c8f03f298", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "17441337-d7f6-412a-882c-3b675b9e43a7": {"doc_hash": "40e8855b5f26a0beeaabf40f174b4ecaf1eeed88a67dd2f919b873635573aeb0", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "950fa927-f93d-4793-9972-08c99a3fa4a4": {"doc_hash": "cbc3bb87460a4b914fc509004f5c952f2cab16ce77aebb8cac8260b87876e7da", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "31f313ba-1782-4f2d-8689-5c97af2e0781": {"doc_hash": "ffacf8dd8a799adb97450002ed857802fd92aead5b8fd37c81b0c99dbed2829f", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "2a42881f-6057-48cc-9b81-e60cda732d61": {"doc_hash": "7231a5f0ad48dbfc643a8bfeddb6d643d3fc50ee09632dab3d98f464f00d6a81", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "fe903f66-e7cf-4aff-9eb3-c1adb5b39d1d": {"doc_hash": "5e48f56f09d2c0f646be425fc3c1cb5af06ce09a5c578aea927646d34d016149", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}, "57619ab6-002c-4dca-b2d7-81cdd3066fb6": {"doc_hash": "4a0cd01a25bf7a36ed02a7da1969721b0190a78bbb7d273f3a43c5686be2196c", "ref_doc_id": "4606e53c-17c6-495b-a30f-81af8ff5ebdc"}}, "docstore/ref_doc_info": {"babee6b7-56fc-4416-b788-8fe24ee564b8": {"node_ids": ["2f3848ba-87c2-4cf3-bec3-a58ce48756f5", "5f1611e9-b0b7-497d-8587-38b687e4c16f", "dcffea4e-3a3b-4f13-bb07-fea3d5fa5cca", "bcd385bf-05b9-4530-97b3-d4e9653e412a", "707073c4-694c-4cc2-8c16-e702670bd52d", "b2cab5b5-45c2-4a2a-80bb-8b66827cf027", "64b09bd3-f490-4575-b265-80123928d632", "0d10be3c-6c31-4230-a2fe-ab5abee3e967", "d8e176be-be9e-4371-8ac4-98e42bb5c85b", "e4eb8b3f-c0b9-4e3d-92f7-d6b455e163ed", "a66c1c2b-18c7-4204-a865-9f801a233763", "4d325935-288b-447a-a567-ceee3243fc3f", "430136dc-7592-45d5-a5f1-81a32baacf4d", "c49c955a-a7b2-4393-bc2d-f40dbc9d1ae3", "da683bb3-78ba-47b5-8b40-1544be9a80ce", "a784b4ff-917a-4ae3-8082-99a3a57f2796", "2a5ef303-ead0-43cf-aa73-ff98de7b4037", "22e5a2e8-7bf2-4d8b-b533-c775a503f4d4", "559c2658-489e-4c95-afe6-3916de83fd21", "104b78be-f357-4138-be65-cb60299cfe2f", "11bbd84b-e055-4fe8-84c3-bfc3cbd74662", "c06ed333-1d18-4899-99a6-66d71c16abba", "cd899c7d-260c-4210-a106-ff77e937ebd9", "b65047a4-bc49-43e7-9795-cc23108d2a41", "3f272b30-e7ce-4a88-ba29-c0136d061553", "dfe36bbf-fdcb-4553-83d9-89ce516ca686", "d0241e82-2271-462e-a7c9-01a7fb1f0c19"], "metadata": {"window": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nNovember 3 , 2023, 8:30AM Eastern  \n \nOperator :  Good day, and welcome to today\u2019s  First-Quarter F inancial Year  2024 Cardinal Health , Inc. \n Earnings Conference Call.  This meeting is being recorded. ", "original_text": " \nPage 1 of 16 \n \nQ1 FY24 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d4643389-38cf-4b2f-a529-2f3c5812eb28": {"node_ids": ["2eff0640-d37d-49b7-a034-eeb3d178da57", "91ac8485-2a92-49bf-8598-d42ae10ec432", "c024bbe4-4675-4a63-98e3-669c3dc47be2", "cea8529f-202c-46f8-bdb0-e672303070c2", "6e7ba431-2d7d-4216-986f-d31e30346df6", "b7491cae-aa47-4636-991a-33b51848fabf", "bd42a543-3b7a-4f29-bf14-4650a67d49c4", "6fe2dba7-3027-4559-a434-dff0bcd53a7f", "802c7326-d786-4cc8-9a29-cf8f7bb19911", "b39de5ee-4909-4fce-aa50-04b3a9c26994", "5abd2e9b-ee5f-410c-b843-dd2b0a894008", "fc7085a0-9f01-4206-9d9e-14c64c058b41", "5462e242-7fcb-4df3-8309-918001d368c2", "f6753711-5613-41de-9cea-4cfe8bf5967d", "17d8a14c-0d72-4db4-b987-3b8132ffa3bd", "3f56653e-2858-4236-82ec-2e19c33f073e", "a110531d-5719-4ae5-b2f7-eb21980eb3d0", "97a72503-efee-4ce0-8428-ac7b3b90aedb"], "metadata": {"window": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance .  In particular, we made notable progress on \ninflation mitigation in the quarter.  \n \n At an enterprise level, we realized notable operating leverage from our efforts to manage costs \nacross the segments.  \n \n And below the operating line, our favorable capital structure and responsible capital deployment \nprovided tailwinds, enabled by our strong cash flow generation.  \n \n", "original_text": " \nPage 2 of 16 \n \ndrive better and more predictable financial performance . ", "page_label": "2", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5b9a20ff-5a2b-4338-adda-f070b3e8f645": {"node_ids": ["e501a3dc-97b6-4017-84bb-0a1fabf685a0", "fcb059ba-3d8f-4b8b-b810-2f205f0e5f28", "0cc45b94-9872-4294-9364-ade1929264d7", "057eea99-543a-457a-8d89-d2ba1288d020", "6b94e48c-0e4a-43d7-b695-9b2430f064c4", "2188e672-3a2e-4767-b0a0-d2c46018894d", "829b4a27-8e83-45dc-bcda-92995da0b123", "b9921e69-0254-49d4-80f0-2779626411de", "928b4b7e-8e46-4f00-b80f-0560ed8d6117", "5687b4e6-690b-476f-b452-b69f91744a49", "4c0c84f3-fc7a-4e05-b0e2-5717e9136abc", "db9d432f-eedd-4f9b-87cd-9dd4f2c74b32", "4dcb295d-29cb-4592-8eba-455f2466d333", "205c1063-0549-4925-bd35-77f196dfb391", "32a7a169-1e47-4874-89a1-96bbecfd49ef", "c5987a61-8d3d-4af7-87d3-5c573e3a85de", "919ecf47-b3f3-4017-b13c-1243f4b7e148", "4a872749-9e06-46ee-bbb5-701df2fceab0"], "metadata": {"window": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints.  We saw positive discrete items in both the current and prior year periods, which were more \nbeneficial a year ago.  \n \n First quarter average diluted shares outstanding were 250 million, 8% lower than a year ago due to \nshare repurchases.  \n \n And as I mentioned earlier, the net result was first quarter EPS of $1.73, an all -time first quarter high \npoint, reflecting growth of 44%.  \n \n", "original_text": " \nPage 3 of 16 \n \nOur first quarter effective tax rate finished at 22.5 %, an increase of approximately 5.5 percentage \npoints. ", "page_label": "3", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "21f040d2-eb1c-4e95-a858-ee913e6d5f56": {"node_ids": ["55f51ea6-54d3-4d49-9a53-d678083ddec5", "77fbd534-60f5-45d2-ac10-cda069dc5c64", "5a4ac9a1-683a-4339-882c-e44e8185e831", "874cac7f-2c4b-41c2-bef6-18eb519119d8", "5ae05320-5489-4436-b35e-e8bff9486dd5", "e07d468c-235b-4496-9170-fa9665351dd5", "17c8732f-eb80-4700-98db-df9248430876", "1bf0fae0-0b22-4291-854e-a94a8da484b3", "5f88f2da-8b9b-42d0-bdd6-c417b303449b", "6f27c981-74b0-42a6-a24c-65957aa1ab22", "fc4febb9-7397-42ef-bd13-d9d3e6d80442", "703cc76a-f348-4b59-acac-befb17fa8751", "07a05c2b-abc2-4435-b3fb-fd7edc4f4388", "af05461d-b1c8-411b-bd76-a49c360dbdbc", "f4b893b8-b5aa-4c30-aebe-9bc005703481", "e3dec6d5-e9ee-4dfc-8557-2dca7ec3ad19", "fb82fb8f-1ec7-45c7-9570-ae0bc7968cad", "6bb13edc-7714-466d-b454-3988e2f8e6c7", "229c7720-91f7-4d1b-a030-c5fdc6865767", "28c868cf-96b6-44a7-a548-ea2ee14f7b93", "7f15a560-06f7-440d-9af5-4879293c57ec"], "metadata": {"window": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This Q1 accounting charge is \ndue to an increase in the discount rate used in our goodw ill impairment analysis.  \n \n Now, turning to the balance sheet . \n \n As I alluded to earlier, in the first quarter, we generated robust adjusted free cash flow of $1  billion , \nand ended the quarter with $3.9 billion of cash on hand.  \n \n", "original_text": " \nPage 4 of 16 \n \nIn the quarter, we also recorded a $581 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results. ", "page_label": "4", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6320064a-bf30-48fd-9ed3-5e691f4bbe49": {"node_ids": ["63de44cc-ebb5-4ed3-99f8-4f73cee2f0ee", "37971da2-8838-4c6e-9742-40d468b42c34", "6ac4250a-30e8-4e90-94ef-2e7e86cfc5f7", "b4ecdd8e-b7d5-4032-b8eb-71eb91c60c82", "dead4661-a24d-4345-9a77-1ffcde33f512", "35f6a5ff-398a-49c9-8535-6083d62d66e5", "670c18d8-1d5c-4140-8369-3753da40c908", "403d8ee1-980b-4732-b14e-18ccb77c7dec", "eb89fbe7-4b93-483f-9b36-1f1bf358a509", "506f6454-72e4-45c3-8e81-59009d0ae286", "4b07b5ae-c82e-4091-914a-cd3171b6636c", "0f490209-183e-4ae4-80d0-c57ef81aa8d0", "14c74394-8e52-411c-8d4e-2e6bbdf48f63", "54cd75b9-632e-4184-9c8a-cb08dad080c2", "0613dd19-cf56-4ce4-a613-6f664e7ca53e", "66ddbf86-6c11-4e14-8313-db4f02bb67c2", "7ee855b9-d5a9-45ba-a037-cdf945452157", "3a3afda5-e6c8-4011-b7d6-45bd9080c33f", "91100f83-3111-42b8-a325-bc9f0377c6db", "0957c6d3-3aad-4e92-8add-e82e704aeb45", "3f0719b0-e391-46bb-b1ea-49c324d4bc6c", "c6a09db3-8c70-4526-82b4-9e7ca3ac7b87", "03768f15-3584-4a27-8683-30ffc33e7f1c"], "metadata": {"window": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery.  We expect continued progress from our Medical Improvement \nPlan initiatives over the course of the year.  \n \n Below the line, Interest and Other is reduced to a range of $100  million  to $120 million, while we are \nmaintaining an effective tax rate in the range of 23% to 25%.  We do expect the tax favorability we \nsaw in the first quarter to be offset in Q2.  \n \n", "original_text": " \nPage 5 of 16 \n \nwhich benefitted from over -delivery. ", "page_label": "5", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d45e826d-e66d-40d2-9f93-fbc52dc9d0ea": {"node_ids": ["433df34d-f9a1-41bd-80df-fb076c7f5aa2", "259a6bec-f3aa-46cd-aa86-da932892be4a", "ba57c2e0-2acb-48fe-97dd-fe5cc7744d4c", "b5855f92-07e3-4e75-810a-ef3eb95d66b8", "82c0ffa5-c95d-414b-9121-eba592c313e1", "3d3b84d2-e476-49ac-a95d-5717572cc4c6", "987d0f58-6d97-46c6-959d-25cee92604f9", "d41e161d-399e-4626-9bee-9ea52c48c27f", "e80597aa-9e1c-42b9-b5b6-27b3cf8bf1b3", "cbaed71a-c55a-4db4-9c02-07f888c0b672", "7620a6b0-a7d7-43ca-b49f-15efcc5090c4", "674a1216-def1-40e3-9178-ddded5dd495f", "8aed07d5-6f44-44e7-8690-776eca66cf7d", "64151535-cae5-4520-9c42-e79335b03085", "c50ca827-ec1a-4ab0-b260-b409a95d07e2", "c9f34189-4675-4830-a241-6ff1997997b5", "12eaa204-30d1-4e69-9809-be8bc8370287", "29e9e2bb-296c-401b-b6c5-78eb0cf545dc", "16a532d1-2ae6-4a8f-b415-495d6499eeb4"], "metadata": {"window": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n We\u2019ve continued to see strong momentum across our Specialty business, both downstream and \nupstream, and have reiterated our focus on this space.  We are very sizable today in Specialty with \nover $30 billion in fiscal \u201823 revenue, which we noted at Investor Day has grown at a 14% CAGR over \nthe last 3 years.  \n \n We are making progress building out our Navista \u2122 Network  offerings, with investments in the \nplatform that will scale over time. ", "original_text": " \nPage 6 of 16 \n \nability to continue to be a strategic partner for manufacturers investing in the important drugs being \ndeveloped and commercialized in this space.  \n \n", "page_label": "6", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "33477d9f-24c3-496c-9932-7d3b3369370d": {"node_ids": ["f47c276b-7ed4-4c03-afbd-c44d6f3b3e0f", "c4ccdd39-b07e-47b5-9222-24b76e75193c", "b9c26e02-7e37-4a15-879e-df74f7f16213", "61a74da0-10d0-4a63-936d-a7080e4253fa", "97272ba8-52d1-4a30-bc77-68a21cb752fa", "fca99689-82b0-408d-ae4d-92b11cbe1c2d", "d67b270a-86d5-4dfc-82de-1bdad334b5b9", "b04a9e00-da7a-495a-92dd-9dc1bf5eed75", "f6baff83-eeff-481c-a0b0-95941e3762e0", "2585e936-646f-4524-a65d-42f3fb6a5360", "f812cd30-4871-4c56-8fae-d92a39890bd8", "6546a90b-4ac0-4de0-9591-147e3a7ed7dc", "c1ff3de7-a095-40b9-9ab3-8f77734e026e", "10fc315d-854d-44bb-884a-ec26c8945056", "0261c168-aac4-4881-a5d3-bbd6b030ed3f", "921d67b3-8555-427e-8532-87c00ccd3139", "0837afd4-266a-46e2-b41b-d2a0a8956c68", "2116156e-bcb2-4af8-935f-ae697c652cf6"], "metadata": {"window": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n We are utilizing a balanced portfolio approach and have made important line extensions within our \ncore products to fill portfolio gaps critical to our distribution offering.  \n \n We\u2019ve also highlighted investments we\u2019re making in new product development and commercialization \nfor our clinically -differentiated specialty medical products, which culminated in two notable product \nlaunches during the quarter.  \n \n We launched our anticipated Kangaroo OMNI \u2122 Enteral Feeding Pump in the U.S., designed to help \nprovide enteral feeding patients with more options to meet their nutritional needs throughout their \nenteral feeding journey , from hospital to home.  \n \n", "original_text": " \nPage 7 of 16 \n \nAdditionally, we have been taking action through our 5 -point plan to grow Cardinal Health Brand \nvolume, which has yielded improvements.  \n \n", "page_label": "7", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a67c6fde-3741-4839-b762-38a12ca39ac5": {"node_ids": ["2820eaec-c762-4334-9280-0d5891773c28", "95df35be-101b-420b-8b33-c231008cd303", "66c20b87-fe56-4041-9aef-458a80089c56", "7265d2f4-2732-424b-84ab-186996e39401", "e704df97-bc24-457a-9fa9-de3a1074cbb6", "03e01d84-f932-412d-bfbb-85d5a33cf84c", "9ede66f6-f888-475b-a0ef-d82c7cf557f9", "fcae312b-b09e-487b-b9d0-c8235d8f648a", "3587cc60-d459-4628-ad59-47f8bf955558", "d5eefcf5-c930-44cf-8295-c12e221adf7b", "4cddde3a-cbe1-47a4-b606-831a3df043ed", "50e8ad10-e52b-4093-a275-a3f6e4ff7445", "cbd82db0-e328-4aba-b8cb-b7247b7e4c39", "5ecae08a-396c-4732-be4b-f54f58d778ab", "91b3091e-8172-48d2-9d44-e6a2c01c7cf6", "eb35b404-79ca-4b6d-b3ed-59efb0d36840", "66a9d1f8-8b33-4ffa-ae8e-d32312e8a0f6", "2fcb0ee8-5445-4dbf-931e-76873dbfc399", "3e6521b2-2e3e-414d-bd9f-fe4fece21eab", "3e95b822-6e7e-434b-b60b-1f03a5a3f4a0", "ff993a18-95aa-45f9-8bc2-cf4e2b14373c", "b6e0e0d4-337d-41f4-bafa-679b3c5e2847", "fbfdb949-d191-4ea3-9948-d17856b3cc9b", "845f05b8-5180-4277-b73a-1390fed5ec55", "66f41d19-0e04-47c4-8bdb-bb68e581bb7f", "23cbf49e-cc9f-4978-9e3e-dfd30cea3bc2", "88aba52c-0ce1-4d38-8699-d75daf831d5f", "aeaab8b4-c04c-4ae4-8ca9-4909fdd5ab86", "733f079b-d6ae-49e8-bae0-e2870b3c7624", "c2852579-9f63-4a47-abb0-64b0bffba9a4", "b444d533-9a36-41f7-902e-354afc854ee9", "1169e367-416d-4bcb-9a0e-ef7392ac2b8d", "7e54aa47-997d-4b6b-9ea6-67fc06413c95"], "metadata": {"window": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases.  We continue to actively evaluate a range of potential partners or acquisition candidates \nfor both the downstream and upstream elements of our Sp ecialty strategy  but have been clear that \nour long -term growth targets are not predicated on inorganic investment.  \n \n We are making progress with our ongoing business and portfolio review, focused on the Medical \nsegment.  While across the company, our team has made significant progress over the past year \nrealigning our operations for focus and simplicity, there is still wo rk and opportunity in front of us. ", "original_text": " \nPage 8 of 16 \n \ncontinue to opportunistically evaluate disciplined M&A in Specialty and potential additional share \nrepurchases. ", "page_label": "8", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b23aaeb4-72c2-462d-8c96-16c55691043d": {"node_ids": ["82962c72-87c5-487b-956b-c956734d978c", "34d28b23-6e5a-4aac-aaed-660f644d746d", "7eb52375-febd-4b5e-8c88-c8015f94b926", "9d8c2712-6ea4-432e-9e02-b4ec24de6648", "338f6738-7751-48fa-acea-fade553f5375", "34ea1318-93fc-4ed3-b306-1eee90bfa3d3", "6831192f-ed4e-4331-b978-884ab35ac9e6", "e7bcf9f7-f3f4-4018-b4dd-d84a015d719f", "f067dcaa-d79f-4e00-9236-c9d76f7cc4cb", "54769bbb-c65a-4360-9d0a-55b803a567a5", "d094a9b2-7d3c-433f-89ac-188a39fd4a01", "2cf4d05f-5110-4f2f-bf38-346bda62acf1", "9ff30789-82c1-4dc7-97d6-155501d8e238", "399ab943-3f94-4553-a526-21f726eaf999", "786d1aeb-ba78-44e4-84be-ec955f414f22", "8594854d-94af-4727-bbc0-51d9ce86bfe7", "b998be1d-cafb-4629-b671-c67c4904fba0", "34ac8749-77d2-43e5-8f4c-aa810547cd28", "29d7fd9c-bf37-46c2-abbd-927ad216cf63", "5f5d2eb9-e671-4f94-ad52-244654fb75c2", "75f5be47-1f29-4854-a124-06ec613e30e5", "13e4bcee-a11b-4cad-b3c8-10cac83184a6", "68977a8d-9c34-4be6-8e1f-bf1c170d24b1", "700536e1-780e-4695-a2ef-31c5361d980e", "955a1205-e270-4295-9d1b-e8fe4d0924e1", "2c1496fe-9d87-48ba-998a-14d8afc43552", "a53f2be6-0e9a-49df-8f6c-8a7621699b22", "bfaca6fc-83e1-4553-a39a-a0c6e92a80e8", "6f35f29f-f0b5-46f3-99ad-0692359a8a74", "6c9693a0-3b0a-4534-9347-03899891f5d4", "d266477f-00c9-4d45-aa1d-5f051ea2292f", "786d7dd0-4205-4d5a-b5dc-46d50ee08398", "42cf2cae-c216-4c73-9365-c0d004b6136a", "6a21edc9-1435-44b8-bb50-5864cf789caf", "546146c8-1e78-4cd1-9522-432a75033b6b", "58cea524-090a-495c-b890-45504db3aa53", "ec0863b1-4e57-4383-a724-2072c31bc2d3", "572c6b88-5b64-4d91-8083-a892403f2f15", "08c462fd-c57b-4624-9bab-284c0b0fec77", "1cfc6bf4-6e4f-4086-bcdc-fbb6c170f19a"], "metadata": {"window": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n Operator:   We'll now move to our next question from Eric Percher from Nephron Research.  Please go \nahead.  \n \n Eric Percher:   Thank you. ", "original_text": " \nPage 9 of 16 \n \nMatt Sims:   Next question, please.  \n \n", "page_label": "9", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d86bc90f-a83f-4f84-b73e-c8d3e9b2ebbc": {"node_ids": ["099e1516-c617-416c-83d2-9eff5649bebb", "d732acb5-3f08-431b-934c-ae38151bd6f3", "328bf653-c03a-499d-8668-fa37a8c00f47", "5f8e3dc3-2599-45d4-924f-94e54b73a616", "0c12f155-2639-4b88-9b5b-9fee55da5a08", "e0657404-80e7-4af7-a3d2-fe95e00121fc", "f00c8034-83f4-4cd3-940e-3ba87d0077f8", "29a9d8e6-674c-4bd3-8c83-7eef06d62eb4", "20938a40-e5e4-455b-a092-522001aa31f3", "455df7b1-c41e-4c59-bccb-ccb9e5b0c1d3", "621e82ff-f64f-402f-bbc4-5cf0858111d4", "996ec2e8-034e-4588-83c7-2f69ae19e36c", "9cd0122f-db5c-4204-a134-55b3ed6c4bee", "17a903d3-f986-47f9-8b45-9827881a5318", "aadc03bb-7622-47bd-94c1-6d423e812afb", "517a627d-3723-4c3b-9b11-7e98b544a423", "eb9376c6-6ef8-44a4-b073-c516e9c1af51", "13cc2127-afa5-4a28-bb91-c1fc8662c967", "43af0314-ff41-40ef-82e1-e4dfbc5d6636", "967041a1-88a5-43fa-813b-f74f7f406860", "68cd16dd-8176-40ee-b355-637e51f592ec", "55b4e255-0a4d-423a-9198-6e8cf860d85c", "39096f86-f478-4e65-86c2-16ca0d246485", "be150bf5-4bce-4f51-885f-7cbaa5c03e40", "d9ebef97-2b25-47ad-8a78-0ea7b2d3a3ff", "e0e71c6d-814c-44fa-88d1-5de81367573a", "c163d222-795d-4993-a489-e84569312913", "c0007bd4-df59-47bf-9e4c-2e349b92f941", "8066bc79-9428-4cb8-9602-150623a53439", "e7a47cf0-a027-4824-93bc-e52985ed983b", "48ea2aae-8278-442e-bea3-c8d524d98f5b", "78732227-8bd4-4ab5-a37f-c829a90ec18d", "cc58a25a-198c-4cea-b038-8cc60498d973", "8f6e784c-2b85-4f95-828a-f83f20669e5b", "87fbc4bc-c813-42ff-9b49-123eb1abab35", "9a768d03-6136-4c78-bcb2-5d56a1114f44", "a37406fa-57af-4a8a-8336-fb7d776946bd", "2210fdba-1ed3-46d0-bab0-d8113e95248c", "4f7ebe58-202a-4399-8019-083272abde1c", "b7181c93-d17b-4610-9d9b-4dcec91e7d63", "4006e18d-cfa0-44c8-966a-d2d92d25fa27", "95466834-b589-4cb1-b893-98f8b49f7e5f", "bf81b24e-e5f8-46e0-a073-f17f237c607a", "d6bce047-fbb7-4841-ae21-66b689ec6160"], "metadata": {"window": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago.  So, there is volatility, no doubt there will always \nbe volatility.  But it's to a much lesser degree and much more balanced and kind of in a normal \nenvironment right now.  And that's why you don't hear us talking about it is because it's just not \nmeaningful in the context of everything else that we have going on.  \n \n", "original_text": " \nPage 10 of 16 \n \nseeing the volatility that we did back 18 months ago. ", "page_label": "10", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "152c004b-fd48-4cac-90ab-f0ad3c88c7da": {"node_ids": ["1c939ec5-170a-4676-bbe0-c0bba0ded20a", "699003ef-f88f-4618-b07b-ca28343d9d3c", "cd1c4a9b-6d53-49ee-8a1d-501d0cf393a8", "ce74601f-674c-42c2-b27d-a1bdf933b726", "53a49faf-27ed-46b4-a607-bbc59a1cf487", "7fdb80c3-d6b5-4b36-93f4-c92de4d63715", "fc9df0ca-e063-46e6-874a-b85e954ba787", "d43269c2-3149-4737-9d7a-6e6c21aacb7d", "fc43e3da-6701-433b-9863-ae01e7d29f63", "c055758b-d566-4759-8edd-b8eb195721de", "be6ee68a-a32f-4091-88ce-4825c02cdf8e", "3c47ff9b-dd7b-4d0a-bcf0-3b22647bdafd", "3321af62-383c-48f4-8fe7-2f328bc06084", "ea11c094-3d47-4057-ab77-5e063e72460d", "2342e942-9e24-4823-946d-5e80bc419d26", "11262282-f56f-4ba4-a6ad-70d83638ec96", "9f480935-93bb-4cae-8254-7bb8864493ae", "b2e4fc83-2273-41a2-8b62-ba27d2633adb", "9f89556c-9bdb-40be-878f-4724fd884ac7", "d40b2cf2-6e65-4f61-b6ff-1ed12be7bc59", "80a67ed4-e145-4f6b-b342-e457b612ec53", "113af8a7-666b-4f51-8948-253c8567d273", "bd6fd90b-3fc8-47c7-876c-5b9b9384dccb", "f333fb26-42d3-485f-870f-3ecc2a41843f", "1c06a753-5d19-45e3-912e-e116f45757a5", "aeaa8dc0-6f43-4f09-8675-84085213cc9b", "09094806-702b-4188-bfbd-97ebde770adc", "d5aa481b-30d9-4ae7-9f81-325f2a98c7d9", "97adcd77-faa6-4bb7-83cf-af9957c77252", "4afc0e2d-9eee-487a-9d56-ab5bbb583290", "5e0f80d2-0ce1-40f4-a12a-a2aa55ca0161", "b31a00d8-5eab-41e3-a139-c5bf5b2b855c", "b9f94bf5-b11d-48ee-8f8d-103b669de36e", "6a3d95d8-896d-4228-b350-849fa741709d", "46a75768-c5b9-412d-aae6-3e252901cdbd", "ba3b6543-b923-4852-9442-fafdd7439910", "5f237f9d-90b6-4d10-b3db-e73d3ddfc70f", "aaf65bf2-f10b-4a08-aa19-967198e4c243", "8356eade-38df-478a-b718-56bdda1d3e76"], "metadata": {"window": " \nPage 11 of 16 \n \nbeen in the past.  So let me just start with just underlying utilization  continues to be strong.  We've \nseen in our commentary this morning, we made a number of comments around just the broad -base \nutilization  being strong in the pharma industry, so we generally benefited from that.  So , volume is \nabsolutely a key component of that. ", "original_text": " \nPage 11 of 16 \n \nbeen in the past. ", "page_label": "11", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "edac5a20-4fd7-4741-8d71-049d72c7c91c": {"node_ids": ["cc94666e-47dc-4a27-b6a4-270b3778a208", "2ff1d61e-5d83-427f-b0b7-2afb7d088783", "1cce5109-7a50-4691-b52c-904e6e282431", "50c68992-bb30-4399-9f4e-f97c35670105", "5481a2ff-5514-4c28-acfc-f49760d55d89", "638a7d12-160b-42a3-8130-448532ee41c7", "9324571b-d160-4ca3-842c-ceb6729ce6ac", "23bfd213-0cd5-4722-81c0-d771496f0ea9", "9c8e4889-5fd5-4d93-a2c3-7ed34540d24e", "cf00d338-e0d1-49cc-9011-29848d723b7d", "3adc3cfe-7fe5-4a6c-a43d-c8b0fb2a1f4c", "ad339732-2922-411c-bcce-8cc142dac9c2", "214030a8-cf2b-438d-b0e6-b1e77b1f9fa9", "5c803a89-8126-40a4-9cc4-4c60fb0a53a3", "b467962b-2099-4631-b981-b4260c8c07a7", "09f35abc-e4cb-4609-b42c-89eb36181829", "3b4e3f56-b119-47e2-8d06-d3114a6de375", "03b46db9-8fd5-490e-81f0-fed98b7d3208", "f647980e-7b8f-4e9c-b352-91665710f286", "2ff35655-a5be-4839-ba99-dc7acb23d689", "6d56965c-1e71-4782-beed-dae97fa2bddb", "87cf121a-c6a3-42cc-94ed-ada7253986bc", "a0361ad4-3005-49a8-ad16-775c242a39f8", "3b375a85-699c-4459-b096-84e3cbd91bdb", "72daba6b-87a7-4bde-8491-c54f50e922b6", "2e5e85aa-92ce-44ac-bba1-915658d2fcf2", "c09b2ec9-2ccf-4670-9862-07eb2e79780f", "63f5b437-f2b9-4fb9-8b4a-89151ed64a60", "cbe20fe2-e589-4eeb-bea5-de9063f78be3", "e09b1724-5a30-4e4c-a3ce-30344f0ccbe1", "efd87e23-ac0b-4736-9f02-27900adfaa93", "9f967f9c-b809-41ce-9629-1ee1c7f32fc7", "51d3f4c4-2761-4c95-953b-6b0504f892fe", "d923c704-3b02-4952-8267-8d8f89819fa9", "5714c10e-21b0-4d50-b75c-4e97a09ffe0d", "28a53c50-3252-4107-8a39-b259bc402ad2", "ff873239-8c85-4801-a49f-2784e686b8cf", "2353576b-1b19-4c83-9336-3ae18bd22669", "3c728dd1-197c-4249-a4c9-13418b0c7930", "708f468b-5f20-4f35-b744-5c4947365e85", "12f244c7-b4c8-4591-92db-e234ae20f1ab"], "metadata": {"window": " \nPage 12 of 16 \n \ntransaction, particular product.  And so GLP -1s today, you hear us talk about it from revenue, it's not a \nmeaningful contributor to our earnings.  And so, we're not going to talk about it from earnings \nperspective.  Contracting, back to your original question will continue to evolve underneath that \ndynamic. ", "original_text": " \nPage 12 of 16 \n \ntransaction, particular product. ", "page_label": "12", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a7ba4038-5d94-4a38-b5ae-c34ef8fb1f20": {"node_ids": ["1272e0d5-ad63-41f1-b752-672ba5e877bc", "87385dc5-8fdf-4ba5-a8e1-ec8d0fce3e86", "ca273c70-c370-48df-9e19-4f590bde4ef5", "926518c7-8c1c-4db1-a534-c70cb3d6dc64", "15060017-62f5-40c9-9eb3-df02b14ec11e", "2a451365-5623-442a-a46f-e8b5ef404b87", "bff655f1-6e78-4dec-82de-fc3c89643730", "194a8d75-5d46-4443-9d9c-2d2d5837ae70", "4a4cca4c-5311-4544-96af-088c898971f1", "cbe90d1d-20ad-441c-a6c6-b4619c248246", "782a08f0-9139-45ab-b322-166dded77e6b", "a3b01afe-41a5-42f8-9f68-75f00c06b562", "229971eb-7602-473c-99ce-4ad5c36d9327", "cf91b05e-2441-48bf-8129-12eb38cad558", "78e52c02-d77a-417c-96e0-09fa23e9b5d7", "80e14891-54dc-49f0-9623-5e186376bdb8", "4d1ff400-bb1e-4920-bbc1-e6bd44feb9ee", "be61aa6b-0ef8-4307-bd49-4d158255e689", "2fd6ea3a-dae3-4bfb-b3f9-0d1de18ba732", "d19764c8-8206-41e2-8bf7-73588bc21027", "55a67ace-2d32-4802-aab2-1cb8cda854c1", "5eb3977e-2dc3-493d-ac16-70e758e14a7b", "d2beb8f2-5f59-479a-a0b1-c8694b616873", "44f81ce5-efef-41e5-81cd-82a8a55c9aee", "02f026d4-78d3-4a23-a9b4-d2119d7afd86", "3b1a9bb6-d0d4-433a-8a50-8c56e4d73014", "e69a96f6-94b0-4a43-a182-b40f785ec731", "b5ff8eae-28ef-4267-9e36-b17b7bfd5660", "e146c1e2-49e5-41bb-8e27-165c5ecdca18", "04c66a11-62ed-474b-a435-e5245e186c78", "4cafc0d5-b293-43b7-9d64-f0d8be04d702", "05ebb30e-bc30-4e4c-890f-12c1ecf5948f"], "metadata": {"window": " \nPage 13 of 16 \n \nthat was part of our response as well.   We didn't know the FDA approval date.  We also didn't know \nwhat was going to happen with the in -stock inventory, which seems to not have been a relevant \nusage at this stage given the variant evolution.  \n \n As it relates to therapeutics, we don't have that same challenge, right? ", "original_text": " \nPage 13 of 16 \n \nthat was part of our response as well.  ", "page_label": "13", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f4cc41fd-611c-43a0-800d-a4568f6d2480": {"node_ids": ["b99c1ed9-a701-43e2-80e5-3f3f9ee5be4a", "d1c4b83a-316e-48c5-9766-7debb6f8f90c", "1e959cef-1a2c-4077-9b3b-b2ed556f5e73", "27896f18-4086-4e15-bed2-1476423fd20a", "5c27c5bb-ffdc-4b3c-8681-617e652dde21", "3899c379-7c5e-4a8e-adb2-2819fbd92581", "c90bf52a-b6c7-4189-8375-4e05fe2103ea", "5d3e216d-8b94-4fd1-9567-ca752aa01033", "48874496-3d53-45dd-a662-d8a56e81d9b3", "48951eaa-bbfd-4a2f-9a02-9b10f1a22b66", "a77d7a9e-8235-48e2-ab24-cc1c99b7bfda", "c4f4f05b-67cf-41fc-bef3-ec6509eb2fb8", "31cc06f2-a77e-4def-85b2-8714bd06f27e", "45478c8f-fe90-42dc-b8c3-319e5552af26", "b8bfda88-5c4e-4a8b-9411-fc9af0cd31cb", "73bee685-65b5-4df4-a11e-ecf148d36018", "df2d8b83-9c8c-421a-b2a1-d594304bc59f", "7909bb20-0226-4c6f-851b-19d57ce46157", "019b842c-8d0c-40ee-aef6-2bcede4da6d2", "9d4a4a10-e809-4d33-a32c-52f2d5351a4e", "74f3163c-20ea-461d-a520-c5b593c61572", "71b5adca-c6b9-4146-a1d3-74208c105684", "c57529f4-164a-456e-b3c5-8730c62f6544", "26a6fc68-9ab3-4109-b893-ae809dc39fcb", "e4628a38-87e4-46aa-8d94-df503d2e2579", "33a8536f-b091-42e6-97e0-7d81919b0148", "8cbd91bd-a31a-4df9-9f31-d68f72e9f7af", "a561e606-362d-48a9-9f70-349d35ee4b1c", "7059de0b-4077-4e95-9bf5-91763a89c657", "9cdbd0d9-ea26-4645-a1f6-5c01220aa5f4", "7da2179f-f433-4f53-80d4-d6d8887df9d3", "3a910e62-e8bc-458c-b0f0-78301eaf21ba"], "metadata": {"window": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is.  And the short answer to maybe get ahead of \nthe question is that we had above the line benefits for which we , and below the line benefits , relative \nto consensus or expectations.  And the real difference between our raise and how you might do that \nmath is just, we are not carrying forward the tax benefit that we saw in Q1 into the updated guidance \nfor reasons I call out during my prepared remar ks.  \n \n Operator:   The next question comes from Charles Rhyee from TD Cowen. ", "original_text": " \nPage 14 of 16 \n \nNow some may ask, and I've seen in some of the headlines  as well, you beat by a particular amount  \nbut your raise is a little bit less than what that amount is. ", "page_label": "14", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a5029d12-6ba1-4600-87e4-6defbf5e44b6": {"node_ids": ["a7029c1e-46b6-4902-aed1-7ade1f589656", "fad4e3a0-4495-46a3-ad02-7f64eecfd922", "2d3e38ce-1105-4282-b245-307ad127dc2e", "b1b3a3be-d940-4924-9728-e4fbb5561528", "6f691a9f-5acb-41fc-a361-59925ee2fb99", "b31f1e96-7b32-4735-b759-23af5f8f1a8c", "8c9a9d51-2e63-4a50-bd5a-34fb1208c942", "31e680df-fe9d-4eaf-9a8a-be9756214d5f", "c3b25bdb-d4cd-4e85-bbf6-a5e2af6188ee", "3efad347-7819-4eb8-a77b-623d63f115cd", "e5975424-58ba-47e9-9de9-f49dafe6055d", "640b2608-428b-43e4-95fa-3e454d03d012", "af642033-ece5-43ad-b9c1-7e0df55c9223", "bc971faa-edbd-4f9f-812a-a32fb8406efc", "da3a77cf-1d9b-4805-bd75-ba86bcb8c25a", "deaa8826-5ae5-45bb-89c6-f98173f21705", "86d362ed-791e-49cf-a093-02a4527ac3ae", "d10e7129-0103-4679-a2cc-937244baac97", "7575a8e9-2da1-4a26-8cef-fbd4ee40663d", "f1813762-52ea-4e31-84f2-a3d2a84519ab", "d834534d-f83d-4082-b583-f452d20ae81e", "fb458a9f-48a6-4968-a6bb-02e7079ac6a1", "d52bbcb8-4020-4cf5-9659-329e6544bb21", "82dc824a-1e3e-4457-8007-95e695fc0d4f", "7887a02d-97ea-4a53-947a-c8c145ef75fc", "b3681391-1c6d-413f-bcee-75b26e53f3ce", "b2555354-2bd9-48ef-9317-73332a7b5620", "cb25bb20-4a4c-406a-9551-8d0a27303a76", "a16f2f2b-f2d4-425c-9f43-964e9c84c538", "b70e87b7-b0f9-4241-86de-5600e18060d7", "46d87dfb-c8a8-46aa-80e3-1ce5a832f0d0", "769e8b4d-3d17-4374-9474-70d10cdc7e0c", "e109b82a-c71f-43b5-b670-d055f676b615"], "metadata": {"window": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions.  I want to go after the Pharma \nmargin dynamic a little bit differently.  So, they were up five b ps year -over-year.  It sounds like the \nvaccine benefit is going to peak in your fiscal 2Q. ", "original_text": " \nPage 15 of 16 \n \nAllen Lutz:  Good morning and  thank you for taking the questions. ", "page_label": "15", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4606e53c-17c6-495b-a30f-81af8ff5ebdc": {"node_ids": ["8c432851-3e9f-45cd-b27b-03c583c5f70d", "64a3aa68-4b8a-446d-ad5d-429b930d98c2", "9287e502-a19e-462a-aaf2-196c7f400063", "b852de42-13c5-49fc-b62b-bf34adbeaa1b", "06f714f1-eed8-4137-856c-5a67e25e4a78", "afb3c28e-6c2a-4eda-a47c-f57d0cf99567", "d408aaab-b50d-495f-a590-c0fa0cb9c935", "e1cd5011-2c55-4ef7-9652-14e650f7f589", "06323d27-3ae8-4e2b-837a-e904558265ab", "ecba36fc-4483-4cc3-99b3-c4348d20c1d7", "7cba35f2-266b-4494-9214-f087d593161b", "4e024f7e-1029-4a2b-b09a-24363507a2b0", "a74870ff-05ce-45e8-8033-1cf859781911", "17441337-d7f6-412a-882c-3b675b9e43a7", "950fa927-f93d-4793-9972-08c99a3fa4a4", "31f313ba-1782-4f2d-8689-5c97af2e0781", "2a42881f-6057-48cc-9b81-e60cda732d61", "fe903f66-e7cf-4aff-9eb3-c1adb5b39d1d", "57619ab6-002c-4dca-b2d7-81cdd3066fb6"], "metadata": {"window": " \nPage 16 of 16 \n \nof year.  As Jason called out earlier, we have the benefit of our cash balance and having  invested, \nhaving  the plans that we do to invest in the business, CapEx wise, $92 million in the first quarter \ntargeting 500 million for the year, continuing to make progress on our investment grade rating.  And \nthe two positive outlook changes that we received during the q uarter, having made our baseline share \nrepurchase during Q1 as well as continuing to pay our dividends as we are, as a dividend aristocrat. \n And now we have the opportunity in support of the plans to take the resources we have available to \nus to invest back in the business with that specialty focus that Jason has called out several times to \nlook at M&A in a disciplined manner as Jason called out. ", "original_text": " \nPage 16 of 16 \n \nof year. ", "page_label": "16", "file_name": "CAH-Q1-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q1-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 195661, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}